<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10{font-size:9px;font-family:Times;color:#0b0b0a;}
	.ft11{font-size:8px;font-family:Times;color:#0b0b0a;}
	.ft12{font-size:9px;font-family:Times;color:#0b0b0a;}
	.ft13{font-size:8px;font-family:Times;color:#000000;}
	.ft14{font-size:8px;font-family:Times;color:#000000;}
	.ft15{font-size:35px;font-family:Times;color:#293e95;}
	.ft16{font-size:12px;font-family:Times;color:#000000;}
	.ft17{font-size:24px;font-family:Times;color:#000000;}
	.ft18{font-size:12px;font-family:Times;color:#000000;}
	.ft19{font-size:9px;font-family:Times;color:#000000;}
	.ft110{font-size:6px;font-family:Times;color:#000000;}
	.ft111{font-size:9px;font-family:Times;color:#000000;}
	.ft112{font-size:11px;font-family:Times;color:#000000;}
	.ft113{font-size:11px;font-family:Times;color:#000000;}
	.ft114{font-size:12px;font-family:Times;color:#0775b7;}
	.ft115{font-size:24px;line-height:28px;font-family:Times;color:#000000;}
	.ft116{font-size:9px;line-height:18px;font-family:Times;color:#000000;}
	.ft117{font-size:9px;line-height:16px;font-family:Times;color:#000000;}
	.ft118{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
	.ft119{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page1-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:569px;left:83px;white-space:nowrap" class="ft10"><a href="https://www.mdpi.com/article/10.3390/cancers14061499?type=check_update&version=1"></a></p>
<p style="position:absolute;top:580px;left:83px;white-space:nowrap" class="ft12"><a href="https://www.mdpi.com/article/10.3390/cancers14061499?type=check_update&version=1"><b></b></a></p>
<p style="position:absolute;top:605px;left:54px;white-space:nowrap" class="ft13"><b>Citation:</b></p>
<p style="position:absolute;top:605px;left:98px;white-space:nowrap" class="ft14">Mathews,&#160;J.;&#160;Kuchling,&#160;F.;</p>
<p style="position:absolute;top:623px;left:54px;white-space:nowrap" class="ft14">Baez-Nieto,&#160;D.;&#160;Diberardinis,&#160;M.;&#160;Pan,</p>
<p style="position:absolute;top:641px;left:53px;white-space:nowrap" class="ft14">J.Q.;&#160;Levin,&#160;M.&#160;Ion&#160;Channel&#160;Drugs</p>
<p style="position:absolute;top:658px;left:54px;white-space:nowrap" class="ft14">Suppress&#160;Cancer&#160;Phenotype&#160;in</p>
<p style="position:absolute;top:676px;left:54px;white-space:nowrap" class="ft14">NG108-15&#160;and&#160;U87&#160;Cells:&#160;Toward</p>
<p style="position:absolute;top:694px;left:54px;white-space:nowrap" class="ft14">Novel&#160;Electroceuticals&#160;for</p>
<p style="position:absolute;top:712px;left:54px;white-space:nowrap" class="ft14">Glioblastoma.&#160;Cancers&#160;<b>2022</b>,&#160;14,&#160;1499.</p>
<p style="position:absolute;top:730px;left:54px;white-space:nowrap" class="ft14"><a href="https://doi.org/10.3390/cancers14061499">https://doi.org/10.3390/</a></p>
<p style="position:absolute;top:748px;left:54px;white-space:nowrap" class="ft14"><a href="https://doi.org/10.3390/cancers14061499">cancers14061499</a></p>
<p style="position:absolute;top:775px;left:54px;white-space:nowrap" class="ft14">Academic&#160;Editors:&#160;Diane&#160;S.&#160;Lidke,</p>
<p style="position:absolute;top:793px;left:53px;white-space:nowrap" class="ft14">Jennifer&#160;M.&#160;Gillette&#160;and</p>
<p style="position:absolute;top:811px;left:53px;white-space:nowrap" class="ft14">Alessandra&#160;Cambi</p>
<p style="position:absolute;top:839px;left:54px;white-space:nowrap" class="ft14">Received:&#160;29&#160;January&#160;2022</p>
<p style="position:absolute;top:857px;left:53px;white-space:nowrap" class="ft14">Accepted:&#160;9&#160;March&#160;2022</p>
<p style="position:absolute;top:875px;left:54px;white-space:nowrap" class="ft14">Published:&#160;15&#160;March&#160;2022</p>
<p style="position:absolute;top:902px;left:54px;white-space:nowrap" class="ft13"><b>Publisher’s&#160;Note:</b></p>
<p style="position:absolute;top:902px;left:139px;white-space:nowrap" class="ft14">MDPI&#160;stays&#160;neutral</p>
<p style="position:absolute;top:919px;left:53px;white-space:nowrap" class="ft14">with&#160;regard&#160;to&#160;jurisdictional&#160;claims&#160;in</p>
<p style="position:absolute;top:937px;left:53px;white-space:nowrap" class="ft14">published&#160;maps&#160;and&#160;institutional&#160;affil-</p>
<p style="position:absolute;top:955px;left:54px;white-space:nowrap" class="ft14">iations.</p>
<p style="position:absolute;top:1026px;left:54px;white-space:nowrap" class="ft13"><b>Copyright:</b></p>
<p style="position:absolute;top:1025px;left:114px;white-space:nowrap" class="ft14">©&#160;2022&#160;by&#160;the&#160;authors.</p>
<p style="position:absolute;top:1043px;left:54px;white-space:nowrap" class="ft14">Licensee&#160;MDPI,&#160;Basel,&#160;Switzerland.</p>
<p style="position:absolute;top:1061px;left:53px;white-space:nowrap" class="ft14">This&#160;article&#160;is&#160;an&#160;open&#160;access&#160;article</p>
<p style="position:absolute;top:1079px;left:54px;white-space:nowrap" class="ft14">distributed&#160;under&#160;the&#160;terms&#160;and</p>
<p style="position:absolute;top:1097px;left:54px;white-space:nowrap" class="ft14">conditions&#160;of&#160;the&#160;Creative&#160;Commons</p>
<p style="position:absolute;top:1115px;left:53px;white-space:nowrap" class="ft14">Attribution&#160;(CC&#160;BY)&#160;license&#160;<a href="https://creativecommons.org/licenses/by/4.0/">(https://</a></p>
<p style="position:absolute;top:1133px;left:54px;white-space:nowrap" class="ft14"><a href="https://creativecommons.org/licenses/by/4.0/">creativecommons.org/licenses/by/</a></p>
<p style="position:absolute;top:1151px;left:54px;white-space:nowrap" class="ft14">4.0/).</p>
<p style="position:absolute;top:86px;left:110px;white-space:nowrap" class="ft15"><a href="https://www.mdpi.com/journal/cancers"><i><b>cancers</b></i></a></p>
<p style="position:absolute;top:159px;left:53px;white-space:nowrap" class="ft16">Article</p>
<p style="position:absolute;top:179px;left:54px;white-space:nowrap" class="ft115"><b>Ion&#160;Channel&#160;Drugs&#160;Suppress&#160;Cancer&#160;Phenotype&#160;in&#160;NG108-15<br/>and&#160;U87&#160;Cells:&#160;Toward&#160;Novel&#160;Electroceuticals&#160;for&#160;Glioblastoma</b></p>
<p style="position:absolute;top:252px;left:53px;white-space:nowrap" class="ft116"><b>Juanita&#160;Mathews&#160;<a href="https://orcid.org/0000-0003-1200-4810">1&#160;,&#160;</a></b><b>Franz&#160;Kuchling&#160;1,&#160;David&#160;Baez-Nieto&#160;2,&#160;Miranda&#160;Diberardinis&#160;1,&#160;Jen&#160;Q.&#160;Pan&#160;2<br/>and&#160;Michael&#160;Levin&#160;1,3,<a href="https://orcid.org/0000-0001-7292-8084">*</a></b></p>
<p style="position:absolute;top:317px;left:250px;white-space:nowrap" class="ft110">1</p>
<p style="position:absolute;top:320px;left:270px;white-space:nowrap" class="ft117">Allen&#160;Discovery&#160;Center&#160;at&#160;Tufts&#160;University,&#160;Medford,&#160;MA&#160;02155,&#160;USA;&#160;juanita.mathews@tufts.edu&#160;(J.M.);<br/>franz.kuchling@tufts.edu&#160;(F.K.);&#160;midiberardinis@comcast.net&#160;(M.D.)</p>
<p style="position:absolute;top:350px;left:250px;white-space:nowrap" class="ft110">2</p>
<p style="position:absolute;top:352px;left:270px;white-space:nowrap" class="ft117">Stanley&#160;Center&#160;of&#160;Psychiatric&#160;Research,&#160;Broad&#160;Institute&#160;of&#160;Harvard&#160;and&#160;MIT,&#160;Cambridge,&#160;MA&#160;02142,&#160;USA;<br/>dbaez@broadinstitute.org&#160;(D.B.-N.);&#160;jpan@broadinstitute.org&#160;(J.Q.P.)</p>
<p style="position:absolute;top:382px;left:250px;white-space:nowrap" class="ft110">3</p>
<p style="position:absolute;top:384px;left:270px;white-space:nowrap" class="ft111">Wyss&#160;Institute&#160;for&#160;Biologically&#160;Inspired&#160;Engineering,&#160;Harvard&#160;University,&#160;Boston,&#160;MA&#160;02115,&#160;USA</p>
<p style="position:absolute;top:400px;left:249px;white-space:nowrap" class="ft19"><b>*</b></p>
<p style="position:absolute;top:400px;left:270px;white-space:nowrap" class="ft111">Correspondence:&#160;michael.levin@tufts.edu;&#160;Tel.:&#160;+1-(617)-627-6161</p>
<p style="position:absolute;top:435px;left:250px;white-space:nowrap" class="ft112"><b>Simple&#160;Summary:</b></p>
<p style="position:absolute;top:435px;left:364px;white-space:nowrap" class="ft113">Glioblastoma&#160;is&#160;a&#160;rapidly&#160;progressing&#160;brain&#160;cancer&#160;that&#160;is&#160;very&#160;difficult&#160;to&#160;treat.</p>
<p style="position:absolute;top:455px;left:250px;white-space:nowrap" class="ft118">Given&#160;that&#160;many&#160;aspects&#160;of&#160;cell&#160;and&#160;tissue&#160;behavior&#160;are&#160;controlled&#160;by&#160;electric&#160;signaling,&#160;we&#160;sought&#160;to<br/>test&#160;whether&#160;drugs&#160;that&#160;target&#160;ion&#160;channel&#160;proteins&#160;might&#160;be&#160;effective&#160;at&#160;controlling&#160;the&#160;spread&#160;and<br/>functionality&#160;of&#160;glioblastoma&#160;cells&#160;in&#160;culture.&#160;Testing&#160;aspects&#160;of&#160;cell&#160;growth&#160;and&#160;physiology,&#160;we&#160;show<br/>that&#160;several&#160;novel&#160;combinations&#160;of&#160;ion&#160;channel&#160;drugs,&#160;which&#160;are&#160;already&#160;approved&#160;in&#160;human&#160;patients<br/>for&#160;other&#160;purposes,&#160;are&#160;highly&#160;effective&#160;against&#160;two&#160;types&#160;of&#160;glioblastoma&#160;cells.&#160;This&#160;facilitates&#160;the<br/>development&#160;of&#160;new&#160;strategies&#160;to&#160;address&#160;cancer&#160;by&#160;repurposing&#160;the&#160;large&#160;class&#160;of&#160;ion&#160;channel&#160;drugs<br/>against&#160;cancer.</p>
<p style="position:absolute;top:609px;left:249px;white-space:nowrap" class="ft112"><b>Abstract:</b></p>
<p style="position:absolute;top:609px;left:311px;white-space:nowrap" class="ft113">Glioblastoma&#160;is&#160;a&#160;lethal&#160;brain&#160;cancer&#160;that&#160;commonly&#160;recurs&#160;after&#160;tumor&#160;resection&#160;and</p>
<p style="position:absolute;top:628px;left:250px;white-space:nowrap" class="ft118">chemotherapy&#160;treatment.&#160;Depolarized&#160;resting&#160;membrane&#160;potentials&#160;and&#160;an&#160;acidic&#160;intertumoral<br/>extracellular&#160;pH&#160;have&#160;been&#160;associated&#160;with&#160;a&#160;proliferative&#160;state&#160;and&#160;drug&#160;resistance,&#160;suggesting<br/>that&#160;forced&#160;hyperpolarization&#160;and&#160;disruption&#160;of&#160;proton&#160;pumps&#160;in&#160;the&#160;plasma&#160;membrane&#160;could<br/>be&#160;a&#160;successful&#160;strategy&#160;for&#160;targeting&#160;glioblastoma&#160;overgrowth.&#160;We&#160;screened&#160;47&#160;compounds&#160;and<br/>compound&#160;combinations,&#160;most&#160;of&#160;which&#160;were&#160;ion-modulating,&#160;at&#160;different&#160;concentrations&#160;in&#160;the<br/>NG108-15&#160;rodent&#160;neuroblastoma/glioma&#160;cell&#160;line.&#160;A&#160;subset&#160;of&#160;these&#160;were&#160;tested&#160;in&#160;the&#160;U87&#160;human<br/>glioblastoma&#160;cell&#160;line.&#160;A&#160;FUCCI&#160;cell&#160;cycle&#160;reporter&#160;was&#160;stably&#160;integrated&#160;into&#160;both&#160;cell&#160;lines&#160;to<br/>monitor&#160;proliferation&#160;and&#160;cell&#160;cycle&#160;response.&#160;Immunocytochemistry,&#160;electrophysiology,&#160;and&#160;a&#160;panel<br/>of&#160;physiological&#160;dyes&#160;reporting&#160;voltage,&#160;calcium,&#160;and&#160;pH&#160;were&#160;used&#160;to&#160;characterize&#160;responses.&#160;The<br/>most&#160;effective&#160;treatments&#160;on&#160;proliferation&#160;in&#160;U87&#160;cells&#160;were&#160;combinations&#160;of&#160;NS1643&#160;and&#160;pantoprazole;<br/>retigabine&#160;and&#160;pantoprazole;&#160;and&#160;pantoprazole&#160;or&#160;NS1643&#160;with&#160;temozolomide.&#160;Marker&#160;analysis<br/>and&#160;physiological&#160;dye&#160;signatures&#160;suggest&#160;that&#160;exposure&#160;to&#160;bioelectric&#160;drugs&#160;significantly&#160;reduces</p>
<p style="position:absolute;top:862px;left:249px;white-space:nowrap" class="ft113">proliferation,&#160;makes&#160;the&#160;cells&#160;senescent,&#160;and&#160;promotes&#160;differentiation.&#160;These&#160;results,&#160;along&#160;with</p>
<p style="position:absolute;top:881px;left:250px;white-space:nowrap" class="ft118">the&#160;observed&#160;low&#160;toxicity&#160;in&#160;human&#160;neurons,&#160;show&#160;the&#160;high&#160;efficacy&#160;of&#160;electroceuticals&#160;utilizing<br/>combinations&#160;of&#160;repurposed&#160;FDA&#160;approved&#160;drugs.</p>
<p style="position:absolute;top:938px;left:250px;white-space:nowrap" class="ft112"><b>Keywords:</b></p>
<p style="position:absolute;top:938px;left:320px;white-space:nowrap" class="ft113">cancer;&#160;glioblastoma;&#160;NG108-15;&#160;U89;&#160;ion&#160;channel;&#160;blockers;&#160;openers</p>
<p style="position:absolute;top:1012px;left:250px;white-space:nowrap" class="ft18"><b>1.&#160;Introduction</b></p>
<p style="position:absolute;top:1036px;left:281px;white-space:nowrap" class="ft16">Glioblastoma&#160;(GBM)&#160;is&#160;a&#160;cancer&#160;of&#160;the&#160;brain&#160;that&#160;has&#160;a&#160;high&#160;mortality&#160;rate&#160;and&#160;a&#160;short</p>
<p style="position:absolute;top:1054px;left:250px;white-space:nowrap" class="ft119">median&#160;survivability&#160;time&#160;of&#160;around&#160;14&#160;to&#160;15&#160;months&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#29">[1].&#160;</a>Prognosis&#160;is&#160;particularly&#160;poor<br/>for&#160;glioblastoma&#160;patients&#160;due&#160;to&#160;the&#160;failure&#160;of&#160;standard&#160;interventions&#160;in&#160;preventing&#160;tumor<br/>re-growth.&#160;Currently,&#160;the&#160;standard&#160;treatment&#160;for&#160;GBM&#160;is&#160;resection&#160;of&#160;the&#160;main&#160;tumor<br/>followed&#160;by&#160;radiation&#160;and&#160;temozolomide&#160;(TMZ)&#160;administration&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#29">[2].&#160;</a>However,&#160;reoccurrence<br/>of&#160;GBM&#160;is&#160;common&#160;(90%)&#160;and&#160;usually&#160;arises&#160;from&#160;the&#160;area&#160;immediately&#160;next&#160;to&#160;the&#160;resected<br/>area&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#29">[3,4].&#160;</a>Thus,&#160;the&#160;invasiveness&#160;and&#160;hypermigratory&#160;nature&#160;of&#160;these&#160;residual&#160;cancer&#160;cells</p>
<p style="position:absolute;top:1222px;left:53px;white-space:nowrap" class="ft111">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499.&#160;<a href="https://doi.org/10.3390/cancers14061499">https://doi.org/10.3390/cancers14061499</a></p>
<p style="position:absolute;top:1222px;left:617px;white-space:nowrap" class="ft111"><a href="https://www.mdpi.com/journal/cancers">https://www.mdpi.com/journal/cancers</a></p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft20{font-size:9px;font-family:Times;color:#000000;}
	.ft21{font-size:9px;font-family:Times;color:#000000;}
	.ft22{font-size:12px;font-family:Times;color:#000000;}
	.ft23{font-size:12px;font-family:Times;color:#0775b7;}
	.ft24{font-size:13px;font-family:Times;color:#000000;}
	.ft25{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page2-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft20">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:804px;white-space:nowrap" class="ft20">2&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:250px;white-space:nowrap" class="ft25">make&#160;resection&#160;alone&#160;ineffective;&#160;additional&#160;interventions&#160;that&#160;prevent&#160;the&#160;proliferation&#160;of<br/>these&#160;cells&#160;are&#160;needed&#160;to&#160;complement&#160;current&#160;methodologies.</p>
<p style="position:absolute;top:184px;left:281px;white-space:nowrap" class="ft22">Targeting&#160;specific&#160;cell&#160;types&#160;in&#160;glioblastoma&#160;has&#160;proven&#160;difficult&#160;due&#160;to&#160;their&#160;heteroge-</p>
<p style="position:absolute;top:203px;left:250px;white-space:nowrap" class="ft25">neous&#160;nature.&#160;Although&#160;the&#160;WHO&#160;classifies&#160;glioblastoma&#160;as&#160;a&#160;grade&#160;IV&#160;astrocytoma,&#160;GBM<br/>likely&#160;arises&#160;from&#160;a&#160;combination&#160;of&#160;both&#160;neural&#160;stem&#160;cells&#160;(NSCs)&#160;in&#160;the&#160;subventricular&#160;zone</p>
<p style="position:absolute;top:241px;left:249px;white-space:nowrap" class="ft22">(SVZ)&#160;and&#160;oligodendrocyte&#160;progenitor&#160;cells&#160;(OPCs)&#160;that&#160;differentiate&#160;from&#160;those&#160;NSCs&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#29">[5–8].</a></p>
<p style="position:absolute;top:260px;left:250px;white-space:nowrap" class="ft25">Further&#160;phenotypic&#160;blurring&#160;occurs&#160;when&#160;oncogenic&#160;gene&#160;expressions&#160;lead&#160;to&#160;an&#160;astrocytic<br/>or&#160;oligodendroglial&#160;appearance&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#29">[9].&#160;</a>In&#160;Vivo,&#160;OPC-like&#160;cells&#160;are&#160;enriched&#160;at&#160;the&#160;periphery&#160;of<br/>GBM&#160;tumors.&#160;These&#160;cells&#160;and&#160;microglia&#160;serve&#160;as&#160;a&#160;source&#160;of&#160;growth&#160;factors&#160;that&#160;give&#160;GBM<br/>cells&#160;more&#160;stemness,&#160;facilitate&#160;growth&#160;and&#160;proliferation,&#160;and&#160;create&#160;a&#160;supportive&#160;tumor<br/>microenvironment&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#29">[10].&#160;</a>In&#160;addition,&#160;GBM&#160;cells&#160;in&#160;the&#160;border&#160;niche&#160;have&#160;upregulated&#160;levels<br/>of&#160;transcripts&#160;for&#160;drug&#160;efflux&#160;transporters&#160;and&#160;radioresistance&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#29">[10],&#160;</a>which&#160;may&#160;underlie<br/>resistance&#160;to&#160;TMZ&#160;treatment&#160;during&#160;radiation&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#29">[10].&#160;</a>Thus,&#160;the&#160;proliferative&#160;capability&#160;of<br/>these&#160;border&#160;areas&#160;and&#160;resistance&#160;to&#160;drug&#160;therapy&#160;and&#160;radiation&#160;likely&#160;explain&#160;the&#160;high<br/>reoccurrence&#160;of&#160;GBM&#160;after&#160;tumor&#160;resection&#160;and&#160;chemotherapy.&#160;Treatment&#160;strategies&#160;that<br/>target&#160;the&#160;proliferative&#160;capability&#160;of&#160;GBM&#160;and&#160;bypass&#160;typical&#160;drug&#160;efflux&#160;transporters&#160;could</p>
<p style="position:absolute;top:448px;left:249px;white-space:nowrap" class="ft22">potentially&#160;increase&#160;the&#160;survivability&#160;of&#160;this&#160;fatal&#160;disease.</p>
<p style="position:absolute;top:467px;left:281px;white-space:nowrap" class="ft22">Differentiation&#160;as&#160;a&#160;treatment&#160;strategy&#160;for&#160;GBM&#160;has&#160;recently&#160;been&#160;explored&#160;by&#160;several</p>
<p style="position:absolute;top:485px;left:250px;white-space:nowrap" class="ft25">labs.&#160;Instead&#160;of&#160;killing&#160;the&#160;cancer&#160;cells,&#160;this&#160;method&#160;attempts&#160;to&#160;remediate&#160;the&#160;cancer&#160;cells&#160;so<br/>that&#160;they&#160;no&#160;longer&#160;proliferate&#160;or&#160;invade&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#29">[11–</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">13].&#160;</a>Studies&#160;have&#160;successfully&#160;used&#160;all-trans-<br/>retinoic&#160;acid&#160;(ATRA),&#160;molecules&#160;that&#160;upregulate&#160;cAMP&#160;production,&#160;bone&#160;morphogenic</p>
<p style="position:absolute;top:542px;left:249px;white-space:nowrap" class="ft22">protein&#160;4&#160;(BMP4),&#160;and&#160;most&#160;recently&#160;Pam3CSK4,&#160;a&#160;synthetic&#160;Toll-like&#160;receptor&#160;2&#160;(TLR2)</p>
<p style="position:absolute;top:561px;left:250px;white-space:nowrap" class="ft25">ligand&#160;to&#160;differentiate&#160;GBM&#160;cells&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[14–19].&#160;</a>However,&#160;retinoid&#160;treatment&#160;can&#160;be&#160;prone&#160;to<br/>resistance&#160;effects,&#160;and&#160;some&#160;of&#160;the&#160;other&#160;methods&#160;suffer&#160;from&#160;off-target&#160;effects&#160;that&#160;can<br/>require&#160;invasive&#160;targeted&#160;treatment&#160;strategies&#160;and&#160;limit&#160;in&#160;vivo&#160;use&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[20].</a></p>
<p style="position:absolute;top:617px;left:281px;white-space:nowrap" class="ft22">Alongside&#160;canonical&#160;biochemical&#160;factors&#160;and&#160;biomechanical&#160;forces,&#160;cell&#160;and&#160;tissue-level</p>
<p style="position:absolute;top:636px;left:250px;white-space:nowrap" class="ft22">order&#160;are&#160;now&#160;known&#160;to&#160;be&#160;regulated&#160;by&#160;bioelectrical&#160;signaling&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#29">[12,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">21].&#160;</a>The&#160;transmembrane</p>
<p style="position:absolute;top:655px;left:249px;white-space:nowrap" class="ft22">voltage&#160;(Vmem)&#160;of&#160;cells&#160;is&#160;regulated&#160;by&#160;ion&#160;channels,&#160;which&#160;are&#160;not&#160;only&#160;important&#160;targets&#160;in</p>
<p style="position:absolute;top:674px;left:250px;white-space:nowrap" class="ft25">embryonic&#160;channelopathies&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[22–24]&#160;</a>but&#160;also&#160;increasingly&#160;seen&#160;as&#160;cancer&#160;targets&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[22,25–36].<br/></a>Overall,&#160;adult&#160;non-proliferative&#160;cells&#160;tend&#160;to&#160;have&#160;hyperpolarized&#160;membrane&#160;potentials</p>
<p style="position:absolute;top:711px;left:249px;white-space:nowrap" class="ft22">(around&#160;−40&#160;mV&#160;to&#160;−90&#160;mV),&#160;whereas&#160;stem&#160;cells,&#160;embryonic&#160;cells,&#160;and&#160;other&#160;highly&#160;prolif-</p>
<p style="position:absolute;top:730px;left:250px;white-space:nowrap" class="ft22">erative&#160;cells&#160;are&#160;much&#160;more&#160;depolarized&#160;(around&#160;−5&#160;mV&#160;to&#160;−40&#160;mV)&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[22,37].&#160;</a>Cancer&#160;cell</p>
<p style="position:absolute;top:749px;left:249px;white-space:nowrap" class="ft22">Vmem&#160;tends&#160;to&#160;have&#160;much&#160;more&#160;depolarized&#160;membrane&#160;potentials&#160;than&#160;their&#160;non-cancerous</p>
<p style="position:absolute;top:768px;left:250px;white-space:nowrap" class="ft25">equivalents&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[24,37].&#160;</a>Indeed,&#160;transformed&#160;cells&#160;can&#160;be&#160;detected&#160;in&#160;vivo&#160;in&#160;animal&#160;models<br/>using&#160;voltage-sensitive&#160;fluorescent&#160;dyes&#160;based&#160;on&#160;their&#160;abnormal&#160;bioelectric&#160;signature&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[38].<br/></a>Importantly,&#160;the&#160;resting&#160;membrane&#160;potential&#160;is&#160;not&#160;only&#160;a&#160;marker&#160;but&#160;is&#160;functionally&#160;instruc-<br/>tive&#160;for&#160;cell&#160;behavior.&#160;Classic&#160;work&#160;by&#160;Cone&#160;showed&#160;that&#160;Vmem&#160;is&#160;an&#160;important&#160;regulator&#160;of</p>
<p style="position:absolute;top:843px;left:249px;white-space:nowrap" class="ft22">proliferation&#160;in&#160;terminally&#160;differentiated&#160;cells&#160;or&#160;cancer&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[39–</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#31">41],&#160;</a>and&#160;this&#160;has&#160;been&#160;confirmed</p>
<p style="position:absolute;top:862px;left:250px;white-space:nowrap" class="ft25">in&#160;recent&#160;work&#160;linking&#160;depolarization&#160;with&#160;a&#160;plastic,&#160;undifferentiated,&#160;highly&#160;proliferative<br/>state.&#160;For&#160;example,&#160;treatment&#160;of&#160;mesenchymal&#160;stem&#160;cells&#160;with&#160;depolarizing&#160;drugs&#160;inhibited<br/>their&#160;differentiation&#160;into&#160;adipocytes&#160;or&#160;osteoblasts,&#160;suggesting&#160;that&#160;hyperpolarization&#160;is<br/>required&#160;for&#160;differentiation&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#31">[42–46].&#160;</a>Importantly,&#160;in&#160;vivo&#160;experiments&#160;in&#160;Xenopus&#160;tadpoles<br/>showed&#160;that&#160;co-expression&#160;of&#160;hyperpolarizing&#160;ion&#160;channels,&#160;or&#160;optogenetic&#160;activation&#160;of<br/>channels&#160;with&#160;human&#160;oncogenes,&#160;can&#160;prevent&#160;the&#160;tumors&#160;induced&#160;by&#160;oncogene&#160;expres-<br/>sion&#160;alone&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[34,38,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#31">47,48].&#160;</a>In&#160;mammalian&#160;models,&#160;several&#160;recent&#160;studies&#160;have&#160;shown&#160;that<br/>ion&#160;channelopathies&#160;that&#160;affect&#160;resting&#160;membrane&#160;potential&#160;are&#160;present&#160;in&#160;many&#160;cancers<br/>and&#160;play&#160;a&#160;key&#160;role&#160;in&#160;cell&#160;proliferation,&#160;progression&#160;through&#160;the&#160;cell&#160;cycle,&#160;and&#160;metasta-<br/>sis&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[25,29,31,36,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#31">49–56].</a></p>
<p style="position:absolute;top:1050px;left:281px;white-space:nowrap" class="ft22">The&#160;location&#160;of&#160;many&#160;ion&#160;channels&#160;in&#160;the&#160;plasma&#160;membrane&#160;also&#160;makes&#160;them&#160;attractive</p>
<p style="position:absolute;top:1069px;left:250px;white-space:nowrap" class="ft25">therapeutics&#160;targets.&#160;Agonists&#160;or&#160;antagonists&#160;used&#160;to&#160;modulate&#160;Vmem&#160;can&#160;be&#160;chosen&#160;for<br/>binding&#160;sites&#160;on&#160;the&#160;outer&#160;side&#160;of&#160;the&#160;membrane,&#160;bypassing&#160;the&#160;challenges&#160;posed&#160;by<br/>increased&#160;drug&#160;efflux&#160;transporters&#160;in&#160;glioblastoma&#160;stem&#160;cells&#160;(GSCs).&#160;Furthermore,&#160;ion<br/>channel&#160;transcripts&#160;have&#160;been&#160;shown&#160;to&#160;be&#160;upregulated&#160;in&#160;GSCs,&#160;including&#160;SCN8A,&#160;which<br/>encodes&#160;a&#160;sodium&#160;channel,&#160;KCNB1,&#160;which&#160;encodes&#160;a&#160;voltage-gated&#160;potassium&#160;channel,&#160;and</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft30{font-size:9px;font-family:Times;color:#000000;}
	.ft31{font-size:9px;font-family:Times;color:#000000;}
	.ft32{font-size:12px;font-family:Times;color:#000000;}
	.ft33{font-size:12px;font-family:Times;color:#0775b7;}
	.ft34{font-size:12px;font-family:Times;color:#000000;}
	.ft35{font-size:13px;font-family:Times;color:#000000;}
	.ft36{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
	.ft37{font-size:12px;line-height:19px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page3-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft30">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:804px;white-space:nowrap" class="ft30">3&#160;of&#160;36</p>
<p style="position:absolute;top:146px;left:249px;white-space:nowrap" class="ft32">GRIA3,&#160;which&#160;encodes&#160;an&#160;ionotropic&#160;glutamate&#160;receptor&#160;that&#160;is&#160;non-selective&#160;for&#160;monovalent</p>
<p style="position:absolute;top:165px;left:250px;white-space:nowrap" class="ft36">cations&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#31">[53].&#160;</a>Other&#160;studies&#160;have&#160;found&#160;multiple&#160;changes&#160;in&#160;a&#160;variety&#160;of&#160;potassium&#160;channels<br/>in&#160;GBM,&#160;including&#160;an&#160;increase&#160;in&#160;BK&#160;channel&#160;expression,&#160;a&#160;decrease&#160;in&#160;hERG1,&#160;and&#160;a<br/>decrease&#160;in&#160;Kir4.1&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#31">[57,58].&#160;</a>In&#160;addition,&#160;intracellular&#160;alkalization&#160;induced&#160;by&#160;dysfunction&#160;in</p>
<p style="position:absolute;top:222px;left:249px;white-space:nowrap" class="ft32">proton&#160;transportation&#160;has&#160;been&#160;shown&#160;to&#160;increase&#160;drug&#160;resistance&#160;in&#160;GBM&#160;and&#160;contributes</p>
<p style="position:absolute;top:241px;left:250px;white-space:nowrap" class="ft36">to&#160;extracellular&#160;acidification,&#160;which&#160;provides&#160;GSCs&#160;with&#160;an&#160;optimized&#160;niche&#160;and&#160;facilitates<br/>the&#160;release&#160;of&#160;large&#160;oncosomes,&#160;a&#160;type&#160;of&#160;extracellular&#160;vesicle&#160;that&#160;can&#160;transform&#160;neighboring<br/>cells&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#31">[59–61].&#160;</a>Thus,&#160;due&#160;to&#160;the&#160;location&#160;and&#160;importance&#160;of&#160;these&#160;channels&#160;in&#160;cancer&#160;cell</p>
<p style="position:absolute;top:297px;left:249px;white-space:nowrap" class="ft32">proliferation,&#160;migration,&#160;and&#160;metastasis,&#160;ion&#160;channels&#160;provide&#160;an&#160;optimal&#160;target&#160;for&#160;the</p>
<p style="position:absolute;top:316px;left:250px;white-space:nowrap" class="ft32">development&#160;of&#160;new&#160;GBM&#160;treatments.</p>
<p style="position:absolute;top:335px;left:281px;white-space:nowrap" class="ft32">A&#160;large&#160;catalogue&#160;of&#160;FDA&#160;approved&#160;pharmaceuticals&#160;that&#160;modulate&#160;ion&#160;channels</p>
<p style="position:absolute;top:354px;left:250px;white-space:nowrap" class="ft36">exist,&#160;creating&#160;an&#160;opportunity&#160;to&#160;directly&#160;assess&#160;the&#160;role&#160;of&#160;Vmem&#160;in&#160;cancer&#160;progression.&#160;To<br/>discover&#160;effective&#160;interventions&#160;for&#160;glioblastoma&#160;using&#160;known&#160;small&#160;molecule&#160;modulators<br/>of&#160;the&#160;bioelectric&#160;state,&#160;we&#160;first&#160;used&#160;the&#160;cell&#160;line,&#160;NG108-15,&#160;to&#160;screen&#160;for&#160;Vmem-modifying<br/>compounds&#160;that&#160;could&#160;potentially&#160;promote&#160;differentiation&#160;in&#160;glioblastoma&#160;cells&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#31">[62].&#160;</a>NG108-</p>
<p style="position:absolute;top:429px;left:249px;white-space:nowrap" class="ft36">15&#160;cells&#160;are&#160;a&#160;hybrid&#160;formed&#160;from&#160;mouse&#160;N18TG2&#160;neuroblastoma&#160;cells&#160;with&#160;rat&#160;C6-BU-<br/>1&#160;glioma&#160;cells&#160;and&#160;is&#160;a&#160;popular&#160;model&#160;system&#160;in&#160;neuronal&#160;differentiation&#160;studies&#160;and</p>
<p style="position:absolute;top:467px;left:250px;white-space:nowrap" class="ft36">shows&#160;cancer&#160;stem&#160;cell&#160;characteristics.&#160;This&#160;line&#160;was&#160;chosen&#160;due&#160;to&#160;its&#160;extensive&#160;use&#160;in<br/>determining&#160;the&#160;factors&#160;necessary&#160;for&#160;neuronal&#160;differentiation,&#160;its&#160;close&#160;resemblance&#160;to&#160;NSCs<br/>and&#160;GSCs,&#160;and&#160;its&#160;well-characterized&#160;membrane&#160;properties&#160;and&#160;electrophysiology&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#31">[63–65].<br/></a>Our&#160;goal&#160;was&#160;to&#160;find&#160;compounds&#160;that&#160;would&#160;safely&#160;abrogate&#160;the&#160;proliferative&#160;potential<br/>in&#160;NG108-15&#160;cells&#160;under&#160;high&#160;serum&#160;conditions,&#160;normally&#160;prohibitive&#160;for&#160;differentiation<br/>and&#160;representative&#160;of&#160;the&#160;high&#160;plasma&#160;protein&#160;content&#160;found&#160;in&#160;vivo,&#160;revealing&#160;robust<br/>candidates&#160;for&#160;subsequent&#160;assessment&#160;in&#160;the&#160;U87&#160;(ATCC)&#160;human&#160;glioblastoma&#160;line,&#160;and&#160;for<br/>future&#160;testing&#160;in&#160;patient-derived&#160;GSCs&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#31">[66–</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">69].</a></p>
<p style="position:absolute;top:617px;left:281px;white-space:nowrap" class="ft32">To&#160;screen&#160;candidate&#160;drugs&#160;for&#160;anti-cancer&#160;activity,&#160;we&#160;first&#160;created&#160;new&#160;cell&#160;lines&#160;as</p>
<p style="position:absolute;top:636px;left:250px;white-space:nowrap" class="ft36">resources&#160;for&#160;future&#160;studies&#160;in&#160;this&#160;field:&#160;an&#160;NG108-15&#160;and&#160;U87&#160;stable&#160;line&#160;expressing&#160;a<br/>Fluorescence&#160;Ubiquitin&#160;Cell&#160;Cycle&#160;Indicator&#160;(FUCCI)&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[70]&#160;</a>and&#160;a&#160;cell&#160;membrane&#160;mTurquoise<br/>tag&#160;for&#160;revealing&#160;whole-cell&#160;morphology.&#160;Automated&#160;electrophysiology&#160;was&#160;used&#160;to&#160;deter-<br/>mine&#160;the&#160;overall&#160;plasma&#160;membrane&#160;potential&#160;in&#160;NG108-15&#160;cells&#160;in&#160;the&#160;presence&#160;of&#160;the&#160;drug<br/>compound&#160;treatment.&#160;For&#160;U87&#160;cells,&#160;we&#160;used&#160;dyes&#160;to&#160;determine&#160;cytoplasmic&#160;calcium&#160;levels,<br/>internal&#160;pH&#160;(pHi),&#160;transmembrane&#160;potential&#160;and&#160;lysosomal&#160;pH&#160;to&#160;gain&#160;comprehensive</p>
<p style="position:absolute;top:749px;left:249px;white-space:nowrap" class="ft32">profiling&#160;of&#160;the&#160;drugs’&#160;effects&#160;on&#160;cell&#160;physiology.&#160;Finally,&#160;a&#160;beta-galactosidase&#160;stain&#160;and</p>
<p style="position:absolute;top:768px;left:250px;white-space:nowrap" class="ft36">immunocytochemistry&#160;were&#160;used&#160;to&#160;analyze&#160;senescence,&#160;cell&#160;cycle&#160;inhibitor&#160;levels,&#160;and<br/>differentiation&#160;status&#160;of&#160;treated&#160;NG108-15&#160;and&#160;U87&#160;cells.&#160;In&#160;addition,&#160;we&#160;used&#160;human<br/>neurons&#160;to&#160;perform&#160;a&#160;Live/Dead&#160;assay&#160;and&#160;a&#160;senescence&#160;assay&#160;to&#160;identify&#160;treatments&#160;that</p>
<p style="position:absolute;top:824px;left:249px;white-space:nowrap" class="ft32">were&#160;toxic&#160;to&#160;non-cancerous&#160;cells.&#160;We&#160;identified&#160;several&#160;combinations&#160;of&#160;compounds&#160;that</p>
<p style="position:absolute;top:843px;left:250px;white-space:nowrap" class="ft36">strongly&#160;and&#160;specifically&#160;reduce&#160;proliferation&#160;and&#160;promote&#160;induction&#160;of&#160;differentiation,<br/>demonstrating&#160;that&#160;this&#160;class&#160;of&#160;electroceuticals,&#160;most&#160;of&#160;which&#160;are&#160;already&#160;FDA&#160;approved<br/>for&#160;human&#160;use&#160;in&#160;other&#160;conditions,&#160;are&#160;good&#160;candidates&#160;for&#160;cancer&#160;remediation&#160;in&#160;GBM.</p>
<p style="position:absolute;top:915px;left:250px;white-space:nowrap" class="ft37"><b>2.&#160;Materials&#160;and&#160;Methods<br/></b>2.1.&#160;Reagents</p>
<p style="position:absolute;top:958px;left:281px;white-space:nowrap" class="ft32">Stocks&#160;of&#160;Rapamycin&#160;(R8781,&#160;Sigma,&#160;St.&#160;Louis,&#160;MO,&#160;USA),&#160;Retigabine&#160;(SML0325,&#160;Sigma),</p>
<p style="position:absolute;top:977px;left:250px;white-space:nowrap" class="ft36">Minoxidil&#160;(M4145,&#160;Sigma),&#160;NS1643&#160;(sc-2041353,&#160;Santa&#160;Cruz&#160;Biotechnology,&#160;Dallas,&#160;TX,&#160;USA),<br/>Lamotrigine&#160;(L3791,&#160;Sigma),&#160;Zolmitriptan&#160;(SML0248,&#160;Sigma),&#160;Cariporide&#160;(SML1360,&#160;Sigma),</p>
<p style="position:absolute;top:1014px;left:249px;white-space:nowrap" class="ft32">Topiramate&#160;(T0575,&#160;Sigma),&#160;Pantoprazole&#160;Sodium&#160;Hydrate&#160;(P0021,&#160;Sigma),&#160;Fenofibrate&#160;(F6020,</p>
<p style="position:absolute;top:1033px;left:250px;white-space:nowrap" class="ft32">Sigma),&#160;Acetazolamide&#160;(A6011,&#160;Sigma),&#160;Quercetin&#160;(Q4951,&#160;Sigma),&#160;Temozolomide&#160;(2706,</p>
<p style="position:absolute;top:1052px;left:249px;white-space:nowrap" class="ft32">Tocris,&#160;Bristol,&#160;UK),&#160;Dexamethasone&#160;(D4902,&#160;Sigma),&#160;ONO-RS-082&#160;(O0766,&#160;Sigma),&#160;Topotecan</p>
<p style="position:absolute;top:1071px;left:250px;white-space:nowrap" class="ft36">hydrochloride&#160;(4562,&#160;Tocris),&#160;CKD&#160;602&#160;(5125,&#160;Tocris),&#160;(Z)-4-hydroxytamoxifen&#160;(3412,&#160;Tocris),<br/>Lansoprazole&#160;(2582,&#160;Tocris),&#160;Chlorzoxazone&#160;(C4397,&#160;Sigma),&#160;and&#160;Sodium&#160;Butyrate&#160;(B5887,<br/>Sigma),&#160;were&#160;made&#160;at&#160;1000×&#160;concentration&#160;in&#160;DMSO.&#160;Stocks&#160;of&#160;Gabapentin&#160;(G154,&#160;Sigma)<br/>and&#160;Cisplatin&#160;(232120,&#160;EMD&#160;Millipore,&#160;Burlington,&#160;MA,&#160;USA)&#160;were&#160;made&#160;in&#160;water&#160;at&#160;1000×.</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft40{font-size:9px;font-family:Times;color:#000000;}
	.ft41{font-size:9px;font-family:Times;color:#000000;}
	.ft42{font-size:12px;font-family:Times;color:#000000;}
	.ft43{font-size:12px;font-family:Times;color:#0775b7;}
	.ft44{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page4-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft40">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:804px;white-space:nowrap" class="ft40">4&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:250px;white-space:nowrap" class="ft44">Dibutyryl&#160;cAMP&#160;sodium&#160;salt&#160;(D0627,&#160;Sigma)&#160;was&#160;the&#160;only&#160;compound&#160;dissolved&#160;directly&#160;in<br/>cell&#160;culture&#160;media&#160;at&#160;1&#160;mM&#160;concentration.</p>
<p style="position:absolute;top:199px;left:250px;white-space:nowrap" class="ft42">2.2.&#160;Cell&#160;Culture</p>
<p style="position:absolute;top:222px;left:281px;white-space:nowrap" class="ft42">NG108-15&#160;cells&#160;(ATCC),&#160;passage&#160;7–10&#160;were&#160;cultured&#160;in&#160;growth&#160;media&#160;containing</p>
<p style="position:absolute;top:241px;left:250px;white-space:nowrap" class="ft42">DMEM&#160;medium&#160;with&#160;high&#160;glucose&#160;and&#160;no&#160;phenol&#160;red&#160;or&#160;sodium&#160;pyruvate&#160;(31053-028,</p>
<p style="position:absolute;top:260px;left:249px;white-space:nowrap" class="ft42">ThermoFisher,&#160;Waltham,&#160;MA,&#160;USA),&#160;which&#160;was&#160;supplemented&#160;with&#160;2&#160;mM&#160;Glutamax,&#160;10%</p>
<p style="position:absolute;top:279px;left:250px;white-space:nowrap" class="ft42">FBS,&#160;HAT&#160;supplement,&#160;and&#160;100&#160;U/mL&#160;penicillin/streptomycin.&#160;Cells&#160;were&#160;disassociated</p>
<p style="position:absolute;top:298px;left:249px;white-space:nowrap" class="ft44">with&#160;Accutase&#160;and&#160;passaged&#160;when&#160;70%&#160;confluent&#160;and&#160;maintained&#160;at&#160;37&#160;◦C&#160;with&#160;5%&#160;CO2.<br/>The&#160;media&#160;were&#160;changed&#160;every&#160;two&#160;days.&#160;For&#160;live&#160;cell&#160;assays,&#160;plates&#160;were&#160;coated&#160;with<br/>1/50&#160;dilution&#160;of&#160;no&#160;phenol&#160;red&#160;growth&#160;factor&#160;reduced&#160;(GFR)&#160;Matrigel&#160;(356231,&#160;Corning,</p>
<p style="position:absolute;top:354px;left:250px;white-space:nowrap" class="ft44">NY,&#160;USA)&#160;in&#160;imaging&#160;media&#160;made&#160;of&#160;Fluorobrite&#160;DMEM&#160;(A1896701,&#160;ThermoFisher)&#160;with<br/>no&#160;added&#160;supplements.&#160;Cell&#160;culture&#160;medium&#160;was&#160;switched&#160;to&#160;Fluorobrite&#160;DMEM&#160;with<br/>2&#160;mM&#160;Glutamax,&#160;10%&#160;FBS,&#160;HAT&#160;supplement,&#160;and&#160;100&#160;U/mL&#160;penicillin/streptomycin&#160;for<br/>all&#160;live&#160;cell&#160;imaging&#160;experiments,&#160;except&#160;for&#160;a&#160;cAMP&#160;with&#160;rapamycin&#160;treatment&#160;which</p>
<p style="position:absolute;top:429px;left:249px;white-space:nowrap" class="ft42">was&#160;conducted&#160;in&#160;the&#160;exact&#160;same&#160;media&#160;except&#160;with&#160;1%&#160;FBS.&#160;All&#160;drug&#160;screens,&#160;including</p>
<p style="position:absolute;top:448px;left:250px;white-space:nowrap" class="ft42">controls,&#160;were&#160;performed&#160;using&#160;0.02%&#160;DMSO&#160;in&#160;the&#160;high&#160;serum&#160;Fluorobrite&#160;DMEM.</p>
<p style="position:absolute;top:467px;left:281px;white-space:nowrap" class="ft42">U87&#160;(ATCC)&#160;cells&#160;were&#160;cultured&#160;under&#160;the&#160;same&#160;conditions&#160;as&#160;the&#160;NG108-15&#160;cells</p>
<p style="position:absolute;top:486px;left:250px;white-space:nowrap" class="ft44">minus&#160;the&#160;HAT&#160;supplement&#160;and&#160;used&#160;at&#160;passage&#160;7–10&#160;for&#160;experiments.&#160;All&#160;cells&#160;plated<br/>for&#160;antibody&#160;staining&#160;and&#160;senescence&#160;assays&#160;were&#160;cultured&#160;on&#160;polyethylenimine&#160;(181978,<br/>Sigma)&#160;coated&#160;plates&#160;at&#160;25&#160;µg/mL&#160;in&#160;150&#160;mM&#160;NaCl&#160;solution&#160;for&#160;1&#160;h&#160;at&#160;room&#160;temperature<br/>followed&#160;by&#160;a&#160;rinse&#160;of&#160;PBS&#160;and&#160;an&#160;additional&#160;coating&#160;of&#160;1/50&#160;Matrigel&#160;as&#160;described&#160;above.</p>
<p style="position:absolute;top:561px;left:281px;white-space:nowrap" class="ft42">Human&#160;neuronal&#160;cells&#160;were&#160;differentiated&#160;from&#160;human&#160;induced&#160;neural&#160;stem&#160;cells</p>
<p style="position:absolute;top:580px;left:249px;white-space:nowrap" class="ft42">(hiNSCs)&#160;(passage&#160;7–10),&#160;a&#160;generous&#160;gift&#160;from&#160;David&#160;Kaplan,&#160;as&#160;described&#160;previously&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[71].</a></p>
<p style="position:absolute;top:599px;left:250px;white-space:nowrap" class="ft44">Briefly,&#160;hiNSCs&#160;were&#160;grown&#160;on&#160;mouse&#160;embryonic&#160;fibroblast&#160;(MEF)&#160;feeder&#160;cells&#160;until&#160;ready<br/>to&#160;differentiate&#160;into&#160;neurons.&#160;Cells&#160;were&#160;then&#160;seeded&#160;on&#160;Poly-D-Lysine&#160;(A3890401,&#160;Ther-<br/>moFisher)&#160;and&#160;laminin&#160;(L2020,&#160;Sigma)&#160;coated&#160;96-well&#160;plates&#160;at&#160;a&#160;density&#160;of&#160;128,000&#160;cells/mL.<br/>Cells&#160;were&#160;differentiated&#160;in&#160;Neurobasal&#160;(12348017,&#160;ThermoFisher)&#160;media&#160;supplemented</p>
<p style="position:absolute;top:674px;left:249px;white-space:nowrap" class="ft42">with&#160;2%&#160;B27&#160;(17504044,&#160;ThermoFisher),&#160;1%&#160;Glutamax,&#160;and&#160;1%&#160;antibiotic-antimycotic&#160;for</p>
<p style="position:absolute;top:693px;left:250px;white-space:nowrap" class="ft44">7&#160;days&#160;with&#160;media&#160;changes&#160;every&#160;2&#160;days.&#160;At&#160;the&#160;end&#160;of&#160;the&#160;7&#160;days&#160;the&#160;treatments&#160;were<br/>added&#160;in&#160;the&#160;differentiation&#160;media&#160;for&#160;3&#160;days.</p>
<p style="position:absolute;top:745px;left:250px;white-space:nowrap" class="ft42">2.3.&#160;Molecular&#160;Biology</p>
<p style="position:absolute;top:769px;left:281px;white-space:nowrap" class="ft42">The&#160;ES-FUCCI&#160;construct&#160;containing&#160;a&#160;hygromycin&#160;resistance&#160;cassette&#160;was&#160;subcloned</p>
<p style="position:absolute;top:788px;left:250px;white-space:nowrap" class="ft42">using&#160;XmnI&#160;and&#160;SalI&#160;from&#160;the&#160;plasmid&#160;ES-FUCCI,&#160;which&#160;was&#160;a&#160;gift&#160;from&#160;Pierre&#160;Neveu</p>
<p style="position:absolute;top:806px;left:249px;white-space:nowrap" class="ft42">(Addgene&#160;(Watertown,&#160;MA,&#160;USA)&#160;plasmid&#160;#62451;&#160;<a href="http://n2t.net/addgene:62451">http://n2t.net/addgene:62451&#160;</a>(9&#160;March</p>
<p style="position:absolute;top:825px;left:250px;white-space:nowrap" class="ft44">2022);&#160;RRID:Addgene_62451)&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[70].&#160;</a>The&#160;CAG&#160;pPalmitoyl-mTurquoise2&#160;construct&#160;was&#160;sub-<br/>cloned&#160;from&#160;the&#160;plasmid&#160;pPalmitoyl-mTurquoise2&#160;using&#160;BamHI&#160;and&#160;NotI,&#160;which&#160;was&#160;a&#160;gift<br/>from&#160;Dorus&#160;Gadella&#160;(Addgene&#160;plasmid&#160;#36209;&#160;<a href="http://n2t.net/addgene:36209">http://n2t.net/addgene:36209&#160;</a>(9&#160;March<br/>2022);&#160;RRID:Addgene_36209)&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[72].&#160;</a>All&#160;subcloned&#160;fragments&#160;were&#160;cloned&#160;into&#160;a&#160;pENTR1A</p>
<p style="position:absolute;top:901px;left:249px;white-space:nowrap" class="ft42">plasmid&#160;with&#160;a&#160;CAG&#160;promoter&#160;and&#160;multiple&#160;cloning&#160;site&#160;(MCS)&#160;followed&#160;by&#160;an&#160;SV40&#160;poly(A)</p>
<p style="position:absolute;top:919px;left:250px;white-space:nowrap" class="ft44">using&#160;the&#160;same&#160;sites&#160;as&#160;were&#160;used&#160;in&#160;excising&#160;the&#160;fragment&#160;from&#160;the&#160;parent&#160;plasmid.&#160;In&#160;the<br/>case&#160;of&#160;ES-FUCCI,&#160;the&#160;CAG&#160;promoter,&#160;MCS,&#160;and&#160;poly(A)&#160;were&#160;removed&#160;from&#160;the&#160;pENTR1A</p>
<p style="position:absolute;top:957px;left:249px;white-space:nowrap" class="ft42">plasmid&#160;with&#160;SpeI,&#160;which&#160;was&#160;blunted,&#160;and&#160;SalI&#160;prior&#160;to&#160;ligation&#160;with&#160;the&#160;fragment.&#160;The</p>
<p style="position:absolute;top:976px;left:250px;white-space:nowrap" class="ft44">resulting&#160;pENTR1A&#160;ES-FUCCI&#160;was&#160;then&#160;Gateway&#160;LR&#160;clonased&#160;(11791020,&#160;ThermoFisher)<br/>into&#160;the&#160;hyperactive&#160;piggyBac&#160;transposase-based,&#160;helper-independent,&#160;and&#160;self-inactivating<br/>delivery&#160;system,&#160;pmhyGENIE-3,&#160;a&#160;gift&#160;from&#160;Stefan&#160;Moisyadi&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[73,74].&#160;</a>The&#160;pENTR1A&#160;CAG</p>
<p style="position:absolute;top:1032px;left:249px;white-space:nowrap" class="ft42">pPalmitoyl-mTurquoise2&#160;was&#160;cloned&#160;into&#160;a&#160;pmhyGENIE-3&#160;containing&#160;a&#160;neomycin&#160;resis-</p>
<p style="position:absolute;top:1051px;left:250px;white-space:nowrap" class="ft44">tance&#160;gene&#160;in&#160;the&#160;backbone.&#160;The&#160;resulting&#160;plasmids,&#160;HypG3&#160;Hygro&#160;ES-FUCCI&#160;and&#160;HypG3<br/>NeoBB&#160;CAG&#160;pPalmitoyl-mTurquoise2&#160;were&#160;used&#160;for&#160;subsequent&#160;transfections.</p>
<p style="position:absolute;top:1104px;left:250px;white-space:nowrap" class="ft42">2.4.&#160;Generation&#160;of&#160;Stable&#160;Lines</p>
<p style="position:absolute;top:1127px;left:281px;white-space:nowrap" class="ft42">All&#160;transgenic&#160;cell&#160;lines&#160;were&#160;made&#160;by&#160;transfecting&#160;cells&#160;at&#160;30%&#160;confluence&#160;with&#160;500&#160;ng</p>
<p style="position:absolute;top:1146px;left:250px;white-space:nowrap" class="ft42">of&#160;appropriate&#160;HypG3&#160;plasmid&#160;via&#160;1&#160;µL&#160;of&#160;lipofectamine&#160;3000&#160;(L3000008,&#160;ThermoFisher)</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft50{font-size:9px;font-family:Times;color:#000000;}
	.ft51{font-size:9px;font-family:Times;color:#000000;}
	.ft52{font-size:12px;font-family:Times;color:#000000;}
	.ft53{font-size:13px;font-family:Times;color:#000000;}
	.ft54{font-size:12px;font-family:Times;color:#0775b7;}
	.ft55{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page5-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft50">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:804px;white-space:nowrap" class="ft50">5&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:249px;white-space:nowrap" class="ft52">per&#160;well&#160;of&#160;24-well&#160;plate&#160;containing&#160;500&#160;µL&#160;of&#160;culture&#160;medium.&#160;The&#160;reagent&#160;was&#160;removed</p>
<p style="position:absolute;top:165px;left:250px;white-space:nowrap" class="ft52">after&#160;24&#160;h,&#160;and&#160;fresh&#160;culture&#160;medium&#160;was&#160;added.&#160;Cells&#160;were&#160;allowed&#160;to&#160;recover&#160;for&#160;24&#160;h</p>
<p style="position:absolute;top:184px;left:249px;white-space:nowrap" class="ft55">prior&#160;to&#160;selection&#160;with&#160;1000&#160;µg/mL&#160;G418&#160;or&#160;200&#160;µg/mL&#160;hygromycin.&#160;After&#160;selection,&#160;cells<br/>were&#160;serially&#160;diluted&#160;into&#160;96-well&#160;plates,&#160;and&#160;single&#160;colony&#160;clones&#160;were&#160;expanded.&#160;Clones</p>
<p style="position:absolute;top:222px;left:250px;white-space:nowrap" class="ft52">showing&#160;robust&#160;growth&#160;and&#160;strong&#160;expression&#160;were&#160;chosen&#160;for&#160;subsequent&#160;experiments.</p>
<p style="position:absolute;top:255px;left:250px;white-space:nowrap" class="ft52">2.5.&#160;Growth&#160;and&#160;FUCCI&#160;Assays</p>
<p style="position:absolute;top:279px;left:281px;white-space:nowrap" class="ft52">Both&#160;cell&#160;lines&#160;were&#160;plated&#160;at&#160;5000&#160;cells&#160;per&#160;mL&#160;into&#160;black-walled&#160;flat-bottom&#160;96-well</p>
<p style="position:absolute;top:298px;left:249px;white-space:nowrap" class="ft52">plates&#160;coated&#160;with&#160;1/50&#160;dilution&#160;of&#160;Matrigel.&#160;Images&#160;of&#160;cells&#160;were&#160;taken&#160;on&#160;Day&#160;0&#160;and&#160;every</p>
<p style="position:absolute;top:316px;left:250px;white-space:nowrap" class="ft55">subsequent&#160;day&#160;for&#160;10&#160;days&#160;using&#160;a&#160;Zeiss&#160;Axio1&#160;fitted&#160;with&#160;an&#160;on-stage&#160;incubator&#160;and&#160;kept<br/>at&#160;37&#160;◦C&#160;with&#160;5%&#160;CO2.&#160;A&#160;5×&#160;objective&#160;was&#160;used&#160;along&#160;with&#160;filters&#160;for&#160;YFP,&#160;RFP,&#160;and&#160;CFP,<br/>and&#160;careful&#160;calibration&#160;of&#160;each&#160;plate&#160;was&#160;undertaken&#160;to&#160;ensure&#160;that&#160;the&#160;same&#160;fields&#160;of&#160;view</p>
<p style="position:absolute;top:373px;left:249px;white-space:nowrap" class="ft52">were&#160;imaged&#160;each&#160;day.&#160;Drugs&#160;were&#160;added&#160;after&#160;the&#160;initial&#160;images&#160;were&#160;taken&#160;and&#160;then</p>
<p style="position:absolute;top:392px;left:250px;white-space:nowrap" class="ft55">changed&#160;every&#160;two&#160;days&#160;until&#160;day&#160;6.&#160;For&#160;recovery&#160;experiments,&#160;after&#160;imaging&#160;on&#160;day&#160;6,&#160;all<br/>drugs&#160;were&#160;removed,&#160;and&#160;cells&#160;were&#160;put&#160;into&#160;imaging&#160;media&#160;without&#160;any&#160;added&#160;drugs.</p>
<p style="position:absolute;top:429px;left:249px;white-space:nowrap" class="ft52">This&#160;media&#160;was&#160;changed&#160;every&#160;two&#160;days&#160;until&#160;day&#160;10.&#160;Analysis&#160;of&#160;growth&#160;and&#160;snap&#160;shots&#160;of</p>
<p style="position:absolute;top:448px;left:250px;white-space:nowrap" class="ft55">FUCCI&#160;reporters&#160;over&#160;the&#160;6&#160;days&#160;or&#160;10&#160;days&#160;was&#160;conducted&#160;using&#160;a&#160;CellProfiler&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[75]&#160;</a>pipeline<br/>designed&#160;by&#160;the&#160;Broad.&#160;The&#160;fractional&#160;difference&#160;in&#160;cell&#160;number&#160;was&#160;calculated&#160;by&#160;dividing<br/>the&#160;total&#160;number&#160;of&#160;cells&#160;each&#160;day&#160;by&#160;the&#160;total&#160;number&#160;of&#160;cells&#160;from&#160;day&#160;0.&#160;The&#160;ratio&#160;of&#160;cells<br/>in&#160;each&#160;cell&#160;cycle&#160;stage&#160;every&#160;day&#160;was&#160;determined&#160;by&#160;counting&#160;all&#160;the&#160;nuclei&#160;of&#160;one&#160;color<br/>and&#160;dividing&#160;it&#160;by&#160;the&#160;total&#160;number&#160;of&#160;nuclei.&#160;Blind&#160;quality&#160;control&#160;was&#160;performed&#160;on&#160;all<br/>the&#160;images&#160;to&#160;make&#160;sure&#160;that&#160;any&#160;fibers&#160;or&#160;image&#160;artifacts&#160;were&#160;not&#160;incorrectly&#160;counted&#160;by<br/>the&#160;program.</p>
<p style="position:absolute;top:595px;left:250px;white-space:nowrap" class="ft52">2.6.&#160;Antibody&#160;Staining,&#160;BrdU&#160;and&#160;Senescence&#160;Assays</p>
<p style="position:absolute;top:618px;left:281px;white-space:nowrap" class="ft52">NG108-15&#160;cells&#160;were&#160;plated&#160;on&#160;PEI&#160;and&#160;Matrigel-coated&#160;plates&#160;at&#160;15,000&#160;or&#160;30,000&#160;cells/mL,</p>
<p style="position:absolute;top:637px;left:250px;white-space:nowrap" class="ft55">U87&#160;cells&#160;at&#160;10,000&#160;cells/mL&#160;and&#160;grown&#160;in&#160;imaging&#160;media&#160;for&#160;6&#160;days&#160;with&#160;drug&#160;treatment.<br/>Fresh&#160;media&#160;was&#160;added&#160;every&#160;2&#160;days.&#160;On&#160;day&#160;6,&#160;cells&#160;were&#160;fixed&#160;with&#160;4%&#160;formaldehyde&#160;in<br/>PBS&#160;for&#160;30&#160;min&#160;for&#160;all&#160;antibody&#160;staining,&#160;except&#160;for&#160;BrdU&#160;which&#160;was&#160;fixed&#160;for&#160;15&#160;min,&#160;and&#160;for<br/>the&#160;senescence&#160;assay,&#160;which&#160;was&#160;fixed&#160;for&#160;20&#160;min&#160;using&#160;the&#160;Senescence&#160;Beta-Galactosidase<br/>Staining&#160;Kit&#160;(9860,&#160;CellSignaling,&#160;Danvers,&#160;MA,&#160;USA)&#160;and&#160;thereafter&#160;stained&#160;according&#160;to&#160;man-<br/>ufacturer’s&#160;protocol.&#160;After&#160;fixing,&#160;cells&#160;were&#160;washed&#160;twice&#160;with&#160;PBS&#160;and&#160;were&#160;permeabilized<br/>in&#160;PBS&#160;with&#160;0.3%&#160;Triton-X&#160;for&#160;15&#160;min,&#160;then&#160;washed&#160;again&#160;twice&#160;with&#160;PBS.&#160;The&#160;cells&#160;for&#160;the<br/>BrdU&#160;assay&#160;were&#160;additionally&#160;treated&#160;with&#160;1N&#160;HCl&#160;for&#160;10&#160;min&#160;on&#160;ice,&#160;followed&#160;by&#160;treatment</p>
<p style="position:absolute;top:788px;left:249px;white-space:nowrap" class="ft52">with&#160;2N&#160;HCl&#160;for&#160;50&#160;min&#160;at&#160;room&#160;temp.&#160;Cells&#160;were&#160;then&#160;blocked&#160;with&#160;standard&#160;blocking&#160;buffer</p>
<p style="position:absolute;top:806px;left:250px;white-space:nowrap" class="ft55">comprised&#160;of&#160;TBS&#160;containing&#160;10%&#160;goat&#160;serum,&#160;0.1%&#160;BSA,&#160;and&#160;with&#160;0.05%&#160;Tween&#160;20&#160;or&#160;without<br/>detergent&#160;for&#160;antibodies&#160;against&#160;phosphorylated&#160;proteins&#160;or&#160;monoclonal&#160;antibodies&#160;except<br/>for&#160;Anti-YAP&#160;and&#160;Anti-BrdU&#160;staining,&#160;which&#160;were&#160;followed&#160;according&#160;to&#160;manufacturer’s</p>
<p style="position:absolute;top:863px;left:249px;white-space:nowrap" class="ft55">protocol.&#160;Primary&#160;antibodies&#160;were&#160;added&#160;at&#160;the&#160;following&#160;concentrations:&#160;1:250&#160;anti-S100&#160;beta<br/>(GTX129573,&#160;Genetex,&#160;Irvine,&#160;CA,&#160;USA),&#160;1:500&#160;anti-GFAP&#160;(AB5804,&#160;EMD-Millipore,&#160;Burling-</p>
<p style="position:absolute;top:901px;left:250px;white-space:nowrap" class="ft55">ton,&#160;MA,&#160;USA),&#160;1:300&#160;anti-SOX10&#160;(ab155279,&#160;Abcam,&#160;Cambridge,&#160;UK),&#160;1:100&#160;MAP2&#160;(4542,<br/>CellSignaling),&#160;1:400&#160;anti-cleaved&#160;caspase&#160;3&#160;(9661,&#160;CellSignaling),&#160;1:300&#160;anti-Cx43&#160;(STJ2411,<br/>St.&#160;John’s&#160;Laboratory,&#160;London,&#160;UK),&#160;1:800&#160;anti-p27Kip1&#160;(3698,&#160;CellSignaling),&#160;1:150&#160;anti-BrdU</p>
<p style="position:absolute;top:957px;left:249px;white-space:nowrap" class="ft52">(5292,&#160;CellSignaling),&#160;1:125&#160;anti-LC3B&#160;(2775,&#160;CellSignaling),&#160;8&#160;µg/mL&#160;anti-O4&#160;(MAB1326,&#160;R&amp;D</p>
<p style="position:absolute;top:976px;left:250px;white-space:nowrap" class="ft52">Systems,&#160;Minneapolis,&#160;MN,&#160;USA),&#160;1:1000&#160;anti-TH&#160;(RPCA-TH,&#160;EnCor,&#160;Gainesville,&#160;FL,&#160;USA),</p>
<p style="position:absolute;top:995px;left:249px;white-space:nowrap" class="ft52">1:4000&#160;anti-NSE&#160;(RPCA-NSE,&#160;EnCor),&#160;1:4000&#160;anti-NFM&#160;(RPCA-NF-M,&#160;EnCor),&#160;0.5&#160;µg/mL</p>
<p style="position:absolute;top:1014px;left:250px;white-space:nowrap" class="ft52">anti-TujI&#160;(801202,&#160;BioLegend,&#160;San&#160;Diego,&#160;CA,&#160;USA),&#160;1:400&#160;anti-NF-KB&#160;p65&#160;(8242,&#160;CellSignaling),</p>
<p style="position:absolute;top:1032px;left:249px;white-space:nowrap" class="ft55">1:125&#160;anti-phospho&#160;CREB&#160;(05-807,&#160;EMD-Millipore),&#160;1:250&#160;anti-vimentin&#160;(ab92547,&#160;Abcam),<br/>1:125&#160;anti-YAP&#160;(14074,&#160;CellSignaling).&#160;Antibodies&#160;were&#160;diluted&#160;in&#160;their&#160;respective&#160;blocking</p>
<p style="position:absolute;top:1070px;left:250px;white-space:nowrap" class="ft55">buffer&#160;and&#160;incubated&#160;overnight&#160;at&#160;4&#160;◦C.&#160;The&#160;next&#160;day,&#160;cells&#160;were&#160;washed&#160;with&#160;TBS-T&#160;or&#160;TBS&#160;for<br/>3×&#160;for&#160;5&#160;min&#160;each,&#160;and&#160;secondary&#160;antibody&#160;was&#160;added&#160;as&#160;follows:&#160;1:1000&#160;donkey&#160;anti-mouse<br/>647&#160;(A-31571,&#160;ThermoFisher)&#160;or&#160;1:1000&#160;donkey&#160;anti-rabbit&#160;647&#160;(A-31573,&#160;ThermoFisher).&#160;Each</p>
<p style="position:absolute;top:1127px;left:249px;white-space:nowrap" class="ft52">was&#160;diluted&#160;in&#160;blocking&#160;buffer&#160;along&#160;with&#160;2.5&#160;µg/mL&#160;Hoechst&#160;33342&#160;and&#160;incubated&#160;for&#160;1&#160;h&#160;at</p>
<p style="position:absolute;top:1145px;left:250px;white-space:nowrap" class="ft52">room&#160;temperature.&#160;Cells&#160;were&#160;then&#160;washed&#160;again&#160;with&#160;TBS-T&#160;or&#160;TBS&#160;for&#160;3×&#160;for&#160;5&#160;min&#160;each</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft60{font-size:9px;font-family:Times;color:#000000;}
	.ft61{font-size:9px;font-family:Times;color:#000000;}
	.ft62{font-size:12px;font-family:Times;color:#000000;}
	.ft63{font-size:12px;font-family:Times;color:#0775b7;}
	.ft64{font-size:13px;font-family:Times;color:#000000;}
	.ft65{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page6-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft60">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:804px;white-space:nowrap" class="ft60">6&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:250px;white-space:nowrap" class="ft65">and&#160;covered&#160;with&#160;Gelvatol.&#160;Cells&#160;were&#160;imaged&#160;with&#160;an&#160;EVOS&#160;M7000&#160;system&#160;at&#160;20X,&#160;with&#160;at<br/>least&#160;50%&#160;of&#160;each&#160;well&#160;in&#160;a&#160;96-well&#160;plate&#160;imaged&#160;and&#160;analyzed&#160;using&#160;a&#160;CellProfiler&#160;pipeline<br/>for&#160;measuring&#160;integrated&#160;intensity,&#160;mean&#160;intensity,&#160;or&#160;nuclear&#160;to&#160;cytoplasmic&#160;ratio&#160;of&#160;mean<br/>intensities&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[76]</a>.&#160;LC3B&#160;stained&#160;cells&#160;were&#160;marked&#160;as&#160;positive&#160;for&#160;autophagy&#160;only&#160;if&#160;very&#160;bright</p>
<p style="position:absolute;top:222px;left:249px;white-space:nowrap" class="ft62">puncta&#160;were&#160;detected.</p>
<p style="position:absolute;top:255px;left:250px;white-space:nowrap" class="ft62">2.7.&#160;Dye&#160;Staining&#160;Protocols</p>
<p style="position:absolute;top:279px;left:281px;white-space:nowrap" class="ft62">For&#160;the&#160;Live/Dead&#160;assay,&#160;1&#160;µM&#160;Calcein&#160;Green&#160;AM&#160;and&#160;0.5&#160;µM&#160;ethidium&#160;homodimer-1</p>
<p style="position:absolute;top:298px;left:249px;white-space:nowrap" class="ft62">(L3224,&#160;ThermoFisher)&#160;were&#160;added&#160;to&#160;PBS&#160;along&#160;with&#160;10&#160;µg/mL&#160;of&#160;Hoechst&#160;to&#160;make&#160;the</p>
<p style="position:absolute;top:316px;left:250px;white-space:nowrap" class="ft65">staining&#160;solution.&#160;Half&#160;the&#160;medium&#160;was&#160;removed&#160;from&#160;the&#160;human&#160;neuronal&#160;cells&#160;that&#160;had<br/>been&#160;incubated&#160;with&#160;treatments&#160;for&#160;3&#160;days&#160;and&#160;replaced&#160;with&#160;staining&#160;solution.&#160;This&#160;was<br/>conducted&#160;four&#160;times&#160;to&#160;make&#160;sure&#160;that&#160;cells&#160;did&#160;not&#160;detach.&#160;Cells&#160;were&#160;then&#160;incubated<br/>for&#160;15&#160;min&#160;at&#160;37&#160;◦C&#160;and&#160;imaged.&#160;For&#160;resting&#160;membrane&#160;potential&#160;staining,&#160;DiBAC4(3)&#160;was<br/>used.&#160;U87&#160;cells&#160;were&#160;seeded&#160;at&#160;10,000&#160;cells&#160;per&#160;mL&#160;on&#160;Matrigel-coated&#160;plates&#160;as&#160;described<br/>above.&#160;Cells&#160;were&#160;treated&#160;with&#160;drugs&#160;for&#160;6&#160;days&#160;with&#160;changes&#160;in&#160;media&#160;every&#160;other&#160;day.<br/>On&#160;day&#160;6&#160;the&#160;media&#160;was&#160;removed&#160;and&#160;washed&#160;once&#160;with&#160;dye&#160;buffer&#160;consisting&#160;of&#160;Hank’s<br/>Balanced&#160;Salt&#160;Solution&#160;(HBSS)&#160;with&#160;20&#160;mM&#160;HEPES&#160;at&#160;pH&#160;7.4,&#160;and&#160;then&#160;the&#160;staining&#160;solution,<br/>consisting&#160;of&#160;dye&#160;buffer&#160;with&#160;2&#160;µM&#160;DiBAC4(3),&#160;was&#160;added&#160;to&#160;the&#160;cells&#160;and&#160;allowed&#160;to<br/>incubate&#160;for&#160;30&#160;min&#160;at&#160;37&#160;◦C.&#160;The&#160;staining&#160;solution&#160;was&#160;then&#160;removed,&#160;and&#160;fresh&#160;staining<br/>solution&#160;containing&#160;the&#160;treatments&#160;were&#160;added&#160;to&#160;the&#160;cells.&#160;For&#160;cytoplasmic&#160;calcium&#160;staining,<br/>Fluo-4&#160;AM&#160;was&#160;used.&#160;The&#160;staining&#160;solution&#160;consisted&#160;of&#160;a&#160;dye&#160;buffer&#160;with&#160;4&#160;µM&#160;Fluo-4&#160;AM<br/>and&#160;a&#160;1:1&#160;ratio&#160;of&#160;Pluronic&#160;F-127&#160;(20%&#160;in&#160;DMSO)&#160;and&#160;allowed&#160;to&#160;incubate&#160;for&#160;30&#160;min&#160;at&#160;room<br/>temperature.&#160;The&#160;staining&#160;solution&#160;was&#160;then&#160;removed,&#160;and&#160;fresh&#160;dye&#160;buffer&#160;was&#160;added&#160;and</p>
<p style="position:absolute;top:580px;left:249px;white-space:nowrap" class="ft65">was&#160;allowed&#160;to&#160;incubate&#160;for&#160;20&#160;min&#160;at&#160;37&#160;◦C.&#160;Then&#160;the&#160;dye&#160;buffer&#160;containing&#160;the&#160;treatments<br/>were&#160;added&#160;to&#160;the&#160;cells.&#160;For&#160;cytoplasmic&#160;pH&#160;staining,&#160;pHrodo&#160;Green&#160;was&#160;used.&#160;The&#160;staining</p>
<p style="position:absolute;top:618px;left:250px;white-space:nowrap" class="ft65">solution&#160;consisted&#160;of&#160;a&#160;dye&#160;buffer&#160;with&#160;a&#160;1:1000&#160;dilution&#160;of&#160;the&#160;pHrodo&#160;Green&#160;stock&#160;and<br/>a&#160;1:100&#160;dilution&#160;of&#160;the&#160;PowerLoad&#160;concentrate&#160;(P35373,&#160;ThermoFisher).&#160;The&#160;cells&#160;were<br/>allowed&#160;to&#160;incubate&#160;for&#160;30&#160;min&#160;at&#160;37&#160;◦C.&#160;The&#160;staining&#160;solution&#160;was&#160;removed&#160;and&#160;washed<br/>once&#160;with&#160;dye&#160;buffer,&#160;then&#160;fresh&#160;dye&#160;buffer&#160;containing&#160;the&#160;treatments&#160;were&#160;added&#160;and<br/>allowed&#160;to&#160;incubate&#160;for&#160;5&#160;min&#160;at&#160;37&#160;◦C.&#160;A&#160;calibration&#160;curve&#160;was&#160;made&#160;by&#160;instead&#160;adding&#160;the<br/>components&#160;of&#160;the&#160;intracellular&#160;pH&#160;calibration&#160;kit&#160;(P35379,&#160;ThermoFisher).&#160;For&#160;lysosomal</p>
<p style="position:absolute;top:731px;left:249px;white-space:nowrap" class="ft65">pH&#160;staining,&#160;LysoSensor&#160;Green&#160;was&#160;used.&#160;The&#160;staining&#160;solution&#160;consisted&#160;of&#160;a&#160;dye&#160;buffer<br/>with&#160;a&#160;1&#160;µM&#160;dilution&#160;of&#160;LysoSensor&#160;Green&#160;DND-187&#160;(L7535,&#160;ThermoFisher).&#160;The&#160;cells&#160;were</p>
<p style="position:absolute;top:768px;left:250px;white-space:nowrap" class="ft65">incubated&#160;as&#160;above,&#160;and&#160;the&#160;staining&#160;solution&#160;was&#160;removed&#160;and&#160;replaced&#160;with&#160;a&#160;dye&#160;buffer<br/>containing&#160;2.5&#160;µg/mL&#160;Hoechst&#160;33342&#160;for&#160;10&#160;min.&#160;Hoechst&#160;was&#160;removed,&#160;and&#160;cells&#160;were</p>
<p style="position:absolute;top:806px;left:249px;white-space:nowrap" class="ft65">washed&#160;with&#160;dye&#160;buffer&#160;one&#160;time&#160;before&#160;adding&#160;dye&#160;buffer&#160;containing&#160;the&#160;treatments.&#160;Cells<br/>were&#160;imaged&#160;using&#160;an&#160;EVOS&#160;M7000&#160;system&#160;outfitted&#160;with&#160;a&#160;GFP&#160;filter&#160;cube&#160;for&#160;stains&#160;and&#160;a</p>
<p style="position:absolute;top:844px;left:250px;white-space:nowrap" class="ft62">DAPI&#160;filter&#160;for&#160;Hoechst.&#160;Images&#160;were&#160;then&#160;analyzed&#160;using&#160;a&#160;CellProfiler&#160;pipeline.</p>
<p style="position:absolute;top:877px;left:250px;white-space:nowrap" class="ft62">2.8.&#160;Electrophysiology</p>
<p style="position:absolute;top:901px;left:281px;white-space:nowrap" class="ft62">The&#160;SyncroPatch&#160;384PE&#160;platform&#160;(Nanion&#160;Technologies®,&#160;Munich,&#160;Germany)&#160;was&#160;used</p>
<p style="position:absolute;top:919px;left:250px;white-space:nowrap" class="ft62">to&#160;perform&#160;the&#160;automated&#160;high-resolution&#160;whole-cell&#160;patch-clamp&#160;recordings&#160;in&#160;a&#160;384-well</p>
<p style="position:absolute;top:938px;left:249px;white-space:nowrap" class="ft65">plate&#160;format.&#160;The&#160;experiments&#160;were&#160;performed&#160;within&#160;one&#160;hour&#160;after&#160;the&#160;harvesting&#160;process.<br/>The&#160;assays&#160;were&#160;carried&#160;out&#160;in&#160;medium&#160;resistance&#160;single-hole&#160;chips&#160;(4–5&#160;M</p>
<p style="position:absolute;top:954px;left:741px;white-space:nowrap" class="ft62">Ω).</p>
<p style="position:absolute;top:976px;left:281px;white-space:nowrap" class="ft62">Cells&#160;were&#160;harvested&#160;48–72&#160;h&#160;after&#160;seeding&#160;1–2&#160;×&#160;106&#160;cells&#160;in&#160;T175&#160;culture&#160;flasks&#160;(Fal-</p>
<p style="position:absolute;top:995px;left:250px;white-space:nowrap" class="ft62">con),&#160;then&#160;cells&#160;were&#160;rinsed&#160;with&#160;PBS&#160;(5&#160;mL)&#160;and&#160;treated&#160;with&#160;3&#160;mL&#160;Accutase&#160;(STEMCELL</p>
<p style="position:absolute;top:1014px;left:249px;white-space:nowrap" class="ft62">Technologies,&#160;Vancouver,&#160;BC,&#160;Canada)&#160;for&#160;5&#160;min&#160;at&#160;37&#160;◦C,&#160;re-suspended&#160;in&#160;10&#160;mL&#160;of&#160;serum-</p>
<p style="position:absolute;top:1032px;left:250px;white-space:nowrap" class="ft62">free&#160;media&#160;and&#160;pelleted&#160;at&#160;160&#160;g&#160;for&#160;5&#160;min&#160;at&#160;RT.&#160;The&#160;supernatant&#160;was&#160;discarded,&#160;and&#160;cells</p>
<p style="position:absolute;top:1051px;left:249px;white-space:nowrap" class="ft62">were&#160;re-suspended&#160;in&#160;serum-free&#160;DMEM&#160;medium&#160;with&#160;high&#160;glucose&#160;and&#160;no&#160;phenol&#160;red</p>
<p style="position:absolute;top:1070px;left:250px;white-space:nowrap" class="ft62">or&#160;sodium&#160;pyruvate&#160;(31053-028,&#160;ThermoFisher),&#160;and&#160;physiological&#160;extracellular&#160;solution</p>
<p style="position:absolute;top:1089px;left:249px;white-space:nowrap" class="ft62">(pECS)&#160;50%&#160;(v:v).&#160;The&#160;cells&#160;were&#160;kept&#160;until&#160;the&#160;moment&#160;of&#160;the&#160;experiment&#160;in&#160;a&#160;temperature-</p>
<p style="position:absolute;top:1108px;left:250px;white-space:nowrap" class="ft62">controlled&#160;dedicated&#160;reservoir&#160;at&#160;10&#160;◦C&#160;and&#160;shaken&#160;at&#160;200&#160;rpm&#160;as&#160;described&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[77].</a></p>
<p style="position:absolute;top:1127px;left:281px;white-space:nowrap" class="ft62">The&#160;chip&#160;was&#160;primed&#160;with&#160;the&#160;following&#160;solutions&#160;(in&#160;mM),&#160;physiological&#160;extracellular</p>
<p style="position:absolute;top:1145px;left:250px;white-space:nowrap" class="ft62">solution&#160;(pECS)&#160;10&#160;HEPES,&#160;140&#160;NaCl,&#160;5&#160;Glucose,&#160;4&#160;KCl,&#160;2&#160;CaCl2,&#160;1&#160;MgCl2,&#160;295–305&#160;mOsm</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft70{font-size:9px;font-family:Times;color:#000000;}
	.ft71{font-size:9px;font-family:Times;color:#000000;}
	.ft72{font-size:12px;font-family:Times;color:#000000;}
	.ft73{font-size:13px;font-family:Times;color:#000000;}
	.ft74{font-size:12px;font-family:Times;color:#000000;}
	.ft75{font-size:12px;font-family:Times;color:#0775b7;}
	.ft76{font-size:11px;font-family:Times;color:#000000;}
	.ft77{font-size:11px;font-family:Times;color:#000000;}
	.ft78{font-size:11px;font-family:Times;color:#0775b7;}
	.ft79{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
	.ft710{font-size:12px;line-height:19px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page7-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft70">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:804px;white-space:nowrap" class="ft70">7&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:249px;white-space:nowrap" class="ft79">pH&#160;7.4&#160;(NaOH).&#160;Internal&#160;recording&#160;solution&#160;(in&#160;mM)&#160;20&#160;EGTA,&#160;50&#160;KCl,&#160;10&#160;NaCl,&#160;60&#160;KF,<br/>10&#160;HEPES&#160;at&#160;pH&#160;7.2,&#160;and&#160;285&#160;mOsm.&#160;15&#160;µL&#160;of&#160;the&#160;cell&#160;suspension&#160;(50%&#160;v/v&#160;pECS/Medium</p>
<p style="position:absolute;top:184px;left:250px;white-space:nowrap" class="ft72">no&#160;serum)&#160;was&#160;added&#160;to&#160;each&#160;well&#160;to&#160;a&#160;final&#160;density&#160;of&#160;50–80&#160;K&#160;cells/mL.&#160;Cell&#160;capture&#160;was</p>
<p style="position:absolute;top:203px;left:249px;white-space:nowrap" class="ft72">promoted&#160;by&#160;holding&#160;negative&#160;pressure&#160;of&#160;−100&#160;mbar&#160;for&#160;20&#160;s.&#160;After&#160;the&#160;capture,&#160;successive</p>
<p style="position:absolute;top:222px;left:250px;white-space:nowrap" class="ft79">hyperpolarization&#160;steps&#160;from&#160;−30&#160;mV&#160;to&#160;−100&#160;mV&#160;were&#160;applied&#160;to&#160;foster&#160;the&#160;electrical<br/>seal&#160;formation.&#160;The&#160;seal&#160;was&#160;enhanced&#160;by&#160;transient&#160;addition&#160;of&#160;a&#160;high&#160;Ca2+&#160;extracellular<br/>solution&#160;(80&#160;mM&#160;NaCl,&#160;3&#160;mM&#160;KCl,&#160;10&#160;mM&#160;CaCl2,&#160;10&#160;mM&#160;MgCl2,&#160;10&#160;mM&#160;HEPES&#160;at&#160;pH<br/>7.4&#160;and&#160;298&#160;mOsm.&#160;High&#160;Ca2+&#160;solution&#160;was&#160;washed&#160;out&#160;by&#160;successive&#160;external&#160;exchanges<br/>replacing&#160;half&#160;of&#160;the&#160;volume&#160;of&#160;the&#160;well&#160;each&#160;time&#160;with&#160;the&#160;external&#160;recording&#160;solution.&#160;All<br/>recording&#160;solutions&#160;were&#160;prepared&#160;with&#160;ultrapure&#160;MilliQ&#160;water&#160;(18&#160;M</p>
<p style="position:absolute;top:313px;left:708px;white-space:nowrap" class="ft72">Ω-cm).</p>
<p style="position:absolute;top:335px;left:281px;white-space:nowrap" class="ft72">After&#160;the&#160;formation&#160;of&#160;the&#160;Giga-seal,&#160;a&#160;−250&#160;mbar&#160;pressure&#160;was&#160;applied&#160;to&#160;break&#160;the</p>
<p style="position:absolute;top:354px;left:250px;white-space:nowrap" class="ft79">membrane&#160;patch.&#160;Once&#160;in&#160;whole-cell&#160;configuration,&#160;the&#160;resting&#160;membrane&#160;potential&#160;was<br/>monitored&#160;in&#160;current-clamp&#160;configuration&#160;“I&#160;=&#160;0”,&#160;the&#160;values&#160;shown&#160;correspond&#160;to&#160;the&#160;aver-<br/>age&#160;of&#160;seven&#160;1&#160;s&#160;length&#160;sweeps,&#160;with&#160;an&#160;inter-sweep&#160;time&#160;of&#160;10&#160;s.&#160;Cells&#160;were&#160;also&#160;recorded&#160;in</p>
<p style="position:absolute;top:410px;left:249px;white-space:nowrap" class="ft72">voltage-clamp&#160;mode&#160;to&#160;characterize&#160;the&#160;different&#160;voltage-dependent&#160;conductance&#160;present</p>
<p style="position:absolute;top:429px;left:250px;white-space:nowrap" class="ft72">in&#160;NG108-15&#160;cells.</p>
<p style="position:absolute;top:448px;left:281px;white-space:nowrap" class="ft72">Compounds&#160;in&#160;DMSO&#160;stocks&#160;were&#160;dissolved&#160;1–2&#160;h&#160;before&#160;the&#160;experiment&#160;in&#160;pECS&#160;to&#160;a</p>
<p style="position:absolute;top:467px;left:250px;white-space:nowrap" class="ft72">final&#160;concentration&#160;of&#160;2×&#160;the&#160;working&#160;concentration.&#160;40&#160;µL&#160;of&#160;the&#160;2×&#160;compound&#160;solution</p>
<p style="position:absolute;top:485px;left:249px;white-space:nowrap" class="ft72">was&#160;applied&#160;to&#160;each&#160;well&#160;to&#160;a&#160;final&#160;volume&#160;of&#160;80&#160;µL.&#160;Before&#160;the&#160;compound&#160;addition,&#160;a&#160;5&#160;min</p>
<p style="position:absolute;top:504px;left:250px;white-space:nowrap" class="ft72">recording&#160;in&#160;0.2%&#160;DMSO&#160;was&#160;used&#160;as&#160;a&#160;baseline&#160;to&#160;normalize&#160;the&#160;changes&#160;in&#160;the&#160;Vmem.</p>
<p style="position:absolute;top:538px;left:250px;white-space:nowrap" class="ft710"><b>3.&#160;Results<br/></b>3.1.&#160;Bioelectric&#160;Compounds&#160;and&#160;Combinations&#160;with&#160;the&#160;Proton&#160;Pump&#160;Inhibitor,&#160;Pantoprazole&#160;Stop</p>
<p style="position:absolute;top:574px;left:249px;white-space:nowrap" class="ft72">Proliferation&#160;of&#160;NG108-15&#160;Cells&#160;in&#160;High&#160;Serum&#160;and&#160;Shift&#160;Proportion&#160;of&#160;Cells&#160;in&#160;Late&#160;S,&#160;G2,&#160;M</p>
<p style="position:absolute;top:597px;left:281px;white-space:nowrap" class="ft72">NG108-15&#160;cells&#160;containing&#160;the&#160;FUCCI&#160;cell&#160;cycle&#160;reporter&#160;and&#160;palmitoyl-mTurquoise2</p>
<p style="position:absolute;top:616px;left:250px;white-space:nowrap" class="ft79">fluorescent&#160;membrane&#160;tag&#160;were&#160;incubated&#160;with&#160;compounds&#160;by&#160;themselves&#160;and&#160;in&#160;combina-<br/>tion,&#160;in&#160;media&#160;containing&#160;high&#160;serum&#160;(known&#160;to&#160;be&#160;prohibitive&#160;for&#160;differentiation&#160;in&#160;this<br/>line),&#160;to&#160;test&#160;for&#160;their&#160;ability&#160;to&#160;suppress&#160;proliferation&#160;(Supplementary&#160;Figures&#160;S1&#160;and&#160;S2).</p>
<p style="position:absolute;top:672px;left:249px;white-space:nowrap" class="ft79">The&#160;compounds&#160;chosen&#160;for&#160;testing&#160;included&#160;compounds&#160;known&#160;to&#160;alter&#160;the&#160;membrane<br/>potential&#160;of&#160;the&#160;cell&#160;by&#160;decreasing&#160;proton&#160;efflux&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[78],&#160;</a>increasing&#160;potassium&#160;efflux&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[79],&#160;</a>or</p>
<p style="position:absolute;top:710px;left:250px;white-space:nowrap" class="ft72">decreasing&#160;sodium&#160;influx&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[80],&#160;</a>and&#160;others&#160;chosen&#160;for&#160;their&#160;potential&#160;combinatorial&#160;effects</p>
<p style="position:absolute;top:729px;left:249px;white-space:nowrap" class="ft72">with&#160;the&#160;ion&#160;modulating&#160;drugs,&#160;including&#160;cell&#160;cycle-specific&#160;disruptors&#160;and&#160;autophagy-</p>
<p style="position:absolute;top:748px;left:250px;white-space:nowrap" class="ft79">inducing&#160;compounds&#160;(Supplementary&#160;Table&#160;S1).&#160;In&#160;addition,&#160;we&#160;also&#160;tested&#160;the&#160;most<br/>clinically&#160;relevant&#160;compound&#160;currently&#160;used&#160;in&#160;the&#160;standard&#160;treatment&#160;of&#160;glioblastoma,<br/>temozolomide&#160;(TMZ).&#160;A&#160;subset&#160;of&#160;the&#160;compounds&#160;exhibiting&#160;the&#160;highest&#160;efficacy&#160;in&#160;the<br/>initial&#160;screens&#160;are&#160;shown&#160;in&#160;Table&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#7">1.</a></p>
<p style="position:absolute;top:839px;left:249px;white-space:nowrap" class="ft76"><b>Table&#160;1.</b></p>
<p style="position:absolute;top:839px;left:300px;white-space:nowrap" class="ft77">Compounds&#160;with&#160;Highest&#160;Efficacy&#160;on&#160;Proliferation&#160;and&#160;their&#160;Mechanism&#160;of&#160;Action&#160;and&#160;Status.</p>
<p style="position:absolute;top:870px;left:313px;white-space:nowrap" class="ft76"><b>Compound</b></p>
<p style="position:absolute;top:870px;left:508px;white-space:nowrap" class="ft76"><b>Mechanism</b></p>
<p style="position:absolute;top:870px;left:722px;white-space:nowrap" class="ft76"><b>Status</b></p>
<p style="position:absolute;top:902px;left:329px;white-space:nowrap" class="ft77">cAMP</p>
<p style="position:absolute;top:894px;left:475px;white-space:nowrap" class="ft77">Activates&#160;variety&#160;of&#160;ion</p>
<p style="position:absolute;top:910px;left:458px;white-space:nowrap" class="ft77">channels&#160;and&#160;protein&#160;kinases</p>
<p style="position:absolute;top:894px;left:656px;white-space:nowrap" class="ft77">Cannot&#160;be&#160;used&#160;clinically&#160;for</p>
<p style="position:absolute;top:910px;left:712px;white-space:nowrap" class="ft77">GBM&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[16]</a></p>
<p style="position:absolute;top:935px;left:314px;white-space:nowrap" class="ft77">Rapamycin</p>
<p style="position:absolute;top:927px;left:462px;white-space:nowrap" class="ft77">Inhibits&#160;mTOR&#160;and&#160;induces</p>
<p style="position:absolute;top:943px;left:512px;white-space:nowrap" class="ft77">autophagy</p>
<p style="position:absolute;top:935px;left:655px;white-space:nowrap" class="ft77">Clinical&#160;trial&#160;for&#160;GBM&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[81,82]</a></p>
<p style="position:absolute;top:968px;left:316px;white-space:nowrap" class="ft77">Retigabine</p>
<p style="position:absolute;top:960px;left:491px;white-space:nowrap" class="ft77">Opens&#160;KCNQ2-5/</p>
<p style="position:absolute;top:976px;left:488px;white-space:nowrap" class="ft77">Kv7.2–7.5&#160;channels</p>
<p style="position:absolute;top:968px;left:660px;white-space:nowrap" class="ft77">Novel&#160;application&#160;for&#160;GBM</p>
<p style="position:absolute;top:992px;left:318px;white-space:nowrap" class="ft77">Minoxidil</p>
<p style="position:absolute;top:992px;left:473px;white-space:nowrap" class="ft77">Opens&#160;K(ATP)&#160;channels</p>
<p style="position:absolute;top:992px;left:660px;white-space:nowrap" class="ft77">Novel&#160;application&#160;for&#160;GBM</p>
<p style="position:absolute;top:1017px;left:325px;white-space:nowrap" class="ft77">NS1643</p>
<p style="position:absolute;top:1009px;left:458px;white-space:nowrap" class="ft77">Opens&#160;hERG&#160;and&#160;potentiates</p>
<p style="position:absolute;top:1025px;left:487px;white-space:nowrap" class="ft77">KCNQ2-4&#160;channels</p>
<p style="position:absolute;top:1017px;left:660px;white-space:nowrap" class="ft77">Novel&#160;application&#160;for&#160;GBM</p>
<p style="position:absolute;top:1050px;left:311px;white-space:nowrap" class="ft77">Lamotrigine</p>
<p style="position:absolute;top:1042px;left:459px;white-space:nowrap" class="ft77">Blocks&#160;voltage&#160;gated&#160;sodium</p>
<p style="position:absolute;top:1058px;left:518px;white-space:nowrap" class="ft77">channels</p>
<p style="position:absolute;top:1050px;left:660px;white-space:nowrap" class="ft77">Novel&#160;application&#160;for&#160;GBM</p>
<p style="position:absolute;top:1075px;left:308px;white-space:nowrap" class="ft77">Pantoprazole</p>
<p style="position:absolute;top:1075px;left:477px;white-space:nowrap" class="ft77">Proton&#160;pump&#160;inhibitor</p>
<p style="position:absolute;top:1075px;left:670px;white-space:nowrap" class="ft77">Published&#160;for&#160;GBM&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[83]</a></p>
<p style="position:absolute;top:1099px;left:304px;white-space:nowrap" class="ft77">Temozolomide</p>
<p style="position:absolute;top:1116px;left:328px;white-space:nowrap" class="ft77">(TMZ)</p>
<p style="position:absolute;top:1091px;left:461px;white-space:nowrap" class="ft77">Alkylates/methylates&#160;DNA,</p>
<p style="position:absolute;top:1107px;left:463px;white-space:nowrap" class="ft77">induces&#160;autophagy,&#160;used&#160;in</p>
<p style="position:absolute;top:1124px;left:498px;white-space:nowrap" class="ft77">GBM&#160;treatment</p>
<p style="position:absolute;top:1099px;left:659px;white-space:nowrap" class="ft77">Current&#160;standard&#160;treatment</p>
<p style="position:absolute;top:1116px;left:702px;white-space:nowrap" class="ft77">for&#160;GBM&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[84]</a></p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft80{font-size:9px;font-family:Times;color:#000000;}
	.ft81{font-size:9px;font-family:Times;color:#000000;}
	.ft82{font-size:12px;font-family:Times;color:#000000;}
	.ft83{font-size:12px;font-family:Times;color:#0775b7;}
	.ft84{font-size:9px;font-family:Times;color:#000000;}
	.ft85{font-size:10px;font-family:Times;color:#000000;}
	.ft86{font-size:10px;font-family:Times;color:#000000;}
	.ft87{font-size:10px;font-family:Times;color:#000000;}
	.ft88{font-size:11px;font-family:Times;color:#000000;}
	.ft89{font-size:11px;font-family:Times;color:#000000;}
	.ft810{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
	.ft811{font-size:10px;line-height:16px;font-family:Times;color:#000000;}
	.ft812{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page8-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft80">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:804px;white-space:nowrap" class="ft80">8&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:281px;white-space:nowrap" class="ft82">Many&#160;of&#160;the&#160;tested&#160;compounds&#160;showed&#160;a&#160;significant&#160;difference&#160;in&#160;proliferation&#160;from&#160;the</p>
<p style="position:absolute;top:165px;left:250px;white-space:nowrap" class="ft810">controls&#160;after&#160;6&#160;days&#160;of&#160;treatment,&#160;but&#160;only&#160;a&#160;few&#160;of&#160;these&#160;were&#160;explored&#160;in&#160;more&#160;detail&#160;due&#160;to<br/>their&#160;novelty&#160;(Table&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#7">1).&#160;</a>Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#8">1&#160;</a>shows&#160;the&#160;best&#160;of&#160;the&#160;individual&#160;and&#160;combination&#160;treatments<br/>chosen&#160;when&#160;compared&#160;to&#160;control&#160;at&#160;day&#160;6.&#160;Note&#160;we&#160;did&#160;not&#160;include&#160;chlorzoxazone<br/>combinations&#160;in&#160;the&#160;NG108-15&#160;analysis&#160;shown,&#160;due&#160;to&#160;its&#160;poor&#160;performance&#160;in&#160;the&#160;U87&#160;cell<br/>line.&#160;The&#160;stacked&#160;bar&#160;graphs&#160;show&#160;the&#160;ratio&#160;of&#160;cells&#160;in&#160;different&#160;parts&#160;of&#160;the&#160;cell&#160;cycle&#160;as<br/>indicated&#160;by&#160;the&#160;FUCCI&#160;cell&#160;cycle&#160;reporter.</p>
<p style="position:absolute;top:-151px;left:63px;white-space:nowrap" class="ft84"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:-151px;left:778px;white-space:nowrap" class="ft80">8 of&#160;38&#160;</p>
<p style="position:absolute;top:-142px;left:63px;white-space:nowrap" class="ft80">&#160;</p>
<p style="position:absolute;top:944px;left:63px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:-92px;left:251px;white-space:nowrap" class="ft811"><b>Table 1.&#160;</b>Compounds with&#160;Highest Efficacy&#160;on Proliferation and their Mechanism of&#160;Action and&#160;<br/>Status.&#160;</p>
<p style="position:absolute;top:-48px;left:108px;white-space:nowrap" class="ft85"><b>Compound Mechanism&#160;</b></p>
<p style="position:absolute;top:-48px;left:674px;white-space:nowrap" class="ft85"><b>Status&#160;</b></p>
<p style="position:absolute;top:-29px;left:124px;white-space:nowrap" class="ft86">cAMP&#160;</p>
<p style="position:absolute;top:-29px;left:243px;white-space:nowrap" class="ft86">Activates&#160;variety&#160;of ion&#160;channels and protein&#160;kinases&#160;</p>
<p style="position:absolute;top:-29px;left:581px;white-space:nowrap" class="ft86">Cannot be used&#160;clinically&#160;for&#160;GBM [16]&#160;</p>
<p style="position:absolute;top:-12px;left:109px;white-space:nowrap" class="ft86">Rapamycin&#160;</p>
<p style="position:absolute;top:-12px;left:282px;white-space:nowrap" class="ft86">Inhibits mTOR and induces autophagy&#160;</p>
<p style="position:absolute;top:-12px;left:610px;white-space:nowrap" class="ft86">Clinical trial for GBM [81,82]&#160;</p>
<p style="position:absolute;top:5px;left:111px;white-space:nowrap" class="ft86">Retigabine&#160;</p>
<p style="position:absolute;top:5px;left:289px;white-space:nowrap" class="ft86">Opens KCNQ2-5/Kv7.2–7.5&#160;channels Novel&#160;</p>
<p style="position:absolute;top:5px;left:653px;white-space:nowrap" class="ft86">application for GBM&#160;</p>
<p style="position:absolute;top:22px;left:113px;white-space:nowrap" class="ft86">Minoxidil Opens&#160;</p>
<p style="position:absolute;top:22px;left:365px;white-space:nowrap" class="ft86">K(ATP)&#160;</p>
<p style="position:absolute;top:22px;left:413px;white-space:nowrap" class="ft86">channels&#160;</p>
<p style="position:absolute;top:22px;left:614px;white-space:nowrap" class="ft86">Novel&#160;application for GBM&#160;</p>
<p style="position:absolute;top:40px;left:120px;white-space:nowrap" class="ft86">NS1643&#160;</p>
<p style="position:absolute;top:40px;left:254px;white-space:nowrap" class="ft86">Opens hERG and potentiates&#160;KCNQ2-4 channels&#160;</p>
<p style="position:absolute;top:40px;left:614px;white-space:nowrap" class="ft86">Novel application for GBM&#160;</p>
<p style="position:absolute;top:57px;left:106px;white-space:nowrap" class="ft86">Lamotrigine&#160;</p>
<p style="position:absolute;top:57px;left:285px;white-space:nowrap" class="ft86">Blocks&#160;voltage&#160;gated sodium&#160;channels&#160;</p>
<p style="position:absolute;top:57px;left:614px;white-space:nowrap" class="ft86">Novel&#160;application for GBM&#160;</p>
<p style="position:absolute;top:74px;left:104px;white-space:nowrap" class="ft86">Pantoprazole&#160;</p>
<p style="position:absolute;top:74px;left:329px;white-space:nowrap" class="ft86">Proton pump inhibitor&#160;</p>
<p style="position:absolute;top:74px;left:625px;white-space:nowrap" class="ft86">Published for&#160;GBM [83]&#160;</p>
<p style="position:absolute;top:92px;left:99px;white-space:nowrap" class="ft86">Temozolomide&#160;</p>
<p style="position:absolute;top:109px;left:123px;white-space:nowrap" class="ft86">(TMZ)&#160;</p>
<p style="position:absolute;top:92px;left:234px;white-space:nowrap" class="ft86">Alkylates/methylates DNA,&#160;induces autophagy,&#160;used&#160;in&#160;</p>
<p style="position:absolute;top:109px;left:350px;white-space:nowrap" class="ft86">GBM treatment&#160;</p>
<p style="position:absolute;top:101px;left:574px;white-space:nowrap" class="ft86">Current standard treatment for GBM [84]&#160;</p>
<p style="position:absolute;top:145px;left:282px;white-space:nowrap" class="ft82">Many&#160;of the tested compounds showed&#160;a significant difference&#160;in&#160;proliferation from&#160;</p>
<p style="position:absolute;top:164px;left:251px;white-space:nowrap" class="ft810">the controls&#160;after 6 days of&#160;treatment, but only&#160;a few of&#160;these were explored&#160;in more detail&#160;<br/>due to&#160;their novelt<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#7">y (T</a>able&#160;1)<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#8">. Fi</a>gure&#160;1&#160;shows the best&#160;of the individual&#160;and combination&#160;<br/>treatments chosen when compared to control&#160;at&#160;day 6. Note&#160;we&#160;did&#160;not include&#160;chlorzox-<br/>azone&#160;combinations&#160;in the&#160;NG108-15&#160;analysis&#160;shown,&#160;due to&#160;its poor performance in the&#160;<br/>U87 cell&#160;line.&#160;The stacked&#160;bar&#160;graphs&#160;show the ratio&#160;of cells&#160;in&#160;different&#160;parts&#160;of&#160;the&#160;cell&#160;<br/>cycle&#160;as indicated by the&#160;FUCCI cell cycle reporter.&#160;</p>
<p style="position:absolute;top:636px;left:790px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:586px;left:68px;white-space:nowrap" class="ft84"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:586px;left:783px;white-space:nowrap" class="ft80">9 of&#160;38&#160;</p>
<p style="position:absolute;top:595px;left:68px;white-space:nowrap" class="ft80">&#160;</p>
<p style="position:absolute;top:1682px;left:68px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:966px;left:804px;white-space:nowrap" class="ft82">&#160;</p>
<p style="position:absolute;top:988px;left:256px;white-space:nowrap" class="ft811"><b>Figure 1.&#160;</b>NG108-15 Proliferation is Significantly&#160;Lowered with Bioelectric Treatment and Show&#160;<br/>Changes&#160;in Cell Cycle Ratios.&#160;(<b>A</b>) Fold&#160;change to&#160;start&#160;cell counts (cells at&#160;day 6/cells at&#160;day 0) after&#160;<br/>6 days&#160;of treatment. Low values indicate less&#160;cell&#160;growth.&#160;Colors indicate&#160;treatments followed up&#160;<br/>for further analysis, and hues represent&#160;concentrations and&#160;combinations. Red shaded&#160;treatments&#160;<br/>correspond to positive&#160;controls&#160;that cannot&#160;be&#160;used&#160;clinically. Only treatments with&#160;significant&#160;val-<br/>ues&#160;are shown&#160;out of 33 treatments&#160;compared to DMSO control.&#160;****:&#160;<i>q</i>&#160;&lt;&#160;0.0001&#160;***:&#160;<i>q</i>&#160;&lt;&#160;0.001, **:&#160;<i>q</i>&#160;&lt;&#160;<br/>0.01, *:&#160;<i>q</i>&#160;&lt;&#160;0.05&#160;(one-way ANOVA with&#160;FDR post&#160;hoc analysis&#160;<i>n &gt;&#160;</i>3&#160;biological replicates). (<b>B</b>) FUCCI&#160;<br/>cell&#160;cycle&#160;data&#160;at day&#160;6.&#160;Increased&#160;red&#160;and orange&#160;fractions&#160;indicate&#160;cell&#160;cycle arrest&#160;at&#160;G1&#160;or G1&#160;to&#160;S&#160;<br/>transition.&#160;</p>
<p style="position:absolute;top:1156px;left:287px;white-space:nowrap" class="ft82">The proliferation of&#160;NG108-15&#160;cells&#160;treated with NS1643,&#160;a&#160;human Ether-a-go-go&#160;</p>
<p style="position:absolute;top:1174px;left:256px;white-space:nowrap" class="ft810">(hERG)&#160;activator&#160;and KCNQ2,&#160;KCNQ4,&#160;KCNQ2/3&#160;potassium&#160;channel&#160;potentiator&#160;[85]&#160;at&#160;<br/>20&#160;µM&#160;and&#160;50&#160;µM&#160;alone were&#160;able&#160;to&#160;lower proliferation significantly&#160;about&#160;1.6-&#160;and&#160;2.4-&#160;<br/>fold decrease&#160;compared to&#160;control respectively (Figure 1A). In fact,&#160;NS1643&#160;at&#160;20&#160;µM was&#160;<br/>very effective&#160;at&#160;lowing&#160;cell&#160;proliferation when&#160;combined with&#160;pantoprazole,&#160;a proton&#160;<br/>pump inhibitor known to&#160;inhibit the&#160;expression&#160;of&#160;the vacuolar-ATPases&#160;(V-ATPases)&#160;in&#160;<br/>human&#160;gastric adenocarcinoma&#160;[86]; this combination worked&#160;significantly better than&#160;<br/>pantoprazole&#160;or NS1643&#160;alone, with&#160;a fold&#160;decrease&#160;of&#160;7.2.&#160;NS1643 at&#160;50&#160;µM&#160;also&#160;signifi-<br/>cantly&#160;lowered proliferation when&#160;combined&#160;with&#160;rapamycin&#160;(autophagy&#160;inducer),&#160;with&#160;<br/>a&#160;4.6-fold&#160;decrease&#160;and&#160;worked better&#160;than rapamycin&#160;or&#160;NS1643&#160;alone.&#160;Retigabine, which&#160;<br/>opens the voltage-activated potassium&#160;channels&#160;KCNQ2-5&#160;[87,88], significantly lowered&#160;<br/>cell proliferation by about&#160;1.6-fold&#160;decrease compared&#160;to&#160;control, but&#160;its combination with&#160;<br/>rapamycin&#160;or&#160;pantoprazole&#160;worked&#160;better than&#160;any&#160;of&#160;those&#160;compounds alone with&#160;a&#160;2.9&#160;<br/>and&#160;6-fold&#160;decrease&#160;as&#160;compared&#160;to&#160;control,&#160;respectively.&#160;Pantoprazole&#160;at&#160;100&#160;µM, how-<br/>ever, was the&#160;most effective compound&#160;alone&#160;(5.1-fold&#160;decrease)&#160;or&#160;in&#160;combination with&#160;<br/>lamotrigine&#160;which blocks&#160;voltage-gated&#160;sodium channels [89], or&#160;NS1643, or rapamycin,&#160;<br/>with&#160;fold&#160;decreases compared to&#160;control&#160;of&#160;6.8,&#160;7.2,&#160;and 9.3&#160;respectively. These three com-<br/>binations worked better than one of&#160;our&#160;positive controls, which consisted&#160;of&#160;a&#160;treatment&#160;<br/>of&#160;1&#160;mM&#160;cAMP&#160;with&#160;rapamycin&#160;at&#160;200&#160;nM&#160;in&#160;full&#160;serum media&#160;(5.1-fold decrease).&#160;This&#160;<br/>same positive control&#160;treatment is&#160;known to&#160;terminally differentiate these&#160;cells&#160;when in&#160;<br/>low serum [90], which we&#160;confirmed.&#160;However, the use of cAMP is&#160;problematic&#160;clinically&#160;<br/>due to&#160;its many off-target&#160;effects&#160;[91].&#160;The cell&#160;cycle&#160;data&#160;in Figure&#160;1B&#160;reveal that&#160;panto-<br/>prazole&#160;increases the proportion of cells&#160;in early&#160;S and that&#160;its combinations&#160;can&#160;also&#160;in-<br/>crease the proportion of cells&#160;in G1.&#160;Rapamycin treatment alone&#160;increased the proportion&#160;<br/>of&#160;cells&#160;in&#160;G1, while&#160;NS1643&#160;treatment did not seem to&#160;affect the cell&#160;cycle proportion. It&#160;<br/>is&#160;worthwhile to note that these compounds were&#160;effective on&#160;NG108-15 cells, while&#160;</p>
<p style="position:absolute;top:991px;left:250px;white-space:nowrap" class="ft88"><b>Figure&#160;1.</b></p>
<p style="position:absolute;top:991px;left:306px;white-space:nowrap" class="ft89">NG108-15&#160;Proliferation&#160;is&#160;Significantly&#160;Lowered&#160;with&#160;Bioelectric&#160;Treatment&#160;and&#160;Show&#160;Changes</p>
<p style="position:absolute;top:1010px;left:250px;white-space:nowrap" class="ft812">in&#160;Cell&#160;Cycle&#160;Ratios.&#160;(<b>A</b>)&#160;Fold&#160;change&#160;to&#160;start&#160;cell&#160;counts&#160;(cells&#160;at&#160;day&#160;6/cells&#160;at&#160;day&#160;0)&#160;after&#160;6&#160;days&#160;of<br/>treatment.&#160;Low&#160;values&#160;indicate&#160;less&#160;cell&#160;growth.&#160;Colors&#160;indicate&#160;treatments&#160;followed&#160;up&#160;for&#160;further<br/>analysis,&#160;and&#160;hues&#160;represent&#160;concentrations&#160;and&#160;combinations.&#160;Red&#160;shaded&#160;treatments&#160;correspond&#160;to</p>
<p style="position:absolute;top:1068px;left:249px;white-space:nowrap" class="ft89">positive&#160;controls&#160;that&#160;cannot&#160;be&#160;used&#160;clinically.&#160;Only&#160;treatments&#160;with&#160;significant&#160;values&#160;are&#160;shown&#160;out&#160;of</p>
<p style="position:absolute;top:1087px;left:250px;white-space:nowrap" class="ft89">33&#160;treatments&#160;compared&#160;to&#160;DMSO&#160;control.&#160;****:&#160;q&#160;&lt;&#160;0.0001&#160;***:&#160;q&#160;&lt;&#160;0.001,&#160;**:&#160;q&#160;&lt;&#160;0.01,&#160;*:&#160;q&#160;&lt;&#160;0.05&#160;(one-way</p>
<p style="position:absolute;top:1106px;left:249px;white-space:nowrap" class="ft89">ANOVA&#160;with&#160;FDR&#160;post&#160;hoc&#160;analysis&#160;n&#160;&gt;&#160;3&#160;biological&#160;replicates).&#160;(<b>B</b>)&#160;FUCCI&#160;cell&#160;cycle&#160;data&#160;at&#160;day&#160;6.</p>
<p style="position:absolute;top:1125px;left:250px;white-space:nowrap" class="ft89">Increased&#160;red&#160;and&#160;orange&#160;fractions&#160;indicate&#160;cell&#160;cycle&#160;arrest&#160;at&#160;G1&#160;or&#160;G1&#160;to&#160;S&#160;transition.</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft90{font-size:9px;font-family:Times;color:#000000;}
	.ft91{font-size:9px;font-family:Times;color:#000000;}
	.ft92{font-size:12px;font-family:Times;color:#000000;}
	.ft93{font-size:12px;font-family:Times;color:#0775b7;}
	.ft94{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page9-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft90">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:804px;white-space:nowrap" class="ft90">9&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:281px;white-space:nowrap" class="ft92">The&#160;proliferation&#160;of&#160;NG108-15&#160;cells&#160;treated&#160;with&#160;NS1643,&#160;a&#160;human&#160;Ether-a-go-go</p>
<p style="position:absolute;top:165px;left:249px;white-space:nowrap" class="ft92">(hERG)&#160;activator&#160;and&#160;KCNQ2,&#160;KCNQ4,&#160;KCNQ2/3&#160;potassium&#160;channel&#160;potentiator&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[85]&#160;</a>at</p>
<p style="position:absolute;top:184px;left:250px;white-space:nowrap" class="ft94">20&#160;µM&#160;and&#160;50&#160;µM&#160;alone&#160;were&#160;able&#160;to&#160;lower&#160;proliferation&#160;significantly&#160;about&#160;1.6-&#160;and&#160;2.4-<br/>fold&#160;decrease&#160;compared&#160;to&#160;control&#160;respectively&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#8">1A).&#160;</a>In&#160;fact,&#160;NS1643&#160;at&#160;20&#160;µM&#160;was</p>
<p style="position:absolute;top:222px;left:249px;white-space:nowrap" class="ft94">very&#160;effective&#160;at&#160;lowing&#160;cell&#160;proliferation&#160;when&#160;combined&#160;with&#160;pantoprazole,&#160;a&#160;proton<br/>pump&#160;inhibitor&#160;known&#160;to&#160;inhibit&#160;the&#160;expression&#160;of&#160;the&#160;vacuolar-ATPases&#160;(V-ATPases)&#160;in</p>
<p style="position:absolute;top:260px;left:250px;white-space:nowrap" class="ft92">human&#160;gastric&#160;adenocarcinoma&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[86];&#160;</a>this&#160;combination&#160;worked&#160;significantly&#160;better&#160;than</p>
<p style="position:absolute;top:278px;left:249px;white-space:nowrap" class="ft92">pantoprazole&#160;or&#160;NS1643&#160;alone,&#160;with&#160;a&#160;fold&#160;decrease&#160;of&#160;7.2.&#160;NS1643&#160;at&#160;50&#160;µM&#160;also&#160;significantly</p>
<p style="position:absolute;top:297px;left:250px;white-space:nowrap" class="ft94">lowered&#160;proliferation&#160;when&#160;combined&#160;with&#160;rapamycin&#160;(autophagy&#160;inducer),&#160;with&#160;a&#160;4.6-fold<br/>decrease&#160;and&#160;worked&#160;better&#160;than&#160;rapamycin&#160;or&#160;NS1643&#160;alone.&#160;Retigabine,&#160;which&#160;opens<br/>the&#160;voltage-activated&#160;potassium&#160;channels&#160;KCNQ2-5&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[87,88],&#160;</a>significantly&#160;lowered&#160;cell</p>
<p style="position:absolute;top:354px;left:249px;white-space:nowrap" class="ft92">proliferation&#160;by&#160;about&#160;1.6-fold&#160;decrease&#160;compared&#160;to&#160;control,&#160;but&#160;its&#160;combination&#160;with</p>
<p style="position:absolute;top:372px;left:250px;white-space:nowrap" class="ft94">rapamycin&#160;or&#160;pantoprazole&#160;worked&#160;better&#160;than&#160;any&#160;of&#160;those&#160;compounds&#160;alone&#160;with&#160;a&#160;2.9&#160;and<br/>6-fold&#160;decrease&#160;as&#160;compared&#160;to&#160;control,&#160;respectively.&#160;Pantoprazole&#160;at&#160;100&#160;µM,&#160;however,&#160;was<br/>the&#160;most&#160;effective&#160;compound&#160;alone&#160;(5.1-fold&#160;decrease)&#160;or&#160;in&#160;combination&#160;with&#160;lamotrigine</p>
<p style="position:absolute;top:429px;left:249px;white-space:nowrap" class="ft92">which&#160;blocks&#160;voltage-gated&#160;sodium&#160;channels&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[89],&#160;</a>or&#160;NS1643,&#160;or&#160;rapamycin,&#160;with&#160;fold</p>
<p style="position:absolute;top:448px;left:250px;white-space:nowrap" class="ft92">decreases&#160;compared&#160;to&#160;control&#160;of&#160;6.8,&#160;7.2,&#160;and&#160;9.3&#160;respectively.&#160;These&#160;three&#160;combinations</p>
<p style="position:absolute;top:467px;left:249px;white-space:nowrap" class="ft92">worked&#160;better&#160;than&#160;one&#160;of&#160;our&#160;positive&#160;controls,&#160;which&#160;consisted&#160;of&#160;a&#160;treatment&#160;of&#160;1&#160;mM</p>
<p style="position:absolute;top:485px;left:250px;white-space:nowrap" class="ft94">cAMP&#160;with&#160;rapamycin&#160;at&#160;200&#160;nM&#160;in&#160;full&#160;serum&#160;media&#160;(5.1-fold&#160;decrease).&#160;This&#160;same&#160;positive<br/>control&#160;treatment&#160;is&#160;known&#160;to&#160;terminally&#160;differentiate&#160;these&#160;cells&#160;when&#160;in&#160;low&#160;serum&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[90],</a></p>
<p style="position:absolute;top:523px;left:249px;white-space:nowrap" class="ft92">which&#160;we&#160;confirmed.&#160;However,&#160;the&#160;use&#160;of&#160;cAMP&#160;is&#160;problematic&#160;clinically&#160;due&#160;to&#160;its&#160;many</p>
<p style="position:absolute;top:542px;left:250px;white-space:nowrap" class="ft94">off-target&#160;effects&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[91].&#160;</a>The&#160;cell&#160;cycle&#160;data&#160;in&#160;Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#8">1B&#160;</a>reveal&#160;that&#160;pantoprazole&#160;increases<br/>the&#160;proportion&#160;of&#160;cells&#160;in&#160;early&#160;S&#160;and&#160;that&#160;its&#160;combinations&#160;can&#160;also&#160;increase&#160;the&#160;proportion<br/>of&#160;cells&#160;in&#160;G1.&#160;Rapamycin&#160;treatment&#160;alone&#160;increased&#160;the&#160;proportion&#160;of&#160;cells&#160;in&#160;G1,&#160;while<br/>NS1643&#160;treatment&#160;did&#160;not&#160;seem&#160;to&#160;affect&#160;the&#160;cell&#160;cycle&#160;proportion.&#160;It&#160;is&#160;worthwhile&#160;to&#160;note<br/>that&#160;these&#160;compounds&#160;were&#160;effective&#160;on&#160;NG108-15&#160;cells,&#160;while&#160;temozolomide&#160;(TMZ),&#160;the<br/>standard&#160;glioblastoma&#160;treatment,&#160;was&#160;not,&#160;a&#160;situation&#160;found&#160;in&#160;many&#160;GBM&#160;cases&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[92].</a></p>
<p style="position:absolute;top:655px;left:281px;white-space:nowrap" class="ft92">The&#160;combination&#160;of&#160;pantoprazole&#160;with&#160;lamotrigine&#160;at&#160;100&#160;µM,&#160;NS1643&#160;at&#160;20&#160;µM,&#160;and</p>
<p style="position:absolute;top:674px;left:250px;white-space:nowrap" class="ft94">rapamycin&#160;at&#160;100&#160;nM&#160;were&#160;the&#160;only&#160;combinations&#160;that&#160;showed&#160;significantly&#160;more&#160;efficacy<br/>than&#160;pantoprazole&#160;alone&#160;at&#160;reducing&#160;cell&#160;proliferation&#160;after&#160;6&#160;days&#160;of&#160;treatment,&#160;with&#160;the<br/>combination&#160;with&#160;rapamycin&#160;showing&#160;the&#160;most&#160;significant&#160;difference&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#10">2A).&#160;</a>The<br/>reductions&#160;in&#160;cell&#160;number&#160;for&#160;these&#160;combinations&#160;compared&#160;to&#160;control&#160;were&#160;85%,&#160;86%,&#160;and<br/>90%,&#160;respectively.&#160;The&#160;proportion&#160;of&#160;cells&#160;in&#160;G1&#160;and&#160;early&#160;S&#160;only&#160;slightly&#160;increased&#160;for</p>
<p style="position:absolute;top:768px;left:249px;white-space:nowrap" class="ft94">pantoprazole&#160;treatments&#160;in&#160;combination&#160;with&#160;lamotrigine&#160;and&#160;NS1643,&#160;but&#160;the&#160;combination<br/>with&#160;rapamycin&#160;did&#160;increase&#160;the&#160;G1&#160;proportion&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#10">2B).&#160;</a>Taken&#160;together,&#160;these&#160;data</p>
<p style="position:absolute;top:806px;left:250px;white-space:nowrap" class="ft94">reveal&#160;that&#160;several&#160;FDA&#160;approved&#160;drugs&#160;for&#160;human&#160;use&#160;can&#160;be&#160;repurposed&#160;in&#160;combination<br/>and&#160;can&#160;significantly&#160;reduce&#160;cancer&#160;cell&#160;proliferation.</p>
<p style="position:absolute;top:858px;left:250px;white-space:nowrap" class="ft92">3.2.&#160;Bioelectric&#160;Drugs&#160;in&#160;Combination&#160;with&#160;Pantoprazole&#160;Have&#160;a&#160;Lasting&#160;Effect&#160;on&#160;NG108-15</p>
<p style="position:absolute;top:874px;left:249px;white-space:nowrap" class="ft92">Proliferation&#160;after&#160;Treatment&#160;Is&#160;Removed</p>
<p style="position:absolute;top:897px;left:281px;white-space:nowrap" class="ft92">To&#160;understand&#160;whether&#160;our&#160;treatments&#160;have&#160;a&#160;persistent&#160;effect&#160;on&#160;the&#160;cells&#160;(stop&#160;the</p>
<p style="position:absolute;top:916px;left:249px;white-space:nowrap" class="ft92">proliferation&#160;of&#160;the&#160;cells&#160;even&#160;after&#160;the&#160;drugs&#160;were&#160;withdrawn),&#160;we&#160;performed&#160;a&#160;recovery</p>
<p style="position:absolute;top:935px;left:250px;white-space:nowrap" class="ft94">test&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#10">3).&#160;</a>Cells&#160;were&#160;treated&#160;with&#160;the&#160;drugs&#160;for&#160;6&#160;days,&#160;and&#160;then&#160;the&#160;drugs&#160;were<br/>removed&#160;(demarcated&#160;by&#160;the&#160;dashed&#160;line),&#160;after&#160;which&#160;the&#160;cells&#160;were&#160;cultured&#160;in&#160;media<br/>containing&#160;no&#160;drugs&#160;for&#160;another&#160;4&#160;days.</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft100{font-size:9px;font-family:Times;color:#000000;}
	.ft101{font-size:9px;font-family:Times;color:#000000;}
	.ft102{font-size:7px;font-family:Times;color:#000000;}
	.ft103{font-size:7px;font-family:Times;color:#000000;}
	.ft104{font-size:7px;font-family:Times;color:#000000;}
	.ft105{font-size:10px;font-family:Times;color:#000000;}
	.ft106{font-size:8px;font-family:Times;color:#000000;}
	.ft107{font-size:8px;font-family:Times;color:#000000;}
	.ft108{font-size:8px;font-family:Times;color:#000000;}
	.ft109{font-size:10px;font-family:Times;color:#000000;}
	.ft1010{font-size:11px;font-family:Times;color:#000000;}
	.ft1011{font-size:11px;font-family:Times;color:#000000;}
	.ft1012{font-size:9px;font-family:Times;color:#000000;}
	.ft1013{font-size:10px;line-height:15px;font-family:Times;color:#000000;}
	.ft1014{font-size:8px;line-height:13px;font-family:Times;color:#000000;}
	.ft1015{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
	.ft1016{font-size:10px;line-height:15px;font-family:Times;color:#000000;}
	.ft1017{font-size:9px;line-height:14px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page10-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft100">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft100">10&#160;of&#160;36</p>
<p style="position:absolute;top:-104px;left:228px;white-space:nowrap" class="ft102"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:-104px;left:819px;white-space:nowrap" class="ft104">10 of&#160;38&#160;</p>
<p style="position:absolute;top:-96px;left:228px;white-space:nowrap" class="ft104">&#160;</p>
<p style="position:absolute;top:809px;left:228px;white-space:nowrap" class="ft105">&#160;</p>
<p style="position:absolute;top:-54px;left:385px;white-space:nowrap" class="ft1013">temozolomide (TMZ),&#160;the&#160;standard glioblastoma&#160;treatment, was not, a&#160;situation found in&#160;<br/>many GBM cases [92].&#160;</p>
<p style="position:absolute;top:-23px;left:410px;white-space:nowrap" class="ft105">The combination of pantoprazole&#160;with lamotrigine&#160;at&#160;100 µM,&#160;NS1643 at&#160;20 µM,&#160;and&#160;</p>
<p style="position:absolute;top:-8px;left:385px;white-space:nowrap" class="ft1013">rapamycin&#160;at&#160;100 nM were&#160;the only combinations&#160;that&#160;showed significantly more&#160;efficacy&#160;<br/>than pantoprazole&#160;alone&#160;at&#160;reducing&#160;cell&#160;proliferation after&#160;6 days&#160;of&#160;treatment,&#160;with the&#160;<br/>combination&#160;with&#160;rapamycin showing the most&#160;significant difference (Figure 2A). The re-<br/>ductions&#160;in&#160;cell&#160;number&#160;for these&#160;combinations&#160;compared&#160;to&#160;control were&#160;85%,&#160;86%,&#160;and&#160;<br/>90%, respectively. The proportion of cells in G1&#160;and&#160;early S only&#160;slightly&#160;increased&#160;for&#160;<br/>pantoprazole&#160;treatments in combination with lamotrigine and NS1643, but the&#160;combina-<br/>tion with rapamycin did increase the&#160;G1&#160;proportion&#160;(Figure 2B). Taken together, these&#160;<br/>data&#160;reveal&#160;that&#160;several FDA approved&#160;drugs for human use&#160;can&#160;be repurposed&#160;in&#160;combi-<br/>nation&#160;and can significantly reduce cancer cell proliferation.&#160;</p>
<p style="position:absolute;top:358px;left:827px;white-space:nowrap" class="ft106">&#160;</p>
<p style="position:absolute;top:613px;left:836px;white-space:nowrap" class="ft105">&#160;</p>
<p style="position:absolute;top:632px;left:385px;white-space:nowrap" class="ft1014"><b>Figure 2.&#160;</b>Combinations of&#160;Pantoprazole with&#160;Bioelectric Compounds Significantly&#160;Decrease&#160;Prolif-<br/>eration Compared to Pantoprazole Alone and Show Changes&#160;in Cell Cycle Ratio.&#160;(<b>A</b>) Percent reduc-<br/>tion&#160;in&#160;cells compared to&#160;control after&#160;6&#160;days of&#160;treatment. Treatments that&#160;were significantly more&#160;<br/>effective&#160;than pantoprazole alone are&#160;shown out of&#160;32&#160;treatments. Statistical&#160;analysis was conducted&#160;<br/>on the log2 of the fold&#160;change in cell number to control on&#160;day 6.&#160;***:<i>&#160;q&#160;</i>&lt; 0.001, *:<i>&#160;q&#160;</i>&lt; 0.05 (one-way&#160;<br/>ANOVA with&#160;FDR post hoc<i>&#160;</i>analysis&#160;<i>n &gt;&#160;</i>3&#160;biological&#160;replicates). (<b>B</b>)&#160;FUCCI cell cycle&#160;data&#160;at day&#160;6.&#160;<br/>Increased&#160;red&#160;and orange&#160;fractions indicate&#160;cell&#160;cycle&#160;arrest at&#160;G1&#160;or G1&#160;to&#160;S&#160;transition.&#160;</p>
<p style="position:absolute;top:746px;left:228px;white-space:nowrap" class="ft105">&#160;</p>
<p style="position:absolute;top:746px;left:401px;white-space:nowrap" class="ft109"><i>&#160;</i></p>
<p style="position:absolute;top:632px;left:250px;white-space:nowrap" class="ft1010"><b>Figure&#160;2.</b></p>
<p style="position:absolute;top:632px;left:309px;white-space:nowrap" class="ft1011">Combinations&#160;of&#160;Pantoprazole&#160;with&#160;Bioelectric&#160;Compounds&#160;Significantly&#160;Decrease&#160;Pro-</p>
<p style="position:absolute;top:651px;left:250px;white-space:nowrap" class="ft1015">liferation&#160;Compared&#160;to&#160;Pantoprazole&#160;Alone&#160;and&#160;Show&#160;Changes&#160;in&#160;Cell&#160;Cycle&#160;Ratio.&#160;(<b>A</b>)&#160;Percent<br/>reduction&#160;in&#160;cells&#160;compared&#160;to&#160;control&#160;after&#160;6&#160;days&#160;of&#160;treatment.&#160;Treatments&#160;that&#160;were&#160;significantly<br/>more&#160;effective&#160;than&#160;pantoprazole&#160;alone&#160;are&#160;shown&#160;out&#160;of&#160;32&#160;treatments.&#160;Statistical&#160;analysis&#160;was<br/>conducted&#160;on&#160;the&#160;log2&#160;of&#160;the&#160;fold&#160;change&#160;in&#160;cell&#160;number&#160;to&#160;control&#160;on&#160;day&#160;6.&#160;***:&#160;q&#160;&lt;&#160;0.001,&#160;*:&#160;q&#160;&lt;&#160;0.05</p>
<p style="position:absolute;top:728px;left:249px;white-space:nowrap" class="ft1011">(one-way&#160;ANOVA&#160;with&#160;FDR&#160;post&#160;hoc&#160;analysis&#160;n&#160;&gt;&#160;3&#160;biological&#160;replicates).&#160;(<b>B</b>)&#160;FUCCI&#160;cell&#160;cycle&#160;data</p>
<p style="position:absolute;top:748px;left:250px;white-space:nowrap" class="ft1011">at&#160;day&#160;6.&#160;Increased&#160;red&#160;and&#160;orange&#160;fractions&#160;indicate&#160;cell&#160;cycle&#160;arrest&#160;at&#160;G1&#160;or&#160;G1&#160;to&#160;S&#160;transition.</p>
<p style="position:absolute;top:601px;left:212px;white-space:nowrap" class="ft102"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:601px;left:817px;white-space:nowrap" class="ft104">11 of&#160;38&#160;</p>
<p style="position:absolute;top:609px;left:212px;white-space:nowrap" class="ft104">&#160;</p>
<p style="position:absolute;top:1537px;left:212px;white-space:nowrap" class="ft105">&#160;</p>
<p style="position:absolute;top:652px;left:372px;white-space:nowrap" class="ft1016"><i>3.2.&#160;Bioelectric Drugs in Combination with&#160;Pantoprazole&#160;Have&#160;a Lasting Effect on NG108-15&#160;<br/>Proliferation after Treatment&#160;Is Removed&#160;</i></p>
<p style="position:absolute;top:687px;left:398px;white-space:nowrap" class="ft105">To understand whether&#160;our treatments&#160;have&#160;a&#160;persistent effect on the cells (stop&#160;the&#160;</p>
<p style="position:absolute;top:703px;left:372px;white-space:nowrap" class="ft1013">proliferation&#160;of the cells even after the drugs were withdrawn), we&#160;performed&#160;a recovery&#160;<br/>test (Figure&#160;3). Cells were treated with the drugs for&#160;6&#160;days, and then the drugs were re-<br/>moved (demarcated by&#160;the&#160;dashed&#160;line),&#160;after&#160;which&#160;the cells&#160;were&#160;cultured&#160;in media&#160;con-<br/>taining no&#160;drugs&#160;for&#160;another 4&#160;days.&#160;</p>
<p style="position:absolute;top:1021px;left:819px;white-space:nowrap" class="ft105">&#160;</p>
<p style="position:absolute;top:1041px;left:372px;white-space:nowrap" class="ft1017"><b>Figure 3.&#160;</b>Recovery Test&#160;of&#160;Bioelectric Treatments in&#160;Combination with&#160;Pantoprazole&#160;in NG108-15&#160;<br/>FUCCI Cells.&#160;The log2&#160;of the fold change&#160;in&#160;cell&#160;counts to Day&#160;0 were recorded for 10&#160;days. Dotted&#160;<br/>line marks the day on which drug treatment&#160;was removed&#160;and replaced&#160;with control media (<i>n &gt;&#160;</i>3&#160;<br/>biological&#160;replicates).&#160;Combination drug&#160;treatment slopes from Day 6 to Day 10 were compared to&#160;<br/>pantoprazole alone,&#160;significance&#160;is&#160;shown with&#160;grey&#160;stars&#160;next&#160;to the&#160;corresponding&#160;line&#160;**:&#160;<i>p&#160;</i>&lt;<i>&#160;</i>0.01,&#160;<br/>*:&#160;<i>p &lt;&#160;</i>0.05&#160;(one-way ANOVA&#160;with Dunnett post hoc<i>&#160;</i>analysis&#160;<i>n &gt;&#160;</i>3 biological replicates).&#160;</p>
<p style="position:absolute;top:1141px;left:398px;white-space:nowrap" class="ft105">Although the three combinations with&#160;pantoprazole&#160;showed&#160;significantly&#160;less&#160;cell&#160;</p>
<p style="position:absolute;top:1157px;left:372px;white-space:nowrap" class="ft1013">proliferation&#160;after&#160;6&#160;days of treatment, the cells&#160;showed&#160;some&#160;recovery&#160;after treatment was&#160;<br/>removed&#160;(Figure 3). The slope of each&#160;combinatorial&#160;treatment from day 6 to&#160;day&#160;10&#160;was&#160;<br/>compared to&#160;pantoprazole&#160;alone. Pantoprazole&#160;in combination with&#160;retigabine&#160;was the&#160;<br/>only&#160;treatment combination that&#160;was significantly&#160;different, except the positive control,&#160;<br/>which&#160;showed&#160;no&#160;recovery,&#160;indicative&#160;of cells&#160;that&#160;had&#160;terminally&#160;differentiated. One&#160;<br/>thing to note&#160;was that&#160;the treatment of pantoprazole&#160;with retigabine,&#160;although&#160;not signif-<br/>icantly&#160;different&#160;than&#160;pantoprazole&#160;at&#160;day&#160;6,&#160;did&#160;show fewer cells than&#160;the treatment of&#160;<br/>pantoprazole&#160;with lamotrigine&#160;at&#160;day&#160;10. Therefore,&#160;we decided to&#160;perform&#160;further anal-<br/>ysis on this combination.&#160;</p>
<p style="position:absolute;top:1313px;left:372px;white-space:nowrap" class="ft1016"><i>3.3. Treatments That&#160;Were Successful in Reducing&#160;the Proliferative Capacity of&#160;NG108-15 Cells&#160;<br/>Were&#160;Also&#160;Largely Successful&#160;in U87 Cells&#160;</i></p>
<p style="position:absolute;top:1349px;left:398px;white-space:nowrap" class="ft105">Many of the&#160;significant treatments in&#160;NG108-15&#160;cells were&#160;also&#160;significantly effective&#160;</p>
<p style="position:absolute;top:1364px;left:372px;white-space:nowrap" class="ft1013">in&#160;human glioblastoma&#160;U87&#160;cells&#160;compared&#160;to&#160;the&#160;control&#160;after&#160;6&#160;days (Figure 4). Notably,&#160;<br/>NS1643&#160;at&#160;50&#160;µM significantly decreased cell&#160;proliferation&#160;as&#160;compared&#160;to&#160;control by&#160;1.7-<br/>fold&#160;but&#160;was&#160;much more&#160;effective&#160;when&#160;combined&#160;with&#160;pantoprazole,&#160;rapamycin, or&#160;te-<br/>mozolomide (TMZ)&#160;with&#160;a&#160;fold&#160;decrease&#160;to&#160;control&#160;of&#160;3.3, 2.7,&#160;and 2.5 respectively.&#160;Panto-<br/>prazole also worked&#160;very well in&#160;this&#160;cell line with&#160;a&#160;significant&#160;percentage reduction in&#160;<br/>cells to&#160;control of&#160;54%&#160;and showed very&#160;significant&#160;differences&#160;in cell&#160;proliferation&#160;as com-<br/>pared to control&#160;when combined with&#160;rapamycin, retigabine,&#160;NS1643,&#160;lamotrigine,&#160;and&#160;<br/>TMZ&#160;with&#160;a&#160;percent&#160;reduction in&#160;cells&#160;of&#160;60%,&#160;72%,&#160;72%,&#160;61%,&#160;and&#160;61%&#160;respectively&#160;(Fig-<br/>ure 5A). TMZ was very effective at reducing&#160;cell number as compared to&#160;control in U87&#160;</p>
<p style="position:absolute;top:1046px;left:250px;white-space:nowrap" class="ft1010"><b>Figure&#160;3.</b></p>
<p style="position:absolute;top:1046px;left:308px;white-space:nowrap" class="ft1011">Recovery&#160;Test&#160;of&#160;Bioelectric&#160;Treatments&#160;in&#160;Combination&#160;with&#160;Pantoprazole&#160;in&#160;NG108-15</p>
<p style="position:absolute;top:1065px;left:250px;white-space:nowrap" class="ft1015">FUCCI&#160;Cells.&#160;The&#160;log2&#160;of&#160;the&#160;fold&#160;change&#160;in&#160;cell&#160;counts&#160;to&#160;Day&#160;0&#160;were&#160;recorded&#160;for&#160;10&#160;days.&#160;Dotted<br/>line&#160;marks&#160;the&#160;day&#160;on&#160;which&#160;drug&#160;treatment&#160;was&#160;removed&#160;and&#160;replaced&#160;with&#160;control&#160;media&#160;(n&#160;&gt;&#160;3<br/>biological&#160;replicates).&#160;Combination&#160;drug&#160;treatment&#160;slopes&#160;from&#160;Day&#160;6&#160;to&#160;Day&#160;10&#160;were&#160;compared&#160;to</p>
<p style="position:absolute;top:1123px;left:249px;white-space:nowrap" class="ft1011">pantoprazole&#160;alone,&#160;significance&#160;is&#160;shown&#160;with&#160;grey&#160;stars&#160;next&#160;to&#160;the&#160;corresponding&#160;line&#160;**:&#160;p&#160;&lt;&#160;0.01,</p>
<p style="position:absolute;top:1142px;left:249px;white-space:nowrap" class="ft1011">*:&#160;p&#160;&lt;&#160;0.05&#160;(one-way&#160;ANOVA&#160;with&#160;Dunnett&#160;post&#160;hoc&#160;analysis&#160;n&#160;&gt;&#160;3&#160;biological&#160;replicates).</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft110{font-size:9px;font-family:Times;color:#000000;}
	.ft111{font-size:9px;font-family:Times;color:#000000;}
	.ft112{font-size:12px;font-family:Times;color:#000000;}
	.ft113{font-size:12px;font-family:Times;color:#0775b7;}
	.ft114{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page11-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft110">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft110">11&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:281px;white-space:nowrap" class="ft112">Although&#160;the&#160;three&#160;combinations&#160;with&#160;pantoprazole&#160;showed&#160;significantly&#160;less&#160;cell</p>
<p style="position:absolute;top:165px;left:249px;white-space:nowrap" class="ft114">proliferation&#160;after&#160;6&#160;days&#160;of&#160;treatment,&#160;the&#160;cells&#160;showed&#160;some&#160;recovery&#160;after&#160;treatment<br/>was&#160;removed&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#10">3).&#160;</a>The&#160;slope&#160;of&#160;each&#160;combinatorial&#160;treatment&#160;from&#160;day&#160;6&#160;to&#160;day<br/>10&#160;was&#160;compared&#160;to&#160;pantoprazole&#160;alone.&#160;Pantoprazole&#160;in&#160;combination&#160;with&#160;retigabine<br/>was&#160;the&#160;only&#160;treatment&#160;combination&#160;that&#160;was&#160;significantly&#160;different,&#160;except&#160;the&#160;positive</p>
<p style="position:absolute;top:241px;left:250px;white-space:nowrap" class="ft114">control,&#160;which&#160;showed&#160;no&#160;recovery,&#160;indicative&#160;of&#160;cells&#160;that&#160;had&#160;terminally&#160;differentiated.<br/>One&#160;thing&#160;to&#160;note&#160;was&#160;that&#160;the&#160;treatment&#160;of&#160;pantoprazole&#160;with&#160;retigabine,&#160;although&#160;not<br/>significantly&#160;different&#160;than&#160;pantoprazole&#160;at&#160;day&#160;6,&#160;did&#160;show&#160;fewer&#160;cells&#160;than&#160;the&#160;treatment<br/>of&#160;pantoprazole&#160;with&#160;lamotrigine&#160;at&#160;day&#160;10.&#160;Therefore,&#160;we&#160;decided&#160;to&#160;perform&#160;further<br/>analysis&#160;on&#160;this&#160;combination.</p>
<p style="position:absolute;top:350px;left:250px;white-space:nowrap" class="ft112">3.3.&#160;Treatments&#160;That&#160;Were&#160;Successful&#160;in&#160;Reducing&#160;the&#160;Proliferative&#160;Capacity&#160;of&#160;NG108-15&#160;Cells</p>
<p style="position:absolute;top:365px;left:249px;white-space:nowrap" class="ft112">Were&#160;Also&#160;Largely&#160;Successful&#160;in&#160;U87&#160;Cells</p>
<p style="position:absolute;top:389px;left:281px;white-space:nowrap" class="ft112">Many&#160;of&#160;the&#160;significant&#160;treatments&#160;in&#160;NG108-15&#160;cells&#160;were&#160;also&#160;significantly&#160;effective</p>
<p style="position:absolute;top:407px;left:250px;white-space:nowrap" class="ft114">in&#160;human&#160;glioblastoma&#160;U87&#160;cells&#160;compared&#160;to&#160;the&#160;control&#160;after&#160;6&#160;days&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#12">4).&#160;</a>Notably,<br/>NS1643&#160;at&#160;50&#160;µM&#160;significantly&#160;decreased&#160;cell&#160;proliferation&#160;as&#160;compared&#160;to&#160;control&#160;by</p>
<p style="position:absolute;top:445px;left:249px;white-space:nowrap" class="ft112">1.7-fold&#160;but&#160;was&#160;much&#160;more&#160;effective&#160;when&#160;combined&#160;with&#160;pantoprazole,&#160;rapamycin,</p>
<p style="position:absolute;top:464px;left:250px;white-space:nowrap" class="ft114">or&#160;temozolomide&#160;(TMZ)&#160;with&#160;a&#160;fold&#160;decrease&#160;to&#160;control&#160;of&#160;3.3,&#160;2.7,&#160;and&#160;2.5&#160;respectively.<br/>Pantoprazole&#160;also&#160;worked&#160;very&#160;well&#160;in&#160;this&#160;cell&#160;line&#160;with&#160;a&#160;significant&#160;percentage&#160;reduction<br/>in&#160;cells&#160;to&#160;control&#160;of&#160;54%&#160;and&#160;showed&#160;very&#160;significant&#160;differences&#160;in&#160;cell&#160;proliferation&#160;as<br/>compared&#160;to&#160;control&#160;when&#160;combined&#160;with&#160;rapamycin,&#160;retigabine,&#160;NS1643,&#160;lamotrigine,<br/>and&#160;TMZ&#160;with&#160;a&#160;percent&#160;reduction&#160;in&#160;cells&#160;of&#160;60%,&#160;72%,&#160;72%,&#160;61%,&#160;and&#160;61%&#160;respectively</p>
<p style="position:absolute;top:558px;left:249px;white-space:nowrap" class="ft112">(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#13">5A).&#160;</a>TMZ&#160;was&#160;very&#160;effective&#160;at&#160;reducing&#160;cell&#160;number&#160;as&#160;compared&#160;to&#160;control&#160;in</p>
<p style="position:absolute;top:577px;left:250px;white-space:nowrap" class="ft114">U87&#160;cells&#160;(43%&#160;decrease),&#160;but&#160;combinations&#160;with&#160;rapamycin,&#160;pantoprazole,&#160;or&#160;NS1643<br/>significantly&#160;increased&#160;the&#160;effectiveness&#160;up&#160;to&#160;55%,&#160;61%,&#160;61%&#160;reduction&#160;in&#160;cells&#160;compared<br/>to&#160;control&#160;respectively&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#13">5A).&#160;</a>The&#160;cell&#160;cycle&#160;data&#160;in&#160;Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#12">4B&#160;</a>shows&#160;that&#160;some&#160;of<br/>the&#160;most&#160;effective&#160;combinations&#160;increased&#160;the&#160;G1&#160;and&#160;early&#160;S&#160;proportion&#160;of&#160;cells&#160;but&#160;not<br/>all.&#160;Pantoprazole&#160;showed&#160;its&#160;characteristic&#160;increase&#160;in&#160;the&#160;early&#160;S&#160;proportion&#160;of&#160;cells&#160;and<br/>rapamycin,&#160;an&#160;increase&#160;in&#160;the&#160;G1&#160;proportion&#160;as&#160;seen&#160;in&#160;the&#160;NG108-15&#160;cells.&#160;TMZ&#160;and&#160;NS1643<br/>treatment&#160;did&#160;not&#160;show&#160;a&#160;large&#160;change&#160;in&#160;the&#160;proportion&#160;of&#160;cells&#160;in&#160;each&#160;stage&#160;of&#160;the&#160;cell<br/>cycle&#160;as&#160;compared&#160;to&#160;control.&#160;TMZ&#160;in&#160;combination&#160;with&#160;rapamycin&#160;increased&#160;the&#160;proportion<br/>of&#160;cells&#160;in&#160;G1,&#160;and&#160;combination&#160;with&#160;NS1643&#160;increased&#160;the&#160;proportion&#160;of&#160;cells&#160;in&#160;early&#160;S<br/>as&#160;compared&#160;to&#160;TMZ&#160;alone&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#13">5B).&#160;</a>Pantoprazole&#160;combinations&#160;consistently&#160;showed<br/>a&#160;larger&#160;proportion&#160;of&#160;cells&#160;in&#160;early&#160;S&#160;as&#160;compared&#160;to&#160;TMZ&#160;alone,&#160;with&#160;a&#160;complimentary<br/>decrease&#160;of&#160;cells&#160;in&#160;late&#160;S,&#160;G2,&#160;and&#160;M&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#13">5B).</a></p>
<p style="position:absolute;top:803px;left:281px;white-space:nowrap" class="ft112">Unfortunately,&#160;we&#160;were&#160;not&#160;able&#160;to&#160;obtain&#160;an&#160;accurate&#160;proportion&#160;of&#160;cells&#160;in&#160;each&#160;cell</p>
<p style="position:absolute;top:822px;left:250px;white-space:nowrap" class="ft114">cycle&#160;stage&#160;for&#160;the&#160;best&#160;treatment&#160;in&#160;U87&#160;cells,&#160;pantoprazole&#160;with&#160;retigabine,&#160;due&#160;to&#160;an<br/>autofluorescent&#160;aggregation&#160;in&#160;the&#160;cytoplasm&#160;that&#160;obscured&#160;the&#160;FUCCI&#160;reporter&#160;signal.</p>
<p style="position:absolute;top:859px;left:281px;white-space:nowrap" class="ft112">The&#160;same&#160;combinations&#160;that&#160;were&#160;significantly&#160;better&#160;than&#160;pantoprazole&#160;in&#160;NG108-15</p>
<p style="position:absolute;top:878px;left:250px;white-space:nowrap" class="ft114">cells&#160;were&#160;also&#160;significant&#160;in&#160;U87&#160;cells,&#160;along&#160;with&#160;the&#160;added&#160;combinations&#160;of&#160;TMZ&#160;or&#160;retiga-<br/>bine&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#13">5A).&#160;</a>Pantoprazole&#160;in&#160;combination&#160;with&#160;rapamycin,&#160;lamotrigine,&#160;NS1643,&#160;TMZ<br/>or&#160;retigabine&#160;were&#160;all&#160;significantly&#160;better&#160;than&#160;pantoprazole&#160;alone.&#160;The&#160;most&#160;significant<br/>combinations&#160;were&#160;with&#160;NS1643&#160;or&#160;retigabine,&#160;a&#160;1.6-fold&#160;decrease&#160;than&#160;pantoprazole&#160;alone.</p>
<p style="position:absolute;top:954px;left:249px;white-space:nowrap" class="ft114">The&#160;combination&#160;of&#160;pantoprazole&#160;with&#160;NS1643&#160;was&#160;so&#160;effective&#160;that&#160;cutting&#160;the&#160;panto-<br/>prazole&#160;concentration&#160;by&#160;half&#160;and&#160;combining&#160;it&#160;with&#160;NS1643&#160;at&#160;50&#160;µM&#160;was&#160;significantly</p>
<p style="position:absolute;top:991px;left:250px;white-space:nowrap" class="ft114">more&#160;effective&#160;than&#160;pantoprazole&#160;at&#160;100&#160;µM&#160;alone&#160;(1.2-fold&#160;decrease).&#160;The&#160;characteristic<br/>increase&#160;in&#160;G1&#160;when&#160;pantoprazole&#160;was&#160;used&#160;in&#160;NG108-15&#160;cells&#160;was&#160;also&#160;seen&#160;in&#160;U87&#160;cells.</p>
<p style="position:absolute;top:1029px;left:249px;white-space:nowrap" class="ft112">Additionally,&#160;when&#160;pantoprazole&#160;was&#160;combined&#160;with&#160;rapamycin&#160;or&#160;NS1643&#160;an&#160;increase&#160;in</p>
<p style="position:absolute;top:1048px;left:250px;white-space:nowrap" class="ft114">the&#160;proportion&#160;of&#160;the&#160;cells&#160;in&#160;early&#160;S&#160;was&#160;seen,&#160;with&#160;a&#160;complementary&#160;decrease&#160;in&#160;late&#160;S,<br/>G2,&#160;and&#160;M&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#13">5B).&#160;</a>Thus,&#160;we&#160;conclude&#160;that&#160;NS1643,&#160;retigabine,&#160;rapamycin,&#160;lamotrig-<br/>ine,&#160;and&#160;pantoprazole&#160;are&#160;also&#160;effective&#160;in&#160;a&#160;human&#160;glioblastoma&#160;cell&#160;line,&#160;and&#160;NS1643&#160;or</p>
<p style="position:absolute;top:1104px;left:249px;white-space:nowrap" class="ft112">pantoprazole&#160;potentiate&#160;the&#160;action&#160;of&#160;the&#160;standard&#160;TMZ&#160;treatment.</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft120{font-size:9px;font-family:Times;color:#000000;}
	.ft121{font-size:9px;font-family:Times;color:#000000;}
	.ft122{font-size:9px;font-family:Times;color:#000000;}
	.ft123{font-size:13px;font-family:Times;color:#000000;}
	.ft124{font-size:11px;font-family:Times;color:#000000;}
	.ft125{font-size:11px;font-family:Times;color:#000000;}
	.ft126{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft127{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
	.ft128{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page12-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft120">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft120">12&#160;of&#160;36</p>
<p style="position:absolute;top:-167px;left:54px;white-space:nowrap" class="ft122"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:-167px;left:792px;white-space:nowrap" class="ft120">12 of&#160;38&#160;</p>
<p style="position:absolute;top:-157px;left:54px;white-space:nowrap" class="ft120">&#160;</p>
<p style="position:absolute;top:973px;left:54px;white-space:nowrap" class="ft123">&#160;</p>
<p style="position:absolute;top:-105px;left:249px;white-space:nowrap" class="ft126">cells (43% decrease),&#160;but&#160;combinations&#160;with&#160;rapamycin, pantoprazole, or&#160;NS1643&#160;signifi-<br/>cantly&#160;increased the&#160;effectiveness&#160;up to&#160;55%,&#160;61%,&#160;61%&#160;reduction&#160;in&#160;cells compared&#160;to&#160;<br/>control&#160;respectively&#160;(Figure&#160;5A).&#160;The&#160;cell&#160;cycle&#160;data&#160;in&#160;Figure&#160;4B&#160;shows&#160;that&#160;some&#160;of&#160;the&#160;<br/>most&#160;effective combinations&#160;increased&#160;the G1&#160;and&#160;early&#160;S&#160;proportion of&#160;cells&#160;but&#160;not&#160;all.&#160;<br/>Pantoprazole&#160;showed its characteristic increase&#160;in the early S proportion of cells and ra-<br/>pamycin,&#160;an&#160;increase&#160;in&#160;the&#160;G1&#160;proportion&#160;as&#160;seen&#160;in&#160;the&#160;NG108-15&#160;cells.&#160;TMZ&#160;and&#160;NS1643&#160;<br/>treatment did not show a large change in the proportion of&#160;cells&#160;in&#160;each&#160;stage&#160;of the cell&#160;<br/>cycle&#160;as compared to control. TMZ&#160;in combination with&#160;rapamycin&#160;increased the&#160;propor-<br/>tion of cells in&#160;G1,&#160;and combination with&#160;NS1643&#160;increased&#160;the proportion of cells&#160;in early&#160;<br/>S&#160;as&#160;compared&#160;to&#160;TMZ&#160;alone (Figure&#160;5B).&#160;Pantoprazole combinations consistently&#160;showed&#160;<br/>a larger proportion of cells&#160;in early&#160;S as&#160;compared to&#160;TMZ&#160;alone,&#160;with&#160;a complimentary&#160;<br/>decrease of&#160;cells&#160;in&#160;late S,&#160;G2,&#160;and&#160;M&#160;(Figure&#160;5B).&#160;</p>
<p style="position:absolute;top:493px;left:812px;white-space:nowrap" class="ft123">&#160;</p>
<p style="position:absolute;top:855px;left:831px;white-space:nowrap" class="ft123">&#160;</p>
<p style="position:absolute;top:879px;left:249px;white-space:nowrap" class="ft127"><b>Figure 4.&#160;</b>Bioelectric&#160;Drugs in Combination with&#160;Each&#160;Other,&#160;Pantoprazole, and TMZ&#160;Reduced Pro-<br/>liferation&#160;in U87 cells and&#160;Changed the Cell&#160;Cycle Ratio Compared to Control. (<b>A</b>) Fold&#160;change to&#160;<br/>start cell&#160;counts (cells&#160;at&#160;day&#160;6/cells at&#160;day&#160;0)&#160;after 6 days of&#160;treatment. Low&#160;values&#160;indicate&#160;less&#160;cell&#160;</p>
<p style="position:absolute;top:884px;left:250px;white-space:nowrap" class="ft124"><b>Figure&#160;4.</b></p>
<p style="position:absolute;top:884px;left:312px;white-space:nowrap" class="ft125">Bioelectric&#160;Drugs&#160;in&#160;Combination&#160;with&#160;Each&#160;Other,&#160;Pantoprazole,&#160;and&#160;TMZ&#160;Reduced</p>
<p style="position:absolute;top:903px;left:250px;white-space:nowrap" class="ft128">Proliferation&#160;in&#160;U87&#160;cells&#160;and&#160;Changed&#160;the&#160;Cell&#160;Cycle&#160;Ratio&#160;Compared&#160;to&#160;Control.&#160;(<b>A</b>)&#160;Fold&#160;change<br/>to&#160;start&#160;cell&#160;counts&#160;(cells&#160;at&#160;day&#160;6/cells&#160;at&#160;day&#160;0)&#160;after&#160;6&#160;days&#160;of&#160;treatment.&#160;Low&#160;values&#160;indicate<br/>less&#160;cell&#160;growth.&#160;Colors&#160;indicate&#160;treatments&#160;followed&#160;up&#160;for&#160;further&#160;analysis&#160;and&#160;hues&#160;represent<br/>concentrations&#160;and&#160;combinations.&#160;Red&#160;shaded&#160;treatment&#160;corresponds&#160;to&#160;positive&#160;control&#160;that&#160;cannot<br/>be&#160;used&#160;clinically.&#160;Only&#160;treatments&#160;with&#160;significant&#160;values&#160;are&#160;shown&#160;out&#160;of&#160;42&#160;treatments&#160;compared<br/>to&#160;DMSO&#160;control.&#160;****:&#160;q&#160;&lt;&#160;0.0001&#160;***:&#160;q&#160;&lt;&#160;0.001,&#160;**:&#160;q&#160;&lt;&#160;0.01,&#160;*:&#160;q&#160;&lt;&#160;0.05&#160;(one-way&#160;ANOVA&#160;with&#160;FDR</p>
<p style="position:absolute;top:1019px;left:249px;white-space:nowrap" class="ft125">post&#160;hoc&#160;analysis&#160;n&#160;&gt;&#160;3&#160;biological&#160;replicates).&#160;(<b>B</b>)&#160;FUCCI&#160;cell&#160;cycle&#160;data&#160;at&#160;day&#160;6.&#160;Increased&#160;red&#160;and</p>
<p style="position:absolute;top:1038px;left:250px;white-space:nowrap" class="ft125">orange&#160;fractions&#160;indicate&#160;cell&#160;cycle&#160;arrest&#160;at&#160;G1&#160;or&#160;G1&#160;to&#160;S&#160;transition.</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft130{font-size:9px;font-family:Times;color:#000000;}
	.ft131{font-size:9px;font-family:Times;color:#000000;}
	.ft132{font-size:9px;font-family:Times;color:#000000;}
	.ft133{font-size:12px;font-family:Times;color:#000000;}
	.ft134{font-size:11px;font-family:Times;color:#000000;}
	.ft135{font-size:11px;font-family:Times;color:#000000;}
	.ft136{font-size:11px;font-family:Times;color:#000000;}
	.ft137{font-size:12px;font-family:Times;color:#0775b7;}
	.ft138{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
	.ft139{font-size:12px;line-height:19px;font-family:Times;color:#000000;}
	.ft1310{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page13-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft130">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft130">13&#160;of&#160;36</p>
<p style="position:absolute;top:-111px;left:56px;white-space:nowrap" class="ft132"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:-111px;left:787px;white-space:nowrap" class="ft130">13 of&#160;38&#160;</p>
<p style="position:absolute;top:-101px;left:56px;white-space:nowrap" class="ft130">&#160;</p>
<p style="position:absolute;top:1018px;left:56px;white-space:nowrap" class="ft133">&#160;</p>
<p style="position:absolute;top:-50px;left:250px;white-space:nowrap" class="ft138">growth. Colors indicate&#160;treatments followed up&#160;for further analysis and&#160;hues represent concentra-<br/>tions&#160;and combinations.&#160;Red shaded treatment&#160;corresponds to&#160;positive&#160;control that&#160;cannot&#160;be&#160;used&#160;<br/>clinically. Only treatments&#160;with&#160;significant values&#160;are&#160;shown out&#160;of&#160;42&#160;treatments&#160;compared to&#160;<br/>DMSO control. ****:&#160;<i>q</i>&#160;&lt; 0.0001&#160;***:&#160;<i>q</i>&#160;&lt; 0.001, **:&#160;<i>q</i>&#160;&lt; 0.01, *:&#160;<i>q</i>&#160;&lt;&#160;0.05 (one-way&#160;ANOVA with&#160;FDR post&#160;<br/>hoc analysis&#160;<i>n &gt;&#160;</i>3 biological replicates). (<b>B</b>) FUCCI&#160;cell&#160;cycle&#160;data at&#160;day&#160;6.&#160;Increased red and orange&#160;<br/>fractions&#160;indicate cell&#160;cycle&#160;arrest&#160;at&#160;G1 or G1&#160;to S&#160;transition.&#160;</p>
<p style="position:absolute;top:70px;left:281px;white-space:nowrap" class="ft133">Unfortunately, we were not able to obtain&#160;an&#160;accurate&#160;proportion&#160;of&#160;cells in&#160;each&#160;cell&#160;</p>
<p style="position:absolute;top:89px;left:250px;white-space:nowrap" class="ft139">cycle stage for the best treatment in&#160;U87&#160;cells, pantoprazole&#160;with&#160;retigabine, due to&#160;an&#160;<br/>autofluorescent aggregation in&#160;the cytoplasm&#160;that&#160;obscured the FUCCI reporter&#160;signal.&#160;</p>
<p style="position:absolute;top:505px;left:797px;white-space:nowrap" class="ft133">&#160;</p>
<p style="position:absolute;top:865px;left:812px;white-space:nowrap" class="ft133">&#160;</p>
<p style="position:absolute;top:889px;left:250px;white-space:nowrap" class="ft138"><b>Figure 5.&#160;</b>Treatments with&#160;Bioelectric Compounds and Pantoprazole or&#160;TMZ were&#160;Significantly&#160;Bet-<br/>ter than TMZ&#160;or Pantoprazole Alone&#160;at Reducing&#160;Proliferation in U87&#160;cells and&#160;Changed the Cell&#160;<br/>Cycle Ratio Compared to Control.&#160;(<b>A</b>) Percent reduction in&#160;cells&#160;compared to&#160;control after&#160;6 days&#160;of&#160;<br/>treatment. Treatments that were significantly more effective than TMZ alone are shown out of 42&#160;<br/>treatments with brown stars. Treatments with pantoprazole that&#160;were significantly&#160;better than&#160;</p>
<p style="position:absolute;top:894px;left:250px;white-space:nowrap" class="ft136"><b>Figure&#160;5.</b></p>
<p style="position:absolute;top:894px;left:307px;white-space:nowrap" class="ft134">Treatments&#160;with&#160;Bioelectric&#160;Compounds&#160;and&#160;Pantoprazole&#160;or&#160;TMZ&#160;were&#160;Significantly&#160;Better</p>
<p style="position:absolute;top:913px;left:250px;white-space:nowrap" class="ft1310">than&#160;TMZ&#160;or&#160;Pantoprazole&#160;Alone&#160;at&#160;Reducing&#160;Proliferation&#160;in&#160;U87&#160;cells&#160;and&#160;Changed&#160;the&#160;Cell&#160;Cycle<br/>Ratio&#160;Compared&#160;to&#160;Control.&#160;(<b>A</b>)&#160;Percent&#160;reduction&#160;in&#160;cells&#160;compared&#160;to&#160;control&#160;after&#160;6&#160;days&#160;of&#160;treatment.</p>
<p style="position:absolute;top:952px;left:249px;white-space:nowrap" class="ft134">Treatments&#160;that&#160;were&#160;significantly&#160;more&#160;effective&#160;than&#160;TMZ&#160;alone&#160;are&#160;shown&#160;out&#160;of&#160;42&#160;treatments&#160;with</p>
<p style="position:absolute;top:971px;left:250px;white-space:nowrap" class="ft1310">brown&#160;stars.&#160;Treatments&#160;with&#160;pantoprazole&#160;that&#160;were&#160;significantly&#160;better&#160;than&#160;pantoprazole&#160;alone&#160;are<br/>shown&#160;out&#160;of&#160;18&#160;treatments&#160;with&#160;grey&#160;stars.&#160;Red&#160;shaded&#160;treatment&#160;corresponds&#160;to&#160;positive&#160;control&#160;that<br/>cannot&#160;be&#160;used&#160;clinically.&#160;Statistical&#160;analysis&#160;was&#160;conducted&#160;on&#160;the&#160;log2&#160;of&#160;the&#160;fold&#160;change&#160;in&#160;cell&#160;number<br/>to&#160;control&#160;on&#160;day&#160;6.&#160;****:&#160;q&#160;&lt;&#160;0.0001,&#160;***:&#160;q&#160;&lt;&#160;0.001,&#160;**:&#160;q&#160;&lt;&#160;0.01,&#160;*:&#160;q&#160;&lt;&#160;0.05&#160;(one-way&#160;ANOVA&#160;with&#160;FDR&#160;post<br/>hoc&#160;analysis&#160;n&#160;&gt;&#160;3&#160;biological&#160;replicates).&#160;(<b>B</b>)&#160;FUCCI&#160;cell&#160;cycle&#160;data&#160;at&#160;day&#160;6.&#160;Increased&#160;red&#160;and&#160;orange<br/>fractions&#160;indicate&#160;cell&#160;cycle&#160;arrest&#160;at&#160;G1&#160;or&#160;G1&#160;to&#160;S&#160;transition.</p>
<p style="position:absolute;top:1096px;left:250px;white-space:nowrap" class="ft133">3.4.&#160;Bioelectric&#160;Drug&#160;Combinations&#160;including&#160;Pantoprazole&#160;Reduce&#160;U87&#160;Proliferation&#160;after</p>
<p style="position:absolute;top:1112px;left:249px;white-space:nowrap" class="ft133">Treatment&#160;Is&#160;Removed</p>
<p style="position:absolute;top:1135px;left:281px;white-space:nowrap" class="ft133">The&#160;combination&#160;of&#160;pantoprazole&#160;with&#160;rapamycin&#160;shows&#160;a&#160;similar&#160;recovery&#160;slope</p>
<p style="position:absolute;top:1154px;left:250px;white-space:nowrap" class="ft133">after&#160;day&#160;6&#160;as&#160;pantoprazole&#160;alone&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#14">6).&#160;</a>However,&#160;combinations&#160;of&#160;pantoprazole</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft140{font-size:9px;font-family:Times;color:#000000;}
	.ft141{font-size:9px;font-family:Times;color:#000000;}
	.ft142{font-size:12px;font-family:Times;color:#000000;}
	.ft143{font-size:9px;font-family:Times;color:#000000;}
	.ft144{font-size:13px;font-family:Times;color:#000000;}
	.ft145{font-size:11px;font-family:Times;color:#000000;}
	.ft146{font-size:11px;font-family:Times;color:#000000;}
	.ft147{font-size:11px;font-family:Times;color:#000000;}
	.ft148{font-size:13px;font-family:Times;color:#000000;}
	.ft149{font-size:12px;font-family:Times;color:#0775b7;}
	.ft1410{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
	.ft1411{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
	.ft1412{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft1413{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft1414{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page14-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft140">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft140">14&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:249px;white-space:nowrap" class="ft142">with&#160;retigabine&#160;or&#160;NS1643&#160;at&#160;50&#160;µM&#160;show&#160;reduced&#160;recoveries&#160;compared&#160;to&#160;pantoprazole</p>
<p style="position:absolute;top:165px;left:250px;white-space:nowrap" class="ft142">alone,&#160;although&#160;not&#160;significantly&#160;so.&#160;TMZ&#160;treatment&#160;alone&#160;only&#160;showed&#160;a&#160;slight&#160;increase&#160;in</p>
<p style="position:absolute;top:184px;left:249px;white-space:nowrap" class="ft1410">proliferation&#160;after&#160;treatment&#160;was&#160;removed,&#160;and&#160;NS1643&#160;alone&#160;showed&#160;a&#160;high&#160;increase&#160;in<br/>proliferation.&#160;However,&#160;the&#160;combination&#160;of&#160;NS1643&#160;with&#160;TMZ&#160;did&#160;not&#160;show&#160;an&#160;increase</p>
<p style="position:absolute;top:222px;left:250px;white-space:nowrap" class="ft1410">in&#160;proliferation&#160;after&#160;removal&#160;of&#160;treatment,&#160;but&#160;the&#160;recovery&#160;slope&#160;was&#160;not&#160;significantly<br/>different&#160;from&#160;TMZ&#160;alone.&#160;Surprisingly&#160;the&#160;positive&#160;control&#160;using&#160;cAMP&#160;in&#160;combination</p>
<p style="position:absolute;top:260px;left:249px;white-space:nowrap" class="ft142">with&#160;rapamycin&#160;started&#160;proliferating&#160;after&#160;day&#160;8,&#160;revealing&#160;that&#160;the&#160;bioelectric&#160;drugs&#160;have&#160;a</p>
<p style="position:absolute;top:278px;left:250px;white-space:nowrap" class="ft142">more&#160;stable&#160;effect&#160;on&#160;the&#160;cells&#160;than&#160;even&#160;the&#160;powerful&#160;cAMP&#160;signal.</p>
<p style="position:absolute;top:-411px;left:53px;white-space:nowrap" class="ft143"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:-411px;left:791px;white-space:nowrap" class="ft140">14 of&#160;38&#160;</p>
<p style="position:absolute;top:-401px;left:53px;white-space:nowrap" class="ft140">&#160;</p>
<p style="position:absolute;top:730px;left:53px;white-space:nowrap" class="ft144">&#160;</p>
<p style="position:absolute;top:-349px;left:249px;white-space:nowrap" class="ft1411">pantoprazole alone are&#160;shown out of&#160;18&#160;treatments&#160;with&#160;grey stars. Red&#160;shaded&#160;treatment corre-<br/>sponds&#160;to&#160;positive&#160;control&#160;that&#160;cannot&#160;be&#160;used&#160;clinically.&#160;Statistical&#160;analysis&#160;was&#160;conducted on&#160;the&#160;<br/>log2 of the fold change in cell&#160;number to control on day 6. ****:&#160;<i>q</i>&#160;&lt; 0.0001, ***:&#160;<i>q</i>&#160;&lt; 0.001, **:&#160;<i>q</i>&#160;&lt;<i>&#160;</i>0.01,&#160;<br/>*:&#160;<i>q</i>&#160;&lt;&#160;0.05&#160;(one-way ANOVA&#160;with FDR post&#160;hoc<i>&#160;</i>analysis&#160;<i>n &gt;&#160;</i>3&#160;biological&#160;replicates).&#160;(<b>B</b>) FUCCI&#160;cell&#160;<br/>cycle&#160;data&#160;at&#160;day 6. Increased red and orange fractions&#160;indicate&#160;cell&#160;cycle&#160;arrest at&#160;G1&#160;or&#160;G1&#160;to&#160;S&#160;<br/>transition.&#160;</p>
<p style="position:absolute;top:-227px;left:280px;white-space:nowrap" class="ft144">The same&#160;combinations&#160;that&#160;were&#160;significantly better than&#160;pantoprazole&#160;in&#160;NG108-</p>
<p style="position:absolute;top:-208px;left:249px;white-space:nowrap" class="ft1412">15 cells were&#160;also significant&#160;in U87 cells, along with&#160;the added combinations of&#160;TMZ&#160;or&#160;<br/>retigabine&#160;(Figure&#160;5A).&#160;Pantoprazole&#160;in combination with&#160;rapamycin,&#160;lamotrigine,&#160;<br/>NS1643,&#160;TMZ&#160;or retigabine&#160;were&#160;all&#160;significantly&#160;better than pantoprazole&#160;alone.&#160;The most&#160;<br/>significant&#160;combinations&#160;were with&#160;NS1643&#160;or&#160;retigabine,&#160;a&#160;1.6-fold&#160;decrease&#160;than&#160;panto-<br/>prazole&#160;alone.&#160;The combination of&#160;pantoprazole with&#160;NS1643&#160;was so&#160;effective that&#160;cutting&#160;<br/>the pantoprazole&#160;concentration&#160;by half&#160;and&#160;combining&#160;it&#160;with&#160;NS1643&#160;at&#160;50&#160;µM&#160;was&#160;sig-<br/>nificantly&#160;more effective than pantoprazole&#160;at&#160;100&#160;µM&#160;alone (1.2-fold decrease). The char-<br/>acteristic&#160;increase&#160;in&#160;G1&#160;when pantoprazole&#160;was used&#160;in NG108-15&#160;cells&#160;was also&#160;seen&#160;in&#160;<br/>U87 cells. Additionally, when pantoprazole&#160;was combined with&#160;rapamycin or&#160;NS1643&#160;an&#160;<br/>increase&#160;in the proportion of the cells in&#160;early S was&#160;seen, with a complementary&#160;decrease&#160;<br/>in late&#160;S,&#160;G2, and M (Figure&#160;5B).&#160;Thus, we&#160;conclude&#160;that&#160;NS1643,&#160;retigabine,&#160;rapamycin,&#160;<br/>lamotrigine,&#160;and&#160;pantoprazole&#160;are also&#160;effective&#160;in&#160;a&#160;human glioblastoma&#160;cell&#160;line,&#160;and&#160;<br/>NS1643&#160;or pantoprazole&#160;potentiate the&#160;action of&#160;the&#160;standard TMZ&#160;treatment.&#160;</p>
<p style="position:absolute;top:59px;left:249px;white-space:nowrap" class="ft1413"><i>3.4.&#160;Bioelectric Drug&#160;Combinations&#160;Including&#160;Pantoprazole Reduce&#160;U87&#160;Proliferation after&#160;<br/>Treatment&#160;Is&#160;Removed&#160;</i></p>
<p style="position:absolute;top:102px;left:280px;white-space:nowrap" class="ft144">The combination of&#160;pantoprazole&#160;with&#160;rapamycin&#160;shows a similar recovery slope&#160;af-</p>
<p style="position:absolute;top:122px;left:249px;white-space:nowrap" class="ft1412">ter day&#160;6&#160;as pantoprazole&#160;alone (Figure&#160;6). However,&#160;combinations&#160;of pantoprazole with&#160;<br/>retigabine&#160;or&#160;NS1643&#160;at&#160;50&#160;µM&#160;show&#160;reduced&#160;recoveries compared&#160;to pantoprazole&#160;alone,&#160;<br/>although not&#160;significantly&#160;so. TMZ&#160;treatment&#160;alone&#160;only&#160;showed&#160;a&#160;slight&#160;increase&#160;in pro-<br/>liferation after treatment was removed,&#160;and NS1643&#160;alone showed&#160;a high&#160;increase in&#160;pro-<br/>liferation. However, the combination of&#160;NS1643&#160;with&#160;TMZ did not&#160;show an increase&#160;in&#160;<br/>proliferation&#160;after removal of&#160;treatment, but&#160;the recovery slope was not significantly dif-<br/>ferent&#160;from TMZ alone.&#160;Surprisingly&#160;the&#160;positive control using cAMP in&#160;combination with&#160;<br/>rapamycin&#160;started proliferating&#160;after&#160;day&#160;8,&#160;revealing that&#160;the&#160;bioelectric&#160;drugs have&#160;a&#160;<br/>more stable effect on&#160;the cells than&#160;even&#160;the powerful&#160;cAMP&#160;signal.&#160;</p>
<p style="position:absolute;top:609px;left:797px;white-space:nowrap" class="ft144">&#160;</p>
<p style="position:absolute;top:632px;left:249px;white-space:nowrap" class="ft1411"><b>Figure 6.&#160;</b>Recovery&#160;Test&#160;of&#160;Bioelectric&#160;Treatments in&#160;Combination with&#160;Pantoprazole or&#160;TMZ in&#160;U87&#160;<br/>cells. The&#160;log2&#160;of the fold&#160;change&#160;in cell&#160;counts to Day&#160;0 were recorded for 10&#160;days. Dotted line marks&#160;<br/>the day on&#160;which drug treatment was removed and replaced&#160;with&#160;control&#160;media (<i>n</i>&#160;&gt; 3 biological&#160;</p>
<p style="position:absolute;top:641px;left:250px;white-space:nowrap" class="ft147"><b>Figure&#160;6.</b></p>
<p style="position:absolute;top:640px;left:307px;white-space:nowrap" class="ft145">Recovery&#160;Test&#160;of&#160;Bioelectric&#160;Treatments&#160;in&#160;Combination&#160;with&#160;Pantoprazole&#160;or&#160;TMZ&#160;in&#160;U87</p>
<p style="position:absolute;top:660px;left:250px;white-space:nowrap" class="ft1414">cells.&#160;The&#160;log2&#160;of&#160;the&#160;fold&#160;change&#160;in&#160;cell&#160;counts&#160;to&#160;Day&#160;0&#160;were&#160;recorded&#160;for&#160;10&#160;days.&#160;Dotted&#160;line&#160;marks<br/>the&#160;day&#160;on&#160;which&#160;drug&#160;treatment&#160;was&#160;removed&#160;and&#160;replaced&#160;with&#160;control&#160;media&#160;(n&#160;&gt;&#160;3&#160;biological<br/>replicates).&#160;Combination&#160;drug&#160;treatment&#160;slopes&#160;from&#160;Day&#160;6&#160;to&#160;Day&#160;10&#160;were&#160;compared&#160;to&#160;pantoprazole<br/>or&#160;TMZ&#160;alone,&#160;but&#160;no&#160;significance&#160;was&#160;found&#160;(one-way&#160;ANOVA&#160;with&#160;Dunnett&#160;post&#160;hoc&#160;analysis&#160;n&#160;&gt;&#160;3<br/>biological&#160;replicates).&#160;3.5.&#160;Electrophysiology&#160;of&#160;NG108-15&#160;Cells&#160;Show&#160;Changes&#160;in&#160;Resting&#160;Membrane<br/>Potential&#160;Induced&#160;by&#160;Treatment.</p>
<p style="position:absolute;top:788px;left:281px;white-space:nowrap" class="ft142">We&#160;performed&#160;electrophysiological&#160;recordings&#160;to&#160;determine&#160;the&#160;change&#160;in&#160;resting&#160;mem-</p>
<p style="position:absolute;top:807px;left:250px;white-space:nowrap" class="ft1410">brane&#160;potential&#160;of&#160;NG108-15&#160;cells&#160;treated&#160;with&#160;the&#160;compounds&#160;that&#160;significantly&#160;reduced<br/>cell&#160;proliferation&#160;as&#160;compared&#160;to&#160;control&#160;immediately&#160;after&#160;application.&#160;We&#160;measured&#160;the<br/>baseline&#160;Vmem&#160;first&#160;and&#160;recorded&#160;the&#160;membrane&#160;potential&#160;continuously&#160;for&#160;3&#160;min&#160;upon<br/>compound&#160;treatment.&#160;We&#160;then&#160;calculated&#160;the&#160;difference&#160;in&#160;Vmem&#160;post&#160;treatment.</p>
<p style="position:absolute;top:883px;left:281px;white-space:nowrap" class="ft142">Rapamycin,&#160;retigabine,&#160;NS1643,&#160;TMZ,&#160;and&#160;lamotrigine&#160;all&#160;significantly&#160;hyperpolar-</p>
<p style="position:absolute;top:901px;left:250px;white-space:nowrap" class="ft1410">ized&#160;the&#160;cells&#160;as&#160;compared&#160;to&#160;the&#160;control&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#15">7).&#160;</a>Retigabine,&#160;lamotrigine,&#160;and&#160;NS1643<br/>are&#160;known&#160;hyperpolarizing&#160;agents,&#160;but&#160;TMZ&#160;has&#160;been&#160;shown&#160;to&#160;depolarize&#160;U373&#160;glioma<br/>cells&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">[93]—an&#160;</a>effect&#160;opposite&#160;to&#160;what&#160;we&#160;observed&#160;in&#160;NG108-15&#160;cells,&#160;possibly&#160;due&#160;to<br/>differential&#160;expression&#160;levels&#160;of&#160;KCa3.1&#160;channels&#160;in&#160;these&#160;two&#160;cell&#160;lines&#160;(not&#160;confirmed).<br/>Rapamycin&#160;also&#160;hyperpolarized&#160;the&#160;NG108-15&#160;cells,&#160;a&#160;novel&#160;effect&#160;suggesting&#160;that&#160;existing<br/>cancer&#160;drugs&#160;could&#160;have&#160;bioelectric&#160;mechanisms&#160;of&#160;action&#160;that&#160;are&#160;not&#160;yet&#160;recognized.&#160;Sur-</p>
<p style="position:absolute;top:1014px;left:249px;white-space:nowrap" class="ft142">prisingly,&#160;while&#160;pantoprazole&#160;did&#160;not&#160;have&#160;an&#160;immediate&#160;effect&#160;on&#160;the&#160;membrane&#160;potential</p>
<p style="position:absolute;top:1033px;left:250px;white-space:nowrap" class="ft142">of&#160;the&#160;cells,&#160;its&#160;combination&#160;with&#160;retigabine&#160;and&#160;rapamycin,&#160;which&#160;both&#160;individually&#160;hy-</p>
<p style="position:absolute;top:1052px;left:249px;white-space:nowrap" class="ft142">perpolarize&#160;the&#160;cells,&#160;instead&#160;depolarized&#160;the&#160;cells.&#160;The&#160;combination&#160;of&#160;pantoprazole&#160;with</p>
<p style="position:absolute;top:1071px;left:250px;white-space:nowrap" class="ft1410">lamotrigine&#160;and&#160;NS1643&#160;did&#160;not&#160;observably&#160;change&#160;the&#160;membrane&#160;potential&#160;as&#160;compared<br/>to&#160;control.</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft150{font-size:9px;font-family:Times;color:#000000;}
	.ft151{font-size:9px;font-family:Times;color:#000000;}
	.ft152{font-size:9px;font-family:Times;color:#000000;}
	.ft153{font-size:13px;font-family:Times;color:#000000;}
	.ft154{font-size:11px;font-family:Times;color:#000000;}
	.ft155{font-size:7px;font-family:Times;color:#000000;}
	.ft156{font-size:13px;font-family:Times;color:#000000;}
	.ft157{font-size:11px;font-family:Times;color:#000000;}
	.ft158{font-size:11px;font-family:Times;color:#000000;}
	.ft159{font-size:12px;font-family:Times;color:#000000;}
	.ft1510{font-size:12px;font-family:Times;color:#0775b7;}
	.ft1511{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
	.ft1512{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft1513{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
	.ft1514{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page15-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft150">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft150">15&#160;of&#160;36</p>
<p style="position:absolute;top:-348px;left:53px;white-space:nowrap" class="ft152"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:-348px;left:791px;white-space:nowrap" class="ft150">15 of&#160;38&#160;</p>
<p style="position:absolute;top:-338px;left:53px;white-space:nowrap" class="ft150">&#160;</p>
<p style="position:absolute;top:793px;left:53px;white-space:nowrap" class="ft153">&#160;</p>
<p style="position:absolute;top:-286px;left:249px;white-space:nowrap" class="ft1511">replicates). Combination drug&#160;treatment slopes from Day 6 to Day 10 were compared to&#160;pantopra-<br/>zole or TMZ&#160;alone, but no significance&#160;was found (one-way ANOVA with&#160;Dunnett post hoc analysis&#160;<br/>n &gt; 3 biological&#160;replicates). 3.5.&#160;Electrophysiology of NG108-15 Cells Show&#160;Changes in Resting Mem-<br/>brane Potential Induced by Treatment.&#160;</p>
<p style="position:absolute;top:-198px;left:280px;white-space:nowrap" class="ft153">We performed electrophysiological recordings&#160;to determine the change&#160;in resting&#160;</p>
<p style="position:absolute;top:-179px;left:249px;white-space:nowrap" class="ft1512">membrane potential&#160;of&#160;NG108-15&#160;cells&#160;treated with the compounds that&#160;significantly re-<br/>duced&#160;cell&#160;proliferation&#160;as&#160;compared to&#160;control immediately&#160;after&#160;application.&#160;We meas-<br/>ured&#160;the baseline Vmem&#160;first and recorded&#160;the&#160;membrane&#160;potential&#160;continuously&#160;for&#160;3&#160;min&#160;<br/>upon compound treatment. We then calculated the difference&#160;in&#160;Vmem&#160;post treatment.<b>&#160;</b></p>
<p style="position:absolute;top:-102px;left:280px;white-space:nowrap" class="ft153">Rapamycin, retigabine,&#160;NS1643, TMZ,&#160;and lamotrigine all significantly hyperpolar-</p>
<p style="position:absolute;top:-83px;left:249px;white-space:nowrap" class="ft1512">ized the cells&#160;as&#160;compared&#160;to the control (Figure&#160;7).&#160;Retigabine,&#160;lamotrigine,&#160;and&#160;NS1643&#160;<br/>are known hyperpolarizing agents, but&#160;TMZ has been shown to&#160;depolarize&#160;U373&#160;glioma&#160;<br/>cells&#160;[93]—an&#160;effect&#160;opposite to what we&#160;observed&#160;in&#160;NG108-15 cells,&#160;possibly&#160;due to&#160;dif-<br/>ferential&#160;expression&#160;levels&#160;of KCa3.1&#160;channels&#160;in&#160;these&#160;two cell&#160;lines&#160;(not&#160;confirmed).&#160;Ra-<br/>pamycin&#160;also hyperpolarized the NG108-15&#160;cells,&#160;a novel effect suggesting that&#160;existing&#160;<br/>cancer drugs&#160;could have bioelectric mechanisms&#160;of&#160;action that&#160;are not yet recognized.&#160;Sur-<br/>prisingly,&#160;while&#160;pantoprazole&#160;did&#160;not&#160;have&#160;an&#160;immediate&#160;effect&#160;on&#160;the membrane&#160;poten-<br/>tial of&#160;the cells, its combination with&#160;retigabine&#160;and&#160;rapamycin,&#160;which both&#160;individually&#160;<br/>hyperpolarize the cells, instead&#160;depolarized&#160;the cells.&#160;The combination of&#160;pantoprazole&#160;<br/>with&#160;lamotrigine and&#160;NS1643 did not&#160;observably change the membrane potential&#160;as com-<br/>pared to control.&#160;</p>
<p style="position:absolute;top:389px;left:730px;white-space:nowrap" class="ft153">&#160;</p>
<p style="position:absolute;top:652px;left:714px;white-space:nowrap" class="ft153">&#160;</p>
<p style="position:absolute;top:676px;left:249px;white-space:nowrap" class="ft1511"><b>Figure 7.&#160;</b>Resting Membrane&#160;Potential Changes Caused&#160;by&#160;Treatments in&#160;NG108-15 FUCCI Cells.&#160;<br/>The change&#160;in resting&#160;membrane potential is&#160;normalized to&#160;DMSO&#160;control. The&#160;negative&#160;values&#160;<br/>represent an increase in hyperpolarization. (<b>A</b>,<b>B</b>) were&#160;conducted on different days. There were&#160;<i>n</i>&#160;=&#160;<br/>55–63 cells per&#160;condition. Statistics&#160;were&#160;calculated for the 400 s time point&#160;(black box with&#160;star on&#160;</p>
<p style="position:absolute;top:675px;left:250px;white-space:nowrap" class="ft157"><b>Figure&#160;7.</b></p>
<p style="position:absolute;top:675px;left:308px;white-space:nowrap" class="ft154">Resting&#160;Membrane&#160;Potential&#160;Changes&#160;Caused&#160;by&#160;Treatments&#160;in&#160;NG108-15&#160;FUCCI&#160;Cells.</p>
<p style="position:absolute;top:694px;left:249px;white-space:nowrap" class="ft154">The&#160;change&#160;in&#160;resting&#160;membrane&#160;potential&#160;is&#160;normalized&#160;to&#160;DMSO&#160;control.&#160;The&#160;negative&#160;values</p>
<p style="position:absolute;top:713px;left:250px;white-space:nowrap" class="ft1513">represent&#160;an&#160;increase&#160;in&#160;hyperpolarization.&#160;(<b>A</b>,<b>B</b>)&#160;were&#160;conducted&#160;on&#160;different&#160;days.&#160;There&#160;were<br/>n&#160;=&#160;55–63&#160;cells&#160;per&#160;condition.&#160;Statistics&#160;were&#160;calculated&#160;for&#160;the&#160;400&#160;s&#160;time&#160;point&#160;(black&#160;box&#160;with&#160;star<br/>on&#160;top).&#160;Significant&#160;values&#160;shown&#160;next&#160;to&#160;legend.&#160;****:&#160;p&#160;&lt;&#160;0.0001,&#160;were&#160;calculated&#160;using&#160;an&#160;ANOVA</p>
<p style="position:absolute;top:771px;left:249px;white-space:nowrap" class="ft154">with&#160;Dunnett&#160;post&#160;hoc&#160;analysis.</p>
<p style="position:absolute;top:800px;left:250px;white-space:nowrap" class="ft159">3.5.&#160;NG108-15&#160;Cells&#160;Express&#160;Neuronal&#160;Markers&#160;with&#160;Drug&#160;Treatments&#160;after&#160;6&#160;Days</p>
<p style="position:absolute;top:823px;left:281px;white-space:nowrap" class="ft159">We&#160;next&#160;wanted&#160;to&#160;ask&#160;whether,&#160;in&#160;addition&#160;to&#160;the&#160;effects&#160;on&#160;proliferation,&#160;our&#160;treat-</p>
<p style="position:absolute;top:842px;left:250px;white-space:nowrap" class="ft1514">ments&#160;also&#160;exerted&#160;a&#160;differentiating&#160;influence,&#160;which&#160;could&#160;be&#160;beneficial&#160;with&#160;respect&#160;to<br/>the&#160;future&#160;behavior&#160;of&#160;treated&#160;cells&#160;in&#160;vivo.&#160;Differentiation&#160;markers&#160;for&#160;neuronal&#160;lineage</p>
<p style="position:absolute;top:880px;left:249px;white-space:nowrap" class="ft159">were&#160;used&#160;to&#160;stain&#160;NG108-15&#160;cells&#160;incubated&#160;for&#160;six&#160;days&#160;with&#160;the&#160;most&#160;effective&#160;treatments</p>
<p style="position:absolute;top:899px;left:250px;white-space:nowrap" class="ft159">observed&#160;in&#160;the&#160;proliferation&#160;data&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#16">8).&#160;</a>We&#160;found&#160;that&#160;treatment&#160;with&#160;pantoprazole&#160;at</p>
<p style="position:absolute;top:918px;left:249px;white-space:nowrap" class="ft159">100&#160;µM&#160;combined&#160;with&#160;NS1643&#160;at&#160;50&#160;µM&#160;or&#160;with&#160;rapamycin&#160;at&#160;100&#160;nM&#160;consistently&#160;showed</p>
<p style="position:absolute;top:936px;left:250px;white-space:nowrap" class="ft1514">a&#160;significant&#160;increase&#160;in&#160;neuronal&#160;differentiation&#160;markers,&#160;including&#160;Microtubule&#160;Associ-<br/>ated&#160;Protein&#160;2&#160;(MAP2)&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">[94],&#160;</a>Neuron-Specific&#160;Class&#160;III&#160;β-Tubulin&#160;(TujI)&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">[95],&#160;</a>Neuron-Specific<br/>Enolase&#160;(NSE)&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">[96],&#160;</a>and&#160;Neural&#160;Filament&#160;Medium&#160;Chain&#160;(NFM)&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">[97].&#160;</a>The&#160;combination&#160;of</p>
<p style="position:absolute;top:993px;left:249px;white-space:nowrap" class="ft1514">pantoprazole&#160;with&#160;retigabine&#160;at&#160;10&#160;µM&#160;showed&#160;increases&#160;in&#160;all&#160;but&#160;MAP2.&#160;Combinations&#160;of<br/>pantoprazole&#160;with&#160;either&#160;NS1643&#160;or&#160;retigabine&#160;showed&#160;a&#160;significant&#160;increase&#160;in&#160;neuronal</p>
<p style="position:absolute;top:1030px;left:250px;white-space:nowrap" class="ft1514">markers&#160;compared&#160;to&#160;either&#160;drug&#160;alone.&#160;The&#160;combination&#160;of&#160;NS1643&#160;with&#160;pantoprazole<br/>showed&#160;higher&#160;levels&#160;of&#160;both&#160;MAP2&#160;and&#160;Tuj1,&#160;than&#160;for&#160;pantoprazole&#160;alone.&#160;Retigabine&#160;in<br/>combination&#160;with&#160;pantoprazole&#160;showed&#160;higher&#160;immunoreactivity&#160;of&#160;NFM&#160;as&#160;compared<br/>to&#160;pantoprazole&#160;alone.&#160;These&#160;observations&#160;suggest&#160;that&#160;these&#160;treatments&#160;are&#160;pushing&#160;the<br/>treated&#160;cells&#160;toward&#160;a&#160;more&#160;differentiated&#160;state.</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft160{font-size:9px;font-family:Times;color:#000000;}
	.ft161{font-size:9px;font-family:Times;color:#000000;}
	.ft162{font-size:9px;font-family:Times;color:#000000;}
	.ft163{font-size:13px;font-family:Times;color:#000000;}
	.ft164{font-size:11px;font-family:Times;color:#000000;}
	.ft165{font-size:11px;font-family:Times;color:#000000;}
	.ft166{font-size:13px;font-family:Times;color:#000000;}
	.ft167{font-size:11px;font-family:Times;color:#000000;}
	.ft168{font-size:12px;font-family:Times;color:#000000;}
	.ft169{font-size:12px;font-family:Times;color:#0775b7;}
	.ft1610{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
	.ft1611{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft1612{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
	.ft1613{font-size:12px;line-height:15px;font-family:Times;color:#000000;}
	.ft1614{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page16-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft160">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft160">16&#160;of&#160;36</p>
<p style="position:absolute;top:-318px;left:56px;white-space:nowrap" class="ft162"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:-318px;left:795px;white-space:nowrap" class="ft160">16 of&#160;38&#160;</p>
<p style="position:absolute;top:-309px;left:56px;white-space:nowrap" class="ft160">&#160;</p>
<p style="position:absolute;top:822px;left:56px;white-space:nowrap" class="ft163">&#160;</p>
<p style="position:absolute;top:-257px;left:252px;white-space:nowrap" class="ft1610">top).&#160;Significant&#160;values&#160;shown next to legend. ****:<i>&#160;p &lt;&#160;</i>0.0001, were&#160;calculated using an&#160;ANOVA&#160;<br/>with Dunnett post hoc<i>&#160;</i>analysis.&#160;</p>
<p style="position:absolute;top:-204px;left:252px;white-space:nowrap" class="ft166"><i>3.5. NG108-15&#160;Cells&#160;Express&#160;Neuronal Markers with Drug&#160;Treatments&#160;after 6 Days&#160;</i></p>
<p style="position:absolute;top:-180px;left:284px;white-space:nowrap" class="ft163">We next wanted to ask whether, in&#160;addition to the effects on proliferation, our treat-</p>
<p style="position:absolute;top:-161px;left:252px;white-space:nowrap" class="ft1611">ments also&#160;exerted a differentiating&#160;influence, which&#160;could be&#160;beneficial with respect to&#160;<br/>the future behavior of&#160;treated cells&#160;in&#160;vivo. Differentiation markers for neuronal lineage&#160;<br/>were used to stain&#160;NG108-15&#160;cells&#160;incubated for six&#160;days with the most effective treat-<br/>ments observed&#160;in the&#160;proliferation&#160;data&#160;(Figure&#160;8).&#160;We found that&#160;treatment with panto-<br/>prazole&#160;at&#160;100 µM combined with NS1643&#160;at&#160;50&#160;µM or&#160;with rapamycin at&#160;100 nM consist-<br/>ently&#160;showed&#160;a significant&#160;increase in&#160;neuronal&#160;differentiation markers,&#160;including&#160;Micro-<br/>tubule&#160;Associated&#160;Protein&#160;2&#160;(MAP2)&#160;[94],&#160;Neuron-Specific Class&#160;III&#160;β-Tubulin&#160;(TujI) [95],&#160;<br/>Neuron-Specific&#160;Enolase (NSE) [96], and Neural&#160;Filament&#160;Medium Chain (NFM) [97].&#160;The&#160;<br/>combination&#160;of pantoprazole with&#160;retigabine&#160;at&#160;10&#160;µM&#160;showed&#160;increases&#160;in&#160;all&#160;but&#160;MAP2.&#160;<br/>Combinations&#160;of pantoprazole with&#160;either NS1643&#160;or&#160;retigabine showed a significant&#160;in-<br/>crease in&#160;neuronal&#160;markers compared to&#160;either drug alone. The combination of&#160;NS1643&#160;<br/>with&#160;pantoprazole&#160;showed&#160;higher&#160;levels&#160;of&#160;both&#160;MAP2&#160;and Tuj1,&#160;than&#160;for pantoprazole&#160;<br/>alone.&#160;Retigabine&#160;in combination with pantoprazole&#160;showed higher&#160;immunoreactivity of&#160;<br/>NFM&#160;as compared to&#160;pantoprazole alone. These observations&#160;suggest that these treat-<br/>ments are pushing the treated cells toward a more differentiated&#160;state.&#160;</p>
<p style="position:absolute;top:566px;left:826px;white-space:nowrap" class="ft163">&#160;</p>
<p style="position:absolute;top:590px;left:252px;white-space:nowrap" class="ft1610"><b>Figure 8.&#160;</b>Differentiation&#160;Analysis of&#160;NG108-15 Cells Reveals that&#160;Treatments with&#160;Pantoprazole&#160;<br/>Increased&#160;Neuronal Markers after 6 days. Immunofluorescence of&#160;cells was&#160;analyzed with&#160;CellPro-<br/>filer&#160;and&#160;quantified&#160;for&#160;integrated&#160;fluorescence&#160;intensity.&#160;(<b>A</b>) Stain of&#160;Microtubule Associated Pro-<br/>tein 2 (MAP2).&#160;(<b>B</b>) Stain of&#160;Neuron-Specific&#160;Class&#160;III&#160;β-Tubulin&#160;(Tuj I). (<b>C</b>)&#160;Stain of&#160;Neural&#160;Filament&#160;<br/>Medium Chain (NFM). (<b>D</b>)&#160;Stain of Neuron-Specific Enolase (NSE).&#160;Treatments corresponding&#160;to&#160;<br/>the colored bars&#160;are outlined&#160;in&#160;the figure itself. The log&#160;of the fold&#160;change&#160;in intensity&#160;was&#160;compared&#160;<br/>between single&#160;treatments and combined treatments, except the positive&#160;control, with&#160;significant&#160;<br/>values shown in&#160;the color of the treatment compared. The initial fluorescence intensities&#160;were com-<br/>pared to their corresponding control,&#160;with&#160;significant values&#160;shown under the bars&#160;as,&#160;***:&#160;<i>p &lt;&#160;</i>0.001,&#160;<br/>**:&#160;<i>p&#160;</i>&lt;<i>&#160;</i>0.01,&#160;<i>*</i>:&#160;<i>p &lt;&#160;</i>0.05&#160;(one-way ANOVA with&#160;Tukey post hoc analysis&#160;<i>n &gt;&#160;</i>3 technical replicates).&#160;</p>
<p style="position:absolute;top:588px;left:250px;white-space:nowrap" class="ft167"><b>Figure&#160;8.</b></p>
<p style="position:absolute;top:588px;left:310px;white-space:nowrap" class="ft164">Differentiation&#160;Analysis&#160;of&#160;NG108-15&#160;Cells&#160;Reveals&#160;that&#160;Treatments&#160;with&#160;Pantoprazole</p>
<p style="position:absolute;top:607px;left:250px;white-space:nowrap" class="ft1612">Increased&#160;Neuronal&#160;Markers&#160;after&#160;6&#160;days.&#160;Immunofluorescence&#160;of&#160;cells&#160;was&#160;analyzed&#160;with&#160;CellProfiler<br/>and&#160;quantified&#160;for&#160;integrated&#160;fluorescence&#160;intensity.&#160;(<b>A</b>)&#160;Stain&#160;of&#160;Microtubule&#160;Associated&#160;Protein&#160;2</p>
<p style="position:absolute;top:645px;left:249px;white-space:nowrap" class="ft164">(MAP2).&#160;(<b>B</b>)&#160;Stain&#160;of&#160;Neuron-Specific&#160;Class&#160;III&#160;β-Tubulin&#160;(Tuj&#160;I).&#160;(<b>C</b>)&#160;Stain&#160;of&#160;Neural&#160;Filament&#160;Medium</p>
<p style="position:absolute;top:665px;left:250px;white-space:nowrap" class="ft1612">Chain&#160;(NFM).&#160;(<b>D</b>)&#160;Stain&#160;of&#160;Neuron-Specific&#160;Enolase&#160;(NSE).&#160;Treatments&#160;corresponding&#160;to&#160;the&#160;colored<br/>bars&#160;are&#160;outlined&#160;in&#160;the&#160;figure&#160;itself.&#160;The&#160;log&#160;of&#160;the&#160;fold&#160;change&#160;in&#160;intensity&#160;was&#160;compared&#160;between<br/>single&#160;treatments&#160;and&#160;combined&#160;treatments,&#160;except&#160;the&#160;positive&#160;control,&#160;with&#160;significant&#160;values&#160;shown<br/>in&#160;the&#160;color&#160;of&#160;the&#160;treatment&#160;compared.&#160;The&#160;initial&#160;fluorescence&#160;intensities&#160;were&#160;compared&#160;to&#160;their<br/>corresponding&#160;control,&#160;with&#160;significant&#160;values&#160;shown&#160;under&#160;the&#160;bars&#160;as,&#160;***:&#160;p&#160;&lt;&#160;0.001,&#160;**:&#160;p&#160;&lt;&#160;0.01,</p>
<p style="position:absolute;top:761px;left:249px;white-space:nowrap" class="ft164">*:&#160;p&#160;&lt;&#160;0.05&#160;(one-way&#160;ANOVA&#160;with&#160;Tukey&#160;post&#160;hoc&#160;analysis&#160;n&#160;&gt;&#160;3&#160;technical&#160;replicates).</p>
<p style="position:absolute;top:790px;left:250px;white-space:nowrap" class="ft1613">3.6.&#160;NG108-15&#160;Cells&#160;Express&#160;Astrocyte&#160;and&#160;Other&#160;Differentiation&#160;Markers&#160;after&#160;Drug&#160;Treatments<br/>for&#160;6&#160;Days</p>
<p style="position:absolute;top:829px;left:281px;white-space:nowrap" class="ft168">Staining&#160;cells&#160;treated&#160;for&#160;6&#160;days&#160;with&#160;S100&#160;calcium-binding&#160;protein&#160;B&#160;(S100B)&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">[98]</a></p>
<p style="position:absolute;top:848px;left:250px;white-space:nowrap" class="ft168">and&#160;Glial&#160;Fibrillary&#160;Acidic&#160;Protein&#160;(GFAP)&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">[99]&#160;</a>markers&#160;revealed&#160;differentiation&#160;of&#160;NG108-</p>
<p style="position:absolute;top:867px;left:249px;white-space:nowrap" class="ft168">15&#160;cells&#160;towards&#160;an&#160;astrocytic/oligodendrocytic&#160;or&#160;astrocytic&#160;lineage,&#160;respectively&#160;(Fig-</p>
<p style="position:absolute;top:886px;left:250px;white-space:nowrap" class="ft1614">ure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#17">9A,B).&#160;</a>Both&#160;markers&#160;were&#160;significantly&#160;upregulated&#160;in&#160;all&#160;combination&#160;treatment&#160;groups<br/>as&#160;well&#160;as&#160;in&#160;pantoprazole&#160;alone.&#160;The&#160;combination&#160;of&#160;NS1643&#160;with&#160;pantoprazole&#160;showed<br/>significantly&#160;higher&#160;S100B&#160;and&#160;GFAP&#160;immunoreactivity&#160;than&#160;with&#160;pantoprazole&#160;alone.</p>
<p style="position:absolute;top:942px;left:249px;white-space:nowrap" class="ft168">All&#160;treatments&#160;but&#160;NS1643&#160;alone&#160;showed&#160;a&#160;significant&#160;increase&#160;in&#160;CREB,&#160;known&#160;to&#160;play</p>
<p style="position:absolute;top:961px;left:250px;white-space:nowrap" class="ft1614">an&#160;important&#160;role&#160;in&#160;driving&#160;differentiation&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[16,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">100–103]&#160;</a>(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#17">9C).&#160;</a>Pantoprazole&#160;alone,<br/>along&#160;with&#160;its&#160;combinations,&#160;also&#160;showed&#160;an&#160;increase&#160;in&#160;connexin&#160;43&#160;(Cx43)&#160;expression,&#160;a<br/>known&#160;marker&#160;for&#160;glioblastoma&#160;differentiation&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">[104].</a></p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft170{font-size:9px;font-family:Times;color:#000000;}
	.ft171{font-size:9px;font-family:Times;color:#000000;}
	.ft172{font-size:9px;font-family:Times;color:#000000;}
	.ft173{font-size:13px;font-family:Times;color:#000000;}
	.ft174{font-size:13px;font-family:Times;color:#000000;}
	.ft175{font-size:11px;font-family:Times;color:#000000;}
	.ft176{font-size:11px;font-family:Times;color:#000000;}
	.ft177{font-size:11px;font-family:Times;color:#000000;}
	.ft178{font-size:7px;font-family:Times;color:#000000;}
	.ft179{font-size:12px;font-family:Times;color:#000000;}
	.ft1710{font-size:12px;font-family:Times;color:#0775b7;}
	.ft1711{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft1712{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft1713{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
	.ft1714{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
	.ft1715{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page17-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft170">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft170">17&#160;of&#160;36</p>
<p style="position:absolute;top:-169px;left:55px;white-space:nowrap" class="ft172"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:-169px;left:793px;white-space:nowrap" class="ft170">17 of&#160;38&#160;</p>
<p style="position:absolute;top:-159px;left:55px;white-space:nowrap" class="ft170">&#160;</p>
<p style="position:absolute;top:972px;left:55px;white-space:nowrap" class="ft173">&#160;</p>
<p style="position:absolute;top:-107px;left:250px;white-space:nowrap" class="ft1711"><i>3.6.&#160;NG108-15 Cells Express&#160;Astrocyte&#160;and Other Differentiation Markers&#160;after Drug&#160;<br/>Treatments&#160;for&#160;6&#160;Days&#160;</i></p>
<p style="position:absolute;top:-64px;left:282px;white-space:nowrap" class="ft173">Staining cells&#160;treated for 6&#160;days with S100&#160;calcium-binding protein&#160;B (S100B)&#160;[98] and&#160;</p>
<p style="position:absolute;top:-44px;left:250px;white-space:nowrap" class="ft1712">Glial Fibrillary&#160;Acidic Protein (GFAP)&#160;[99] markers revealed&#160;differentiation of&#160;NG108-15&#160;<br/>cells towards&#160;an&#160;astrocytic/oligodendrocytic or&#160;astrocytic lineage, respectively&#160;(Figure&#160;<br/>9A,B). Both&#160;markers were&#160;significantly&#160;upregulated&#160;in all combination treatment groups&#160;<br/>as&#160;well as&#160;in&#160;pantoprazole&#160;alone. The combination of&#160;NS1643 with&#160;pantoprazole&#160;showed&#160;<br/>significantly&#160;higher&#160;S100B&#160;and GFAP&#160;immunoreactivity&#160;than with&#160;pantoprazole&#160;alone. All&#160;<br/>treatments but NS1643 alone showed&#160;a&#160;significant&#160;increase in&#160;CREB, known&#160;to play&#160;an&#160;<br/>important&#160;role&#160;in driving&#160;differentiation [16,100–103]&#160;(Figure&#160;9C). Pantoprazole alone,&#160;<br/>along&#160;with&#160;its&#160;combinations,&#160;also&#160;showed&#160;an&#160;increase&#160;in connexin&#160;43 (Cx43) expression,&#160;a&#160;<br/>known marker for&#160;glioblastoma differentiation&#160;[104].&#160;</p>
<p style="position:absolute;top:563px;left:825px;white-space:nowrap" class="ft173">&#160;</p>
<p style="position:absolute;top:586px;left:250px;white-space:nowrap" class="ft1713"><b>Figure 9.&#160;</b>Differentiation&#160;Analysis of&#160;NG108-15 Cells Reveals that&#160;Treatments with&#160;Pantoprazole&#160;<br/>Increased&#160;Astrocytic&#160;and&#160;Differentiation Markers after 6&#160;days.&#160;Immunofluorescence&#160;of&#160;cells&#160;was&#160;<br/>conducted and analyzed with CellProfiler and measured for integrated fluorescence&#160;intensity. (<b>A</b>)&#160;<br/>Stain of&#160;S100&#160;calcium-binding&#160;protein B (S100B). (<b>B</b>)&#160;Stain&#160;Glial Fibrillary&#160;Acidic&#160;Protein&#160;(GFAP).&#160;(<b>C</b>)&#160;<br/>Stain of the phosphorylated cAMP-Response&#160;Element Binding&#160;Protein (Phospho CREB).&#160;(<b>D</b>) Stain&#160;<br/>of Connexin 43&#160;(Cx43). Treatments corresponding to&#160;the&#160;colored bars&#160;are&#160;outlined&#160;in the&#160;figure itself.&#160;<br/>The log&#160;of the&#160;fold&#160;change&#160;in&#160;intensity&#160;was compared between single treatments and&#160;combined&#160;<br/>treatments,&#160;except the&#160;positive&#160;control, with&#160;significant&#160;values shown&#160;in&#160;the color&#160;of&#160;the&#160;treatment&#160;<br/>compared. The&#160;initial&#160;fluorescence intensities&#160;were&#160;compared to&#160;their&#160;corresponding&#160;control,&#160;with&#160;<br/>significant values&#160;shown under the bars&#160;as, ***:&#160;<i>p &lt;&#160;</i>0.001, **:&#160;<i>p&#160;</i>&lt;<i>&#160;</i>0.01,&#160;<i>*</i>:&#160;<i>p &lt;&#160;</i>0.05 (one-way&#160;ANOVA&#160;<br/>with Tukey post&#160;hoc analysis&#160;<i>n &gt;&#160;</i>3 technical&#160;replicates).&#160;</p>
<p style="position:absolute;top:795px;left:250px;white-space:nowrap" class="ft1711"><i>3.7.&#160;NG108-15&#160;Cells Show&#160;an Increase in p27Kip1&#160;and Senescence&#160;Markers&#160;When Treated&#160;with&#160;<br/>Pantoprazole&#160;Alone or&#160;in Combination&#160;with Hyperpolarizing Compounds&#160;</i></p>
<p style="position:absolute;top:838px;left:282px;white-space:nowrap" class="ft173">We&#160;also sought to determine whether our treatments may induce senescence,&#160;as&#160;this&#160;</p>
<p style="position:absolute;top:857px;left:250px;white-space:nowrap" class="ft1712">would be an&#160;important outcome with&#160;respect&#160;to the&#160;course of&#160;the malignancy&#160;in&#160;vivo.&#160;<br/>Treatments&#160;of&#160;NG108-15&#160;cells with&#160;pantoprazole alone or in combination with&#160;NS1643,&#160;<br/>retigabine, and&#160;rapamycin all showed&#160;a very&#160;significant increase&#160;in&#160;a senescence-associ-<br/>ated beta-galactosidase activi<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">ty stain [105</a>]&#160;(<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#18">Figure 10A)</a>.&#160;To explain this&#160;increase, we also&#160;</p>
<p style="position:absolute;top:583px;left:250px;white-space:nowrap" class="ft175"><b>Figure&#160;9.</b></p>
<p style="position:absolute;top:583px;left:310px;white-space:nowrap" class="ft176">Differentiation&#160;Analysis&#160;of&#160;NG108-15&#160;Cells&#160;Reveals&#160;that&#160;Treatments&#160;with&#160;Pantoprazole</p>
<p style="position:absolute;top:603px;left:250px;white-space:nowrap" class="ft1714">Increased&#160;Astrocytic&#160;and&#160;Differentiation&#160;Markers&#160;after&#160;6&#160;days.&#160;Immunofluorescence&#160;of&#160;cells&#160;was&#160;con-<br/>ducted&#160;and&#160;analyzed&#160;with&#160;CellProfiler&#160;and&#160;measured&#160;for&#160;integrated&#160;fluorescence&#160;intensity.&#160;(<b>A</b>)&#160;Stain<br/>of&#160;S100&#160;calcium-binding&#160;protein&#160;B&#160;(S100B).&#160;(<b>B</b>)&#160;Stain&#160;Glial&#160;Fibrillary&#160;Acidic&#160;Protein&#160;(GFAP).&#160;(<b>C</b>)&#160;Stain<br/>of&#160;the&#160;phosphorylated&#160;cAMP-Response&#160;Element&#160;Binding&#160;Protein&#160;(Phospho&#160;CREB).&#160;(<b>D</b>)&#160;Stain&#160;of&#160;Con-<br/>nexin&#160;43&#160;(Cx43).&#160;Treatments&#160;corresponding&#160;to&#160;the&#160;colored&#160;bars&#160;are&#160;outlined&#160;in&#160;the&#160;figure&#160;itself.&#160;The&#160;log<br/>of&#160;the&#160;fold&#160;change&#160;in&#160;intensity&#160;was&#160;compared&#160;between&#160;single&#160;treatments&#160;and&#160;combined&#160;treatments,<br/>except&#160;the&#160;positive&#160;control,&#160;with&#160;significant&#160;values&#160;shown&#160;in&#160;the&#160;color&#160;of&#160;the&#160;treatment&#160;compared.&#160;The<br/>initial&#160;fluorescence&#160;intensities&#160;were&#160;compared&#160;to&#160;their&#160;corresponding&#160;control,&#160;with&#160;significant&#160;values<br/>shown&#160;under&#160;the&#160;bars&#160;as,&#160;***:&#160;p&#160;&lt;&#160;0.001,&#160;**:&#160;p&#160;&lt;&#160;0.01,&#160;*:&#160;p&#160;&lt;&#160;0.05&#160;(one-way&#160;ANOVA&#160;with&#160;Tukey&#160;post&#160;hoc<br/>analysis&#160;n&#160;&gt;&#160;3&#160;technical&#160;replicates).</p>
<p style="position:absolute;top:805px;left:250px;white-space:nowrap" class="ft179">3.7.&#160;NG108-15&#160;Cells&#160;Show&#160;an&#160;Increase&#160;in&#160;p27Kip1&#160;and&#160;Senescence&#160;Markers&#160;When&#160;Treated&#160;with</p>
<p style="position:absolute;top:821px;left:249px;white-space:nowrap" class="ft179">Pantoprazole&#160;Alone&#160;or&#160;in&#160;Combination&#160;with&#160;Hyperpolarizing&#160;Compounds</p>
<p style="position:absolute;top:844px;left:281px;white-space:nowrap" class="ft179">We&#160;also&#160;sought&#160;to&#160;determine&#160;whether&#160;our&#160;treatments&#160;may&#160;induce&#160;senescence,&#160;as&#160;this</p>
<p style="position:absolute;top:863px;left:249px;white-space:nowrap" class="ft1715">would&#160;be&#160;an&#160;important&#160;outcome&#160;with&#160;respect&#160;to&#160;the&#160;course&#160;of&#160;the&#160;malignancy&#160;in&#160;vivo.<br/>Treatments&#160;of&#160;NG108-15&#160;cells&#160;with&#160;pantoprazole&#160;alone&#160;or&#160;in&#160;combination&#160;with&#160;NS1643,</p>
<p style="position:absolute;top:900px;left:250px;white-space:nowrap" class="ft1715">retigabine,&#160;and&#160;rapamycin&#160;all&#160;showed&#160;a&#160;very&#160;significant&#160;increase&#160;in&#160;a&#160;senescence-associated<br/>beta-galactosidase&#160;activity&#160;stain&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">[105]&#160;</a>(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#18">10A).&#160;</a>To&#160;explain&#160;this&#160;increase,&#160;we&#160;also&#160;looked<br/>at&#160;the&#160;p27Kip1&#160;level,&#160;which&#160;is&#160;known&#160;to&#160;inhibit&#160;the&#160;cell&#160;cycle&#160;and&#160;cause&#160;senescence&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">[106–113]</a></p>
<p style="position:absolute;top:957px;left:249px;white-space:nowrap" class="ft1715">(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#18">10E).&#160;</a>Immunoreactivity&#160;levels&#160;of&#160;p27Kip1&#160;in&#160;all&#160;combined&#160;treatments&#160;except&#160;for<br/>pantoprazole&#160;with&#160;rapamycin&#160;were&#160;elevated.&#160;To&#160;confirm&#160;the&#160;senescence&#160;phenotype,&#160;we</p>
<p style="position:absolute;top:995px;left:250px;white-space:nowrap" class="ft1715">also&#160;looked&#160;at&#160;the&#160;size&#160;of&#160;the&#160;nuclei,&#160;which&#160;were&#160;significantly&#160;larger&#160;in&#160;the&#160;pantoprazole,<br/>NS1643,&#160;and&#160;pantoprazole&#160;in&#160;combination&#160;with&#160;NS1643,&#160;retigabine,&#160;or&#160;rapamycin-treated<br/>groups&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#18">10F).&#160;</a>We&#160;also&#160;tested&#160;the&#160;cells&#160;for&#160;cleaved&#160;caspase&#160;3&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#18">10D),&#160;</a>a&#160;marker&#160;of<br/>apoptosis&#160;and&#160;LC3B&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#18">10C),&#160;</a>a&#160;marker&#160;of&#160;autophagy.&#160;We&#160;found&#160;that&#160;levels&#160;for&#160;both<br/>these&#160;markers&#160;were&#160;under&#160;1.4%&#160;and&#160;2.5%,&#160;respectively,&#160;after&#160;6&#160;days&#160;of&#160;treatment&#160;which&#160;may<br/>indicate&#160;a&#160;small&#160;percentage&#160;of&#160;cells&#160;that&#160;did&#160;not&#160;senesce&#160;due&#160;to&#160;the&#160;highly&#160;heterogeneous&#160;na-<br/>ture&#160;of&#160;these&#160;cancer&#160;cells.&#160;Although&#160;low,&#160;there&#160;was&#160;a&#160;significant&#160;increase&#160;in&#160;cleaved&#160;caspase<br/>3&#160;staining&#160;for&#160;cells&#160;treated&#160;with&#160;pantoprazole&#160;or&#160;pantoprazole&#160;with&#160;NS1643,&#160;retigabine,&#160;or<br/>rapamycin.&#160;Surprisingly,&#160;we&#160;observed&#160;that&#160;treatment&#160;with&#160;retigabine&#160;or&#160;NS1643&#160;decreased</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft180{font-size:9px;font-family:Times;color:#000000;}
	.ft181{font-size:9px;font-family:Times;color:#000000;}
	.ft182{font-size:12px;font-family:Times;color:#000000;}
	.ft183{font-size:12px;font-family:Times;color:#0775b7;}
	.ft184{font-size:9px;font-family:Times;color:#000000;}
	.ft185{font-size:13px;font-family:Times;color:#000000;}
	.ft186{font-size:7px;font-family:Times;color:#000000;}
	.ft187{font-size:11px;font-family:Times;color:#000000;}
	.ft188{font-size:11px;font-family:Times;color:#000000;}
	.ft189{font-size:6px;font-family:Times;color:#000000;}
	.ft1810{font-size:8px;font-family:Times;color:#000000;}
	.ft1811{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
	.ft1812{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft1813{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
	.ft1814{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page18-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft180">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft180">18&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:250px;white-space:nowrap" class="ft1811">the&#160;cleaved&#160;caspase&#160;3&#160;positive&#160;cells&#160;significantly&#160;as&#160;compared&#160;to&#160;the&#160;control.&#160;In&#160;addition,<br/>the&#160;LC3B&#160;stain&#160;showed&#160;an&#160;increase&#160;in&#160;cells&#160;treated&#160;with&#160;pantoprazole&#160;and&#160;pantoprazole</p>
<p style="position:absolute;top:184px;left:249px;white-space:nowrap" class="ft182">with&#160;NS1643,&#160;although&#160;not&#160;significant&#160;with&#160;this&#160;assay.&#160;However,&#160;there&#160;was&#160;a&#160;significant</p>
<p style="position:absolute;top:203px;left:250px;white-space:nowrap" class="ft1811">increase&#160;in&#160;bright&#160;LC3B&#160;puncta&#160;in&#160;cells&#160;that&#160;were&#160;treated&#160;with&#160;any&#160;combination&#160;containing<br/>rapamycin,&#160;as&#160;was&#160;expected&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#18">10C).&#160;</a>Proliferation&#160;in&#160;NG108-15&#160;cells&#160;as&#160;measured<br/>by&#160;BrdU&#160;incorporation&#160;showed&#160;a&#160;significant&#160;decrease&#160;with&#160;treatments&#160;of&#160;pantoprazole<br/>alone,&#160;retigabine&#160;alone,&#160;and&#160;combinations&#160;of&#160;pantoprazole&#160;with&#160;NS1643,&#160;retigabine,&#160;and<br/>rapamycin&#160;after&#160;6&#160;days&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#18">10B),&#160;</a>agreeing&#160;with&#160;the&#160;live&#160;cell&#160;counts&#160;obtained&#160;in&#160;Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#8">1A.</a></p>
<p style="position:absolute;top:297px;left:249px;white-space:nowrap" class="ft1811">Thus,&#160;we&#160;conclude&#160;that&#160;the&#160;combinatorial&#160;treatments&#160;that&#160;resulted&#160;in&#160;the&#160;lowest&#160;cellular<br/>proliferation&#160;also&#160;showed&#160;increased&#160;markers&#160;for&#160;senescence,&#160;some&#160;increase&#160;in&#160;autophagy,</p>
<p style="position:absolute;top:335px;left:250px;white-space:nowrap" class="ft182">and&#160;did&#160;not&#160;show&#160;a&#160;large&#160;fraction&#160;of&#160;apoptotic&#160;cells.</p>
<p style="position:absolute;top:-149px;left:54px;white-space:nowrap" class="ft184"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:-149px;left:792px;white-space:nowrap" class="ft180">18 of&#160;38&#160;</p>
<p style="position:absolute;top:-140px;left:54px;white-space:nowrap" class="ft180">&#160;</p>
<p style="position:absolute;top:991px;left:54px;white-space:nowrap" class="ft185">&#160;</p>
<p style="position:absolute;top:-87px;left:249px;white-space:nowrap" class="ft1812">looked&#160;at the p27Kip1&#160;level,&#160;which is known to&#160;inhibit&#160;the cell cycle&#160;and cause&#160;senescence&#160;<br/>[106–113]&#160;(Figure&#160;10E).&#160;Immunoreactivity&#160;levels&#160;of&#160;p27Kip1&#160;in all combined treatments ex-<br/>cept for&#160;pantoprazole&#160;with&#160;rapamycin&#160;were elevated. To&#160;confirm&#160;the senescence pheno-<br/>type, we&#160;also&#160;looked&#160;at the&#160;size of&#160;the nuclei, which&#160;were significantly larger&#160;in the panto-<br/>prazole,&#160;NS1643,&#160;and pantoprazole&#160;in combination&#160;with&#160;NS1643,&#160;retigabine, or&#160;rapamy-<br/>cin-treated groups (Figure&#160;10F). We&#160;also&#160;tested&#160;the cells for cleaved caspase&#160;3 (Figure&#160;10D),&#160;<br/>a marker&#160;of&#160;apoptosis&#160;and&#160;LC3B&#160;(Figure&#160;10C),&#160;a&#160;marker&#160;of&#160;autophagy. We&#160;found&#160;that&#160;lev-<br/>els&#160;for both these markers were&#160;under&#160;1.4%&#160;and&#160;2.5%, respectively,&#160;after&#160;6 days of&#160;treat-<br/>ment which may indicate a&#160;small&#160;percentage of&#160;cells&#160;that&#160;did not senesce due to the highly&#160;<br/>heterogeneous nature of&#160;these cancer cells.&#160;Although&#160;low,&#160;there was a&#160;significant increase&#160;<br/>in cleaved caspase&#160;3&#160;staining for cells treated&#160;with&#160;pantoprazole&#160;or pantoprazole&#160;with&#160;<br/>NS1643, retigabine, or rapamycin.&#160;Surprisingly,&#160;we observed that&#160;treatment with&#160;retiga-<br/>bine or&#160;NS1643 decreased&#160;the cleaved caspase 3&#160;positive cells significantly&#160;as compared to&#160;<br/>the control.&#160;In addition, the&#160;LC3B&#160;stain showed&#160;an&#160;increase in&#160;cells treated with pantopra-<br/>zole&#160;and pantoprazole with&#160;NS1643,&#160;although not&#160;significant&#160;with&#160;this&#160;assay.&#160;However,&#160;<br/>there was&#160;a&#160;significant&#160;increase&#160;in bright&#160;LC3B&#160;puncta&#160;in&#160;cells that&#160;were treated&#160;with&#160;any&#160;<br/>combination&#160;containing&#160;rapamycin,<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#18">&#160;as was ex</a>pected (Figure 10C). Proliferation in&#160;NG108-<br/>15&#160;cells&#160;as&#160;measured by&#160;BrdU&#160;incorporation showed&#160;a&#160;significant&#160;decrease&#160;with&#160;treatments&#160;<br/>of pantoprazole&#160;alone, retigabine alone, and combinations of&#160;pantoprazole&#160;with NS1643,&#160;<br/>retigabine, and rapamycin af<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#18">ter&#160;</a>6&#160;days (Figure 10B),&#160;agreeing with the live cell<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#8">&#160;counts&#160;<br/></a>obtained&#160;in&#160;Figure&#160;1A. Thus, we conclude that&#160;the combinatorial treatments that&#160;resulted&#160;<br/>in the&#160;lowest&#160;cellular&#160;proliferation&#160;also&#160;showed&#160;increased markers&#160;for senescence, some&#160;<br/>increase in&#160;autophagy, and did&#160;not show a&#160;large fraction&#160;of&#160;apoptotic&#160;cells.&#160;</p>
<p style="position:absolute;top:798px;left:827px;white-space:nowrap" class="ft185">&#160;</p>
<p style="position:absolute;top:822px;left:249px;white-space:nowrap" class="ft1813"><b>Figure 10.&#160;</b>Senescence&#160;and Proliferation&#160;Analysis of&#160;NG108-15 Cells Reveals that Treatments with&#160;<br/>Pantoprazole&#160;Increased&#160;Senescence,&#160;Decreased&#160;BrdU Incorporation, and Increased a p27Kip1&#160;after 6&#160;<br/>days.&#160;A senescence associated&#160;beta-galactosidase&#160;stain was&#160;conducted and&#160;scored by&#160;eye.&#160;Immuno-<br/>fluorescence&#160;of&#160;cells was conducted and analyzed with CellProfiler for&#160;integrated fluorescence&#160;in-<br/>tensity&#160;or presence or absence of a cellular signal. (<b>A</b>) Stain&#160;of senescence&#160;associated beta-galacto-<br/>sidase stain (SA-Beta Gal). (<b>B</b>) Stain of bromodeoxyuridine incorporation&#160;(BrdU). (<b>C</b>) Stain of the&#160;<br/>microtubule-associated protein light chain 3&#160;B (LC3B). (<b>D</b>)&#160;Stain of cleaved caspase 3 (Casp 3). (<b>E</b>)&#160;</p>
<p style="position:absolute;top:830px;left:250px;white-space:nowrap" class="ft187"><b>Figure&#160;10.</b></p>
<p style="position:absolute;top:830px;left:313px;white-space:nowrap" class="ft188">Senescence&#160;and&#160;Proliferation&#160;Analysis&#160;of&#160;NG108-15&#160;Cells&#160;Reveals&#160;that&#160;Treatments&#160;with&#160;Pan-</p>
<p style="position:absolute;top:849px;left:250px;white-space:nowrap" class="ft188">toprazole&#160;Increased&#160;Senescence,&#160;Decreased&#160;BrdU&#160;Incorporation,&#160;and&#160;Increased&#160;a&#160;p27Kip1&#160;after&#160;6&#160;days.</p>
<p style="position:absolute;top:869px;left:249px;white-space:nowrap" class="ft188">A&#160;senescence&#160;associated&#160;beta-galactosidase&#160;stain&#160;was&#160;conducted&#160;and&#160;scored&#160;by&#160;eye.&#160;Immunofluores-</p>
<p style="position:absolute;top:888px;left:250px;white-space:nowrap" class="ft188">cence&#160;of&#160;cells&#160;was&#160;conducted&#160;and&#160;analyzed&#160;with&#160;CellProfiler&#160;for&#160;integrated&#160;fluorescence&#160;intensity&#160;or</p>
<p style="position:absolute;top:907px;left:249px;white-space:nowrap" class="ft1814">presence&#160;or&#160;absence&#160;of&#160;a&#160;cellular&#160;signal.&#160;(<b>A</b>)&#160;Stain&#160;of&#160;senescence&#160;associated&#160;beta-galactosidase&#160;stain<br/>(SA-Beta&#160;Gal).&#160;(<b>B</b>)&#160;Stain&#160;of&#160;bromodeoxyuridine&#160;incorporation&#160;(BrdU).&#160;(<b>C</b>)&#160;Stain&#160;of&#160;the&#160;microtubule-</p>
<p style="position:absolute;top:945px;left:250px;white-space:nowrap" class="ft1814">associated&#160;protein&#160;light&#160;chain&#160;3&#160;B&#160;(LC3B).&#160;(<b>D</b>)&#160;Stain&#160;of&#160;cleaved&#160;caspase&#160;3&#160;(Casp&#160;3).&#160;(<b>E</b>)&#160;Stain&#160;of<br/>cyclin-dependent&#160;kinase&#160;inhibitor&#160;1B&#160;(p27Kip).&#160;(<b>F</b>)&#160;Size&#160;of&#160;Nuclei,&#160;determined&#160;by&#160;area&#160;of&#160;the&#160;Hoechst<br/>stain.&#160;Treatments&#160;corresponding&#160;to&#160;the&#160;colored&#160;bars&#160;are&#160;outlined&#160;in&#160;the&#160;figure&#160;itself.&#160;The&#160;log&#160;of&#160;the<br/>fold&#160;change&#160;in&#160;intensity&#160;was&#160;compared&#160;between&#160;single&#160;treatments&#160;and&#160;combined&#160;treatments,&#160;except<br/>the&#160;positive&#160;control,&#160;with&#160;significant&#160;values&#160;shown&#160;in&#160;the&#160;color&#160;of&#160;the&#160;treatment&#160;compared.&#160;The&#160;initial<br/>fluorescence&#160;intensities&#160;were&#160;compared&#160;to&#160;their&#160;corresponding&#160;control,&#160;with&#160;significant&#160;values&#160;shown<br/>under&#160;the&#160;bars.&#160;The&#160;logit&#160;of&#160;the&#160;percent&#160;positive&#160;cells&#160;was&#160;compared&#160;between&#160;single&#160;treatments&#160;and<br/>control,&#160;in&#160;cases&#160;of&#160;0&#160;values,&#160;the&#160;arcsine&#160;transformation&#160;was&#160;used.&#160;Significance&#160;was&#160;expressed&#160;as,</p>
<p style="position:absolute;top:1099px;left:249px;white-space:nowrap" class="ft188">***:&#160;p&#160;&lt;&#160;0.001,&#160;**:&#160;p&#160;&lt;&#160;0.01,&#160;*:&#160;p&#160;&lt;&#160;0.05&#160;(one-way&#160;ANOVA&#160;with&#160;Tukey&#160;post&#160;hoc&#160;analysis&#160;n&#160;&gt;&#160;3&#160;technical</p>
<p style="position:absolute;top:1119px;left:250px;white-space:nowrap" class="ft188">replicates).</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft190{font-size:9px;font-family:Times;color:#000000;}
	.ft191{font-size:9px;font-family:Times;color:#000000;}
	.ft192{font-size:12px;font-family:Times;color:#000000;}
	.ft193{font-size:12px;font-family:Times;color:#0775b7;}
	.ft194{font-size:9px;font-family:Times;color:#000000;}
	.ft195{font-size:13px;font-family:Times;color:#000000;}
	.ft196{font-size:11px;font-family:Times;color:#000000;}
	.ft197{font-size:11px;font-family:Times;color:#000000;}
	.ft198{font-size:11px;font-family:Times;color:#000000;}
	.ft199{font-size:13px;font-family:Times;color:#000000;}
	.ft1910{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
	.ft1911{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
	.ft1912{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
	.ft1913{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft1914{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft1915{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page19-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft190">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft190">19&#160;of&#160;36</p>
<p style="position:absolute;top:146px;left:250px;white-space:nowrap" class="ft192">3.8.&#160;U87&#160;Cells&#160;Show&#160;Increases&#160;in&#160;Neuronal&#160;Markers&#160;When&#160;Treated&#160;with&#160;Combination&#160;Treatments&#160;of</p>
<p style="position:absolute;top:162px;left:249px;white-space:nowrap" class="ft192">Hyperpolarizing&#160;Drugs&#160;and&#160;Pantoprazole&#160;or&#160;NS1643&#160;and&#160;TMZ</p>
<p style="position:absolute;top:186px;left:281px;white-space:nowrap" class="ft192">U87&#160;cells&#160;showed&#160;a&#160;significant&#160;increase&#160;in&#160;neuronal&#160;markers&#160;for&#160;the&#160;combination&#160;treat-</p>
<p style="position:absolute;top:204px;left:250px;white-space:nowrap" class="ft1910">ments&#160;with&#160;TMZ&#160;as&#160;compared&#160;to&#160;control&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#19">11)</a>.&#160;NFM&#160;and&#160;NSE,&#160;similar&#160;to&#160;what&#160;was<br/>seen&#160;in&#160;NG108-15&#160;cells,&#160;were&#160;also&#160;increased&#160;in&#160;cells&#160;treated&#160;with&#160;pantoprazole&#160;or&#160;combination<br/>treatments&#160;with&#160;pantoprazole&#160;and&#160;NS1643&#160;or&#160;retigabine&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#19">11C</a>).&#160;TujI&#160;was&#160;only&#160;highly<br/>elevated&#160;in&#160;the&#160;U87&#160;cells&#160;treated&#160;with&#160;NS1643&#160;and&#160;TMZ&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#19">11B</a>).&#160;MAP2&#160;showed&#160;high<br/>levels&#160;of&#160;immunoreactivity&#160;when&#160;cells&#160;were&#160;treated&#160;with&#160;combinations&#160;of&#160;TMZ&#160;and&#160;NS1643&#160;or</p>
<p style="position:absolute;top:299px;left:249px;white-space:nowrap" class="ft1910">pantoprazole&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#19">11A</a>).&#160;It&#160;should&#160;be&#160;noted&#160;that&#160;cell&#160;staining&#160;was&#160;highly&#160;heterogeneous,<br/>with&#160;some&#160;cells&#160;staining&#160;more&#160;brightly&#160;than&#160;others&#160;with&#160;the&#160;same&#160;treatment.</p>
<p style="position:absolute;top:-115px;left:56px;white-space:nowrap" class="ft194"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:-115px;left:794px;white-space:nowrap" class="ft190">19 of&#160;38&#160;</p>
<p style="position:absolute;top:-105px;left:56px;white-space:nowrap" class="ft190">&#160;</p>
<p style="position:absolute;top:1026px;left:56px;white-space:nowrap" class="ft195">&#160;</p>
<p style="position:absolute;top:-53px;left:251px;white-space:nowrap" class="ft1912">Stain of&#160;cyclin-dependent kinase inhibitor 1B&#160;(p27Kip).&#160;(<b>F</b>)&#160;Size of&#160;Nuclei,&#160;determined by&#160;area of the&#160;<br/>Hoechst&#160;stain.&#160;Treatments corresponding to the colored&#160;bars&#160;are outlined&#160;in&#160;the figure itself. The&#160;log&#160;<br/>of the&#160;fold&#160;change&#160;in&#160;intensity&#160;was&#160;compared&#160;between single&#160;treatments&#160;and combined&#160;treatments,&#160;<br/>except the positive control,&#160;with significant values shown in&#160;the color of the treatment compared.&#160;<br/>The initial fluorescence&#160;intensities&#160;were&#160;compared&#160;to their&#160;corresponding&#160;control, with significant&#160;<br/>values&#160;shown under the bars. The logit&#160;of the percent positive&#160;cells was compared between single&#160;<br/>treatments and control, in cases&#160;of 0&#160;values,&#160;the arcsine transformation was used. Significance was&#160;<br/>expressed as, ***:&#160;<i>p &lt;&#160;</i>0.001, **:&#160;<i>p&#160;</i>&lt;<i>&#160;</i>0.01,&#160;<i>*</i>:&#160;<i>p &lt;&#160;</i>0.05 (one-way ANOVA with&#160;Tukey post hoc&#160;analysis&#160;<i>n&#160;<br/>&gt;&#160;</i>3 technical replicates).&#160;</p>
<p style="position:absolute;top:120px;left:251px;white-space:nowrap" class="ft1913"><i>3.8. U87&#160;Cells Show&#160;Increases&#160;in&#160;Neuronal Markers&#160;When&#160;Treated with Combination&#160;<br/>Treatments&#160;of&#160;Hyperpolarizing&#160;Drugs and&#160;Pantoprazole or&#160;NS1643 and&#160;TMZ&#160;</i></p>
<p style="position:absolute;top:163px;left:283px;white-space:nowrap" class="ft195">U87&#160;cells showed a significant&#160;increase&#160;in&#160;neuronal&#160;markers&#160;for&#160;the combination&#160;</p>
<p style="position:absolute;top:182px;left:251px;white-space:nowrap" class="ft1914">treatments with TMZ as&#160;compared to control&#160;(Figure&#160;11).&#160;NFM&#160;and NSE, similar&#160;to what&#160;<br/>was&#160;seen&#160;in&#160;NG108-15&#160;cells,&#160;were&#160;also&#160;increased&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#19">in&#160;cel</a>ls&#160;treated&#160;with&#160;pantoprazole&#160;or com-<br/>bination treatments with pantoprazole&#160;and NS1643&#160;or retigabine (Figure 11C). TujI was&#160;<br/>only highly&#160;elevated&#160;in the&#160;U87 cells treated with&#160;NS1643&#160;an<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#19">d TMZ (</a>Figure 11B). MAP2&#160;<br/>showed high&#160;levels&#160;of&#160;immunoreactivity&#160;when&#160;cells&#160;were&#160;tre<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#19">ated</a>&#160;with&#160;combinations&#160;of&#160;<br/>TMZ&#160;and NS1643&#160;or pantoprazole (Figure 11A). It&#160;should be&#160;noted that&#160;cell staining was&#160;<br/>highly hetero<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#19">geneous, w</a>ith&#160;some cells&#160;staining&#160;more&#160;brightly&#160;than&#160;others&#160;with&#160;the&#160;same&#160;<br/>treatment.&#160;</p>
<p style="position:absolute;top:770px;left:820px;white-space:nowrap" class="ft195">&#160;</p>
<p style="position:absolute;top:793px;left:251px;white-space:nowrap" class="ft1911"><b>Figure 11.&#160;</b>Differentiation Analysis&#160;of U87&#160;Cells Reveals that Treatments with&#160;Pantoprazole In-<br/>creased&#160;Neuronal Markers after 6 days.&#160;Immunofluorescence of cells was conducted and&#160;analyzed&#160;<br/>with CellProfiler for&#160;integrated fluorescence&#160;intensity.&#160;(<b>A</b>)&#160;Stain of&#160;Microtubule Associated&#160;Protein&#160;<br/>2 (MAP2). (<b>B</b>)&#160;Stain of&#160;Neuron-Specific Class&#160;III&#160;β-Tubulin&#160;(TujI).&#160;(<b>C</b>)&#160;Stain of&#160;Neural Filament Me-<br/>dium Chain (NFM). (<b>D</b>)&#160;Stain&#160;of Neuron-Specific&#160;Enolase&#160;(NSE).&#160;Treatments corresponding to the&#160;<br/>colored bars&#160;are outlined&#160;in the figure itself.&#160;The&#160;log&#160;of the&#160;fold change&#160;in&#160;intensity&#160;was&#160;compared&#160;<br/>between single&#160;treatments and combined treatments, except the positive&#160;control, with&#160;significant&#160;<br/>values shown in&#160;the color of the treatment compared. The initial fluorescence intensities&#160;were com-<br/>pared to their corresponding control,&#160;with&#160;significant values&#160;shown under the bars&#160;as,&#160;***:&#160;<i>p &lt;&#160;</i>0.001,&#160;<br/>**:&#160;<i>p&#160;</i>&lt;<i>&#160;</i>0.01,&#160;<i>*</i>:&#160;<i>p &lt;&#160;</i>0.05&#160;(one-way ANOVA with&#160;Tukey post hoc analysis&#160;<i>n &gt;&#160;</i>3 technical replicates).&#160;</p>
<p style="position:absolute;top:791px;left:250px;white-space:nowrap" class="ft197"><b>Figure&#160;11.</b></p>
<p style="position:absolute;top:791px;left:313px;white-space:nowrap" class="ft196">Differentiation&#160;Analysis&#160;of&#160;U87&#160;Cells&#160;Reveals&#160;that&#160;Treatments&#160;with&#160;Pantoprazole&#160;Increased</p>
<p style="position:absolute;top:810px;left:250px;white-space:nowrap" class="ft1915">Neuronal&#160;Markers&#160;after&#160;6&#160;days.&#160;Immunofluorescence&#160;of&#160;cells&#160;was&#160;conducted&#160;and&#160;analyzed&#160;with<br/>CellProfiler&#160;for&#160;integrated&#160;fluorescence&#160;intensity.&#160;(<b>A</b>)&#160;Stain&#160;of&#160;Microtubule&#160;Associated&#160;Protein&#160;2</p>
<p style="position:absolute;top:849px;left:249px;white-space:nowrap" class="ft196">(MAP2).&#160;(<b>B</b>)&#160;Stain&#160;of&#160;Neuron-Specific&#160;Class&#160;III&#160;β-Tubulin&#160;(TujI).&#160;(<b>C</b>)&#160;Stain&#160;of&#160;Neural&#160;Filament&#160;Medium</p>
<p style="position:absolute;top:868px;left:250px;white-space:nowrap" class="ft1915">Chain&#160;(NFM).&#160;(<b>D</b>)&#160;Stain&#160;of&#160;Neuron-Specific&#160;Enolase&#160;(NSE).&#160;Treatments&#160;corresponding&#160;to&#160;the&#160;colored<br/>bars&#160;are&#160;outlined&#160;in&#160;the&#160;figure&#160;itself.&#160;The&#160;log&#160;of&#160;the&#160;fold&#160;change&#160;in&#160;intensity&#160;was&#160;compared&#160;between<br/>single&#160;treatments&#160;and&#160;combined&#160;treatments,&#160;except&#160;the&#160;positive&#160;control,&#160;with&#160;significant&#160;values&#160;shown<br/>in&#160;the&#160;color&#160;of&#160;the&#160;treatment&#160;compared.&#160;The&#160;initial&#160;fluorescence&#160;intensities&#160;were&#160;compared&#160;to&#160;their<br/>corresponding&#160;control,&#160;with&#160;significant&#160;values&#160;shown&#160;under&#160;the&#160;bars&#160;as,&#160;***:&#160;p&#160;&lt;&#160;0.001,&#160;**:&#160;p&#160;&lt;&#160;0.01,</p>
<p style="position:absolute;top:964px;left:249px;white-space:nowrap" class="ft196">*:&#160;p&#160;&lt;&#160;0.05&#160;(one-way&#160;ANOVA&#160;with&#160;Tukey&#160;post&#160;hoc&#160;analysis&#160;n&#160;&gt;&#160;3&#160;technical&#160;replicates).</p>
<p style="position:absolute;top:993px;left:250px;white-space:nowrap" class="ft192">3.9.&#160;U87&#160;Cells&#160;Also&#160;Show&#160;Increases&#160;in&#160;Astrocytic&#160;Markers&#160;When&#160;Treated&#160;with&#160;Combination</p>
<p style="position:absolute;top:1009px;left:249px;white-space:nowrap" class="ft192">Treatments&#160;of&#160;Hyperpolarizing&#160;Drugs&#160;and&#160;Pantoprazole&#160;or&#160;NS1643&#160;and&#160;TMZ</p>
<p style="position:absolute;top:1032px;left:281px;white-space:nowrap" class="ft192">Astrocytic&#160;differentiation&#160;markers&#160;were&#160;increased&#160;in&#160;treatments&#160;with&#160;pantoprazole</p>
<p style="position:absolute;top:1051px;left:250px;white-space:nowrap" class="ft1910">and&#160;pantoprazole&#160;in&#160;combination&#160;with&#160;NS1643,&#160;retigabine,&#160;rapamycin,&#160;and&#160;TMZ,&#160;as&#160;well<br/>as&#160;NS1643&#160;in&#160;combination&#160;with&#160;TMZ&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#20">12).&#160;</a>Vimentin,&#160;a&#160;known&#160;marker&#160;for&#160;astro-<br/>cytes&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">[114,115],&#160;</a>was&#160;significantly&#160;increased&#160;when&#160;cells&#160;were&#160;treated&#160;with&#160;pantoprazole&#160;in<br/>combination&#160;with&#160;NS1643,&#160;TMZ,&#160;and&#160;rapamycin&#160;and&#160;with&#160;NS1643&#160;in&#160;combination&#160;with</p>
<p style="position:absolute;top:1127px;left:249px;white-space:nowrap" class="ft1910">TMZ&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#20">12A).&#160;</a>CREB&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#20">12B),&#160;</a>a&#160;known&#160;marker&#160;for&#160;differentiation&#160;and&#160;S100B<br/>(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#20">12C</a>)&#160;and&#160;GFAP&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#20">12D),&#160;</a>markers&#160;for&#160;astrocytic&#160;differentiation,&#160;also&#160;were&#160;in-</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft200{font-size:9px;font-family:Times;color:#000000;}
	.ft201{font-size:9px;font-family:Times;color:#000000;}
	.ft202{font-size:12px;font-family:Times;color:#000000;}
	.ft203{font-size:12px;font-family:Times;color:#0775b7;}
	.ft204{font-size:9px;font-family:Times;color:#000000;}
	.ft205{font-size:13px;font-family:Times;color:#000000;}
	.ft206{font-size:13px;font-family:Times;color:#000000;}
	.ft207{font-size:11px;font-family:Times;color:#000000;}
	.ft208{font-size:11px;font-family:Times;color:#000000;}
	.ft209{font-size:11px;font-family:Times;color:#000000;}
	.ft2010{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
	.ft2011{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft2012{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft2013{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
	.ft2014{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page20-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft200">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft200">20&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:250px;white-space:nowrap" class="ft2010">creased&#160;by&#160;these&#160;same&#160;treatments&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#20">12B).&#160;</a>These&#160;results&#160;agreed&#160;well&#160;with&#160;what&#160;was<br/>found&#160;in&#160;NG108-15&#160;cells.</p>
<p style="position:absolute;top:-95px;left:55px;white-space:nowrap" class="ft204"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:-95px;left:794px;white-space:nowrap" class="ft200">20 of&#160;38&#160;</p>
<p style="position:absolute;top:-86px;left:55px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:1045px;left:55px;white-space:nowrap" class="ft205">&#160;</p>
<p style="position:absolute;top:-33px;left:251px;white-space:nowrap" class="ft2011"><i>3.9.&#160;U87 Cells&#160;Also Show&#160;Increases in&#160;Astrocytic&#160;Markers&#160;When Treated&#160;with Combination&#160;<br/>Treatments&#160;of&#160;Hyperpolarizing&#160;Drugs and&#160;Pantoprazole or&#160;NS1643 and&#160;TMZ&#160;</i></p>
<p style="position:absolute;top:9px;left:283px;white-space:nowrap" class="ft205">Astrocytic&#160;differentiation&#160;markers were&#160;increased in treatments&#160;with pantoprazole&#160;</p>
<p style="position:absolute;top:28px;left:251px;white-space:nowrap" class="ft2012">and&#160;pantoprazole&#160;in combination&#160;with&#160;NS1643,&#160;retigabine,&#160;rapamycin,&#160;and&#160;TMZ,&#160;as&#160;well&#160;<br/>as NS1643&#160;in combination with&#160;TMZ&#160;(Figure 12).&#160;Vimentin, a&#160;known&#160;marker&#160;for astrocytes&#160;<br/>[114,115], was significantly increased&#160;when cells were treated with pantoprazole&#160;in&#160;com-<br/>bination with NS1643, TMZ, and&#160;rapamycin&#160;and with NS1643&#160;in&#160;combination&#160;with TMZ&#160;<br/>(Figure&#160;12A).&#160;CREB&#160;(Figure 12B),&#160;a&#160;known marker&#160;for differentiation and&#160;S100B&#160;(Figure&#160;<br/>12C) and GFAP (Figure&#160;12D), markers&#160;for astrocytic&#160;differentiation, also were&#160;increased&#160;<br/>by these same&#160;treatments&#160;(Figure&#160;12B)<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#20">. These results agree</a>d&#160;well with&#160;what&#160;was found&#160;in&#160;<br/>NG108-15&#160;cells.&#160;</p>
<p style="position:absolute;top:632px;left:831px;white-space:nowrap" class="ft205">&#160;</p>
<p style="position:absolute;top:656px;left:251px;white-space:nowrap" class="ft2013"><b>Figure 12.&#160;</b>Differentiation Analysis&#160;of U87&#160;Cells Reveals that Treatments with&#160;Pantoprazole In-<br/>creased&#160;Astrocytic and&#160;Differentiation&#160;Markers after 6&#160;days.&#160;Immunofluorescence&#160;of&#160;cells&#160;was&#160;con-<br/>ducted and analyzed with CellProfiler for integrated fluorescence&#160;intensity.&#160;(<b>A</b>) Stain of&#160;Vimentin.&#160;<br/>(<b>B</b>) Stain&#160;of&#160;the&#160;phosphorylated cAMP-Response Element Binding Protein&#160;(CREB). (<b>C</b>)&#160;Stain of S100&#160;<br/>calcium&#160;binding&#160;protein&#160;B&#160;(S100B).&#160;(<b>D</b>)&#160;Stain&#160;Glial&#160;Fibrillary&#160;Acidic&#160;Protein&#160;(GFAP).&#160;Treatments&#160;cor-<br/>responding&#160;to&#160;the colored&#160;bars&#160;are&#160;outlined&#160;in&#160;the figure itself. The&#160;log&#160;of&#160;the&#160;fold&#160;change&#160;in&#160;intensity&#160;<br/>was compared&#160;between single&#160;treatments and combined treatments, except the positive&#160;control,&#160;<br/>with significant values&#160;shown&#160;in the&#160;color&#160;of&#160;the treatment&#160;compared. The&#160;initial fluorescence&#160;inten-<br/>sities&#160;were&#160;compared to their corresponding&#160;control,&#160;with&#160;significant&#160;values shown under the bars&#160;<br/>as,&#160;***:&#160;<i>p &lt;&#160;</i>0.001, **:&#160;<i>p&#160;</i>&lt;<i>&#160;</i>0.01,&#160;<i>*</i>:&#160;<i>p &lt;&#160;</i>0.05 (one-way&#160;ANOVA with&#160;Tukey post hoc analysis&#160;<i>n &gt;&#160;</i>3 technical&#160;<br/>replicates).&#160;</p>
<p style="position:absolute;top:865px;left:251px;white-space:nowrap" class="ft2011"><i>3.10. U87&#160;Cells Show Increase in Oligodendrocyte&#160;Markers&#160;When&#160;Treated with Pantoprazole in&#160;<br/>Combination with&#160;Hyperpolarizing Compounds&#160;or&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#21">NS16</a></i><i>43&#160;and TMZ&#160;</i></p>
<p style="position:absolute;top:908px;left:283px;white-space:nowrap" class="ft205">U87 cells showed increases in O4&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#21">(Figure 13A)&#160;</a>for&#160;all treatments&#160;except those con-</p>
<p style="position:absolute;top:927px;left:251px;white-space:nowrap" class="ft2012">taining retigabine.&#160;Sox10&#160;levels&#160;(Figure&#160;13B)&#160;also&#160;increased&#160;for&#160;all&#160;treatments,&#160;excluding&#160;<br/>retigabine alone. When taken together, the above data&#160;suggest that&#160;the differentiating ac-<br/>tivity of these&#160;treatments&#160;are not specific&#160;to one species or one type&#160;of&#160;cell&#160;line.&#160;</p>
<p style="position:absolute;top:651px;left:250px;white-space:nowrap" class="ft207"><b>Figure&#160;12.</b></p>
<p style="position:absolute;top:651px;left:313px;white-space:nowrap" class="ft208">Differentiation&#160;Analysis&#160;of&#160;U87&#160;Cells&#160;Reveals&#160;that&#160;Treatments&#160;with&#160;Pantoprazole&#160;Increased</p>
<p style="position:absolute;top:670px;left:249px;white-space:nowrap" class="ft208">Astrocytic&#160;and&#160;Differentiation&#160;Markers&#160;after&#160;6&#160;days.&#160;Immunofluorescence&#160;of&#160;cells&#160;was&#160;conducted&#160;and</p>
<p style="position:absolute;top:689px;left:250px;white-space:nowrap" class="ft208">analyzed&#160;with&#160;CellProfiler&#160;for&#160;integrated&#160;fluorescence&#160;intensity.&#160;(<b>A</b>)&#160;Stain&#160;of&#160;Vimentin.&#160;(<b>B</b>)&#160;Stain&#160;of&#160;the</p>
<p style="position:absolute;top:708px;left:249px;white-space:nowrap" class="ft2014">phosphorylated&#160;cAMP-Response&#160;Element&#160;Binding&#160;Protein&#160;(CREB).&#160;(<b>C</b>)&#160;Stain&#160;of&#160;S100&#160;calcium&#160;binding<br/>protein&#160;B&#160;(S100B).&#160;(<b>D</b>)&#160;Stain&#160;Glial&#160;Fibrillary&#160;Acidic&#160;Protein&#160;(GFAP).&#160;Treatments&#160;corresponding&#160;to&#160;the</p>
<p style="position:absolute;top:747px;left:250px;white-space:nowrap" class="ft2014">colored&#160;bars&#160;are&#160;outlined&#160;in&#160;the&#160;figure&#160;itself.&#160;The&#160;log&#160;of&#160;the&#160;fold&#160;change&#160;in&#160;intensity&#160;was&#160;compared<br/>between&#160;single&#160;treatments&#160;and&#160;combined&#160;treatments,&#160;except&#160;the&#160;positive&#160;control,&#160;with&#160;significant&#160;values<br/>shown&#160;in&#160;the&#160;color&#160;of&#160;the&#160;treatment&#160;compared.&#160;The&#160;initial&#160;fluorescence&#160;intensities&#160;were&#160;compared&#160;to<br/>their&#160;corresponding&#160;control,&#160;with&#160;significant&#160;values&#160;shown&#160;under&#160;the&#160;bars&#160;as,&#160;***:&#160;p&#160;&lt;&#160;0.001,&#160;**:&#160;p&#160;&lt;&#160;0.01,</p>
<p style="position:absolute;top:824px;left:249px;white-space:nowrap" class="ft208">*:&#160;p&#160;&lt;&#160;0.05&#160;(one-way&#160;ANOVA&#160;with&#160;Tukey&#160;post&#160;hoc&#160;analysis&#160;n&#160;&gt;&#160;3&#160;technical&#160;replicates).</p>
<p style="position:absolute;top:853px;left:250px;white-space:nowrap" class="ft202">3.10.&#160;U87&#160;Cells&#160;Show&#160;Increase&#160;in&#160;Oligodendrocyte&#160;Markers&#160;When&#160;Treated&#160;with&#160;Pantoprazole&#160;in</p>
<p style="position:absolute;top:869px;left:249px;white-space:nowrap" class="ft202">Combination&#160;with&#160;Hyperpolarizing&#160;Compounds&#160;or&#160;NS1643&#160;and&#160;TMZ</p>
<p style="position:absolute;top:892px;left:281px;white-space:nowrap" class="ft202">U87&#160;cells&#160;showed&#160;increases&#160;in&#160;O4&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#21">13A)&#160;</a>for&#160;all&#160;treatments&#160;except&#160;those&#160;con-</p>
<p style="position:absolute;top:911px;left:250px;white-space:nowrap" class="ft2010">taining&#160;retigabine.&#160;Sox10&#160;levels&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#21">13B)&#160;</a>also&#160;increased&#160;for&#160;all&#160;treatments,&#160;excluding<br/>retigabine&#160;alone.&#160;When&#160;taken&#160;together,&#160;the&#160;above&#160;data&#160;suggest&#160;that&#160;the&#160;differentiating<br/>activity&#160;of&#160;these&#160;treatments&#160;are&#160;not&#160;specific&#160;to&#160;one&#160;species&#160;or&#160;one&#160;type&#160;of&#160;cell&#160;line.</p>
<p style="position:absolute;top:986px;left:250px;white-space:nowrap" class="ft202">3.11.&#160;U87&#160;Cells&#160;Also&#160;Show&#160;an&#160;Increase&#160;in&#160;p27Kip1&#160;and&#160;Senescence&#160;Markers&#160;When&#160;Treated&#160;with</p>
<p style="position:absolute;top:1001px;left:249px;white-space:nowrap" class="ft202">Pantoprazole&#160;Alone&#160;or&#160;in&#160;Combination&#160;with&#160;Hyperpolarizing&#160;Compounds</p>
<p style="position:absolute;top:1025px;left:281px;white-space:nowrap" class="ft202">We&#160;tested&#160;U87&#160;cells&#160;for&#160;the&#160;same&#160;proliferation,&#160;senescence,&#160;autophagy,&#160;and&#160;apoptosis</p>
<p style="position:absolute;top:1044px;left:250px;white-space:nowrap" class="ft2010">markers&#160;that&#160;we&#160;had&#160;tested&#160;in&#160;NG108-15&#160;cells&#160;and&#160;found&#160;similar&#160;results&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#22">14).&#160;</a>All<br/>treatments&#160;showed&#160;an&#160;increase&#160;in&#160;senescence&#160;markers,&#160;with&#160;the&#160;most&#160;significant&#160;being&#160;the<br/>combination&#160;of&#160;pantoprazole&#160;with&#160;NS1643,&#160;TMZ,&#160;and&#160;the&#160;combination&#160;of&#160;NS1643&#160;and&#160;TMZ</p>
<p style="position:absolute;top:1100px;left:249px;white-space:nowrap" class="ft202">(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#22">14A).&#160;</a>The&#160;size&#160;of&#160;the&#160;nuclei&#160;for&#160;the&#160;combination&#160;treatments&#160;with&#160;the&#160;highest&#160;levels</p>
<p style="position:absolute;top:1119px;left:250px;white-space:nowrap" class="ft202">of&#160;senescent&#160;cells&#160;was&#160;also&#160;significantly&#160;larger&#160;than&#160;the&#160;control,&#160;confirming&#160;this&#160;phenotype</p>
<p style="position:absolute;top:1138px;left:249px;white-space:nowrap" class="ft202">(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#22">14F).&#160;</a>We&#160;also&#160;looked&#160;at&#160;p27Kip1&#160;levels&#160;and&#160;saw&#160;similar&#160;changes&#160;to&#160;those&#160;observed&#160;in</p>
<p style="position:absolute;top:1157px;left:250px;white-space:nowrap" class="ft202">NG108-15&#160;cells&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#18">10E).&#160;</a>All&#160;the&#160;treatments&#160;with&#160;pantoprazole&#160;showed&#160;an&#160;increase&#160;in</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft210{font-size:9px;font-family:Times;color:#000000;}
	.ft211{font-size:9px;font-family:Times;color:#000000;}
	.ft212{font-size:12px;font-family:Times;color:#000000;}
	.ft213{font-size:12px;font-family:Times;color:#0775b7;}
	.ft214{font-size:9px;font-family:Times;color:#000000;}
	.ft215{font-size:13px;font-family:Times;color:#000000;}
	.ft216{font-size:11px;font-family:Times;color:#000000;}
	.ft217{font-size:11px;font-family:Times;color:#000000;}
	.ft218{font-size:11px;font-family:Times;color:#000000;}
	.ft219{font-size:13px;font-family:Times;color:#000000;}
	.ft2110{font-size:7px;font-family:Times;color:#000000;}
	.ft2111{font-size:7px;font-family:Times;color:#000000;}
	.ft2112{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
	.ft2113{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
	.ft2114{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft2115{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft2116{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page21-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft210">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft210">21&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:249px;white-space:nowrap" class="ft212">p27Kip1&#160;levels,&#160;and&#160;NS1643&#160;in&#160;combination&#160;with&#160;TMZ&#160;showed&#160;the&#160;highest&#160;increase.&#160;Cleaved</p>
<p style="position:absolute;top:165px;left:250px;white-space:nowrap" class="ft2112">caspase&#160;3&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#22">14E)&#160;</a>and&#160;LC3B&#160;puncta&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#22">14C)&#160;</a>positive&#160;cells&#160;indicated&#160;very&#160;low&#160;non-<br/>significant&#160;levels&#160;of&#160;expression,&#160;indicating&#160;that&#160;the&#160;cells&#160;were&#160;not&#160;undergoing&#160;a&#160;high&#160;level<br/>of&#160;apoptosis&#160;or&#160;autophagy&#160;relative&#160;to&#160;control,&#160;respectively.&#160;BrdU&#160;incorporation&#160;decreased<br/>in&#160;all&#160;treatments&#160;that&#160;showed&#160;lower&#160;proliferation&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#22">14B).&#160;</a>These&#160;data&#160;show&#160;that&#160;the<br/>low&#160;proliferation&#160;of&#160;the&#160;U87&#160;cells&#160;treated&#160;with&#160;the&#160;most&#160;successful&#160;drug&#160;combinations&#160;was<br/>driven&#160;by&#160;increased&#160;levels&#160;of&#160;senescence.</p>
<p style="position:absolute;top:236px;left:56px;white-space:nowrap" class="ft214"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:236px;left:794px;white-space:nowrap" class="ft210">21 of&#160;38&#160;</p>
<p style="position:absolute;top:246px;left:56px;white-space:nowrap" class="ft210">&#160;</p>
<p style="position:absolute;top:1377px;left:56px;white-space:nowrap" class="ft215">&#160;</p>
<p style="position:absolute;top:575px;left:830px;white-space:nowrap" class="ft215">&#160;</p>
<p style="position:absolute;top:599px;left:252px;white-space:nowrap" class="ft2113"><b>Figure 13.&#160;</b>Differentiation Analysis&#160;of U87&#160;Cells Reveals that Treatments with&#160;Pantoprazole In-<br/>creased&#160;Oligodendrocyte Markers after 6 days. Immunofluorescence&#160;of cells was conducted and&#160;<br/>analyzed with&#160;CellProfiler for integrated fluorescence&#160;intensity.&#160;(<b>A</b>)&#160;Stain of oligodendrocyte&#160;<br/>marker O4.&#160;(<b>B</b>) Stain of the Sry-related HMg-Box gene 10 (SOX10). Treatments corresponding to the&#160;<br/>colored bars&#160;are outlined&#160;in the figure itself.&#160;The&#160;log&#160;of the&#160;fold change&#160;in&#160;intensity&#160;was&#160;compared&#160;<br/>between single&#160;treatments and combined treatments, except the positive&#160;control, with&#160;significant&#160;<br/>values shown in&#160;the color of the treatment compared. The initial fluorescence intensities&#160;were com-<br/>pared to their corresponding control,&#160;with&#160;significant values&#160;shown under the bars&#160;as,&#160;***:&#160;<i>p &lt;&#160;</i>0.001,&#160;<br/>**:&#160;<i>p&#160;</i>&lt;<i>&#160;</i>0.01,&#160;<i>*</i>:&#160;<i>p &lt;&#160;</i>0.05&#160;(one-way ANOVA with&#160;Tukey post hoc analysis&#160;<i>n &gt;&#160;</i>3 technical replicates).&#160;</p>
<p style="position:absolute;top:773px;left:252px;white-space:nowrap" class="ft2114"><i>3.11. U87 Cells Also&#160;Show&#160;an&#160;Increase&#160;in&#160;p27Kip1&#160;and Senescence&#160;Markers When&#160;Treated&#160;with&#160;<br/>Pantoprazole&#160;Alone or&#160;in Combination&#160;with Hyperpolarizing Compounds&#160;</i></p>
<p style="position:absolute;top:816px;left:283px;white-space:nowrap" class="ft215">We tested&#160;U87 cells for&#160;the&#160;same&#160;proliferation,&#160;senescence,&#160;autophagy,&#160;and&#160;apoptosis&#160;</p>
<p style="position:absolute;top:835px;left:252px;white-space:nowrap" class="ft2115">markers that&#160;we had&#160;tested&#160;in&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">NG108-15 cells&#160;and&#160;</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">fo</a>und similar results (Figure&#160;14). All&#160;<br/>treatments showed an&#160;increase&#160;in&#160;senescence&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#23">markers, wi</a>th the most significant being the&#160;<br/>combination&#160;of pantoprazole with&#160;NS1643,&#160;TMZ,&#160;and the combination of&#160;NS1643&#160;and&#160;<br/>TMZ (Figure&#160;14A). The&#160;size of&#160;the nuclei&#160;for the combination treatments with the highest&#160;<br/>levels&#160;of&#160;senescent&#160;cells&#160;was also&#160;significantly&#160;larger&#160;th<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#23">an th</a>e control, confirming&#160;this&#160;phe-<br/>notype (Figure 14F). We&#160;also&#160;looked&#160;at&#160;p27Kip1&#160;levels&#160;and saw&#160;similar changes&#160;to&#160;those&#160;<br/>observed&#160;in&#160;NG108-15 cells (Figure&#160;10E). All the treatments with&#160;pantoprazole&#160;showed an&#160;<br/>increase in&#160;p27Kip1&#160;levels,&#160;and NS1643&#160;in&#160;combination with&#160;TMZ showed the highest&#160;in-<br/>crease. Cl<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">eaved casp</a>ase 3&#160;(Figure&#160;14E)&#160;and LC3B pun<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#23">cta&#160;(F</a>igure&#160;14C)&#160;positive&#160;cells&#160;indi-<br/>cated very low non-significant levels of&#160;expression, indicating that&#160;the cells&#160;were not un-<br/>dergoing&#160;a high level of&#160;apoptosis or autophagy relative to control,&#160;respectively. BrdU&#160;<br/>incorporation&#160;decreased&#160;in&#160;all treatments&#160;that&#160;showed&#160;lower proliferation (Figure 14B).&#160;<br/><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">These data&#160;show tha</a>t&#160;the low proliferation of&#160;the U87&#160;cells treated with the most successful&#160;<br/>drug&#160;combinations&#160;was driven by&#160;increased&#160;levels&#160;of&#160;senescence.&#160;</p>
<p style="position:absolute;top:599px;left:250px;white-space:nowrap" class="ft216"><b>Figure&#160;13.</b></p>
<p style="position:absolute;top:599px;left:313px;white-space:nowrap" class="ft217">Differentiation&#160;Analysis&#160;of&#160;U87&#160;Cells&#160;Reveals&#160;that&#160;Treatments&#160;with&#160;Pantoprazole&#160;Increased</p>
<p style="position:absolute;top:618px;left:250px;white-space:nowrap" class="ft217">Oligodendrocyte&#160;Markers&#160;after&#160;6&#160;days.&#160;Immunofluorescence&#160;of&#160;cells&#160;was&#160;conducted&#160;and&#160;analyzed</p>
<p style="position:absolute;top:638px;left:249px;white-space:nowrap" class="ft2116">with&#160;CellProfiler&#160;for&#160;integrated&#160;fluorescence&#160;intensity.&#160;(<b>A</b>)&#160;Stain&#160;of&#160;oligodendrocyte&#160;marker&#160;O4.<br/>(<b>B</b>)&#160;Stain&#160;of&#160;the&#160;Sry-related&#160;HMg-Box&#160;gene&#160;10&#160;(SOX10).&#160;Treatments&#160;corresponding&#160;to&#160;the&#160;colored</p>
<p style="position:absolute;top:676px;left:250px;white-space:nowrap" class="ft2116">bars&#160;are&#160;outlined&#160;in&#160;the&#160;figure&#160;itself.&#160;The&#160;log&#160;of&#160;the&#160;fold&#160;change&#160;in&#160;intensity&#160;was&#160;compared&#160;between<br/>single&#160;treatments&#160;and&#160;combined&#160;treatments,&#160;except&#160;the&#160;positive&#160;control,&#160;with&#160;significant&#160;values&#160;shown<br/>in&#160;the&#160;color&#160;of&#160;the&#160;treatment&#160;compared.&#160;The&#160;initial&#160;fluorescence&#160;intensities&#160;were&#160;compared&#160;to&#160;their<br/>corresponding&#160;control,&#160;with&#160;significant&#160;values&#160;shown&#160;under&#160;the&#160;bars&#160;as,&#160;***:&#160;p&#160;&lt;&#160;0.001,&#160;**:&#160;p&#160;&lt;&#160;0.01,</p>
<p style="position:absolute;top:753px;left:249px;white-space:nowrap" class="ft217">*:&#160;p&#160;&lt;&#160;0.05&#160;(one-way&#160;ANOVA&#160;with&#160;Tukey&#160;post&#160;hoc&#160;analysis&#160;n&#160;&gt;&#160;3&#160;technical&#160;replicates).</p>
<p style="position:absolute;top:782px;left:250px;white-space:nowrap" class="ft212">3.12.&#160;U87&#160;Cells&#160;Are&#160;Hyperpolarized&#160;by&#160;Treatment&#160;with&#160;NS1643&#160;and&#160;Its&#160;Combination&#160;with</p>
<p style="position:absolute;top:798px;left:249px;white-space:nowrap" class="ft212">Pantoprazole&#160;and&#160;the&#160;Combination&#160;of&#160;NS1643&#160;with&#160;Pantoprazole&#160;or&#160;TMZ&#160;Increases&#160;the</p>
<p style="position:absolute;top:814px;left:249px;white-space:nowrap" class="ft212">Translocation&#160;of&#160;YAP&#160;to&#160;the&#160;Cytoplasm</p>
<p style="position:absolute;top:837px;left:281px;white-space:nowrap" class="ft212">We&#160;used&#160;the&#160;voltage&#160;dye&#160;DiBAC4(3)&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">[116,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">117]&#160;</a>to&#160;measure&#160;the&#160;resting&#160;membrane</p>
<p style="position:absolute;top:856px;left:249px;white-space:nowrap" class="ft212">potential&#160;of&#160;six-day-treated&#160;U87&#160;cells&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#23">15B).&#160;</a>We&#160;found&#160;that&#160;NS1643&#160;alone&#160;and&#160;in</p>
<p style="position:absolute;top:875px;left:250px;white-space:nowrap" class="ft2112">combination&#160;with&#160;pantoprazole&#160;showed&#160;a&#160;significant&#160;hyperpolarization&#160;as&#160;compared&#160;to<br/>control.&#160;To&#160;investigate&#160;further,&#160;we&#160;used&#160;pHRodo&#160;Green&#160;to&#160;see&#160;if&#160;the&#160;internal&#160;pH&#160;of&#160;the<br/>cells&#160;was&#160;being&#160;changed&#160;in&#160;response&#160;to&#160;treatment&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#23">15C).&#160;</a>We&#160;saw&#160;a&#160;dramatic&#160;increase<br/>in&#160;pH&#160;with&#160;all&#160;the&#160;treatments&#160;that&#160;incorporated&#160;NS1643,&#160;and&#160;we&#160;saw&#160;a&#160;slight&#160;increase<br/>in&#160;pH&#160;for&#160;pantoprazole&#160;with&#160;retigabine.&#160;In&#160;addition&#160;to&#160;the&#160;cytoplasmic&#160;pH,&#160;we&#160;wanted<br/>to&#160;test&#160;the&#160;lysosomal&#160;pH&#160;due&#160;to&#160;reports&#160;that&#160;pantoprazole&#160;de-acidifies&#160;the&#160;lumen&#160;of&#160;the<br/>lysosome&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[118,119]</a>.&#160;The&#160;dye,&#160;LysoSensor&#160;Green&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#23">15A),&#160;</a>showed&#160;a&#160;dramatic&#160;alkaliza-<br/>tion&#160;of&#160;the&#160;lysosomes&#160;when&#160;treated&#160;by&#160;NS1643&#160;alone&#160;or&#160;in&#160;combination.&#160;Pantoprazole&#160;did<br/>not&#160;show&#160;an&#160;alkalinization&#160;of&#160;the&#160;lysosome&#160;in&#160;the&#160;U87&#160;cells,&#160;in&#160;agreement&#160;with&#160;what&#160;has</p>
<p style="position:absolute;top:1044px;left:249px;white-space:nowrap" class="ft2112">previously&#160;been&#160;reported&#160;when&#160;pantoprazole&#160;is&#160;delivered&#160;in&#160;neutral&#160;cell&#160;culture&#160;media&#160;at<br/>pH&#160;7.4&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[120].&#160;</a>In&#160;fact,&#160;pantoprazole&#160;and&#160;its&#160;combination&#160;with&#160;TMZ&#160;showed&#160;a&#160;significant</p>
<p style="position:absolute;top:1082px;left:250px;white-space:nowrap" class="ft2112">increase&#160;in&#160;lysosomes,&#160;which&#160;also&#160;agrees&#160;with&#160;that&#160;same&#160;study&#160;performed&#160;in&#160;neutral&#160;pH<br/>media&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[120].&#160;</a>In&#160;addition&#160;to&#160;the&#160;dyes,&#160;we&#160;also&#160;tested&#160;the&#160;ratio&#160;of&#160;cytoplasmic&#160;to&#160;nuclear&#160;YAP</p>
<p style="position:absolute;top:1120px;left:249px;white-space:nowrap" class="ft212">(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#23">15E).&#160;</a>Pantoprazole&#160;has&#160;been&#160;found&#160;to&#160;decrease&#160;YAP&#160;activity&#160;in&#160;ovarian&#160;cancer&#160;and</p>
<p style="position:absolute;top:1138px;left:250px;white-space:nowrap" class="ft2112">in&#160;the&#160;liver&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[121,122].&#160;</a>Since&#160;YAP&#160;has&#160;been&#160;found&#160;to&#160;be&#160;a&#160;master&#160;regulator&#160;of&#160;the&#160;cell&#160;cycle,<br/>especially&#160;in&#160;cancer,&#160;we&#160;were&#160;interested&#160;to&#160;see&#160;the&#160;effect&#160;our&#160;treatments&#160;would&#160;have&#160;on&#160;this</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft220{font-size:9px;font-family:Times;color:#000000;}
	.ft221{font-size:9px;font-family:Times;color:#000000;}
	.ft222{font-size:12px;font-family:Times;color:#000000;}
	.ft223{font-size:12px;font-family:Times;color:#0775b7;}
	.ft224{font-size:9px;font-family:Times;color:#000000;}
	.ft225{font-size:13px;font-family:Times;color:#000000;}
	.ft226{font-size:11px;font-family:Times;color:#000000;}
	.ft227{font-size:11px;font-family:Times;color:#000000;}
	.ft228{font-size:6px;font-family:Times;color:#000000;}
	.ft229{font-size:11px;font-family:Times;color:#000000;}
	.ft2210{font-size:13px;font-family:Times;color:#000000;}
	.ft2211{font-size:8px;font-family:Times;color:#000000;}
	.ft2212{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
	.ft2213{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
	.ft2214{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft2215{font-size:13px;line-height:19px;font-family:Times;color:#000000;}
	.ft2216{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page22-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft220">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft220">22&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:249px;white-space:nowrap" class="ft222">protein&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[122–125].&#160;</a>We&#160;found&#160;that&#160;pantoprazole&#160;alone&#160;did&#160;not&#160;have&#160;a&#160;significant&#160;effect&#160;on&#160;the</p>
<p style="position:absolute;top:165px;left:250px;white-space:nowrap" class="ft2212">cytoplasmic&#160;to&#160;nuclear&#160;ratio&#160;of&#160;YAP,&#160;but&#160;when&#160;combined&#160;with&#160;NS1643&#160;or&#160;TMZ,&#160;it&#160;showed&#160;a<br/>significant&#160;decrease&#160;indicative&#160;of&#160;less&#160;YAP&#160;in&#160;the&#160;nucleus&#160;as&#160;compared&#160;to&#160;the&#160;cytoplasm.</p>
<p style="position:absolute;top:203px;left:249px;white-space:nowrap" class="ft222">This&#160;significant&#160;decrease&#160;in&#160;the&#160;YAP&#160;nucleus&#160;to&#160;cytoplasmic&#160;ratio&#160;was&#160;also&#160;evident&#160;for&#160;the</p>
<p style="position:absolute;top:222px;left:250px;white-space:nowrap" class="ft2212">NS1643&#160;in&#160;combination&#160;with&#160;TMZ&#160;treatment.&#160;When&#160;taken&#160;together,&#160;these&#160;data&#160;indicate<br/>that&#160;NS1643,&#160;in&#160;combination&#160;or&#160;alone,&#160;can&#160;increase&#160;cytoplasmic&#160;calcium&#160;levels,&#160;increase<br/>cytoplasmic&#160;pH,&#160;and&#160;increase&#160;lysosomal&#160;pH,&#160;but&#160;a&#160;significant&#160;decrease&#160;in&#160;the&#160;YAP&#160;nuclear<br/>to&#160;cytoplasmic&#160;ratio&#160;is&#160;only&#160;seen&#160;when&#160;it&#160;is&#160;in&#160;combination&#160;with&#160;pantoprazole&#160;or&#160;TMZ.</p>
<p style="position:absolute;top:253px;left:52px;white-space:nowrap" class="ft224"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:253px;left:790px;white-space:nowrap" class="ft220">22 of&#160;38&#160;</p>
<p style="position:absolute;top:263px;left:52px;white-space:nowrap" class="ft220">&#160;</p>
<p style="position:absolute;top:1394px;left:52px;white-space:nowrap" class="ft225">&#160;</p>
<p style="position:absolute;top:741px;left:823px;white-space:nowrap" class="ft225">&#160;</p>
<p style="position:absolute;top:765px;left:247px;white-space:nowrap" class="ft2213"><b>Figure 14.&#160;</b>Senescence&#160;and&#160;Proliferation&#160;Analysis of&#160;U87&#160;Cells Reveals that&#160;Treatments with&#160;Panto-<br/>prazole or NS164 with TMZ Increased Senescence,&#160;Decreased BrdU&#160;Incorporation, and Increased a&#160;<br/>p27Kip1&#160;after&#160;6&#160;days&#160;A&#160;senescence associated&#160;beta-galactosidase stain was&#160;conducted&#160;and&#160;scored by&#160;<br/>eye. Immunofluorescence of&#160;cells was&#160;conducted and analyzed&#160;with CellProfiler&#160;for integrated&#160;flu-<br/>orescence&#160;intensity&#160;or presence or absence&#160;of a cellular signal. (<b>A</b>) Stain&#160;of senescence&#160;associated&#160;<br/>beta-galactosidase stain (SA-Beta Gal). (<b>B</b>) Stain of bromodeoxyuridine&#160;incorporation (BrdU). (<b>C</b>)&#160;<br/>Stain of&#160;the&#160;microtubule-associated&#160;protein&#160;light chain&#160;3&#160;B&#160;(LC3B).&#160;(<b>D</b>)&#160;Stain of&#160;cleaved&#160;caspase&#160;3&#160;<br/>(Casp 3).&#160;(<b>E</b>) Stain of&#160;cyclin-dependent kinase inhibitor 1B (p27Kip).&#160;(<b>F</b>)&#160;Size&#160;of Nuclei,&#160;determined&#160;<br/>by area of the&#160;Hoechst&#160;stain.&#160;Treatments corresponding&#160;to the colored bars&#160;are outlined&#160;in&#160;the figure&#160;<br/>itself.&#160;The&#160;log&#160;of&#160;the&#160;fold&#160;change&#160;in&#160;intensity&#160;was&#160;compared&#160;between single&#160;treatments and&#160;combined&#160;<br/>treatments,&#160;except the&#160;positive&#160;control, with&#160;significant&#160;values shown&#160;in&#160;the color&#160;of&#160;the&#160;treatment&#160;<br/>compared. The&#160;initial&#160;fluorescence intensities&#160;were&#160;compared to&#160;their&#160;corresponding&#160;control,&#160;with&#160;<br/>significant&#160;values shown under the bars. The logit&#160;of the&#160;percent positive&#160;cells was&#160;compared be-<br/>tween single&#160;treatments and&#160;control,&#160;in cases of&#160;0&#160;values, the arcsine transformation was&#160;used. Sig-<br/>nificance was expressed as, ***:&#160;<i>p &lt;&#160;</i>0.001, **:&#160;<i>p&#160;</i>&lt;<i>&#160;</i>0.01,&#160;<i>*</i>:&#160;<i>p &lt;&#160;</i>0.05 (one-way ANOVA with&#160;Tukey post&#160;<br/>hoc analysis&#160;<i>n &gt;&#160;</i>3 technical replicates).&#160;</p>
<p style="position:absolute;top:1060px;left:247px;white-space:nowrap" class="ft2214"><i>3.12. U87 Cells Are&#160;Hyperpolarized by Treatment&#160;with&#160;NS1643&#160;and&#160;Its Combination&#160;with&#160;<br/>Pantoprazole and&#160;the Combination of NS1643&#160;with Pantoprazole or&#160;TMZ Increases the&#160;<br/>Translocation of&#160;YAP to&#160;the&#160;Cytoplasm&#160;</i></p>
<p style="position:absolute;top:1122px;left:279px;white-space:nowrap" class="ft225">We used the&#160;voltage&#160;dye&#160;DiBAC4(3) [116,117] to measure the resting membrane&#160;po-</p>
<p style="position:absolute;top:1141px;left:247px;white-space:nowrap" class="ft2215">tential of&#160;six-day-treated U87 cells (Figure 15B).&#160;We&#160;found that&#160;NS1643&#160;alone&#160;and in&#160;com-<br/>bination with&#160;pantoprazole&#160;showed&#160;a&#160;significant&#160;hyperpolarization as&#160;compared&#160;to&#160;con-<br/>trol. To&#160;investigate&#160;further,&#160;we&#160;used&#160;pHRodo Green to see&#160;if the internal pH&#160;of the cells&#160;<br/>was being changed&#160;in response to&#160;treatment&#160;(Figure&#160;15C). We&#160;saw&#160;a dramatic increase&#160;in&#160;<br/>pH with all the treatments that&#160;incorporated NS1643,&#160;and we&#160;saw a slight increase in&#160;pH&#160;<br/>for pantoprazole&#160;with retigabine. In&#160;addition to the cytoplasmic pH,&#160;we wanted to test the&#160;<br/>lysosomal pH&#160;due&#160;to reports that&#160;pantoprazole&#160;de-acidifies&#160;the&#160;lumen of&#160;the&#160;lysosome&#160;<br/>[118,119].&#160;The dye,&#160;LysoSensor&#160;Green&#160;(Figure&#160;15A),&#160;showed&#160;a&#160;dramatic&#160;alkalization of&#160;the&#160;<br/>lysosomes when treated&#160;by NS1643&#160;alone or&#160;in combination.&#160;Pantoprazole did&#160;not&#160;show&#160;<br/>an&#160;alkalinization of&#160;the lysosome in&#160;the&#160;U87&#160;cells, in&#160;agreement with&#160;what has previously&#160;<br/>been reported&#160;when pantoprazole&#160;is&#160;delivered&#160;in neutral cell&#160;culture&#160;media&#160;at&#160;pH&#160;7.4&#160;[120].&#160;</p>
<p style="position:absolute;top:763px;left:250px;white-space:nowrap" class="ft226"><b>Figure&#160;14.</b></p>
<p style="position:absolute;top:763px;left:314px;white-space:nowrap" class="ft227">Senescence&#160;and&#160;Proliferation&#160;Analysis&#160;of&#160;U87&#160;Cells&#160;Reveals&#160;that&#160;Treatments&#160;with&#160;Panto-</p>
<p style="position:absolute;top:782px;left:249px;white-space:nowrap" class="ft227">prazole&#160;or&#160;NS164&#160;with&#160;TMZ&#160;Increased&#160;Senescence,&#160;Decreased&#160;BrdU&#160;Incorporation,&#160;and&#160;Increased</p>
<p style="position:absolute;top:802px;left:250px;white-space:nowrap" class="ft2216">a&#160;p27Kip1&#160;after&#160;6&#160;days&#160;A&#160;senescence&#160;associated&#160;beta-galactosidase&#160;stain&#160;was&#160;conducted&#160;and&#160;scored<br/>by&#160;eye.&#160;Immunofluorescence&#160;of&#160;cells&#160;was&#160;conducted&#160;and&#160;analyzed&#160;with&#160;CellProfiler&#160;for&#160;integrated<br/>fluorescence&#160;intensity&#160;or&#160;presence&#160;or&#160;absence&#160;of&#160;a&#160;cellular&#160;signal.&#160;(<b>A</b>)&#160;Stain&#160;of&#160;senescence&#160;associ-<br/>ated&#160;beta-galactosidase&#160;stain&#160;(SA-Beta&#160;Gal).&#160;(<b>B</b>)&#160;Stain&#160;of&#160;bromodeoxyuridine&#160;incorporation&#160;(BrdU).</p>
<p style="position:absolute;top:879px;left:249px;white-space:nowrap" class="ft2216">(<b>C</b>)&#160;Stain&#160;of&#160;the&#160;microtubule-associated&#160;protein&#160;light&#160;chain&#160;3&#160;B&#160;(LC3B).&#160;(<b>D</b>)&#160;Stain&#160;of&#160;cleaved&#160;caspase&#160;3<br/>(Casp&#160;3).&#160;(<b>E</b>)&#160;Stain&#160;of&#160;cyclin-dependent&#160;kinase&#160;inhibitor&#160;1B&#160;(p27Kip).&#160;(<b>F</b>)&#160;Size&#160;of&#160;Nuclei,&#160;determined</p>
<p style="position:absolute;top:917px;left:250px;white-space:nowrap" class="ft2216">by&#160;area&#160;of&#160;the&#160;Hoechst&#160;stain.&#160;Treatments&#160;corresponding&#160;to&#160;the&#160;colored&#160;bars&#160;are&#160;outlined&#160;in&#160;the&#160;figure<br/>itself.&#160;The&#160;log&#160;of&#160;the&#160;fold&#160;change&#160;in&#160;intensity&#160;was&#160;compared&#160;between&#160;single&#160;treatments&#160;and&#160;combined<br/>treatments,&#160;except&#160;the&#160;positive&#160;control,&#160;with&#160;significant&#160;values&#160;shown&#160;in&#160;the&#160;color&#160;of&#160;the&#160;treatment<br/>compared.&#160;The&#160;initial&#160;fluorescence&#160;intensities&#160;were&#160;compared&#160;to&#160;their&#160;corresponding&#160;control,&#160;with<br/>significant&#160;values&#160;shown&#160;under&#160;the&#160;bars.&#160;The&#160;logit&#160;of&#160;the&#160;percent&#160;positive&#160;cells&#160;was&#160;compared&#160;between<br/>single&#160;treatments&#160;and&#160;control,&#160;in&#160;cases&#160;of&#160;0&#160;values,&#160;the&#160;arcsine&#160;transformation&#160;was&#160;used.&#160;Significance</p>
<p style="position:absolute;top:1032px;left:249px;white-space:nowrap" class="ft227">was&#160;expressed&#160;as,&#160;***:&#160;p&#160;&lt;&#160;0.001,&#160;**:&#160;p&#160;&lt;&#160;0.01,&#160;*:&#160;p&#160;&lt;&#160;0.05&#160;(one-way&#160;ANOVA&#160;with&#160;Tukey&#160;post&#160;hoc&#160;analysis</p>
<p style="position:absolute;top:1052px;left:250px;white-space:nowrap" class="ft227">n&#160;&gt;&#160;3&#160;technical&#160;replicates).</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft230{font-size:9px;font-family:Times;color:#000000;}
	.ft231{font-size:9px;font-family:Times;color:#000000;}
	.ft232{font-size:9px;font-family:Times;color:#000000;}
	.ft233{font-size:12px;font-family:Times;color:#000000;}
	.ft234{font-size:11px;font-family:Times;color:#000000;}
	.ft235{font-size:11px;font-family:Times;color:#000000;}
	.ft236{font-size:11px;font-family:Times;color:#000000;}
	.ft237{font-size:12px;font-family:Times;color:#0775b7;}
	.ft238{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
	.ft239{font-size:12px;line-height:19px;font-family:Times;color:#000000;}
	.ft2310{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
	.ft2311{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page23-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft230">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft230">23&#160;of&#160;36</p>
<p style="position:absolute;top:-200px;left:59px;white-space:nowrap" class="ft232"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:-200px;left:790px;white-space:nowrap" class="ft230">23 of&#160;38&#160;</p>
<p style="position:absolute;top:-190px;left:59px;white-space:nowrap" class="ft230">&#160;</p>
<p style="position:absolute;top:929px;left:59px;white-space:nowrap" class="ft233">&#160;</p>
<p style="position:absolute;top:-138px;left:252px;white-space:nowrap" class="ft239">In fact,&#160;pantoprazole&#160;and&#160;its combination with&#160;TMZ showed a significant&#160;increase&#160;in ly-<br/>sosomes,&#160;which also agrees&#160;with that same study performed in neutral pH media [120]. In&#160;<br/>addition to the dyes, we&#160;also tested the ratio of cytoplasmic to nuclear YAP&#160;(Figure 15E).&#160;<br/>Pantoprazole&#160;has been found to decrease YAP&#160;activity&#160;in ovarian cancer&#160;and in&#160;the liver&#160;<br/>[121,122]. Since YAP has been found to&#160;be a&#160;master regulator of&#160;the cell cycle, especially&#160;<br/>in cancer, we&#160;were interested to see the effect our treatments would have on this protein&#160;<br/>[122–125]. We found that&#160;pantoprazole&#160;alone did not&#160;have&#160;a significant effect&#160;on&#160;the cyto-<br/>plasmic to&#160;nuclear ratio&#160;of&#160;YAP,&#160;but&#160;when&#160;combined&#160;with&#160;NS1643&#160;or&#160;TMZ,&#160;it&#160;showed&#160;a&#160;<br/>significant&#160;decrease&#160;indicative of&#160;less&#160;YAP&#160;in&#160;the nucleus&#160;as compared to&#160;the&#160;cytoplasm.&#160;<br/>This&#160;significant&#160;decrease&#160;in&#160;the YAP&#160;nucleus&#160;to cytoplasmic&#160;ratio was&#160;also&#160;evident&#160;for the&#160;<br/>NS1643&#160;in combination with&#160;TMZ treatment.&#160;When&#160;taken together, these data&#160;indicate&#160;<br/>that&#160;NS1643,&#160;in combination or alone,&#160;can increase&#160;cytoplasmic calcium&#160;levels,&#160;increase&#160;<br/>cytoplasmic pH,&#160;and&#160;increase lysosomal&#160;pH, but&#160;a&#160;significant&#160;decrease&#160;in the&#160;YAP nuclear&#160;<br/>to&#160;cytoplasmic ratio&#160;is&#160;only&#160;seen when it&#160;is&#160;in combination with&#160;pantoprazole or&#160;TMZ.&#160;</p>
<p style="position:absolute;top:571px;left:827px;white-space:nowrap" class="ft233">&#160;</p>
<p style="position:absolute;top:594px;left:252px;white-space:nowrap" class="ft2310"><b>Figure 15.&#160;</b>Voltage Dyes Showed that U87 Cells Treated with&#160;NS1643 and a&#160;Combination of NS1643&#160;<br/>and&#160;Pantoprazole&#160;for 6 Days&#160;Showed&#160;a Hyperpolarization&#160;and YAP Increases its Translocation&#160;to&#160;<br/>the Cytoplasm in&#160;NS1643&#160;or&#160;Pantoprazole&#160;with&#160;TMZ, and&#160;Pantoprazole&#160;with&#160;NS1643&#160;Treatment.&#160;<br/>Immunofluorescence&#160;of&#160;cells&#160;was conducted&#160;and analyzed with&#160;CellProfiler&#160;for integrated&#160;fluores-<br/>cence intensity.&#160;Dye assays were analyzed for mean intensity,&#160;except&#160;for&#160;LysoSensor&#160;Green&#160;which&#160;<br/>was analyzed for integrated intensity. (<b>A</b>) Stain of lysosomal&#160;pH with LysoSensor Green, low levels&#160;<br/>indicate&#160;alkalization.&#160;(<b>B</b>)&#160;Dye&#160;indicator&#160;of&#160;membrane voltage, DiBAC4(3),&#160;low&#160;levels&#160;indicate&#160;hy-<br/>perpolarization. (<b>C</b>) Dye indicator of cytoplasmic pH,&#160;pHRodo Green, low levels&#160;indicate alkaliza-<br/>tion. (<b>D</b>)&#160;Dye&#160;indicator&#160;of&#160;cytoplasmic&#160;calcium,&#160;Fluo-4AM, high&#160;levels&#160;indicate&#160;an&#160;increase&#160;in&#160;cal-<br/>cium. (<b>E</b>)&#160;The&#160;ratio of&#160;nuclear to&#160;cytoplasmic&#160;Yes-associated protein (YAP),&#160;lower&#160;levels&#160;indicate&#160;<br/>translocation&#160;to&#160;the cytoplasm. Treatments corresponding&#160;to the&#160;colored bars are outlined in the&#160;<br/>figure itself.&#160;The log&#160;of&#160;the&#160;fold&#160;change&#160;in&#160;intensity was compared between single&#160;treatments and&#160;<br/>combined&#160;treatments, except&#160;the positive&#160;control,&#160;with&#160;significant&#160;values&#160;shown in the&#160;color of&#160;the&#160;<br/>treatment compared. The&#160;initial fluorescence&#160;intensities were&#160;compared to&#160;their corresponding&#160;con-<br/>trol, with&#160;significant&#160;values shown under the bars as, ***:&#160;<i>p &lt;&#160;</i>0.001, **:&#160;<i>p&#160;</i>&lt;<i>&#160;</i>0.01,&#160;<i>*</i>:&#160;<i>p &lt;&#160;</i>0.05&#160;(one-way&#160;<br/>ANOVA with&#160;Tukey post hoc analysis&#160;<i>n &gt;&#160;</i>3 technical replicates).&#160;</p>
<p style="position:absolute;top:592px;left:250px;white-space:nowrap" class="ft234"><b>Figure&#160;15.</b></p>
<p style="position:absolute;top:592px;left:314px;white-space:nowrap" class="ft235">Voltage&#160;Dyes&#160;Showed&#160;that&#160;U87&#160;Cells&#160;Treated&#160;with&#160;NS1643&#160;and&#160;a&#160;Combination&#160;of&#160;NS1643</p>
<p style="position:absolute;top:611px;left:250px;white-space:nowrap" class="ft2311">and&#160;Pantoprazole&#160;for&#160;6&#160;Days&#160;Showed&#160;a&#160;Hyperpolarization&#160;and&#160;YAP&#160;Increases&#160;its&#160;Translocation&#160;to<br/>the&#160;Cytoplasm&#160;in&#160;NS1643&#160;or&#160;Pantoprazole&#160;with&#160;TMZ,&#160;and&#160;Pantoprazole&#160;with&#160;NS1643&#160;Treatment.<br/>Immunofluorescence&#160;of&#160;cells&#160;was&#160;conducted&#160;and&#160;analyzed&#160;with&#160;CellProfiler&#160;for&#160;integrated&#160;fluores-<br/>cence&#160;intensity.&#160;Dye&#160;assays&#160;were&#160;analyzed&#160;for&#160;mean&#160;intensity,&#160;except&#160;for&#160;LysoSensor&#160;Green&#160;which</p>
<p style="position:absolute;top:688px;left:249px;white-space:nowrap" class="ft235">was&#160;analyzed&#160;for&#160;integrated&#160;intensity.&#160;(<b>A</b>)&#160;Stain&#160;of&#160;lysosomal&#160;pH&#160;with&#160;LysoSensor&#160;Green,&#160;low&#160;levels</p>
<p style="position:absolute;top:707px;left:250px;white-space:nowrap" class="ft2311">indicate&#160;alkalization.&#160;(<b>B</b>)&#160;Dye&#160;indicator&#160;of&#160;membrane&#160;voltage,&#160;DiBAC4(3),&#160;low&#160;levels&#160;indicate&#160;hyperpo-<br/>larization.&#160;(<b>C</b>)&#160;Dye&#160;indicator&#160;of&#160;cytoplasmic&#160;pH,&#160;pHRodo&#160;Green,&#160;low&#160;levels&#160;indicate&#160;alkalization.&#160;(<b>D</b>)<br/>Dye&#160;indicator&#160;of&#160;cytoplasmic&#160;calcium,&#160;Fluo-4AM,&#160;high&#160;levels&#160;indicate&#160;an&#160;increase&#160;in&#160;calcium.&#160;(<b>E</b>)&#160;The<br/>ratio&#160;of&#160;nuclear&#160;to&#160;cytoplasmic&#160;Yes-associated&#160;protein&#160;(YAP),&#160;lower&#160;levels&#160;indicate&#160;translocation&#160;to&#160;the<br/>cytoplasm.&#160;Treatments&#160;corresponding&#160;to&#160;the&#160;colored&#160;bars&#160;are&#160;outlined&#160;in&#160;the&#160;figure&#160;itself.&#160;The&#160;log<br/>of&#160;the&#160;fold&#160;change&#160;in&#160;intensity&#160;was&#160;compared&#160;between&#160;single&#160;treatments&#160;and&#160;combined&#160;treatments,<br/>except&#160;the&#160;positive&#160;control,&#160;with&#160;significant&#160;values&#160;shown&#160;in&#160;the&#160;color&#160;of&#160;the&#160;treatment&#160;compared.&#160;The<br/>initial&#160;fluorescence&#160;intensities&#160;were&#160;compared&#160;to&#160;their&#160;corresponding&#160;control,&#160;with&#160;significant&#160;values<br/>shown&#160;under&#160;the&#160;bars&#160;as,&#160;***:&#160;p&#160;&lt;&#160;0.001,&#160;**:&#160;p&#160;&lt;&#160;0.01,&#160;*:&#160;p&#160;&lt;&#160;0.05&#160;(one-way&#160;ANOVA&#160;with&#160;Tukey&#160;post&#160;hoc<br/>analysis&#160;n&#160;&gt;&#160;3&#160;technical&#160;replicates).</p>
<p style="position:absolute;top:910px;left:250px;white-space:nowrap" class="ft233">3.13.&#160;Neuronal&#160;Cell&#160;Toxicity&#160;Was&#160;Minimal&#160;after&#160;a&#160;Three-Day&#160;Treatment&#160;with&#160;the&#160;Top&#160;Performing</p>
<p style="position:absolute;top:925px;left:249px;white-space:nowrap" class="ft233">Drugs&#160;and&#160;Drug&#160;Combinations</p>
<p style="position:absolute;top:949px;left:281px;white-space:nowrap" class="ft233">To&#160;determine&#160;whether&#160;the&#160;effects&#160;we&#160;observed&#160;were&#160;specific&#160;for&#160;cancer&#160;cells&#160;and</p>
<p style="position:absolute;top:968px;left:250px;white-space:nowrap" class="ft238">could&#160;be&#160;expected&#160;to&#160;be&#160;usable&#160;in&#160;vivo&#160;without&#160;harming&#160;native&#160;neurons,&#160;we&#160;tested&#160;these<br/>compounds&#160;on&#160;human&#160;induced&#160;pluripotent&#160;stem&#160;cells&#160;derived&#160;from&#160;fibroblasts&#160;and&#160;made<br/>to&#160;commit&#160;to&#160;a&#160;neuronal&#160;stem&#160;cell&#160;lineage.&#160;These&#160;hiNSCs&#160;were&#160;differentiated&#160;for&#160;7&#160;days&#160;in<br/>neuronal&#160;media&#160;and&#160;then&#160;treated&#160;with&#160;electroceuticals&#160;for&#160;3&#160;days.&#160;The&#160;short&#160;treatment&#160;time</p>
<p style="position:absolute;top:1043px;left:249px;white-space:nowrap" class="ft233">was&#160;necessary&#160;to&#160;be&#160;able&#160;to&#160;perform&#160;a&#160;Live/Dead&#160;assay&#160;without&#160;too&#160;much&#160;cell&#160;detachment.</p>
<p style="position:absolute;top:1062px;left:281px;white-space:nowrap" class="ft233">Toxicity&#160;analysis&#160;by&#160;Live/Dead&#160;stain&#160;in&#160;human&#160;neurons&#160;shows&#160;that&#160;only&#160;three&#160;out</p>
<p style="position:absolute;top:1081px;left:250px;white-space:nowrap" class="ft238">of&#160;24&#160;treatments&#160;showed&#160;significant&#160;toxicity&#160;(Figure&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#24">16A).&#160;</a>Pantoprazole&#160;showed&#160;a&#160;slight<br/>increase&#160;in&#160;toxicity&#160;that&#160;was&#160;significant&#160;compared&#160;to&#160;control,&#160;and&#160;pantoprazole&#160;with&#160;lamot-<br/>rigine&#160;also&#160;showed&#160;a&#160;slight&#160;increase&#160;but&#160;was&#160;more&#160;significant&#160;than&#160;pantoprazole&#160;alone&#160;when<br/>compared&#160;to&#160;the&#160;control.&#160;NS1643&#160;at&#160;50&#160;µM&#160;in&#160;combination&#160;with&#160;TMZ&#160;showed&#160;the&#160;most<br/>toxicity&#160;when&#160;compared&#160;to&#160;control.&#160;However,&#160;the&#160;difference&#160;between&#160;the&#160;control&#160;toxicity</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft240{font-size:9px;font-family:Times;color:#000000;}
	.ft241{font-size:9px;font-family:Times;color:#000000;}
	.ft242{font-size:12px;font-family:Times;color:#000000;}
	.ft243{font-size:12px;font-family:Times;color:#0775b7;}
	.ft244{font-size:9px;font-family:Times;color:#000000;}
	.ft245{font-size:12px;font-family:Times;color:#000000;}
	.ft246{font-size:11px;font-family:Times;color:#000000;}
	.ft247{font-size:11px;font-family:Times;color:#000000;}
	.ft248{font-size:11px;font-family:Times;color:#000000;}
	.ft249{font-size:12px;font-family:Times;color:#000000;}
	.ft2410{font-size:6px;font-family:Times;color:#000000;}
	.ft2411{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
	.ft2412{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
	.ft2413{font-size:11px;line-height:16px;font-family:Times;color:#000000;}
	.ft2414{font-size:11px;line-height:19px;font-family:Times;color:#000000;}
	.ft2415{font-size:12px;line-height:19px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page24-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft240">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft240">24&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:250px;white-space:nowrap" class="ft2411">and&#160;the&#160;most&#160;toxic&#160;combination&#160;of&#160;NS1643&#160;at&#160;50&#160;µM&#160;and&#160;TMZ&#160;was&#160;still&#160;only&#160;5.7%&#160;higher<br/>than&#160;control.&#160;A&#160;senescence&#160;assay&#160;was&#160;also&#160;performed&#160;on&#160;the&#160;neurons&#160;under&#160;all&#160;treatments<br/>tested&#160;in&#160;the&#160;Live/Dead&#160;stain,&#160;but&#160;no&#160;significant&#160;differences&#160;were&#160;found,&#160;and&#160;all&#160;senescence<br/>levels&#160;were&#160;all&#160;under&#160;1.75%,&#160;a&#160;stark&#160;contrast&#160;to&#160;the&#160;greater&#160;than&#160;50%&#160;senescence&#160;levels&#160;in<br/>NG108-15&#160;and&#160;U87&#160;cells&#160;after&#160;6&#160;days&#160;of&#160;treatment&#160;(Figures&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#18">10A&#160;</a>and&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#22">14A).</a></p>
<p style="position:absolute;top:-177px;left:65px;white-space:nowrap" class="ft244"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:-177px;left:781px;white-space:nowrap" class="ft240">24 of&#160;38&#160;</p>
<p style="position:absolute;top:-168px;left:65px;white-space:nowrap" class="ft240">&#160;</p>
<p style="position:absolute;top:929px;left:65px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:-117px;left:255px;white-space:nowrap" class="ft2412"><i>3.13. Neuronal&#160;Cell&#160;Toxicity&#160;Was&#160;Minimal&#160;after a Three-Day&#160;Treatment with the Top&#160;<br/>Performing Drugs and Drug&#160;Combinations&#160;</i></p>
<p style="position:absolute;top:-75px;left:286px;white-space:nowrap" class="ft242">To determine whether the effects we observed&#160;were specific for cancer&#160;cells and could&#160;</p>
<p style="position:absolute;top:-57px;left:255px;white-space:nowrap" class="ft2411">be&#160;expected&#160;to&#160;be&#160;usable&#160;in&#160;vivo&#160;without&#160;harming native neurons, we tested these com-<br/>pounds on human induced pluripotent stem cells derived from&#160;fibroblasts&#160;and&#160;made to&#160;<br/>commit&#160;to&#160;a neuronal stem&#160;cell lineage. These hiNSCs&#160;were differentiated&#160;for&#160;7 days&#160;in&#160;<br/>neuronal&#160;media and then treated with electroceuticals&#160;for&#160;3&#160;days. The short treatment time&#160;<br/>was necessary to be&#160;able&#160;to perform&#160;a&#160;Live/Dead&#160;assay without too much cell&#160;detachment.&#160;</p>
<p style="position:absolute;top:36px;left:286px;white-space:nowrap" class="ft242">Toxicity&#160;analysis&#160;by&#160;Live/Dead&#160;stain&#160;in&#160;human&#160;neurons shows that only&#160;three&#160;out of&#160;</p>
<p style="position:absolute;top:54px;left:255px;white-space:nowrap" class="ft2411">24&#160;treatments showed&#160;significant toxicity (Figure&#160;16A). Pantoprazole showed&#160;a slight&#160;in-<br/>crease in&#160;toxicity that&#160;was significant&#160;compared to control,&#160;and pantoprazole&#160;with&#160;<br/>lamotrigine&#160;also showed a&#160;slight&#160;increase&#160;but&#160;was&#160;more significant&#160;than pantoprazole&#160;<br/>alone&#160;when&#160;compared&#160;to the control.&#160;NS1643&#160;at&#160;50&#160;µM&#160;in combination with&#160;TMZ showed&#160;<br/>the most toxicity when compared to control. However, the difference between the control&#160;<br/>toxicity and&#160;the&#160;most&#160;toxic combination of&#160;NS1643&#160;at&#160;50&#160;µM&#160;and&#160;TMZ&#160;was&#160;still&#160;only&#160;5.7%&#160;<br/>higher than control. A senescence&#160;assay&#160;was&#160;also performed on the neurons&#160;under all&#160;<br/>treatments tested in&#160;the&#160;Live/Dead&#160;stain, but&#160;no&#160;significant&#160;differences were&#160;found,&#160;and&#160;<br/>all senescence&#160;levels&#160;were&#160;all under&#160;1.75%, a stark&#160;contrast&#160;to&#160;the&#160;greater&#160;than&#160;50% senes-<br/>cence levels&#160;in NG108-15 and U87 cells&#160;after&#160;6&#160;days of&#160;trea<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#18">tment&#160;</a>(Fi<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#22">gures&#160;</a>10A&#160;and 14A).&#160;</p>
<p style="position:absolute;top:572px;left:787px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:526px;left:68px;white-space:nowrap" class="ft244"><i>Cancers&#160;</i><b>2022</b>,<i>&#160;14</i>, x&#160;</p>
<p style="position:absolute;top:526px;left:784px;white-space:nowrap" class="ft240">25 of&#160;38&#160;</p>
<p style="position:absolute;top:535px;left:68px;white-space:nowrap" class="ft240">&#160;</p>
<p style="position:absolute;top:1633px;left:68px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:897px;left:784px;white-space:nowrap" class="ft242">&#160;</p>
<p style="position:absolute;top:920px;left:258px;white-space:nowrap" class="ft2413"><b>Figure 16.&#160;</b>Live/Dead assay&#160;and Senescence assay&#160;of&#160;Human Neuronal Cells After 3&#160;Day&#160;Treatment&#160;<br/>Shows&#160;Low&#160;Level&#160;of&#160;Toxicity.&#160;Low&#160;values&#160;indicate&#160;less&#160;death&#160;or senescent&#160;cells.&#160;(<b>A</b>)&#160;Live/Dead assay&#160;<br/>conducted on&#160;human&#160;neuronal cells&#160;cultured&#160;with drug for 3 days.&#160;(<b>B</b>) Senescence assay&#160;results of&#160;<br/>senescence associated&#160;beta-galactosidase&#160;staining&#160;on human neuronal cells&#160;cultured with&#160;drug&#160;for 3&#160;<br/>days. Treatments with&#160;best&#160;reduction&#160;of proliferation&#160;in&#160;NG108-15 or&#160;U87 cells are&#160;shown out of&#160;a&#160;<br/>24-sample toxicity&#160;screen, with&#160;significant&#160;values shown. **:&#160;<i>q&#160;</i>&lt;<i>&#160;</i>0.01,&#160;<i>*</i>:&#160;<i>q&#160;</i>&lt; 0.05 (one-way&#160;ANOVA&#160;<br/>with FDR post&#160;hoc analysis&#160;<i>n &gt;&#160;</i>3&#160;technical replicates).&#160;Increase&#160;in percent&#160;dead&#160;or&#160;senescent cells&#160;<br/>indicative&#160;of toxic treatment.&#160;</p>
<p style="position:absolute;top:1072px;left:258px;white-space:nowrap" class="ft249"><b>4. Discussion&#160;</b></p>
<p style="position:absolute;top:1095px;left:258px;white-space:nowrap" class="ft245"><i>4.1. Putative&#160;Electroceuticals for&#160;Cancer&#160;</i></p>
<p style="position:absolute;top:1118px;left:289px;white-space:nowrap" class="ft242">Our&#160;drugs were&#160;selected&#160;based&#160;on&#160;their&#160;predicted effects on&#160;Vmem, which has been&#160;</p>
<p style="position:absolute;top:1137px;left:258px;white-space:nowrap" class="ft2411">shown in&#160;amphibian&#160;models&#160;in&#160;vivo to&#160;prevent&#160;and&#160;reverse tumorigenesis&#160;and&#160;metastatic&#160;<br/>behavior [34,47].&#160;Indeed, a number&#160;of drugs&#160;with&#160;bioelectric targets, such&#160;as ivermectin (a&#160;<br/>chloride channel&#160;drug)&#160;[126–129], salinomycin&#160;and monensin&#160;(ionophores)&#160;[126,130], a&#160;va-<br/>riety of&#160;potassium&#160;channel&#160;drugs [25,55,131–134],&#160;and&#160;drugs targeting proton pumps [135]&#160;<br/>have been discovered to have anti-cancer activity in&#160;various&#160;screens [26,136–139]. Thus,&#160;<br/>our combinations of compounds represent novel&#160;entries to the field&#160;of electroceuticals: the&#160;<br/>repurposing&#160;of known ion&#160;channel-targeting drugs to&#160;manipulate complex cell&#160;outcomes&#160;<br/>[140,141]. This approach has&#160;already been used&#160;for the design of&#160;interventions&#160;to repair&#160;<br/>birth defects&#160;of&#160;the brain&#160;[142,143]. It is&#160;likely that&#160;a&#160;better understanding of&#160;the control&#160;of&#160;<br/>cell&#160;behavior, alone&#160;and in&#160;tissues, will&#160;enable&#160;much&#160;more precisely targeted&#160;electroceuti-<br/>cal interventions in&#160;cancer&#160;as&#160;part of&#160;the&#160;goal&#160;of&#160;normalizing&#160;cells&#160;as&#160;an&#160;alternative to&#160;tra-<br/>ditional&#160;chemotherapy&#160;[144].&#160;</p>
<p style="position:absolute;top:1378px;left:258px;white-space:nowrap" class="ft245"><i>4.2.&#160;Effects&#160;on Proliferation&#160;</i></p>
<p style="position:absolute;top:1401px;left:289px;white-space:nowrap" class="ft242">The NG108-15 hybrid cell&#160;line used&#160;in this&#160;study&#160;shows cancer stem&#160;cell characteris-</p>
<p style="position:absolute;top:1419px;left:258px;white-space:nowrap" class="ft2411">tics, can be easily transfected&#160;and selected&#160;and&#160;has been&#160;used&#160;to&#160;study neuronal&#160;differen-<br/>tiation for many years. To find treatments that would&#160;be robust, we&#160;screened&#160;all&#160;our com-<br/>pounds&#160;in high serum media,&#160;which is&#160;usually&#160;prohibitive for NG108-15&#160;differentiation&#160;<br/>[90,145,146]. In&#160;addition, the high serum&#160;media provided an&#160;abundance of growth&#160;factors&#160;<br/>that&#160;have been shown to be secreted&#160;in&#160;the&#160;peripheral zone of&#160;resected GBM tumors and&#160;<br/>are thought to&#160;drive the migration and&#160;proliferation&#160;of GBM stem&#160;cells in the area [10].&#160;<br/>The best&#160;performing novel&#160;combinations&#160;were pantoprazole with&#160;retigabine,&#160;lamotrigine,&#160;<br/>NS1643, or&#160;rapamycin&#160;and&#160;reduced proliferation when&#160;compared&#160;to&#160;the control&#160;by&#160;80%,&#160;<br/>85%,&#160;86%, and 90%, respectively.&#160;FUCCI analysis&#160;showed that&#160;the cell&#160;cycle&#160;proportion&#160;</p>
<p style="position:absolute;top:926px;left:250px;white-space:nowrap" class="ft246"><b>Figure&#160;16.</b></p>
<p style="position:absolute;top:926px;left:314px;white-space:nowrap" class="ft247">Live/Dead&#160;assay&#160;and&#160;Senescence&#160;assay&#160;of&#160;Human&#160;Neuronal&#160;Cells&#160;After&#160;3&#160;Day&#160;Treatment</p>
<p style="position:absolute;top:945px;left:250px;white-space:nowrap" class="ft2414">Shows&#160;Low&#160;Level&#160;of&#160;Toxicity.&#160;Low&#160;values&#160;indicate&#160;less&#160;death&#160;or&#160;senescent&#160;cells.&#160;(<b>A</b>)&#160;Live/Dead&#160;assay<br/>conducted&#160;on&#160;human&#160;neuronal&#160;cells&#160;cultured&#160;with&#160;drug&#160;for&#160;3&#160;days.&#160;(<b>B</b>)&#160;Senescence&#160;assay&#160;results&#160;of<br/>senescence&#160;associated&#160;beta-galactosidase&#160;staining&#160;on&#160;human&#160;neuronal&#160;cells&#160;cultured&#160;with&#160;drug&#160;for<br/>3&#160;days.&#160;Treatments&#160;with&#160;best&#160;reduction&#160;of&#160;proliferation&#160;in&#160;NG108-15&#160;or&#160;U87&#160;cells&#160;are&#160;shown&#160;out&#160;of&#160;a<br/>24-sample&#160;toxicity&#160;screen,&#160;with&#160;significant&#160;values&#160;shown.&#160;**:&#160;q&#160;&lt;&#160;0.01,&#160;*:&#160;q&#160;&lt;&#160;0.05&#160;(one-way&#160;ANOVA</p>
<p style="position:absolute;top:1041px;left:249px;white-space:nowrap" class="ft247">with&#160;FDR&#160;post&#160;hoc&#160;analysis&#160;n&#160;&gt;&#160;3&#160;technical&#160;replicates).&#160;Increase&#160;in&#160;percent&#160;dead&#160;or&#160;senescent&#160;cells</p>
<p style="position:absolute;top:1060px;left:250px;white-space:nowrap" class="ft247">indicative&#160;of&#160;toxic&#160;treatment.</p>
<p style="position:absolute;top:1090px;left:250px;white-space:nowrap" class="ft2415"><b>4.&#160;Discussion<br/></b>4.1.&#160;Putative&#160;Electroceuticals&#160;for&#160;Cancer</p>
<p style="position:absolute;top:1133px;left:281px;white-space:nowrap" class="ft242">Our&#160;drugs&#160;were&#160;selected&#160;based&#160;on&#160;their&#160;predicted&#160;effects&#160;on&#160;Vmem,&#160;which&#160;has&#160;been</p>
<p style="position:absolute;top:1152px;left:250px;white-space:nowrap" class="ft242">shown&#160;in&#160;amphibian&#160;models&#160;in&#160;vivo&#160;to&#160;prevent&#160;and&#160;reverse&#160;tumorigenesis&#160;and&#160;metastatic</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft250{font-size:9px;font-family:Times;color:#000000;}
	.ft251{font-size:9px;font-family:Times;color:#000000;}
	.ft252{font-size:12px;font-family:Times;color:#000000;}
	.ft253{font-size:12px;font-family:Times;color:#0775b7;}
	.ft254{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page25-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft250">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft250">25&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:250px;white-space:nowrap" class="ft254">behavior&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[34,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#31">47].&#160;</a>Indeed,&#160;a&#160;number&#160;of&#160;drugs&#160;with&#160;bioelectric&#160;targets,&#160;such&#160;as&#160;ivermectin&#160;(a<br/>chloride&#160;channel&#160;drug)&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[126–129],&#160;</a>salinomycin&#160;and&#160;monensin&#160;(ionophores)&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[126,130],&#160;</a>a&#160;va-<br/>riety&#160;of&#160;potassium&#160;channel&#160;drugs&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[25,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#31">55,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">131–134],&#160;</a>and&#160;drugs&#160;targeting&#160;proton&#160;pumps&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[135]<br/></a>have&#160;been&#160;discovered&#160;to&#160;have&#160;anti-cancer&#160;activity&#160;in&#160;various&#160;screens&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[26,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">136–139].&#160;</a>Thus,<br/>our&#160;combinations&#160;of&#160;compounds&#160;represent&#160;novel&#160;entries&#160;to&#160;the&#160;field&#160;of&#160;electroceuticals:<br/>the&#160;repurposing&#160;of&#160;known&#160;ion&#160;channel-targeting&#160;drugs&#160;to&#160;manipulate&#160;complex&#160;cell&#160;out-<br/>comes&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[140,141].&#160;</a>This&#160;approach&#160;has&#160;already&#160;been&#160;used&#160;for&#160;the&#160;design&#160;of&#160;interventions&#160;to<br/>repair&#160;birth&#160;defects&#160;of&#160;the&#160;brain&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[142,143].&#160;</a>It&#160;is&#160;likely&#160;that&#160;a&#160;better&#160;understanding&#160;of&#160;the<br/>control&#160;of&#160;cell&#160;behavior,&#160;alone&#160;and&#160;in&#160;tissues,&#160;will&#160;enable&#160;much&#160;more&#160;precisely&#160;targeted&#160;elec-<br/>troceutical&#160;interventions&#160;in&#160;cancer&#160;as&#160;part&#160;of&#160;the&#160;goal&#160;of&#160;normalizing&#160;cells&#160;as&#160;an&#160;alternative<br/>to&#160;traditional&#160;chemotherapy&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[144].</a></p>
<p style="position:absolute;top:368px;left:250px;white-space:nowrap" class="ft252">4.2.&#160;Effects&#160;on&#160;Proliferation</p>
<p style="position:absolute;top:392px;left:281px;white-space:nowrap" class="ft252">The&#160;NG108-15&#160;hybrid&#160;cell&#160;line&#160;used&#160;in&#160;this&#160;study&#160;shows&#160;cancer&#160;stem&#160;cell&#160;characteristics,</p>
<p style="position:absolute;top:411px;left:250px;white-space:nowrap" class="ft254">can&#160;be&#160;easily&#160;transfected&#160;and&#160;selected&#160;and&#160;has&#160;been&#160;used&#160;to&#160;study&#160;neuronal&#160;differentiation<br/>for&#160;many&#160;years.&#160;To&#160;find&#160;treatments&#160;that&#160;would&#160;be&#160;robust,&#160;we&#160;screened&#160;all&#160;our&#160;compounds&#160;in<br/>high&#160;serum&#160;media,&#160;which&#160;is&#160;usually&#160;prohibitive&#160;for&#160;NG108-15&#160;differentiation&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[90,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">145,146].<br/></a>In&#160;addition,&#160;the&#160;high&#160;serum&#160;media&#160;provided&#160;an&#160;abundance&#160;of&#160;growth&#160;factors&#160;that&#160;have<br/>been&#160;shown&#160;to&#160;be&#160;secreted&#160;in&#160;the&#160;peripheral&#160;zone&#160;of&#160;resected&#160;GBM&#160;tumors&#160;and&#160;are&#160;thought<br/>to&#160;drive&#160;the&#160;migration&#160;and&#160;proliferation&#160;of&#160;GBM&#160;stem&#160;cells&#160;in&#160;the&#160;area&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#29">[10].&#160;</a>The&#160;best</p>
<p style="position:absolute;top:524px;left:249px;white-space:nowrap" class="ft252">performing&#160;novel&#160;combinations&#160;were&#160;pantoprazole&#160;with&#160;retigabine,&#160;lamotrigine,&#160;NS1643,&#160;or</p>
<p style="position:absolute;top:542px;left:250px;white-space:nowrap" class="ft254">rapamycin&#160;and&#160;reduced&#160;proliferation&#160;when&#160;compared&#160;to&#160;the&#160;control&#160;by&#160;80%,&#160;85%,&#160;86%,&#160;and<br/>90%,&#160;respectively.&#160;FUCCI&#160;analysis&#160;showed&#160;that&#160;the&#160;cell&#160;cycle&#160;proportion&#160;was&#160;dominated<br/>by&#160;cells&#160;in&#160;either&#160;G1&#160;or&#160;early&#160;S.&#160;All&#160;these&#160;compounds&#160;are&#160;already&#160;FDA&#160;approved&#160;for&#160;other<br/>conditions&#160;except&#160;for&#160;NS1643.</p>
<p style="position:absolute;top:618px;left:281px;white-space:nowrap" class="ft252">We&#160;then&#160;used&#160;the&#160;best&#160;performing&#160;novel&#160;combinations&#160;to&#160;inform&#160;a&#160;screen&#160;of&#160;compounds</p>
<p style="position:absolute;top:637px;left:250px;white-space:nowrap" class="ft254">on&#160;a&#160;human&#160;glioblastoma&#160;cell&#160;line,&#160;U87&#160;(ATCC).&#160;Our&#160;proliferation&#160;assays&#160;showed&#160;13&#160;drug<br/>or&#160;drug&#160;combinations&#160;that&#160;reduced&#160;proliferation&#160;compared&#160;to&#160;control&#160;more&#160;significantly<br/>than&#160;the&#160;leading&#160;glioblastoma&#160;treatment,&#160;TMZ.&#160;Of&#160;these&#160;13,&#160;the&#160;top&#160;four&#160;treatments&#160;were<br/>combinations&#160;of&#160;pantoprazole&#160;or&#160;NS1643&#160;with&#160;TMZ,&#160;and&#160;the&#160;combination&#160;of&#160;pantoprazole</p>
<p style="position:absolute;top:712px;left:249px;white-space:nowrap" class="ft252">with&#160;retigabine&#160;or&#160;NS1643,&#160;which&#160;reduced&#160;proliferation&#160;when&#160;compared&#160;to&#160;control&#160;by&#160;62%,</p>
<p style="position:absolute;top:731px;left:250px;white-space:nowrap" class="ft254">63%,&#160;71%,&#160;and&#160;74%,&#160;respectively.&#160;FUCCI&#160;analysis&#160;showed&#160;that&#160;the&#160;cell&#160;cycle&#160;proportion&#160;was<br/>again&#160;dominated&#160;by&#160;cells&#160;in&#160;either&#160;G1&#160;or&#160;early&#160;S.</p>
<p style="position:absolute;top:783px;left:250px;white-space:nowrap" class="ft252">4.3.&#160;Effects&#160;on&#160;Differentiation</p>
<p style="position:absolute;top:806px;left:281px;white-space:nowrap" class="ft252">Differentiation&#160;therapy&#160;for&#160;GBM&#160;is&#160;an&#160;alternative&#160;treatment&#160;strategy&#160;that&#160;could&#160;possibly</p>
<p style="position:absolute;top:825px;left:250px;white-space:nowrap" class="ft254">overcome&#160;the&#160;issue&#160;of&#160;reoccurrence&#160;after&#160;resection&#160;of&#160;the&#160;tumor&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#30">[15].&#160;</a>For&#160;differentiation<br/>therapy&#160;to&#160;be&#160;successful,&#160;treatment&#160;needs&#160;to&#160;be&#160;effective&#160;at&#160;clinically&#160;relevant&#160;concentrations,<br/>and&#160;differentiation&#160;needs&#160;to&#160;be&#160;permanent,&#160;without&#160;cell&#160;cycle&#160;re-entry&#160;after&#160;treatment<br/>is&#160;stopped.&#160;This&#160;study&#160;showed&#160;that&#160;hyperpolarizing&#160;compounds&#160;in&#160;combination&#160;with</p>
<p style="position:absolute;top:901px;left:249px;white-space:nowrap" class="ft252">pantoprazole&#160;can&#160;be&#160;used&#160;to&#160;arrest&#160;the&#160;cell&#160;cycle&#160;of&#160;proliferating&#160;cells&#160;and&#160;drive&#160;them</p>
<p style="position:absolute;top:919px;left:250px;white-space:nowrap" class="ft252">towards&#160;partial&#160;differentiation&#160;and&#160;senescence.</p>
<p style="position:absolute;top:938px;left:281px;white-space:nowrap" class="ft252">NG108-15&#160;cells&#160;treated&#160;with&#160;the&#160;most&#160;successful&#160;drug&#160;combinations&#160;showed&#160;neuronal,</p>
<p style="position:absolute;top:957px;left:250px;white-space:nowrap" class="ft252">astrocytic,&#160;and&#160;oligodendrocyte&#160;differentiation&#160;markers&#160;as&#160;well&#160;as&#160;senescence&#160;markers.</p>
<p style="position:absolute;top:976px;left:249px;white-space:nowrap" class="ft252">The&#160;mixed&#160;nature&#160;of&#160;differentiation&#160;markers&#160;in&#160;NG108-15&#160;cells&#160;has&#160;been&#160;reported&#160;previ-</p>
<p style="position:absolute;top:995px;left:250px;white-space:nowrap" class="ft254">ously&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[147]&#160;</a>and&#160;might&#160;be&#160;due&#160;to&#160;their&#160;hybrid&#160;neuroblastoma/glioma&#160;status.&#160;Many&#160;of&#160;the<br/>combinations&#160;of&#160;drugs&#160;we&#160;tested&#160;in&#160;NG108-15&#160;cells&#160;were&#160;also&#160;successful&#160;in&#160;U87&#160;cells&#160;and<br/>resulted&#160;in&#160;dramatically&#160;less&#160;proliferation,&#160;less&#160;progression&#160;through&#160;the&#160;cell&#160;cycle&#160;and&#160;a<br/>significant&#160;increase&#160;in&#160;differentiation&#160;markers,&#160;which&#160;need&#160;the&#160;cell&#160;cycle&#160;to&#160;be&#160;arrested&#160;long<br/>enough&#160;to&#160;accumulate&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[148].&#160;</a>The&#160;mixed&#160;nature&#160;of&#160;the&#160;differentiation&#160;markers&#160;that&#160;were<br/>elevated&#160;in&#160;U87&#160;cells&#160;shows&#160;that&#160;this&#160;line&#160;can&#160;differentiate&#160;into&#160;the&#160;neuron,&#160;astrocyte,&#160;and<br/>oligodendrocyte&#160;lineages,&#160;in&#160;agreement&#160;with&#160;past&#160;studies&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[149,150].&#160;</a>It&#160;is&#160;important&#160;to&#160;note<br/>that&#160;many&#160;of&#160;the&#160;differentiation&#160;markers&#160;were&#160;heterogeneously&#160;expressed&#160;and&#160;that&#160;there<br/>is&#160;a&#160;possibility&#160;that&#160;in&#160;each&#160;sample,&#160;there&#160;exist&#160;a&#160;multitude&#160;of&#160;differentiated&#160;phenotypes</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft260{font-size:9px;font-family:Times;color:#000000;}
	.ft261{font-size:9px;font-family:Times;color:#000000;}
	.ft262{font-size:12px;font-family:Times;color:#000000;}
	.ft263{font-size:12px;font-family:Times;color:#0775b7;}
	.ft264{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
	.ft265{font-size:9px;line-height:18px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page26-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft260">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft260">26&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:250px;white-space:nowrap" class="ft264">instead&#160;of&#160;just&#160;one&#160;type.&#160;Connexin&#160;43&#160;was&#160;also&#160;upregulated&#160;in&#160;treated&#160;NG108-15&#160;cells,<br/>showing&#160;that&#160;this&#160;marker&#160;of&#160;cell-to-cell&#160;communication&#160;was&#160;increased&#160;as&#160;cells&#160;went&#160;to<br/>a&#160;more&#160;differentiated&#160;state,&#160;as&#160;supported&#160;by&#160;a&#160;previous&#160;study&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">[104].&#160;</a>Interestingly,&#160;both<br/>NS1643&#160;and&#160;retigabine&#160;are&#160;known&#160;to&#160;work&#160;on&#160;KCNQ2/3&#160;channels,&#160;which&#160;are&#160;important&#160;for<br/>neuronal&#160;differentiation&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[151],&#160;</a>and&#160;NS1643&#160;activates&#160;hERG&#160;channels&#160;which&#160;have&#160;also&#160;been<br/>shown&#160;to&#160;be&#160;important&#160;in&#160;neuronal&#160;differentiation&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#31">[65].</a></p>
<p style="position:absolute;top:274px;left:250px;white-space:nowrap" class="ft262">4.4.&#160;Electrophysiology,&#160;pH,&#160;and&#160;Cell&#160;Cycle&#160;Regulation</p>
<p style="position:absolute;top:298px;left:281px;white-space:nowrap" class="ft262">NS1643,&#160;a&#160;hERG&#160;channel&#160;opener&#160;and&#160;potassium&#160;modulator&#160;which&#160;also&#160;potentiates</p>
<p style="position:absolute;top:316px;left:250px;white-space:nowrap" class="ft264">KCNQ2,&#160;KCNQ4,&#160;and&#160;KCNQ2/3&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[85,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">152],&#160;</a>was&#160;shown&#160;to&#160;hyperpolarize&#160;both&#160;cell&#160;lines<br/>that&#160;we&#160;tested&#160;and&#160;was&#160;one&#160;of&#160;the&#160;most&#160;successful&#160;single&#160;treatments.&#160;In&#160;combination&#160;with</p>
<p style="position:absolute;top:354px;left:249px;white-space:nowrap" class="ft262">pantoprazole,&#160;it&#160;could&#160;arrest&#160;the&#160;NG108-15&#160;cell&#160;cycle&#160;long&#160;enough&#160;to&#160;enable&#160;differentiation</p>
<p style="position:absolute;top:373px;left:250px;white-space:nowrap" class="ft262">in&#160;a&#160;high&#160;serum&#160;medium&#160;and&#160;work&#160;well&#160;in&#160;U87&#160;cells.&#160;Treatment&#160;with&#160;NS1643&#160;in&#160;combination</p>
<p style="position:absolute;top:392px;left:249px;white-space:nowrap" class="ft264">with&#160;pantoprazole&#160;showed&#160;a&#160;significant&#160;effect&#160;that&#160;was&#160;not&#160;seen&#160;with&#160;either&#160;treatment&#160;alone.<br/>Assays&#160;in&#160;U87&#160;cells&#160;showed&#160;that&#160;this&#160;novel&#160;combinatorial&#160;treatment&#160;caused&#160;the&#160;pH&#160;of&#160;the</p>
<p style="position:absolute;top:429px;left:250px;white-space:nowrap" class="ft264">cytoplasm&#160;and&#160;lysosomes&#160;to&#160;alkalize&#160;drastically&#160;and&#160;that&#160;cytoplasmic&#160;calcium&#160;increased<br/>significantly&#160;along&#160;with&#160;an&#160;increase&#160;in&#160;the&#160;cell&#160;cycle&#160;inhibitor&#160;p27Kip1&#160;and&#160;an&#160;increase&#160;in<br/>senescence-associated&#160;beta-galactosidase&#160;positive&#160;cells.&#160;In&#160;addition,&#160;combination&#160;treatments</p>
<p style="position:absolute;top:486px;left:249px;white-space:nowrap" class="ft262">with&#160;NS1643&#160;also&#160;resulted&#160;in&#160;a&#160;decrease&#160;in&#160;YAP&#160;nuclear&#160;to&#160;cytoplasmic&#160;ratio,&#160;elevated&#160;levels</p>
<p style="position:absolute;top:505px;left:250px;white-space:nowrap" class="ft264">of&#160;which&#160;are&#160;known&#160;to&#160;accelerate&#160;cancer&#160;cell&#160;cycle&#160;progression,&#160;proliferation,&#160;therapy&#160;resis-<br/>tance,&#160;and&#160;metastasis&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[124,125,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">153].&#160;</a>Thus,&#160;both&#160;YAP&#160;translocation&#160;and&#160;increased&#160;p27Kip1<br/>levels&#160;were&#160;found&#160;in&#160;the&#160;cells&#160;that&#160;showed&#160;the&#160;most&#160;senescence,&#160;confirming&#160;what&#160;other<br/>studies&#160;have&#160;reported:&#160;that&#160;both&#160;proteins&#160;are&#160;involved&#160;in&#160;senescence&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#33">[111,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">154].&#160;</a>Proliferation<br/>under&#160;these&#160;senescence-inducing&#160;treatments&#160;was&#160;reduced&#160;dramatically,&#160;and&#160;U87&#160;cells&#160;did<br/>not&#160;re-enter&#160;the&#160;cell&#160;cycle&#160;up&#160;to&#160;4&#160;days&#160;after&#160;treatment&#160;was&#160;removed.&#160;The&#160;combination&#160;of<br/>NS1643&#160;with&#160;TMZ&#160;was&#160;also&#160;very&#160;effective&#160;at&#160;reducing&#160;proliferation&#160;in&#160;U87&#160;cells,&#160;although<br/>according&#160;to&#160;our&#160;voltage&#160;dye&#160;assays,&#160;it&#160;did&#160;not&#160;hyperpolarize&#160;U87&#160;cells.&#160;However,&#160;the&#160;cells<br/>did&#160;significantly&#160;express&#160;a&#160;variety&#160;of&#160;differentiation&#160;markers&#160;after&#160;6&#160;days&#160;of&#160;treatment.&#160;The<br/>cells&#160;treated&#160;with&#160;NS1643&#160;and&#160;TMZ&#160;also&#160;showed,&#160;similar&#160;to&#160;the&#160;other&#160;NS1643&#160;containing<br/>treatments,&#160;an&#160;increase&#160;in&#160;lysosomal&#160;and&#160;cytoplasmic&#160;pH,&#160;an&#160;increase&#160;in&#160;p27kip1,&#160;and&#160;a&#160;sig-<br/>nificant&#160;decrease&#160;in&#160;the&#160;YAP&#160;nuclear&#160;to&#160;cytoplasmic&#160;ratio.&#160;It&#160;is&#160;possible&#160;that&#160;the&#160;voltage&#160;dye<br/>did&#160;not&#160;correctly&#160;report&#160;the&#160;membrane&#160;potential&#160;with&#160;this&#160;combination&#160;due&#160;to&#160;an&#160;interaction</p>
<p style="position:absolute;top:750px;left:249px;white-space:nowrap" class="ft262">with&#160;the&#160;dye&#160;molecule&#160;itself,&#160;as&#160;has&#160;been&#160;reported&#160;for&#160;other&#160;compounds&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[155,156].</a></p>
<p style="position:absolute;top:768px;left:281px;white-space:nowrap" class="ft262">In&#160;agreement&#160;with&#160;our&#160;results,&#160;NS1643&#160;has&#160;also&#160;been&#160;shown&#160;to&#160;induce&#160;senescence&#160;in</p>
<p style="position:absolute;top:787px;left:250px;white-space:nowrap" class="ft264">melanoma&#160;and&#160;breast&#160;cancer&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#31">[55,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">131,</a><a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">157].&#160;</a>This&#160;senescent&#160;phenotype&#160;is&#160;thought&#160;to&#160;occur<br/>through&#160;elevated&#160;internal&#160;calcium&#160;levels&#160;(a&#160;response&#160;to&#160;hyperpolarization),&#160;which&#160;trigger<br/>the&#160;activation&#160;of&#160;calcineurin,&#160;which&#160;in&#160;turn&#160;dephosphorylates&#160;NFAT&#160;and&#160;results&#160;in&#160;its<br/>translocation&#160;to&#160;the&#160;nucleus&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[134].&#160;</a>In&#160;the&#160;nucleus,&#160;it&#160;is&#160;possible&#160;that&#160;translocated&#160;NFAT&#160;and<br/>activated&#160;calcineurin&#160;could&#160;be&#160;increasing&#160;the&#160;expression&#160;of&#160;p21WAF1/CIP1,&#160;also&#160;found&#160;caused<br/>by&#160;NS1643&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[134],&#160;</a>by&#160;a&#160;mechanism&#160;similar&#160;to&#160;that&#160;found&#160;in&#160;differentiating&#160;keratinocytes</p>
<p style="position:absolute;top:900px;left:249px;white-space:nowrap" class="ft262">where&#160;calcineurin&#160;increases&#160;Sp1/Sp3-dependent&#160;transcription&#160;and&#160;p21&#160;promoter&#160;activity&#160;in</p>
<p style="position:absolute;top:919px;left:250px;white-space:nowrap" class="ft264">combination&#160;with&#160;NFAT&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[158].&#160;</a>That&#160;same&#160;study&#160;performed&#160;on&#160;keratinocytes&#160;showed&#160;that<br/>calcineurin&#160;inactivation&#160;resulted&#160;in&#160;less&#160;p27kip1&#160;as&#160;well&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[158].&#160;</a>Interestingly,&#160;mitochondrial<br/>ROS&#160;production&#160;has&#160;been&#160;found&#160;to&#160;be&#160;increased&#160;by&#160;calcineurin&#160;activation&#160;in&#160;neurons&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[159],<br/></a>and&#160;ROS&#160;levels&#160;were&#160;found&#160;elevated&#160;in&#160;breast&#160;cancer&#160;cells&#160;treated&#160;with&#160;NS1643&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[131].<br/></a>Elevated&#160;ROS&#160;levels&#160;have&#160;been&#160;found&#160;to&#160;decrease&#160;the&#160;proteasome&#160;function&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[160]&#160;</a>and&#160;could</p>
<p style="position:absolute;top:1013px;left:249px;white-space:nowrap" class="ft262">possibly&#160;increase&#160;p27kip1&#160;levels&#160;through&#160;decreased&#160;ubiquitination&#160;and&#160;degradation&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[161].</a></p>
<p style="position:absolute;top:1032px;left:250px;white-space:nowrap" class="ft264">Currently,&#160;no&#160;publications&#160;have&#160;shown&#160;the&#160;efficacy&#160;of&#160;NS1643&#160;on&#160;glioblastoma&#160;or&#160;its&#160;efficacy<br/>in&#160;combination&#160;with&#160;rapamycin,&#160;pantoprazole,&#160;or&#160;TMZ.</p>
<p style="position:absolute;top:1070px;left:281px;white-space:nowrap" class="ft262">Another&#160;successful&#160;combination&#160;included&#160;the&#160;KCNQ2-5/Kv7.2–7.5&#160;channel&#160;opener,</p>
<p style="position:absolute;top:1088px;left:250px;white-space:nowrap" class="ft264">and&#160;FDAapproved&#160;epilepsy&#160;treatment,&#160;retigabine&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[87].&#160;</a>Although&#160;the&#160;application&#160;of&#160;reti-<br/>gabine&#160;alone&#160;hyperpolarized&#160;NG108-15&#160;cells&#160;only&#160;slightly&#160;and&#160;reduced&#160;proliferation&#160;only<br/>marginally&#160;by&#160;itself,&#160;its&#160;ability&#160;to&#160;stop&#160;NG108-15&#160;proliferation&#160;was&#160;increased&#160;most&#160;signifi-<br/>cantly&#160;with&#160;pantoprazole.&#160;Pantoprazole,&#160;a&#160;proton-pump&#160;inhibitor,&#160;worked&#160;well&#160;on&#160;its&#160;own</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft270{font-size:9px;font-family:Times;color:#000000;}
	.ft271{font-size:9px;font-family:Times;color:#000000;}
	.ft272{font-size:12px;font-family:Times;color:#000000;}
	.ft273{font-size:12px;font-family:Times;color:#0775b7;}
	.ft274{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page27-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft270">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft270">27&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:250px;white-space:nowrap" class="ft274">at&#160;reducing&#160;proliferation&#160;in&#160;these&#160;two&#160;cell&#160;lines.&#160;However,&#160;when&#160;treatment&#160;was&#160;removed,<br/>the&#160;cells&#160;immediately&#160;re-entered&#160;the&#160;cell&#160;cycle,&#160;illustrating&#160;that&#160;treatment&#160;with&#160;pantoprazole<br/>alone&#160;does&#160;not&#160;arrest&#160;the&#160;cell&#160;cycle&#160;long&#160;enough&#160;to&#160;allow&#160;for&#160;terminal&#160;differentiation.&#160;When</p>
<p style="position:absolute;top:203px;left:249px;white-space:nowrap" class="ft272">pantoprazole&#160;was&#160;combined&#160;with&#160;retigabine,&#160;a&#160;synergistic&#160;effect&#160;was&#160;achieved&#160;that&#160;resulted</p>
<p style="position:absolute;top:222px;left:250px;white-space:nowrap" class="ft274">in&#160;fewer&#160;cells&#160;re-entering&#160;the&#160;cell&#160;cycle&#160;after&#160;treatment&#160;was&#160;removed.&#160;Interestingly&#160;we&#160;saw&#160;a<br/>depolarization&#160;of&#160;the&#160;NG108-15&#160;cells&#160;when&#160;they&#160;were&#160;treated&#160;with&#160;the&#160;combination,&#160;but&#160;no<br/>change&#160;was&#160;seen&#160;in&#160;the&#160;membrane&#160;potential&#160;of&#160;the&#160;U87&#160;cells.</p>
<p style="position:absolute;top:278px;left:281px;white-space:nowrap" class="ft272">Pantoprazole&#160;alone&#160;has&#160;been&#160;reported&#160;to&#160;increase&#160;the&#160;alkalinity&#160;of&#160;the&#160;lysosomes&#160;by</p>
<p style="position:absolute;top:297px;left:250px;white-space:nowrap" class="ft274">inhibiting&#160;V-ATPase&#160;channels&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[86].&#160;</a>However,&#160;we&#160;saw&#160;no&#160;alkalization&#160;of&#160;the&#160;lysosomes&#160;and<br/>the&#160;lysosomal&#160;signal&#160;was&#160;increased.&#160;Our&#160;results&#160;agree&#160;with&#160;a&#160;recent&#160;study&#160;showing&#160;that</p>
<p style="position:absolute;top:335px;left:249px;white-space:nowrap" class="ft272">pantoprazole&#160;at&#160;neutral&#160;pH&#160;does&#160;not&#160;inhibit&#160;V-ATPase&#160;channels&#160;and&#160;that&#160;it&#160;instead&#160;increases</p>
<p style="position:absolute;top:354px;left:250px;white-space:nowrap" class="ft274">lysosomal&#160;biogenesis&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[120].&#160;</a>Interestingly,&#160;that&#160;same&#160;study&#160;showed&#160;that&#160;pantoprazole<br/>interfered&#160;with&#160;proteasome&#160;function,&#160;which&#160;might&#160;explain&#160;why&#160;it&#160;worked&#160;so&#160;well&#160;as&#160;a<br/>combinatorial&#160;treatment.&#160;Recent&#160;studies&#160;have&#160;shown&#160;that&#160;proteasome&#160;dysfunction&#160;along</p>
<p style="position:absolute;top:410px;left:249px;white-space:nowrap" class="ft274">with&#160;an&#160;increase&#160;in&#160;p27Kip1&#160;leads&#160;to&#160;senescence&#160;and&#160;endoreplication,&#160;resulting&#160;in&#160;cells<br/>with&#160;large&#160;nuclei&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[162].&#160;</a>In&#160;addition,&#160;the&#160;loss&#160;of&#160;PTEN&#160;in&#160;U87&#160;(ATCC)&#160;cells&#160;results&#160;in&#160;cells</p>
<p style="position:absolute;top:448px;left:250px;white-space:nowrap" class="ft274">that&#160;preferentially&#160;senesce&#160;in&#160;response&#160;to&#160;stress&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[163].&#160;</a>The&#160;presence&#160;of&#160;endoreplication&#160;in<br/>strongly&#160;senescent&#160;cells&#160;was&#160;evidenced&#160;by&#160;the&#160;size&#160;of&#160;the&#160;nuclei&#160;in&#160;both&#160;cell&#160;lines&#160;and&#160;may<br/>explain&#160;why&#160;the&#160;BrdU&#160;incorporation&#160;results&#160;were&#160;not&#160;as&#160;low&#160;as&#160;the&#160;cell&#160;count&#160;data&#160;would<br/>suggest&#160;they&#160;should&#160;be.&#160;The&#160;treatment&#160;with&#160;pantoprazole&#160;alone&#160;showed&#160;less&#160;differentiation<br/>and&#160;senescence&#160;when&#160;compared&#160;to&#160;pantoprazole&#160;in&#160;combination&#160;with&#160;retigabine,&#160;NS1643,</p>
<p style="position:absolute;top:542px;left:249px;white-space:nowrap" class="ft272">TMZ,&#160;or&#160;rapamycin&#160;in&#160;U87&#160;cells.&#160;Pantoprazole&#160;has&#160;been&#160;shown&#160;to&#160;be&#160;effective&#160;against</p>
<p style="position:absolute;top:561px;left:250px;white-space:nowrap" class="ft274">glioblastoma&#160;in&#160;vitro&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#32">[83],&#160;</a>but&#160;to&#160;our&#160;knowledge,&#160;this&#160;is&#160;the&#160;first&#160;study&#160;that&#160;has&#160;tested&#160;its<br/>efficacy&#160;in&#160;combination&#160;with&#160;NS1643,&#160;lamotrigine,&#160;retigabine,&#160;rapamycin,&#160;or&#160;temozolomide.</p>
<p style="position:absolute;top:598px;left:281px;white-space:nowrap" class="ft272">The&#160;leading&#160;GBM&#160;treatment,&#160;TMZ,&#160;was&#160;not&#160;significantly&#160;effective&#160;at&#160;reducing&#160;prolifer-</p>
<p style="position:absolute;top:617px;left:250px;white-space:nowrap" class="ft274">ation&#160;in&#160;NG108-15&#160;cells.&#160;This&#160;has&#160;also&#160;been&#160;observed&#160;for&#160;some&#160;GBM&#160;cases&#160;as&#160;well.&#160;However,<br/>our&#160;combination&#160;of&#160;TMZ&#160;with&#160;pantoprazole&#160;in&#160;NG108-15&#160;cells&#160;did&#160;significantly&#160;lower&#160;their</p>
<p style="position:absolute;top:655px;left:249px;white-space:nowrap" class="ft272">proliferation&#160;as&#160;compared&#160;to&#160;pantoprazole&#160;alone,&#160;but&#160;did&#160;not&#160;terminally&#160;differentiate&#160;them,</p>
<p style="position:absolute;top:674px;left:250px;white-space:nowrap" class="ft274">as&#160;evidenced&#160;by&#160;the&#160;recovery&#160;assay.&#160;However,&#160;we&#160;do&#160;note&#160;that&#160;TMZ&#160;by&#160;itself&#160;was&#160;not<br/>effective&#160;in&#160;NG108-15&#160;cells&#160;but&#160;was&#160;significantly&#160;effective&#160;in&#160;U87&#160;cells.&#160;This&#160;effectiveness&#160;in<br/>U87&#160;cells&#160;might&#160;explain&#160;why&#160;the&#160;combination&#160;of&#160;pantoprazole&#160;or&#160;NS1643&#160;with&#160;TMZ&#160;was<br/>so&#160;effective&#160;at&#160;reducing&#160;proliferation&#160;and&#160;increasing&#160;differentiation&#160;markers&#160;in&#160;these&#160;cells<br/>and&#160;not&#160;in&#160;the&#160;NG108-15&#160;line.&#160;It&#160;should&#160;be&#160;noted&#160;that&#160;these&#160;combinations&#160;also&#160;dramatically<br/>increased&#160;senescence&#160;markers&#160;in&#160;these&#160;cells&#160;and&#160;caused&#160;a&#160;significant&#160;decrease&#160;of&#160;the&#160;YAP<br/>nuclear&#160;to&#160;cytoplasmic&#160;ratio.</p>
<p style="position:absolute;top:820px;left:250px;white-space:nowrap" class="ft272">4.5.&#160;Drug&#160;Concentrations&#160;and&#160;FDA&#160;Status:&#160;Paths&#160;towards&#160;Clinical&#160;Use</p>
<p style="position:absolute;top:844px;left:281px;white-space:nowrap" class="ft272">The&#160;drug&#160;concentrations&#160;used&#160;in&#160;these&#160;studies&#160;were&#160;chosen&#160;to&#160;be&#160;close&#160;to&#160;the&#160;Cmax</p>
<p style="position:absolute;top:863px;left:250px;white-space:nowrap" class="ft274">reported&#160;for&#160;the&#160;highest&#160;dosages&#160;that&#160;did&#160;not&#160;result&#160;in&#160;unacceptable&#160;toxicity.&#160;Retigabine,<br/>FDA-approved&#160;for&#160;epilepsy,&#160;was&#160;used&#160;at&#160;10&#160;µM,&#160;which&#160;is&#160;close&#160;to&#160;the&#160;reported&#160;upper&#160;Cmax</p>
<p style="position:absolute;top:900px;left:249px;white-space:nowrap" class="ft272">values&#160;obtained&#160;with&#160;a&#160;1200&#160;mg/day&#160;dose&#160;of&#160;about&#160;2250&#160;ng/mL&#160;or&#160;about&#160;7.4&#160;µM&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[164].</a></p>
<p style="position:absolute;top:919px;left:250px;white-space:nowrap" class="ft274">Blood-brain&#160;barrier&#160;penetrance&#160;is&#160;good&#160;for&#160;retigabine,&#160;with&#160;free&#160;plasma&#160;concentrations<br/>being&#160;about&#160;the&#160;same&#160;as&#160;free&#160;brain&#160;concentrations&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[165].&#160;</a>Our&#160;choice&#160;of&#160;using&#160;a&#160;high&#160;serum<br/>to&#160;test&#160;our&#160;drugs&#160;and&#160;drug&#160;combinations&#160;also&#160;helps&#160;in&#160;strengthening&#160;the&#160;clinical&#160;relevance<br/>of&#160;our&#160;treatments,&#160;since&#160;retigabine&#160;also&#160;has&#160;a&#160;high&#160;plasma&#160;protein&#160;binding&#160;affinity&#160;of&#160;about<br/>80%&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[165].&#160;</a>We&#160;do&#160;note,&#160;however,&#160;that&#160;the&#160;binding&#160;of&#160;a&#160;compound&#160;in&#160;fetal&#160;bovine&#160;serum&#160;can<br/>be&#160;different&#160;from&#160;the&#160;binding&#160;in&#160;human&#160;serum&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[166].</a></p>
<p style="position:absolute;top:1032px;left:281px;white-space:nowrap" class="ft272">Rapamycin,&#160;an&#160;FDA-approved&#160;drug&#160;for&#160;immunosuppression,&#160;was&#160;used&#160;at&#160;a&#160;dose&#160;of</p>
<p style="position:absolute;top:1051px;left:249px;white-space:nowrap" class="ft272">100&#160;nM&#160;for&#160;our&#160;immunological&#160;studies.&#160;This&#160;concentration&#160;is&#160;under&#160;the&#160;highest&#160;dosage</p>
<p style="position:absolute;top:1070px;left:250px;white-space:nowrap" class="ft274">of&#160;40&#160;mg/day&#160;of&#160;a&#160;nano-amorphous&#160;oral&#160;formulation&#160;in&#160;a&#160;fasted&#160;state,&#160;with&#160;a&#160;Cmax&#160;of<br/>219&#160;ng/mL&#160;or&#160;about&#160;239&#160;nM,&#160;and&#160;toxicity&#160;at&#160;this&#160;level&#160;was&#160;deemed&#160;manageable&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[167].<br/></a>Furthermore,&#160;rapamycin&#160;has&#160;been&#160;used&#160;in&#160;a&#160;phase&#160;1&#160;clinical&#160;trial&#160;for&#160;glioblastoma&#160;and&#160;was<br/>found&#160;to&#160;cross&#160;the&#160;blood-brain&#160;barrier&#160;effectively&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[168].</a></p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft280{font-size:9px;font-family:Times;color:#000000;}
	.ft281{font-size:9px;font-family:Times;color:#000000;}
	.ft282{font-size:12px;font-family:Times;color:#000000;}
	.ft283{font-size:12px;font-family:Times;color:#0775b7;}
	.ft284{font-size:12px;font-family:Times;color:#000000;}
	.ft285{font-size:12px;line-height:18px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page28-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft280">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft280">28&#160;of&#160;36</p>
<p style="position:absolute;top:147px;left:281px;white-space:nowrap" class="ft282">Pantoprazole,&#160;an&#160;FDA-approved&#160;proton&#160;pump&#160;inhibitor,&#160;was&#160;used&#160;at&#160;a&#160;dose&#160;of&#160;100&#160;µM.</p>
<p style="position:absolute;top:165px;left:249px;white-space:nowrap" class="ft282">The&#160;highest&#160;dosage&#160;of&#160;pantoprazole,&#160;given&#160;for&#160;Zollinger-Ellison&#160;syndrome&#160;is&#160;240&#160;mg/day</p>
<p style="position:absolute;top:184px;left:250px;white-space:nowrap" class="ft285">and&#160;results&#160;in&#160;a&#160;Cmax&#160;of&#160;42&#160;mg/L&#160;or&#160;about&#160;110&#160;µM&#160;if&#160;the&#160;Cmax&#160;is&#160;proportional&#160;to&#160;that<br/>given&#160;for&#160;a&#160;30&#160;mg/day&#160;dose&#160;(as&#160;it&#160;is&#160;for&#160;dosages&#160;up&#160;to&#160;80&#160;mg/day)&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#35">[169].&#160;</a>However,</p>
<p style="position:absolute;top:222px;left:249px;white-space:nowrap" class="ft282">pantoprazole&#160;has&#160;poor&#160;blood-brain&#160;barrier&#160;penetrance&#160;of&#160;only&#160;2%&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#36">[170].&#160;</a>Therefore,&#160;its&#160;use</p>
<p style="position:absolute;top:241px;left:250px;white-space:nowrap" class="ft285">in&#160;glioblastoma&#160;therapy&#160;will&#160;have&#160;to&#160;rely&#160;on&#160;novel&#160;methods&#160;for&#160;delivery&#160;across&#160;the&#160;blood-<br/>brain&#160;barrier,&#160;of&#160;which&#160;there&#160;are&#160;many&#160;new&#160;strategies&#160;being&#160;developed&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#36">[171].&#160;</a>It&#160;should&#160;be<br/>noted,&#160;however,&#160;that&#160;all&#160;tests&#160;performed&#160;on&#160;pantoprazole&#160;in&#160;this&#160;study&#160;were&#160;conducted&#160;at&#160;a<br/>neutral&#160;pH,&#160;so&#160;pantoprazole’s&#160;efficacy&#160;may&#160;increase&#160;in&#160;an&#160;in&#160;vivo&#160;setting&#160;where&#160;the&#160;tumor<br/>microenvironment&#160;is&#160;more&#160;acidic&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#36">[172].</a></p>
<p style="position:absolute;top:335px;left:281px;white-space:nowrap" class="ft282">NS1643,&#160;a&#160;hERG&#160;activator&#160;and&#160;potentiator&#160;of&#160;KCNQ2,&#160;KCNQ4,&#160;and&#160;KCNQ2/3&#160;chan-</p>
<p style="position:absolute;top:354px;left:250px;white-space:nowrap" class="ft285">nels,&#160;is&#160;not&#160;currently&#160;approved&#160;by&#160;the&#160;FDA.&#160;However,&#160;it&#160;has&#160;recently&#160;been&#160;used&#160;in&#160;a&#160;breast<br/>cancer&#160;xenograft&#160;model&#160;in&#160;immunodeficient&#160;mice&#160;and&#160;did&#160;not&#160;show&#160;any&#160;overt&#160;toxicity&#160;on<br/>the&#160;heart&#160;or&#160;on&#160;normal&#160;breast&#160;epithelial&#160;cells&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#34">[131].</a></p>
<p style="position:absolute;top:425px;left:250px;white-space:nowrap" class="ft282">4.6.&#160;Limitations&#160;of&#160;the&#160;Study</p>
<p style="position:absolute;top:448px;left:281px;white-space:nowrap" class="ft282">The&#160;electrophysiological&#160;analysis&#160;in&#160;NG108&#160;cells&#160;showed&#160;what&#160;immediate&#160;changes</p>
<p style="position:absolute;top:467px;left:250px;white-space:nowrap" class="ft285">the&#160;compounds&#160;had&#160;on&#160;membrane&#160;potential&#160;and&#160;did&#160;not&#160;show&#160;the&#160;changes&#160;in&#160;potential<br/>over&#160;time.&#160;Pantoprazole&#160;did&#160;not&#160;have&#160;a&#160;significant&#160;effect&#160;on&#160;the&#160;membrane&#160;potential<br/>of&#160;the&#160;NG108-15&#160;cells&#160;alone;&#160;however,&#160;the&#160;effect&#160;of&#160;pantoprazole&#160;on&#160;the&#160;negation&#160;of&#160;the<br/>hyperpolarization&#160;seen&#160;with&#160;retigabine,&#160;lamotrigine,&#160;NS1643,&#160;and&#160;rapamycin&#160;is&#160;extremely<br/>interesting&#160;considering&#160;how&#160;quickly&#160;it&#160;occurred.&#160;If&#160;pantoprazole&#160;was&#160;merely&#160;blocking<br/>the&#160;function&#160;of&#160;those&#160;other&#160;compounds,&#160;then&#160;it&#160;is&#160;curious&#160;as&#160;to&#160;why&#160;the&#160;combination&#160;of<br/>the&#160;compounds&#160;would&#160;be&#160;more&#160;effective&#160;than&#160;pantoprazole&#160;alone.&#160;More&#160;study&#160;into&#160;the<br/>mechanism&#160;of&#160;this&#160;block&#160;is&#160;needed.&#160;In&#160;addition,&#160;the&#160;lack&#160;of&#160;hyperpolarization&#160;in&#160;the&#160;NG108-</p>
<p style="position:absolute;top:618px;left:249px;white-space:nowrap" class="ft282">15&#160;cells&#160;with&#160;the&#160;combination&#160;treatments&#160;points&#160;to&#160;the&#160;fact&#160;that&#160;the&#160;hyperpolarization&#160;of</p>
<p style="position:absolute;top:637px;left:250px;white-space:nowrap" class="ft285">the&#160;membrane&#160;potential&#160;is&#160;not&#160;necessarily&#160;needed&#160;for&#160;ion&#160;modulating&#160;drugs&#160;to&#160;have&#160;an<br/>effect.&#160;The&#160;depolarization&#160;of&#160;NG108-15&#160;cells&#160;seen&#160;in&#160;the&#160;combination&#160;of&#160;pantoprazole&#160;with<br/>retigabine&#160;or&#160;rapamycin&#160;could&#160;have&#160;effects&#160;on&#160;the&#160;ability&#160;of&#160;the&#160;cell&#160;cycle&#160;to&#160;proceed&#160;if&#160;the<br/>needed&#160;level&#160;of&#160;hyperpolarization&#160;to&#160;proceed&#160;through&#160;the&#160;S&#160;phase&#160;is&#160;not&#160;reached,&#160;an&#160;effect<br/>seen&#160;specifically&#160;in&#160;OPCs&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#36">[173–175].&#160;</a>However,&#160;this&#160;is&#160;not&#160;the&#160;case&#160;for&#160;the&#160;combination&#160;of</p>
<p style="position:absolute;top:731px;left:249px;white-space:nowrap" class="ft282">pantoprazole&#160;with&#160;NS1643&#160;or&#160;lamotrigine,&#160;which&#160;did&#160;not&#160;have&#160;any&#160;significant&#160;change&#160;in</p>
<p style="position:absolute;top:750px;left:250px;white-space:nowrap" class="ft282">resting&#160;membrane&#160;potential&#160;as&#160;compared&#160;to&#160;control&#160;in&#160;NG108-15&#160;cells.</p>
<p style="position:absolute;top:768px;left:281px;white-space:nowrap" class="ft282">A&#160;more&#160;detailed&#160;electrophysiological&#160;analysis&#160;also&#160;needs&#160;to&#160;be&#160;undertaken&#160;on&#160;the</p>
<p style="position:absolute;top:787px;left:250px;white-space:nowrap" class="ft285">U87&#160;cells.&#160;In&#160;this&#160;study,&#160;we&#160;were&#160;only&#160;able&#160;to&#160;find&#160;a&#160;DiBAC4(3)&#160;based&#160;analysis&#160;of&#160;resting<br/>membrane&#160;potential&#160;and&#160;may&#160;have&#160;had&#160;some&#160;interference&#160;with&#160;the&#160;dye&#160;caused&#160;by&#160;the<br/>compounds&#160;themselves.&#160;The&#160;differences&#160;in&#160;the&#160;U87&#160;cell’s&#160;membrane&#160;potential&#160;as&#160;compared<br/>to&#160;the&#160;NG108-15&#160;cells&#160;after&#160;immediate&#160;and&#160;long-term&#160;treatment&#160;should&#160;also&#160;be&#160;investigated.</p>
<p style="position:absolute;top:863px;left:281px;white-space:nowrap" class="ft282">As&#160;for&#160;the&#160;differentiation&#160;analysis,&#160;it&#160;would&#160;be&#160;interesting&#160;to&#160;do&#160;a&#160;more&#160;thorough&#160;study</p>
<p style="position:absolute;top:881px;left:249px;white-space:nowrap" class="ft282">where&#160;multiple&#160;markers&#160;are&#160;stained&#160;for&#160;in&#160;the&#160;same&#160;sample&#160;to&#160;see&#160;whether&#160;markers&#160;for</p>
<p style="position:absolute;top:900px;left:250px;white-space:nowrap" class="ft282">more&#160;than&#160;one&#160;lineage&#160;are&#160;co-expressed&#160;in&#160;U87&#160;or&#160;NG108-15&#160;cells.</p>
<p style="position:absolute;top:934px;left:250px;white-space:nowrap" class="ft284"><b>5.&#160;Conclusions</b></p>
<p style="position:absolute;top:957px;left:281px;white-space:nowrap" class="ft282">The&#160;use&#160;of&#160;the&#160;NG108-15&#160;cell&#160;line&#160;in&#160;high&#160;serum&#160;conditions&#160;for&#160;the&#160;initial&#160;screening&#160;of</p>
<p style="position:absolute;top:976px;left:250px;white-space:nowrap" class="ft285">many&#160;compounds&#160;and&#160;combinations&#160;gave&#160;us&#160;a&#160;subset&#160;of&#160;drugs&#160;that&#160;showed&#160;a&#160;significant<br/>decrease&#160;in&#160;proliferation&#160;in&#160;the&#160;human&#160;U87&#160;glioblastoma&#160;cell&#160;line&#160;treated&#160;for&#160;six&#160;days&#160;and<br/>showed&#160;depressed&#160;growth&#160;up&#160;to&#160;four&#160;days&#160;after&#160;treatment&#160;was&#160;removed.&#160;These&#160;results<br/>suggest&#160;that&#160;treatment&#160;could&#160;be&#160;given&#160;in&#160;an&#160;intermittent&#160;manner.&#160;The&#160;top&#160;combinations</p>
<p style="position:absolute;top:1051px;left:249px;white-space:nowrap" class="ft282">were&#160;capable&#160;of&#160;terminally&#160;differentiating&#160;and&#160;causing&#160;senescence&#160;in&#160;NG108-15&#160;cells&#160;under</p>
<p style="position:absolute;top:1070px;left:250px;white-space:nowrap" class="ft285">normally&#160;prohibitive&#160;conditions,&#160;giving&#160;us&#160;robust&#160;candidates&#160;that&#160;showed&#160;terminal&#160;differ-<br/>entiation&#160;and&#160;senescence&#160;in&#160;U87&#160;cells.&#160;Future&#160;studies&#160;will&#160;test&#160;these&#160;same&#160;compounds&#160;on</p>
<p style="position:absolute;top:1108px;left:249px;white-space:nowrap" class="ft282">primary&#160;human&#160;glioblastoma&#160;cell&#160;lines,&#160;patient&#160;tumor&#160;slices,&#160;and&#160;in&#160;vivo&#160;mouse&#160;models.</p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft290{font-size:9px;font-family:Times;color:#000000;}
	.ft291{font-size:9px;font-family:Times;color:#000000;}
	.ft292{font-size:11px;font-family:Times;color:#000000;}
	.ft293{font-size:11px;font-family:Times;color:#000000;}
	.ft294{font-size:11px;font-family:Times;color:#0775b7;}
	.ft295{font-size:12px;font-family:Times;color:#000000;}
	.ft296{font-size:11px;line-height:18px;font-family:Times;color:#000000;}
	.ft297{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page29-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft290">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft290">29&#160;of&#160;36</p>
<p style="position:absolute;top:148px;left:250px;white-space:nowrap" class="ft292"><b>Supplementary&#160;Materials:</b></p>
<p style="position:absolute;top:148px;left:418px;white-space:nowrap" class="ft293">The&#160;following&#160;supporting&#160;information&#160;can&#160;be&#160;downloaded&#160;at:&#160;<a href="https://www.mdpi.com/article/10.3390/cancers14061499/s1">https:</a></p>
<p style="position:absolute;top:166px;left:248px;white-space:nowrap" class="ft294"><a href="https://www.mdpi.com/article/10.3390/cancers14061499/s1">//www.mdpi.com/article/10.3390/cancers14061499/s1,&#160;</a>Figure&#160;S1:&#160;NG108-15&#160;Initial&#160;Screen&#160;of&#160;Com-</p>
<p style="position:absolute;top:184px;left:249px;white-space:nowrap" class="ft293">pounds&#160;Part&#160;A;&#160;Figure&#160;S2:&#160;NG108-15&#160;Initial&#160;Screen&#160;of&#160;Compounds&#160;Part&#160;B;&#160;Figure&#160;S3:&#160;U87&#160;Initial&#160;Screen</p>
<p style="position:absolute;top:202px;left:250px;white-space:nowrap" class="ft296">of&#160;Compounds;&#160;Table&#160;S1:&#160;Compounds&#160;Tested&#160;on&#160;NG108-15&#160;cells&#160;for&#160;Effect&#160;on&#160;Proliferation&#160;and&#160;their<br/>Mechanism&#160;of&#160;Action&#160;and&#160;Status&#160;<a href="18c018a9e0aa0e8c5cdc2d633e07fa8fs.html#36">[176–192].</a></p>
<p style="position:absolute;top:246px;left:249px;white-space:nowrap" class="ft292"><b>Author&#160;Contributions:</b></p>
<p style="position:absolute;top:246px;left:390px;white-space:nowrap" class="ft293">Conceptualization:&#160;J.M.&#160;and&#160;M.L.&#160;Methodology:&#160;J.M.&#160;and&#160;M.D.&#160;for&#160;cell&#160;assays,</p>
<p style="position:absolute;top:264px;left:249px;white-space:nowrap" class="ft297">J.Q.P.&#160;and&#160;D.B.-N.&#160;for&#160;electrophysiology.&#160;Software:&#160;F.K.&#160;Formal&#160;analysis:&#160;J.M.&#160;and&#160;F.K.&#160;for&#160;cell&#160;assays,<br/>J.Q.P.&#160;and&#160;D.B.-N.&#160;for&#160;electrophysiology.&#160;Resources:&#160;M.L.&#160;and&#160;J.Q.P.&#160;Data&#160;curation:&#160;J.M.&#160;and&#160;F.K.<br/>for&#160;cell&#160;assays,&#160;J.Q.P.&#160;and&#160;D.B.-N.&#160;for&#160;electrophysiology.&#160;Writing—original&#160;draft&#160;preparation:&#160;J.M.</p>
<p style="position:absolute;top:317px;left:249px;white-space:nowrap" class="ft293">Writing—review&#160;and&#160;editing:&#160;J.M.,&#160;M.L.,&#160;J.Q.P.&#160;and&#160;D.B.-N.&#160;Supervision:&#160;J.M.,&#160;M.L.&#160;and&#160;J.Q.P.&#160;Project</p>
<p style="position:absolute;top:334px;left:250px;white-space:nowrap" class="ft293">administration:&#160;M.L.&#160;Funding&#160;acquisition:&#160;M.L&#160;and&#160;J.Q.P.&#160;All&#160;authors&#160;have&#160;read&#160;and&#160;agreed&#160;to&#160;the</p>
<p style="position:absolute;top:352px;left:249px;white-space:nowrap" class="ft293">published&#160;version&#160;of&#160;the&#160;manuscript.</p>
<p style="position:absolute;top:378px;left:250px;white-space:nowrap" class="ft292"><b>Funding:</b></p>
<p style="position:absolute;top:378px;left:309px;white-space:nowrap" class="ft293">This&#160;project&#160;was&#160;funded&#160;by&#160;Augmanity&#160;Nano,&#160;Ltd.,&#160;Rehovot,&#160;Israel.</p>
<p style="position:absolute;top:405px;left:250px;white-space:nowrap" class="ft292"><b>Institutional&#160;Review&#160;Board&#160;Statement:</b></p>
<p style="position:absolute;top:405px;left:489px;white-space:nowrap" class="ft293">Not&#160;applicable.</p>
<p style="position:absolute;top:431px;left:250px;white-space:nowrap" class="ft292"><b>Informed&#160;Consent&#160;Statement:</b></p>
<p style="position:absolute;top:431px;left:435px;white-space:nowrap" class="ft293">Not&#160;applicable.</p>
<p style="position:absolute;top:458px;left:250px;white-space:nowrap" class="ft292"><b>Data&#160;Availability&#160;Statement:</b></p>
<p style="position:absolute;top:458px;left:428px;white-space:nowrap" class="ft293">Primary&#160;data&#160;not&#160;included&#160;in&#160;the&#160;primary&#160;or&#160;Supplemental&#160;Material</p>
<p style="position:absolute;top:476px;left:250px;white-space:nowrap" class="ft293">are&#160;available&#160;upon&#160;request.</p>
<p style="position:absolute;top:502px;left:249px;white-space:nowrap" class="ft292"><b>Acknowledgments:</b></p>
<p style="position:absolute;top:502px;left:372px;white-space:nowrap" class="ft293">We&#160;gratefully&#160;acknowledge&#160;the&#160;Carpenter&#160;lab&#160;at&#160;the&#160;Broad&#160;Institute&#160;for&#160;design</p>
<p style="position:absolute;top:520px;left:250px;white-space:nowrap" class="ft297">of&#160;the&#160;FUCCI&#160;CellProfiler&#160;pipeline&#160;used&#160;in&#160;these&#160;experiments&#160;and&#160;Mridushi&#160;Daga&#160;for&#160;her&#160;help&#160;with<br/>the&#160;validation&#160;of&#160;the&#160;FUCCI&#160;CellProfiler&#160;pipeline.&#160;We&#160;also&#160;thank&#160;Alan&#160;Chang,&#160;Caroline&#160;McCarthy,<br/>Isha&#160;Singh,&#160;and&#160;Avery&#160;Caulfield&#160;for&#160;their&#160;help&#160;with&#160;manual&#160;analysis.&#160;We&#160;are&#160;also&#160;grateful&#160;to&#160;Adam<br/>Strandberg&#160;for&#160;his&#160;help&#160;with&#160;the&#160;analysis&#160;parser&#160;program.</p>
<p style="position:absolute;top:599px;left:250px;white-space:nowrap" class="ft292"><b>Conflicts&#160;of&#160;Interest:</b></p>
<p style="position:absolute;top:599px;left:378px;white-space:nowrap" class="ft293">The&#160;authors&#160;declare&#160;no&#160;conflict&#160;of&#160;interest.&#160;The&#160;funder&#160;had&#160;no&#160;role&#160;in&#160;the&#160;design</p>
<p style="position:absolute;top:616px;left:250px;white-space:nowrap" class="ft297">of&#160;the&#160;experiments,&#160;the&#160;collection,&#160;analyses,&#160;or&#160;interpretation&#160;of&#160;data,&#160;in&#160;the&#160;writing&#160;of&#160;the&#160;manuscript,<br/>or&#160;in&#160;the&#160;decision&#160;to&#160;publish&#160;the&#160;results.</p>
<p style="position:absolute;top:670px;left:54px;white-space:nowrap" class="ft295"><b>References</b></p>
<p style="position:absolute;top:693px;left:54px;white-space:nowrap" class="ft293">1.</p>
<p style="position:absolute;top:693px;left:86px;white-space:nowrap" class="ft297">Hanif,&#160;F.;&#160;Muzaffar,&#160;K.;&#160;Perveen,&#160;K.;&#160;Malhi,&#160;S.M.;&#160;Simjee&#160;Sh,&#160;U.&#160;Glioblastoma&#160;Multiforme:&#160;A&#160;Review&#160;of&#160;its&#160;Epidemiology&#160;and<br/>Pathogenesis&#160;through&#160;Clinical&#160;Presentation&#160;and&#160;Treatment.&#160;Asian&#160;Pac.&#160;J.&#160;Cancer&#160;Prev.&#160;<b>2017</b>,&#160;18,&#160;3–9.&#160;<a href="http://doi.org/10.22034/APJCP.2017.18.1.3">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/28239999">[PubMed]</a></p>
<p style="position:absolute;top:727px;left:54px;white-space:nowrap" class="ft293">2.</p>
<p style="position:absolute;top:727px;left:86px;white-space:nowrap" class="ft297">Davis,&#160;M.E.&#160;Glioblastoma:&#160;Overview&#160;of&#160;Disease&#160;and&#160;Treatment.&#160;Clin.&#160;J.&#160;Oncol.&#160;Nurs.&#160;<b>2016</b>,&#160;20&#160;(Suppl.&#160;5),&#160;S2–S8.&#160;<a href="http://doi.org/10.1188/16.CJON.S1.2-8">[CrossRef]<br/></a><a href="http://www.ncbi.nlm.nih.gov/pubmed/27668386">[PubMed]</a></p>
<p style="position:absolute;top:762px;left:54px;white-space:nowrap" class="ft293">3.</p>
<p style="position:absolute;top:762px;left:86px;white-space:nowrap" class="ft297">Lemee,&#160;J.M.;&#160;Clavreul,&#160;A.;&#160;Aubry,&#160;M.;&#160;Com,&#160;E.;&#160;de&#160;Tayrac,&#160;M.;&#160;Eliat,&#160;P.A.;&#160;Henry,&#160;C.;&#160;Rousseau,&#160;A.;&#160;Mosser,&#160;J.;&#160;Menei,&#160;P.<br/>Characterizing&#160;the&#160;peritumoral&#160;brain&#160;zone&#160;in&#160;glioblastoma:&#160;A&#160;multidisciplinary&#160;analysis.&#160;J.&#160;Neurooncol.&#160;<b>2015</b>,&#160;122,&#160;53–61.<br/><a href="http://doi.org/10.1007/s11060-014-1695-8">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/25559687">[PubMed]</a></p>
<p style="position:absolute;top:813px;left:54px;white-space:nowrap" class="ft293">4.</p>
<p style="position:absolute;top:813px;left:86px;white-space:nowrap" class="ft293">Weller,&#160;M.;&#160;Cloughesy,&#160;T.;&#160;Perry,&#160;J.R.;&#160;Wick,&#160;W.&#160;Standards&#160;of&#160;care&#160;for&#160;treatment&#160;of&#160;recurrent&#160;glioblastoma—Are&#160;we&#160;there&#160;yet?&#160;Neuro</p>
<p style="position:absolute;top:831px;left:85px;white-space:nowrap" class="ft293">Oncol.&#160;<b>2013</b>,&#160;15,&#160;4–27.&#160;<a href="http://doi.org/10.1093/neuonc/nos273">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/23136223">[PubMed]</a></p>
<p style="position:absolute;top:848px;left:54px;white-space:nowrap" class="ft293">5.</p>
<p style="position:absolute;top:848px;left:86px;white-space:nowrap" class="ft297">Fan,&#160;X.;&#160;Xiong,&#160;Y.;&#160;Wang,&#160;Y.&#160;A&#160;reignited&#160;debate&#160;over&#160;the&#160;cell(s)&#160;of&#160;origin&#160;for&#160;glioblastoma&#160;and&#160;its&#160;clinical&#160;implications.&#160;Front.&#160;Med.<br/><b>2019</b></p>
<p style="position:absolute;top:865px;left:113px;white-space:nowrap" class="ft293">,&#160;13,&#160;531–539.&#160;<a href="http://doi.org/10.1007/s11684-019-0700-1">[CrossRef]</a></p>
<p style="position:absolute;top:882px;left:54px;white-space:nowrap" class="ft293">6.</p>
<p style="position:absolute;top:882px;left:86px;white-space:nowrap" class="ft297">Liu,&#160;C.;&#160;Sage,&#160;J.C.;&#160;Miller,&#160;M.R.;&#160;Verhaak,&#160;R.G.;&#160;Hippenmeyer,&#160;S.;&#160;Vogel,&#160;H.;&#160;Foreman,&#160;O.;&#160;Bronson,&#160;R.T.;&#160;Nishiyama,&#160;A.;&#160;Luo,&#160;L.;<br/>et&#160;al.&#160;Mosaic&#160;analysis&#160;with&#160;double&#160;markers&#160;reveals&#160;tumor&#160;cell&#160;of&#160;origin&#160;in&#160;glioma.&#160;Cell&#160;<b>2011</b>,&#160;146,&#160;209–221.&#160;<a href="http://doi.org/10.1016/j.cell.2011.06.014">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/21737130">[PubMed]</a></p>
<p style="position:absolute;top:917px;left:54px;white-space:nowrap" class="ft293">7.</p>
<p style="position:absolute;top:917px;left:86px;white-space:nowrap" class="ft297">Alessandrini,&#160;F.;&#160;Ceresa,&#160;D.;&#160;Appolloni,&#160;I.;&#160;Pagani,&#160;F.;&#160;Poliani,&#160;P.L.;&#160;Marubbi,&#160;D.;&#160;Malatesta,&#160;P.&#160;Glioblastoma&#160;models&#160;driven&#160;by<br/>different&#160;mutations&#160;converge&#160;to&#160;the&#160;proneural&#160;subtype.&#160;Cancer&#160;Lett.&#160;<b>2020</b>,&#160;469,&#160;447–455.&#160;<a href="http://doi.org/10.1016/j.canlet.2019.11.010">[CrossRef]</a></p>
<p style="position:absolute;top:951px;left:54px;white-space:nowrap" class="ft293">8.</p>
<p style="position:absolute;top:951px;left:86px;white-space:nowrap" class="ft293">Alcantara&#160;Llaguno,&#160;S.R.;&#160;Wang,&#160;Z.;&#160;Sun,&#160;D.;&#160;Chen,&#160;J.;&#160;Xu,&#160;J.;&#160;Kim,&#160;E.;&#160;Hatanpaa,&#160;K.J.;&#160;Raisanen,&#160;J.M.;&#160;Burns,&#160;D.K.;&#160;Johnson,&#160;J.E.;&#160;et&#160;al.</p>
<p style="position:absolute;top:969px;left:85px;white-space:nowrap" class="ft293">Adult&#160;Lineage-Restricted&#160;CNS&#160;Progenitors&#160;Specify&#160;Distinct&#160;Glioblastoma&#160;Subtypes.&#160;Cancer&#160;Cell&#160;<b>2015</b>,&#160;28,&#160;429–440.&#160;<a href="http://doi.org/10.1016/j.ccell.2015.09.007">[CrossRef]</a></p>
<p style="position:absolute;top:986px;left:86px;white-space:nowrap" class="ft293"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26461091">[PubMed]</a></p>
<p style="position:absolute;top:1003px;left:54px;white-space:nowrap" class="ft293">9.</p>
<p style="position:absolute;top:1003px;left:86px;white-space:nowrap" class="ft297">Lindberg,&#160;N.;&#160;Jiang,&#160;Y.;&#160;Xie,&#160;Y.;&#160;Bolouri,&#160;H.;&#160;Kastemar,&#160;M.;&#160;Olofsson,&#160;T.;&#160;Holland,&#160;E.C.;&#160;Uhrbom,&#160;L.&#160;Oncogenic&#160;signaling&#160;is&#160;dominant<br/>to&#160;cell&#160;of&#160;origin&#160;and&#160;dictates&#160;astrocytic&#160;or&#160;oligodendroglial&#160;tumor&#160;development&#160;from&#160;oligodendrocyte&#160;precursor&#160;cells.&#160;J.&#160;Neurosci.<br/><b>2014</b></p>
<p style="position:absolute;top:1038px;left:113px;white-space:nowrap" class="ft293">,&#160;34,&#160;14644–14651.&#160;<a href="http://doi.org/10.1523/JNEUROSCI.2977-14.2014">[CrossRef]</a></p>
<p style="position:absolute;top:1055px;left:54px;white-space:nowrap" class="ft293">10.</p>
<p style="position:absolute;top:1055px;left:86px;white-space:nowrap" class="ft293">Hide,&#160;T.;&#160;Shibahara,&#160;I.;&#160;Kumabe,&#160;T.&#160;Novel&#160;concept&#160;of&#160;the&#160;border&#160;niche:&#160;Glioblastoma&#160;cells&#160;use&#160;oligodendrocytes&#160;progenitor&#160;cells</p>
<p style="position:absolute;top:1072px;left:85px;white-space:nowrap" class="ft293">(GAOs)&#160;and&#160;microglia&#160;to&#160;acquire&#160;stem&#160;cell-like&#160;features.&#160;Brain&#160;Tumor&#160;Pathol.&#160;<b>2019</b>,&#160;36,&#160;63–73.&#160;<a href="http://doi.org/10.1007/s10014-019-00341-2">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/30968276">[PubMed]</a></p>
<p style="position:absolute;top:1090px;left:54px;white-space:nowrap" class="ft293">11.</p>
<p style="position:absolute;top:1090px;left:86px;white-space:nowrap" class="ft297">Yan,&#160;M.;&#160;Liu,&#160;Q.&#160;Differentiation&#160;therapy:&#160;A&#160;promising&#160;strategy&#160;for&#160;cancer&#160;treatment.&#160;Chin.&#160;J.&#160;Cancer&#160;<b>2016</b>,&#160;35,&#160;3.&#160;<a href="http://doi.org/10.1186/s40880-015-0059-x">[CrossRef]<br/></a><a href="http://www.ncbi.nlm.nih.gov/pubmed/26739838">[PubMed]</a></p>
<p style="position:absolute;top:1124px;left:54px;white-space:nowrap" class="ft293">12.</p>
<p style="position:absolute;top:1124px;left:86px;white-space:nowrap" class="ft297">Levin,&#160;M.;&#160;Pezzulo,&#160;G.;&#160;Finkelstein,&#160;J.M.&#160;Endogenous&#160;Bioelectric&#160;Signaling&#160;Networks:&#160;Exploiting&#160;Voltage&#160;Gradients&#160;for&#160;Control&#160;of<br/>Growth&#160;and&#160;Form.&#160;Annu.&#160;Rev.&#160;Biomed.&#160;Eng.&#160;<b>2017</b>,&#160;19,&#160;353–387.&#160;<a href="http://doi.org/10.1146/annurev-bioeng-071114-040647">[CrossRef]</a></p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft300{font-size:9px;font-family:Times;color:#000000;}
	.ft301{font-size:9px;font-family:Times;color:#000000;}
	.ft302{font-size:11px;font-family:Times;color:#000000;}
	.ft303{font-size:11px;font-family:Times;color:#000000;}
	.ft304{font-size:11px;font-family:Times;color:#0775b7;}
	.ft305{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page30-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft300">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft300">30&#160;of&#160;36</p>
<p style="position:absolute;top:148px;left:54px;white-space:nowrap" class="ft302">13.</p>
<p style="position:absolute;top:148px;left:86px;white-space:nowrap" class="ft305">Panicker,&#160;S.P.;&#160;Raychaudhuri,&#160;B.;&#160;Sharma,&#160;P.;&#160;Tipps,&#160;R.;&#160;Mazumdar,&#160;T.;&#160;Mal,&#160;A.K.;&#160;Palomo,&#160;J.M.;&#160;Vogelbaum,&#160;M.A.;&#160;Haque,&#160;S.J.&#160;p300-<br/>and&#160;Myc-mediated&#160;regulation&#160;of&#160;glioblastoma&#160;multiforme&#160;cell&#160;differentiation.&#160;Oncotarget&#160;<b>2010</b>,&#160;1,&#160;289–303.&#160;<a href="http://doi.org/10.18632/oncotarget.139">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/21304179">[PubMed]</a></p>
<p style="position:absolute;top:182px;left:54px;white-space:nowrap" class="ft302">14.</p>
<p style="position:absolute;top:182px;left:86px;white-space:nowrap" class="ft305">Heo,&#160;J.C.;&#160;Jung,&#160;T.H.;&#160;Lee,&#160;S.;&#160;Kim,&#160;H.Y.;&#160;Choi,&#160;G.;&#160;Jung,&#160;M.;&#160;Jung,&#160;D.;&#160;Lee,&#160;H.K.;&#160;Lee,&#160;J.O.;&#160;Park,&#160;J.H.;&#160;et&#160;al.&#160;Effect&#160;of&#160;bexarotene&#160;on<br/>differentiation&#160;of&#160;glioblastoma&#160;multiforme&#160;compared&#160;with&#160;ATRA.&#160;Clin.&#160;Exp.&#160;Metastasis&#160;<b>2016</b>,&#160;33,&#160;417–429.&#160;<a href="http://doi.org/10.1007/s10585-016-9786-x">[CrossRef]</a></p>
<p style="position:absolute;top:217px;left:54px;white-space:nowrap" class="ft302">15.</p>
<p style="position:absolute;top:217px;left:86px;white-space:nowrap" class="ft305">Kang,&#160;T.W.;&#160;Choi,&#160;S.W.;&#160;Yang,&#160;S.R.;&#160;Shin,&#160;T.H.;&#160;Kim,&#160;H.S.;&#160;Yu,&#160;K.R.;&#160;Hong,&#160;I.S.;&#160;Ro,&#160;S.;&#160;Cho,&#160;J.M.;&#160;Kang,&#160;K.S.&#160;Growth&#160;arrest&#160;and<br/>forced&#160;differentiation&#160;of&#160;human&#160;primary&#160;glioblastoma&#160;multiforme&#160;by&#160;a&#160;novel&#160;small&#160;molecule.&#160;Sci.&#160;Rep.&#160;<b>2014</b>,&#160;4,&#160;5546.&#160;<a href="http://doi.org/10.1038/srep05546">[CrossRef]</a></p>
<p style="position:absolute;top:251px;left:54px;white-space:nowrap" class="ft302">16.</p>
<p style="position:absolute;top:251px;left:86px;white-space:nowrap" class="ft305">Xing,&#160;F.;&#160;Luan,&#160;Y.;&#160;Cai,&#160;J.;&#160;Wu,&#160;S.;&#160;Mai,&#160;J.;&#160;Gu,&#160;J.;&#160;Zhang,&#160;H.;&#160;Li,&#160;K.;&#160;Lin,&#160;Y.;&#160;Xiao,&#160;X.;&#160;et&#160;al.&#160;The&#160;Anti-Warburg&#160;Effect&#160;Elicited&#160;by&#160;the<br/>cAMP-PGC1alpha&#160;Pathway&#160;Drives&#160;Differentiation&#160;of&#160;Glioblastoma&#160;Cells&#160;into&#160;Astrocytes.&#160;Cell&#160;Rep.&#160;<b>2017</b>,&#160;18,&#160;468–481.&#160;<a href="http://doi.org/10.1016/j.celrep.2016.12.037">[CrossRef]<br/></a><a href="http://www.ncbi.nlm.nih.gov/pubmed/28076790">[PubMed]</a></p>
<p style="position:absolute;top:303px;left:54px;white-space:nowrap" class="ft302">17.</p>
<p style="position:absolute;top:303px;left:86px;white-space:nowrap" class="ft305">Piccirillo,&#160;S.G.;&#160;Reynolds,&#160;B.A.;&#160;Zanetti,&#160;N.;&#160;Lamorte,&#160;G.;&#160;Binda,&#160;E.;&#160;Broggi,&#160;G.;&#160;Brem,&#160;H.;&#160;Olivi,&#160;A.;&#160;Dimeco,&#160;F.;&#160;Vescovi,&#160;A.L.&#160;Bone<br/>morphogenetic&#160;proteins&#160;inhibit&#160;the&#160;tumorigenic&#160;potential&#160;of&#160;human&#160;brain&#160;tumour-initiating&#160;cells.&#160;Nature&#160;<b>2006</b>,&#160;444,&#160;761–765.<br/><a href="http://doi.org/10.1038/nature05349">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/17151667">[PubMed]</a></p>
<p style="position:absolute;top:355px;left:54px;white-space:nowrap" class="ft302">18.</p>
<p style="position:absolute;top:355px;left:86px;white-space:nowrap" class="ft305">Park,&#160;D.M.;&#160;Li,&#160;J.;&#160;Okamoto,&#160;H.;&#160;Akeju,&#160;O.;&#160;Kim,&#160;S.H.;&#160;Lubensky,&#160;I.;&#160;Vortmeyer,&#160;A.;&#160;Dambrosia,&#160;J.;&#160;Weil,&#160;R.J.;&#160;Oldfield,&#160;E.H.;&#160;et&#160;al.<br/>N-CoR&#160;pathway&#160;targeting&#160;induces&#160;glioblastoma&#160;derived&#160;cancer&#160;stem&#160;cell&#160;differentiation.&#160;Cell&#160;Cycle&#160;<b>2007</b>,&#160;6,&#160;467–470.&#160;<a href="http://doi.org/10.4161/cc.6.4.3856">[CrossRef]<br/></a><a href="http://www.ncbi.nlm.nih.gov/pubmed/17312396">[PubMed]</a></p>
<p style="position:absolute;top:407px;left:54px;white-space:nowrap" class="ft302">19.</p>
<p style="position:absolute;top:407px;left:86px;white-space:nowrap" class="ft305">Dong,&#160;Y.;&#160;Han,&#160;Q.;&#160;Zou,&#160;Y.;&#160;Deng,&#160;Z.;&#160;Lu,&#160;X.;&#160;Wang,&#160;X.;&#160;Zhang,&#160;W.;&#160;Jin,&#160;H.;&#160;Su,&#160;J.;&#160;Jiang,&#160;T.;&#160;et&#160;al.&#160;Long-term&#160;exposure&#160;to&#160;imatinib<br/>reduced&#160;cancer&#160;stem&#160;cell&#160;ability&#160;through&#160;induction&#160;of&#160;cell&#160;differentiation&#160;via&#160;activation&#160;of&#160;MAPK&#160;signaling&#160;in&#160;glioblastoma&#160;cells.<br/>Mol.&#160;Cell.&#160;Biochem.&#160;<b>2012</b>,&#160;370,&#160;89–102.&#160;<a href="http://doi.org/10.1007/s11010-012-1401-0">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/22829019">[PubMed]</a></p>
<p style="position:absolute;top:458px;left:54px;white-space:nowrap" class="ft302">20.</p>
<p style="position:absolute;top:458px;left:86px;white-space:nowrap" class="ft305">Chlapek,&#160;P.;&#160;Slavikova,&#160;V.;&#160;Mazanek,&#160;P.;&#160;Sterba,&#160;J.;&#160;Veselska,&#160;R.&#160;Why&#160;Differentiation&#160;Therapy&#160;Sometimes&#160;Fails:&#160;Molecular<br/>Mechanisms&#160;of&#160;Resistance&#160;to&#160;Retinoids.&#160;Int.&#160;J.&#160;Mol.&#160;Sci.&#160;<b>2018</b>,&#160;19,&#160;132.&#160;<a href="http://doi.org/10.3390/ijms19010132">[CrossRef]</a></p>
<p style="position:absolute;top:493px;left:54px;white-space:nowrap" class="ft302">21.</p>
<p style="position:absolute;top:493px;left:86px;white-space:nowrap" class="ft305">Mathews,&#160;J.;&#160;Levin,&#160;M.&#160;The&#160;body&#160;electric&#160;2.0:&#160;Recent&#160;advances&#160;in&#160;developmental&#160;bioelectricity&#160;for&#160;regenerative&#160;and&#160;synthetic<br/>bioengineering.&#160;Curr.&#160;Opin.&#160;Biotechnol.&#160;<b>2018</b>,&#160;52,&#160;134–144.&#160;<a href="http://doi.org/10.1016/j.copbio.2018.03.008">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/29684787">[PubMed]</a></p>
<p style="position:absolute;top:527px;left:54px;white-space:nowrap" class="ft302">22.</p>
<p style="position:absolute;top:527px;left:86px;white-space:nowrap" class="ft302">Bates,&#160;E.&#160;Ion&#160;channels&#160;in&#160;development&#160;and&#160;cancer.&#160;Annu.&#160;Rev.&#160;Cell&#160;Dev.&#160;Biol.&#160;<b>2015</b>,&#160;31,&#160;231–247.&#160;<a href="http://doi.org/10.1146/annurev-cellbio-100814-125338">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/26566112">[PubMed]</a></p>
<p style="position:absolute;top:545px;left:54px;white-space:nowrap" class="ft302">23.</p>
<p style="position:absolute;top:545px;left:86px;white-space:nowrap" class="ft302">Levin,&#160;M.&#160;Bioelectric&#160;signaling:&#160;Reprogrammable&#160;circuits&#160;underlying&#160;embryogenesis,&#160;regeneration,&#160;and&#160;cancer.&#160;Cell&#160;<b>2021</b>,&#160;184,</p>
<p style="position:absolute;top:562px;left:85px;white-space:nowrap" class="ft302">1971–1989.&#160;<a href="http://doi.org/10.1016/j.cell.2021.02.034">[CrossRef]</a></p>
<p style="position:absolute;top:579px;left:54px;white-space:nowrap" class="ft302">24.</p>
<p style="position:absolute;top:579px;left:86px;white-space:nowrap" class="ft302">Srivastava,&#160;P.;&#160;Kane,&#160;A.;&#160;Harrison,&#160;C.;&#160;Levin,&#160;M.&#160;A&#160;Meta-Analysis&#160;of&#160;Bioelectric&#160;Data&#160;in&#160;Cancer,&#160;Embryogenesis,&#160;and&#160;Regeneration.</p>
<p style="position:absolute;top:596px;left:85px;white-space:nowrap" class="ft302">Bioelectricity&#160;<b>2021</b>,&#160;3,&#160;42–67.&#160;<a href="http://doi.org/10.1089/bioe.2019.0034">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/34476377">[PubMed]</a></p>
<p style="position:absolute;top:614px;left:54px;white-space:nowrap" class="ft302">25.</p>
<p style="position:absolute;top:614px;left:86px;white-space:nowrap" class="ft305">Rao,&#160;V.R.;&#160;Perez-Neut,&#160;M.;&#160;Kaja,&#160;S.;&#160;Gentile,&#160;S.&#160;Voltage-gated&#160;ion&#160;channels&#160;in&#160;cancer&#160;cell&#160;proliferation.&#160;Cancers&#160;<b>2015</b>,&#160;7,&#160;849–875.<br/><a href="http://doi.org/10.3390/cancers7020813">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/26010603">[PubMed]</a></p>
<p style="position:absolute;top:648px;left:54px;white-space:nowrap" class="ft302">26.</p>
<p style="position:absolute;top:648px;left:86px;white-space:nowrap" class="ft302">Arcangeli,&#160;A.;&#160;Becchetti,&#160;A.&#160;New&#160;Trends&#160;in&#160;Cancer&#160;Therapy:&#160;Targeting&#160;Ion&#160;Channels&#160;and&#160;Transporters.&#160;Pharmaceuticals&#160;<b>2010</b>,&#160;3,</p>
<p style="position:absolute;top:665px;left:85px;white-space:nowrap" class="ft302">1202–1224.&#160;<a href="http://doi.org/10.3390/ph3041202">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/27713296">[PubMed]</a></p>
<p style="position:absolute;top:683px;left:54px;white-space:nowrap" class="ft302">27.</p>
<p style="position:absolute;top:683px;left:86px;white-space:nowrap" class="ft302">Litan,&#160;A.;&#160;Langhans,&#160;S.A.&#160;Cancer&#160;as&#160;a&#160;channelopathy:&#160;Ion&#160;channels&#160;and&#160;pumps&#160;in&#160;tumor&#160;development&#160;and&#160;progression.&#160;Front.</p>
<p style="position:absolute;top:700px;left:85px;white-space:nowrap" class="ft302">Cell.&#160;Neurosci.&#160;<b>2015</b>,&#160;9,&#160;86.&#160;<a href="http://doi.org/10.3389/fncel.2015.00086">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/25852478">[PubMed]</a></p>
<p style="position:absolute;top:717px;left:54px;white-space:nowrap" class="ft302">28.</p>
<p style="position:absolute;top:717px;left:86px;white-space:nowrap" class="ft305">Rapetti-Mauss,&#160;R.;&#160;Berenguier,&#160;C.;&#160;Allegrini,&#160;B.;&#160;Soriani,&#160;O.&#160;Interplay&#160;between&#160;Ion&#160;Channels&#160;and&#160;the&#160;Wnt/beta-Catenin&#160;Signaling<br/>Pathway&#160;in&#160;Cancers.&#160;Front.&#160;Pharmacol.&#160;<b>2020</b>,&#160;11,&#160;525020.&#160;<a href="http://doi.org/10.3389/fphar.2020.525020">[CrossRef]</a></p>
<p style="position:absolute;top:752px;left:54px;white-space:nowrap" class="ft302">29.</p>
<p style="position:absolute;top:752px;left:86px;white-space:nowrap" class="ft305">Dowd,&#160;J.;&#160;Hendin,&#160;J.;&#160;Fukushiro-Lopes,&#160;D.F.;&#160;Laczynski,&#160;D.;&#160;Gentile,&#160;S.&#160;Ion&#160;Channels&#160;in&#160;Breast&#160;Cancer:&#160;From&#160;Signaling&#160;to&#160;Therapy;<br/>InTech:&#160;London,&#160;UK,&#160;2017.</p>
<p style="position:absolute;top:786px;left:54px;white-space:nowrap" class="ft302">30.</p>
<p style="position:absolute;top:786px;left:86px;white-space:nowrap" class="ft305">Lang,&#160;F.;&#160;Stournaras,&#160;C.&#160;Ion&#160;channels&#160;in&#160;cancer:&#160;Future&#160;perspectives&#160;and&#160;clinical&#160;potential.&#160;Philos.&#160;Trans.&#160;R.&#160;Soc.&#160;Lond.&#160;B&#160;Biol.&#160;Sci.<br/><b>2014</b></p>
<p style="position:absolute;top:803px;left:113px;white-space:nowrap" class="ft302">,&#160;369,&#160;20130108.&#160;<a href="http://doi.org/10.1098/rstb.2013.0108">[CrossRef]</a></p>
<p style="position:absolute;top:821px;left:54px;white-space:nowrap" class="ft302">31.</p>
<p style="position:absolute;top:821px;left:86px;white-space:nowrap" class="ft302">Yang,&#160;M.;&#160;Brackenbury,&#160;W.J.&#160;Membrane&#160;potential&#160;and&#160;cancer&#160;progression.&#160;Front.&#160;Physiol.&#160;<b>2013</b>,&#160;4,&#160;185.&#160;<a href="http://doi.org/10.3389/fphys.2013.00185">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/23882223">[PubMed]</a></p>
<p style="position:absolute;top:838px;left:54px;white-space:nowrap" class="ft302">32.</p>
<p style="position:absolute;top:838px;left:86px;white-space:nowrap" class="ft305">Cheng,&#160;Q.;&#160;Chen,&#160;A.;&#160;Du,&#160;Q.;&#160;Liao,&#160;Q.;&#160;Shuai,&#160;Z.;&#160;Chen,&#160;C.;&#160;Yang,&#160;X.;&#160;Hu,&#160;Y.;&#160;Zhao,&#160;J.;&#160;Liu,&#160;S.;&#160;et&#160;al.&#160;Novel&#160;insights&#160;into&#160;ion&#160;channels<br/>in&#160;cancer&#160;stem&#160;cells&#160;(Review).&#160;Int.&#160;J.&#160;Oncol.&#160;<b>2018</b>,&#160;53,&#160;1435–1441.&#160;<a href="http://doi.org/10.3892/ijo.2018.4500">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/30066845">[PubMed]</a></p>
<p style="position:absolute;top:873px;left:54px;white-space:nowrap" class="ft302">33.</p>
<p style="position:absolute;top:873px;left:86px;white-space:nowrap" class="ft305">Leanza,&#160;L.;&#160;Manago,&#160;A.;&#160;Zoratti,&#160;M.;&#160;Gulbins,&#160;E.;&#160;Szabo,&#160;I.&#160;Pharmacological&#160;targeting&#160;of&#160;ion&#160;channels&#160;for&#160;cancer&#160;therapy:&#160;In&#160;Vivo<br/>evidences.&#160;Biochim.&#160;Biophys.&#160;Acta&#160;<b>2016</b>,&#160;1863&#160;6&#160;Pt&#160;B,&#160;1385–1397.&#160;<a href="http://doi.org/10.1016/j.bbamcr.2015.11.032">[CrossRef]</a></p>
<p style="position:absolute;top:907px;left:54px;white-space:nowrap" class="ft302">34.</p>
<p style="position:absolute;top:907px;left:86px;white-space:nowrap" class="ft305">Lobikin,&#160;M.;&#160;Chernet,&#160;B.;&#160;Lobo,&#160;D.;&#160;Levin,&#160;M.&#160;Resting&#160;potential,&#160;oncogene-induced&#160;tumorigenesis,&#160;and&#160;metastasis:&#160;The&#160;bioelectric<br/>basis&#160;of&#160;cancer&#160;in&#160;vivo.&#160;Phys.&#160;Biol.&#160;<b>2012</b>,&#160;9,&#160;065002.&#160;<a href="http://doi.org/10.1088/1478-3975/9/6/065002">[CrossRef]</a></p>
<p style="position:absolute;top:942px;left:54px;white-space:nowrap" class="ft302">35.</p>
<p style="position:absolute;top:942px;left:86px;white-space:nowrap" class="ft305">Becchetti,&#160;A.;&#160;Munaron,&#160;L.;&#160;Arcangeli,&#160;A.&#160;The&#160;role&#160;of&#160;ion&#160;channels&#160;and&#160;transporters&#160;in&#160;cell&#160;proliferation&#160;and&#160;cancer.&#160;Front.&#160;Physiol.<br/><b>2013</b></p>
<p style="position:absolute;top:959px;left:113px;white-space:nowrap" class="ft302">,&#160;4,&#160;312.&#160;<a href="http://doi.org/10.3389/fphys.2013.00312">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/24194722">[PubMed]</a></p>
<p style="position:absolute;top:976px;left:54px;white-space:nowrap" class="ft302">36.</p>
<p style="position:absolute;top:976px;left:86px;white-space:nowrap" class="ft305">Sontheimer,&#160;H.&#160;An&#160;unexpected&#160;role&#160;for&#160;ion&#160;channels&#160;in&#160;brain&#160;tumor&#160;metastasis.&#160;Exp.&#160;Biol.&#160;Med.&#160;<b>2008</b>,&#160;233,&#160;779–791.&#160;<a href="http://doi.org/10.3181/0711-MR-308">[CrossRef]<br/></a><a href="http://www.ncbi.nlm.nih.gov/pubmed/18445774">[PubMed]</a></p>
<p style="position:absolute;top:1011px;left:54px;white-space:nowrap" class="ft302">37.</p>
<p style="position:absolute;top:1011px;left:86px;white-space:nowrap" class="ft305">Binggeli,&#160;R.;&#160;Weinstein,&#160;R.C.&#160;Membrane&#160;potentials&#160;and&#160;sodium&#160;channels:&#160;Hypotheses&#160;for&#160;growth&#160;regulation&#160;and&#160;cancer&#160;formation<br/>based&#160;on&#160;changes&#160;in&#160;sodium&#160;channels&#160;and&#160;gap&#160;junctions.&#160;J.&#160;Theor.&#160;Biol.&#160;<b>1986</b>,&#160;123,&#160;377–401.&#160;<a href="http://doi.org/10.1016/S0022-5193(86)80209-0">[CrossRef]</a></p>
<p style="position:absolute;top:1045px;left:54px;white-space:nowrap" class="ft302">38.</p>
<p style="position:absolute;top:1045px;left:86px;white-space:nowrap" class="ft305">Chernet,&#160;B.T.;&#160;Levin,&#160;M.&#160;Transmembrane&#160;voltage&#160;potential&#160;is&#160;an&#160;essential&#160;cellular&#160;parameter&#160;for&#160;the&#160;detection&#160;and&#160;control&#160;of&#160;tumor<br/>development&#160;in&#160;a&#160;Xenopus&#160;model.&#160;Dis.&#160;Model.&#160;Mech.&#160;<b>2013</b>,&#160;6,&#160;595–607.&#160;<a href="http://doi.org/10.1242/dmm.010835">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/23471912">[PubMed]</a></p>
<p style="position:absolute;top:1080px;left:54px;white-space:nowrap" class="ft302">39.</p>
<p style="position:absolute;top:1080px;left:86px;white-space:nowrap" class="ft302">Cone,&#160;C.D.,&#160;Jr.;&#160;Tongier,&#160;M.,&#160;Jr.&#160;Control&#160;of&#160;somatic&#160;cell&#160;mitosis&#160;by&#160;simulated&#160;changes&#160;in&#160;the&#160;transmembrane&#160;potential&#160;level.</p>
<p style="position:absolute;top:1097px;left:85px;white-space:nowrap" class="ft302">Oncology&#160;<b>1971</b>,&#160;25,&#160;168–182.&#160;<a href="http://doi.org/10.1159/000224567">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/5148061">[PubMed]</a></p>
<p style="position:absolute;top:1114px;left:54px;white-space:nowrap" class="ft302">40.</p>
<p style="position:absolute;top:1114px;left:86px;white-space:nowrap" class="ft302">Stillwell,&#160;E.F.;&#160;Cone,&#160;C.M.;&#160;Cone,&#160;C.D.,&#160;Jr.&#160;Stimulation&#160;of&#160;DNA&#160;synthesis&#160;in&#160;CNS&#160;neurones&#160;by&#160;sustained&#160;depolarisation.&#160;Nat.&#160;New</p>
<p style="position:absolute;top:1131px;left:85px;white-space:nowrap" class="ft302">Biol.&#160;<b>1973</b>,&#160;246,&#160;110–111.&#160;<a href="http://doi.org/10.1038/newbio246110a0">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/4518935">[PubMed]</a></p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft310{font-size:9px;font-family:Times;color:#000000;}
	.ft311{font-size:9px;font-family:Times;color:#000000;}
	.ft312{font-size:11px;font-family:Times;color:#000000;}
	.ft313{font-size:11px;font-family:Times;color:#000000;}
	.ft314{font-size:11px;font-family:Times;color:#0775b7;}
	.ft315{font-size:8px;font-family:Times;color:#000000;}
	.ft316{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page31-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft310">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft310">31&#160;of&#160;36</p>
<p style="position:absolute;top:148px;left:54px;white-space:nowrap" class="ft312">41.</p>
<p style="position:absolute;top:148px;left:86px;white-space:nowrap" class="ft316">Cone,&#160;C.D.&#160;Unified&#160;theory&#160;on&#160;the&#160;basic&#160;mechanism&#160;of&#160;normal&#160;mitotic&#160;control&#160;and&#160;oncogenesis.&#160;J.&#160;Theor.&#160;Biol.&#160;<b>1971</b>,&#160;30,&#160;151–181.<br/><a href="http://doi.org/10.1016/0022-5193(71)90042-7">[CrossRef]</a></p>
<p style="position:absolute;top:182px;left:54px;white-space:nowrap" class="ft312">42.</p>
<p style="position:absolute;top:182px;left:86px;white-space:nowrap" class="ft316">Sundelacruz,&#160;S.;&#160;Levin,&#160;M.;&#160;Kaplan,&#160;D.L.&#160;Depolarization&#160;alters&#160;phenotype,&#160;maintains&#160;plasticity&#160;of&#160;predifferentiated&#160;mesenchymal<br/>stem&#160;cells.&#160;Tissue&#160;Eng.&#160;Part&#160;A&#160;<b>2013</b>,&#160;19,&#160;1889–1908.&#160;<a href="http://doi.org/10.1089/ten.tea.2012.0425.rev">[CrossRef]</a></p>
<p style="position:absolute;top:217px;left:54px;white-space:nowrap" class="ft312">43.</p>
<p style="position:absolute;top:217px;left:86px;white-space:nowrap" class="ft316">Sundelacruz,&#160;S.;&#160;Levin,&#160;M.;&#160;Kaplan,&#160;D.L.&#160;Membrane&#160;potential&#160;controls&#160;adipogenic&#160;and&#160;osteogenic&#160;differentiation&#160;of&#160;mesenchymal<br/>stem&#160;cells.&#160;PLoS&#160;ONE&#160;<b>2008</b>,&#160;3,&#160;e3737.&#160;<a href="http://doi.org/10.1371/journal.pone.0003737">[CrossRef]</a></p>
<p style="position:absolute;top:251px;left:54px;white-space:nowrap" class="ft312">44.</p>
<p style="position:absolute;top:251px;left:86px;white-space:nowrap" class="ft316">Zhang,&#160;Y.Y.;&#160;Yue,&#160;J.;&#160;Che,&#160;H.;&#160;Sun,&#160;H.Y.;&#160;Tse,&#160;H.F.;&#160;Li,&#160;G.R.&#160;BKCa&#160;and&#160;hEag1&#160;channels&#160;regulate&#160;cell&#160;proliferation&#160;and&#160;differentiation<br/>in&#160;human&#160;bone&#160;marrow-derived&#160;mesenchymal&#160;stem&#160;cells.&#160;J.&#160;Cell.&#160;Physiol.&#160;<b>2014</b>,&#160;229,&#160;202–212.&#160;<a href="http://doi.org/10.1002/jcp.24435">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/23881642">[PubMed]</a></p>
<p style="position:absolute;top:286px;left:54px;white-space:nowrap" class="ft312">45.</p>
<p style="position:absolute;top:286px;left:86px;white-space:nowrap" class="ft316">Meszaros,&#160;B.;&#160;Papp,&#160;F.;&#160;Mocsar,&#160;G.;&#160;Kokai,&#160;E.;&#160;Kovacs,&#160;K.;&#160;Tajti,&#160;G.;&#160;Panyi,&#160;G.&#160;The&#160;voltage-gated&#160;proton&#160;channel&#160;hHv1&#160;is&#160;functionally<br/>expressed&#160;in&#160;human&#160;chorion-derived&#160;mesenchymal&#160;stem&#160;cells.&#160;Sci.&#160;Rep.&#160;<b>2020</b>,&#160;10,&#160;7100.&#160;<a href="http://doi.org/10.1038/s41598-020-63517-3">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/32346069">[PubMed]</a></p>
<p style="position:absolute;top:320px;left:54px;white-space:nowrap" class="ft312">46.</p>
<p style="position:absolute;top:320px;left:86px;white-space:nowrap" class="ft316">Pillozzi,&#160;S.;&#160;Becchetti,&#160;A.&#160;Ion&#160;Channels&#160;in&#160;Hematopoietic&#160;and&#160;Mesenchymal&#160;Stem&#160;Cells.&#160;Stem&#160;Cells&#160;Int.&#160;<b>2012</b>,&#160;2012,&#160;217910.<br/><a href="http://doi.org/10.1155/2012/217910">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/22919401">[PubMed]</a></p>
<p style="position:absolute;top:355px;left:54px;white-space:nowrap" class="ft312">47.</p>
<p style="position:absolute;top:355px;left:86px;white-space:nowrap" class="ft316">Chernet,&#160;B.;&#160;Levin,&#160;M.&#160;Endogenous&#160;Voltage&#160;Potentials&#160;and&#160;the&#160;Microenvironment:&#160;Bioelectric&#160;Signals&#160;that&#160;Reveal,&#160;Induce&#160;and<br/>Normalize&#160;Cancer.&#160;J.&#160;Clin.&#160;Exp.&#160;Oncol.&#160;<b>2013</b>,&#160;(Suppl.&#160;1),&#160;S1-002.&#160;<a href="http://doi.org/10.4172/2324-9110.S1-002">[CrossRef]</a></p>
<p style="position:absolute;top:389px;left:54px;white-space:nowrap" class="ft312">48.</p>
<p style="position:absolute;top:389px;left:86px;white-space:nowrap" class="ft316">Chernet,&#160;B.T.;&#160;Adams,&#160;D.S.;&#160;Lobikin,&#160;M.;&#160;Levin,&#160;M.&#160;Use&#160;of&#160;genetically&#160;encoded,&#160;light-gated&#160;ion&#160;translocators&#160;to&#160;control&#160;tumorigene-<br/>sis.&#160;Oncotarget&#160;<b>2016</b>,&#160;7,&#160;19575–19588.&#160;<a href="http://doi.org/10.18632/oncotarget.8036">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/26988909">[PubMed]</a></p>
<p style="position:absolute;top:424px;left:54px;white-space:nowrap" class="ft312">49.</p>
<p style="position:absolute;top:424px;left:86px;white-space:nowrap" class="ft316">Blackiston,&#160;D.J.;&#160;McLaughlin,&#160;K.A.;&#160;Levin,&#160;M.&#160;Bioelectric&#160;controls&#160;of&#160;cell&#160;proliferation:&#160;Ion&#160;channels,&#160;membrane&#160;voltage&#160;and&#160;the<br/>cell&#160;cycle.&#160;Cell&#160;Cycle&#160;<b>2009</b>,&#160;8,&#160;3527–3536.&#160;<a href="http://doi.org/10.4161/cc.8.21.9888">[CrossRef]</a></p>
<p style="position:absolute;top:458px;left:54px;white-space:nowrap" class="ft312">50.</p>
<p style="position:absolute;top:458px;left:86px;white-space:nowrap" class="ft316">Payne,&#160;S.L.;&#160;Levin,&#160;M.;&#160;Oudin,&#160;M.J.&#160;Bioelectric&#160;Control&#160;of&#160;Metastasis&#160;in&#160;Solid&#160;Tumors.&#160;Bioelectricity&#160;<b>2019</b>,&#160;1,&#160;114–130.&#160;<a href="http://doi.org/10.1089/bioe.2019.0013">[CrossRef]<br/></a><a href="http://www.ncbi.nlm.nih.gov/pubmed/32292893">[PubMed]</a></p>
<p style="position:absolute;top:493px;left:54px;white-space:nowrap" class="ft312">51.</p>
<p style="position:absolute;top:493px;left:86px;white-space:nowrap" class="ft312">Ruggieri,&#160;P.;&#160;Mangino,&#160;G.;&#160;Fioretti,&#160;B.;&#160;Catacuzzeno,&#160;L.;&#160;Puca,&#160;R.;&#160;Ponti,&#160;D.;&#160;Miscusi,&#160;M.;&#160;Franciolini,&#160;F.;&#160;Ragona,&#160;G.;&#160;Calogero,&#160;A.</p>
<p style="position:absolute;top:510px;left:85px;white-space:nowrap" class="ft312">The&#160;inhibition&#160;of&#160;KCa3.1&#160;channels&#160;activity&#160;reduces&#160;cell&#160;motility&#160;in&#160;glioblastoma&#160;derived&#160;cancer&#160;stem&#160;cells.&#160;PLoS&#160;ONE&#160;<b>2012</b>,&#160;7,</p>
<p style="position:absolute;top:527px;left:86px;white-space:nowrap" class="ft312">e47825.&#160;<a href="http://doi.org/10.1371/journal.pone.0047825">[CrossRef]</a></p>
<p style="position:absolute;top:545px;left:54px;white-space:nowrap" class="ft312">52.</p>
<p style="position:absolute;top:545px;left:86px;white-space:nowrap" class="ft316">Comes,&#160;N.;&#160;Serrano-Albarras,&#160;A.;&#160;Capera,&#160;J.;&#160;Serrano-Novillo,&#160;C.;&#160;Condom,&#160;E.;&#160;Ramon,&#160;Y.C.S.;&#160;Ferreres,&#160;J.C.;&#160;Felipe,&#160;A.&#160;Involvement<br/>of&#160;potassium&#160;channels&#160;in&#160;the&#160;progression&#160;of&#160;cancer&#160;to&#160;a&#160;more&#160;malignant&#160;phenotype.&#160;Biochim.&#160;Biophys.&#160;Acta&#160;<b>2015</b>,&#160;1848&#160;Pt&#160;B,<br/>2477–2492.&#160;<a href="http://doi.org/10.1016/j.bbamem.2014.12.008">[CrossRef]</a></p>
<p style="position:absolute;top:596px;left:54px;white-space:nowrap" class="ft312">53.</p>
<p style="position:absolute;top:596px;left:86px;white-space:nowrap" class="ft316">Pollak,&#160;J.;&#160;Rai,&#160;K.G.;&#160;Funk,&#160;C.C.;&#160;Arora,&#160;S.;&#160;Lee,&#160;E.;&#160;Zhu,&#160;J.;&#160;Price,&#160;N.D.;&#160;Paddison,&#160;P.J.;&#160;Ramirez,&#160;J.M.;&#160;Rostomily,&#160;R.C.&#160;Ion&#160;channel<br/>expression&#160;patterns&#160;in&#160;glioblastoma&#160;stem&#160;cells&#160;with&#160;functional&#160;and&#160;therapeutic&#160;implications&#160;for&#160;malignancy.&#160;PLoS&#160;ONE&#160;<b>2017</b>,&#160;12,<br/>e0172884.&#160;<a href="http://doi.org/10.1371/journal.pone.0172884">[CrossRef]</a></p>
<p style="position:absolute;top:648px;left:54px;white-space:nowrap" class="ft312">54.</p>
<p style="position:absolute;top:648px;left:86px;white-space:nowrap" class="ft312">Jehle,&#160;J.;&#160;Schweizer,&#160;P.A.;&#160;Katus,&#160;H.A.;&#160;Thomas,&#160;D.&#160;Novel&#160;roles&#160;for&#160;hERG&#160;K(+)&#160;channels&#160;in&#160;cell&#160;proliferation&#160;and&#160;apoptosis.&#160;Cell</p>
<p style="position:absolute;top:665px;left:85px;white-space:nowrap" class="ft312">Death&#160;Dis.&#160;<b>2011</b>,&#160;2,&#160;e193.&#160;<a href="http://doi.org/10.1038/cddis.2011.77">[CrossRef]</a></p>
<p style="position:absolute;top:683px;left:54px;white-space:nowrap" class="ft312">55.</p>
<p style="position:absolute;top:683px;left:86px;white-space:nowrap" class="ft316">Breuer,&#160;E.K.;&#160;Fukushiro-Lopes,&#160;D.;&#160;Dalheim,&#160;A.;&#160;Burnette,&#160;M.;&#160;Zartman,&#160;J.;&#160;Kaja,&#160;S.;&#160;Wells,&#160;C.;&#160;Campo,&#160;L.;&#160;Curtis,&#160;K.J.;<br/>Romero-Moreno,&#160;R.;&#160;et&#160;al.&#160;Potassium&#160;channel&#160;activity&#160;controls&#160;breast&#160;cancer&#160;metastasis&#160;by&#160;affecting&#160;beta-catenin&#160;signaling.&#160;Cell</p>
<p style="position:absolute;top:717px;left:85px;white-space:nowrap" class="ft312">Death&#160;Dis.&#160;<b>2019</b>,&#160;10,&#160;180.&#160;<a href="http://doi.org/10.1038/s41419-019-1429-0">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/30792401">[PubMed]</a></p>
<p style="position:absolute;top:734px;left:54px;white-space:nowrap" class="ft312">56.</p>
<p style="position:absolute;top:734px;left:86px;white-space:nowrap" class="ft312">Li,&#160;N.;&#160;Liu,&#160;L.;&#160;Li,&#160;G.;&#160;Xia,&#160;M.;&#160;Du,&#160;C.;&#160;Zheng,&#160;Z.&#160;The&#160;role&#160;of&#160;BKCa&#160;in&#160;endometrial&#160;cancer&#160;HEC-1-B&#160;cell&#160;proliferation&#160;and&#160;migration.</p>
<p style="position:absolute;top:752px;left:85px;white-space:nowrap" class="ft312">Gene&#160;<b>2018</b>,&#160;655,&#160;42–47.&#160;<a href="http://doi.org/10.1016/j.gene.2018.02.055">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/29477869">[PubMed]</a></p>
<p style="position:absolute;top:769px;left:54px;white-space:nowrap" class="ft312">57.</p>
<p style="position:absolute;top:769px;left:86px;white-space:nowrap" class="ft316">Brandalise,&#160;F.;&#160;Ratto,&#160;D.;&#160;Leone,&#160;R.;&#160;Olivero,&#160;F.;&#160;Roda,&#160;E.;&#160;Locatelli,&#160;C.A.;&#160;Grazia&#160;Bottone,&#160;M.;&#160;Rossi,&#160;P.&#160;Deeper&#160;and&#160;Deeper&#160;on&#160;the<br/>Role&#160;of&#160;BK&#160;and&#160;Kir4.1&#160;Channels&#160;in&#160;Glioblastoma&#160;Invasiveness:&#160;A&#160;Novel&#160;Summative&#160;Mechanism?&#160;Front.&#160;Neurosci.&#160;<b>2020</b>,&#160;14,&#160;595664.<br/><a href="http://doi.org/10.3389/fnins.2020.595664">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/33328867">[PubMed]</a></p>
<p style="position:absolute;top:821px;left:54px;white-space:nowrap" class="ft312">58.</p>
<p style="position:absolute;top:821px;left:86px;white-space:nowrap" class="ft312">Liu,&#160;J.;&#160;Qu,&#160;C.;&#160;Han,&#160;C.;&#160;Chen,&#160;M.M.;&#160;An,&#160;L.J.;&#160;Zou,&#160;W.&#160;Potassium&#160;channels&#160;and&#160;their&#160;role&#160;in&#160;glioma:&#160;A&#160;mini&#160;review.&#160;Mol.&#160;Membr.</p>
<p style="position:absolute;top:838px;left:85px;white-space:nowrap" class="ft312">Biol.&#160;<b>2019</b>,&#160;35,&#160;76–85.&#160;<a href="http://doi.org/10.1080/09687688.2020.1729428">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/32067536">[PubMed]</a></p>
<p style="position:absolute;top:855px;left:54px;white-space:nowrap" class="ft312">59.</p>
<p style="position:absolute;top:855px;left:86px;white-space:nowrap" class="ft316">Terrasi,&#160;A.;&#160;Bertolini,&#160;I.;&#160;Martelli,&#160;C.;&#160;Gaudioso,&#160;G.;&#160;Di&#160;Cristofori,&#160;A.;&#160;Storaci,&#160;A.M.;&#160;Formica,&#160;M.;&#160;Bosari,&#160;S.;&#160;Caroli,&#160;M.;&#160;Ottobrini,&#160;L.;<br/>et&#160;al.&#160;Specific&#160;V-ATPase&#160;expression&#160;sub-classifies&#160;IDHwt&#160;lower-grade&#160;gliomas&#160;and&#160;impacts&#160;glioma&#160;growth&#160;in&#160;vivo.&#160;EBioMedicine<br/><b>2019</b></p>
<p style="position:absolute;top:890px;left:113px;white-space:nowrap" class="ft312">,&#160;41,&#160;214–224.&#160;<a href="http://doi.org/10.1016/j.ebiom.2019.01.052">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/30737087">[PubMed]</a></p>
<p style="position:absolute;top:907px;left:54px;white-space:nowrap" class="ft312">60.</p>
<p style="position:absolute;top:907px;left:86px;white-space:nowrap" class="ft316">Yekula,&#160;A.;&#160;Yekula,&#160;A.;&#160;Muralidharan,&#160;K.;&#160;Kang,&#160;K.;&#160;Carter,&#160;B.S.;&#160;Balaj,&#160;L.&#160;Extracellular&#160;Vesicles&#160;in&#160;Glioblastoma&#160;Tumor&#160;Microenvi-<br/>ronment.&#160;Front.&#160;Immunol.&#160;<b>2019</b>,&#160;10,&#160;3137.&#160;<a href="http://doi.org/10.3389/fimmu.2019.03137">[CrossRef]</a></p>
<p style="position:absolute;top:942px;left:54px;white-space:nowrap" class="ft312">61.</p>
<p style="position:absolute;top:942px;left:86px;white-space:nowrap" class="ft316">Harguindey,&#160;S.;&#160;Polo&#160;Orozco,&#160;J.;&#160;Alfarouk,&#160;K.O.;&#160;Devesa,&#160;J.&#160;Hydrogen&#160;Ion&#160;Dynamics&#160;of&#160;Cancer&#160;and&#160;a&#160;New&#160;Molecular,&#160;Biochemical<br/>and&#160;Metabolic&#160;Approach&#160;to&#160;the&#160;Etiopathogenesis&#160;and&#160;Treatment&#160;of&#160;Brain&#160;Malignancies.&#160;Int.&#160;J.&#160;Mol.&#160;Sci.&#160;<b>2019</b>,&#160;20,&#160;4278.&#160;<a href="http://doi.org/10.3390/ijms20174278">[CrossRef]</a></p>
<p style="position:absolute;top:976px;left:54px;white-space:nowrap" class="ft312">62.</p>
<p style="position:absolute;top:976px;left:86px;white-space:nowrap" class="ft316">Hamprecht,&#160;B.;&#160;Glaser,&#160;T.;&#160;Reiser,&#160;G.;&#160;Bayer,&#160;E.;&#160;Propst,&#160;F.&#160;Culture&#160;and&#160;characteristics&#160;of&#160;hormone-responsive&#160;neuroblastoma&#160;X<br/>glioma&#160;hybrid&#160;cells.&#160;Methods&#160;Enzymol.&#160;<b>1985</b>,&#160;109,&#160;316–341.&#160;<a href="http://doi.org/10.1016/0076-6879(85)09096-6">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/2985920">[PubMed]</a></p>
<p style="position:absolute;top:1011px;left:54px;white-space:nowrap" class="ft312">63.</p>
<p style="position:absolute;top:1011px;left:86px;white-space:nowrap" class="ft316">Lichtshtein,&#160;D.;&#160;Dunlop,&#160;K.;&#160;Kaback,&#160;H.R.;&#160;Blume,&#160;A.J.&#160;Mechanism&#160;of&#160;monensin-induced&#160;hyperpolarization&#160;of&#160;neuroblastoma-<br/>glioma&#160;hybrid&#160;NG108-15.&#160;Proc.&#160;Natl.&#160;Acad.&#160;Sci.&#160;USA&#160;<b>1979</b>,&#160;76,&#160;2580–2584.&#160;<a href="http://doi.org/10.1073/pnas.76.6.2580">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/288048">[PubMed]</a></p>
<p style="position:absolute;top:1045px;left:54px;white-space:nowrap" class="ft312">64.</p>
<p style="position:absolute;top:1045px;left:86px;white-space:nowrap" class="ft316">Mitchell,&#160;P.J.;&#160;Hanson,&#160;J.C.;&#160;Quets-Nguyen,&#160;A.T.;&#160;Bergeron,&#160;M.;&#160;Smith,&#160;R.C.&#160;A&#160;quantitative&#160;method&#160;for&#160;analysis&#160;of&#160;in&#160;vitro&#160;neurite<br/>outgrowth.&#160;J.&#160;Neurosci.&#160;Methods&#160;<b>2007</b>,&#160;164,&#160;350–362.&#160;<a href="http://doi.org/10.1016/j.jneumeth.2007.04.021">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/17570533">[PubMed]</a></p>
<p style="position:absolute;top:1080px;left:54px;white-space:nowrap" class="ft312">65.</p>
<p style="position:absolute;top:1080px;left:86px;white-space:nowrap" class="ft316">Pancrazio,&#160;J.J.;&#160;Ma,&#160;W.;&#160;Grant,&#160;G.M.;&#160;Shaffer,&#160;K.M.;&#160;Kao,&#160;W.Y.;&#160;Liu,&#160;Q.-Y.;&#160;Manos,&#160;P.;&#160;Barker,&#160;J.L.;&#160;Stenger,&#160;D.A.&#160;A&#160;role&#160;for&#160;inwardly<br/>rectifying&#160;K+&#160;channels&#160;in&#160;differentiation&#160;of&#160;NG108-15&#160;neuroblastoma&#160;glioma&#160;cells.&#160;J.&#160;Neurobiol.&#160;<b>1999</b>,&#160;38,&#160;466–474.&#160;<a href="http://doi.org/10.1002/(SICI)1097-4695(199903)38:4&lt;466::AID-NEU3&gt;3.0.CO;2-8">[CrossRef]</a></p>
<p style="position:absolute;top:1114px;left:54px;white-space:nowrap" class="ft312">66.</p>
<p style="position:absolute;top:1114px;left:86px;white-space:nowrap" class="ft316">Lee,&#160;J.;&#160;Kotliarova,&#160;S.;&#160;Kotliarov,&#160;Y.;&#160;Li,&#160;A.;&#160;Su,&#160;Q.;&#160;Donin,&#160;N.M.;&#160;Pastorino,&#160;S.;&#160;Purow,&#160;B.W.;&#160;Christopher,&#160;N.;&#160;Zhang,&#160;W.;&#160;et&#160;al.&#160;Tumor<br/>stem&#160;cells&#160;derived&#160;from&#160;glioblastomas&#160;cultured&#160;in&#160;bFGF&#160;and&#160;EGF&#160;more&#160;closely&#160;mirror&#160;the&#160;phenotype&#160;and&#160;genotype&#160;of&#160;primary<br/>tumors&#160;than&#160;do&#160;serum-cultured&#160;cell&#160;lines.&#160;Cancer&#160;Cell&#160;<b>2006</b>,&#160;9,&#160;391–403.&#160;<a href="http://doi.org/10.1016/j.ccr.2006.03.030">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/16697959">[PubMed]</a></p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft320{font-size:9px;font-family:Times;color:#000000;}
	.ft321{font-size:9px;font-family:Times;color:#000000;}
	.ft322{font-size:11px;font-family:Times;color:#000000;}
	.ft323{font-size:11px;font-family:Times;color:#000000;}
	.ft324{font-size:11px;font-family:Times;color:#0775b7;}
	.ft325{font-size:8px;font-family:Times;color:#000000;}
	.ft326{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page32-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft320">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft320">32&#160;of&#160;36</p>
<p style="position:absolute;top:148px;left:54px;white-space:nowrap" class="ft322">67.</p>
<p style="position:absolute;top:148px;left:86px;white-space:nowrap" class="ft326">Ledur,&#160;P.F.;&#160;Onzi,&#160;G.R.;&#160;Zong,&#160;H.;&#160;Lenz,&#160;G.&#160;Culture&#160;conditions&#160;defining&#160;glioblastoma&#160;cells&#160;behavior:&#160;What&#160;is&#160;the&#160;impact&#160;for&#160;novel<br/>discoveries?&#160;Oncotarget&#160;<b>2017</b>,&#160;8,&#160;69185–69197.&#160;<a href="http://doi.org/10.18632/oncotarget.20193">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/28978189">[PubMed]</a></p>
<p style="position:absolute;top:182px;left:54px;white-space:nowrap" class="ft322">68.</p>
<p style="position:absolute;top:182px;left:86px;white-space:nowrap" class="ft326">Hong,&#160;X.;&#160;Chedid,&#160;K.;&#160;Kalkanis,&#160;S.N.&#160;Glioblastoma&#160;cell&#160;line-derived&#160;spheres&#160;in&#160;serumcontaining&#160;medium&#160;versus&#160;serum-free<br/>medium:&#160;A&#160;comparison&#160;of&#160;cancer&#160;stem&#160;cell&#160;properties.&#160;Int.&#160;J.&#160;Oncol.&#160;<b>2012</b>,&#160;41,&#160;1693–1700.&#160;<a href="http://doi.org/10.3892/ijo.2012.1592">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/22922964">[PubMed]</a></p>
<p style="position:absolute;top:217px;left:54px;white-space:nowrap" class="ft322">69.</p>
<p style="position:absolute;top:217px;left:86px;white-space:nowrap" class="ft322">Haspels,&#160;H.N.;&#160;Rahman,&#160;M.A.;&#160;Joseph,&#160;J.V.;&#160;Gras&#160;Navarro,&#160;A.;&#160;Chekenya,&#160;M.&#160;Glioblastoma&#160;Stem-Like&#160;Cells&#160;Are&#160;More&#160;Susceptible</p>
<p style="position:absolute;top:234px;left:85px;white-space:nowrap" class="ft326">Than&#160;Differentiated&#160;Cells&#160;to&#160;Natural&#160;Killer&#160;Cell&#160;Lysis&#160;Mediated&#160;through&#160;Killer&#160;Immunoglobulin-Like&#160;Receptors-Human&#160;Leukocyte<br/>Antigen&#160;Ligand&#160;Mismatch&#160;and&#160;Activation&#160;Receptor-Ligand&#160;Interactions.&#160;Front.&#160;Immunol.&#160;<b>2018</b>,&#160;9,&#160;1345.&#160;<a href="http://doi.org/10.3389/fimmu.2018.01345">[CrossRef]</a></p>
<p style="position:absolute;top:268px;left:54px;white-space:nowrap" class="ft322">70.</p>
<p style="position:absolute;top:268px;left:86px;white-space:nowrap" class="ft326">Sladitschek,&#160;H.L.;&#160;Neveu,&#160;P.A.&#160;MXS-Chaining:&#160;A&#160;Highly&#160;Efficient&#160;Cloning&#160;Platform&#160;for&#160;Imaging&#160;and&#160;Flow&#160;Cytometry&#160;Approaches<br/>in&#160;Mammalian&#160;Systems.&#160;PLoS&#160;ONE&#160;<b>2015</b>,&#160;10,&#160;e0124958.&#160;<a href="http://doi.org/10.1371/journal.pone.0124958">[CrossRef]</a></p>
<p style="position:absolute;top:303px;left:54px;white-space:nowrap" class="ft322">71.</p>
<p style="position:absolute;top:303px;left:86px;white-space:nowrap" class="ft326">Cairns,&#160;D.M.;&#160;Chwalek,&#160;K.;&#160;Moore,&#160;Y.E.;&#160;Kelley,&#160;M.R.;&#160;Abbott,&#160;R.D.;&#160;Moss,&#160;S.;&#160;Kaplan,&#160;D.L.&#160;Expandable&#160;and&#160;Rapidly&#160;Differentiating<br/>Human&#160;Induced&#160;Neural&#160;Stem&#160;Cell&#160;Lines&#160;for&#160;Multiple&#160;Tissue&#160;Engineering&#160;Applications.&#160;Stem&#160;Cell&#160;Rep.&#160;<b>2016</b>,&#160;7,&#160;557–570.&#160;<a href="http://doi.org/10.1016/j.stemcr.2016.07.017">[CrossRef]<br/></a><a href="http://www.ncbi.nlm.nih.gov/pubmed/27569063">[PubMed]</a></p>
<p style="position:absolute;top:355px;left:54px;white-space:nowrap" class="ft322">72.</p>
<p style="position:absolute;top:355px;left:86px;white-space:nowrap" class="ft326">Goedhart,&#160;J.;&#160;von&#160;Stetten,&#160;D.;&#160;Noirclerc-Savoye,&#160;M.;&#160;Lelimousin,&#160;M.;&#160;Joosen,&#160;L.;&#160;Hink,&#160;M.A.;&#160;van&#160;Weeren,&#160;L.;&#160;Gadella,&#160;T.W.,&#160;Jr.;<br/>Royant,&#160;A.&#160;Structure-guided&#160;evolution&#160;of&#160;cyan&#160;fluorescent&#160;proteins&#160;towards&#160;a&#160;quantum&#160;yield&#160;of&#160;93%.&#160;Nat.&#160;Commun.&#160;<b>2012</b>,&#160;3,&#160;751.<br/><a href="http://doi.org/10.1038/ncomms1738">[CrossRef]</a></p>
<p style="position:absolute;top:407px;left:54px;white-space:nowrap" class="ft322">73.</p>
<p style="position:absolute;top:407px;left:86px;white-space:nowrap" class="ft326">Marh,&#160;J.;&#160;Stoytcheva,&#160;Z.;&#160;Urschitz,&#160;J.;&#160;Sugawara,&#160;A.;&#160;Yamashiro,&#160;H.;&#160;Owens,&#160;J.B.;&#160;Stoytchev,&#160;I.;&#160;Pelczar,&#160;P.;&#160;Yanagimachi,&#160;R.;&#160;Moisyadi,<br/>S.&#160;Hyperactive&#160;self-inactivating&#160;piggyBac&#160;for&#160;transposase-enhanced&#160;pronuclear&#160;microinjection&#160;transgenesis.&#160;Proc.&#160;Natl.&#160;Acad.&#160;Sci.</p>
<p style="position:absolute;top:441px;left:85px;white-space:nowrap" class="ft322">USA&#160;<b>2012</b>,&#160;109,&#160;19184–19189.&#160;<a href="http://doi.org/10.1073/pnas.1216473109">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/23093669">[PubMed]</a></p>
<p style="position:absolute;top:458px;left:54px;white-space:nowrap" class="ft322">74.</p>
<p style="position:absolute;top:458px;left:86px;white-space:nowrap" class="ft326">Owens,&#160;J.B.;&#160;Mathews,&#160;J.;&#160;Davy,&#160;P.;&#160;Stoytchev,&#160;I.;&#160;Moisyadi,&#160;S.;&#160;Allsopp,&#160;R.&#160;Effective&#160;Targeted&#160;Gene&#160;Knockdown&#160;in&#160;Mammalian<br/>Cells&#160;Using&#160;the&#160;piggyBac&#160;Transposase-based&#160;Delivery&#160;System.&#160;Mol.&#160;Ther.&#160;Nucleic&#160;Acids&#160;<b>2013</b>,&#160;2,&#160;e137.&#160;<a href="http://doi.org/10.1038/mtna.2013.61">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/24326734">[PubMed]</a></p>
<p style="position:absolute;top:493px;left:54px;white-space:nowrap" class="ft322">75.</p>
<p style="position:absolute;top:493px;left:86px;white-space:nowrap" class="ft326">Kamentsky,&#160;L.;&#160;Jones,&#160;T.R.;&#160;Fraser,&#160;A.;&#160;Bray,&#160;M.-A.;&#160;Logan,&#160;D.J.;&#160;Madden,&#160;K.L.;&#160;Ljosa,&#160;V.;&#160;Rueden,&#160;C.;&#160;Eliceiri,&#160;K.W.;&#160;Carpenter,&#160;A.E.<br/>Improved&#160;structure,&#160;function&#160;and&#160;compatibility&#160;for&#160;CellProfiler:&#160;Modular&#160;high-throughput&#160;image&#160;analysis&#160;software.&#160;Bioinformatics<br/><b>2011</b></p>
<p style="position:absolute;top:527px;left:113px;white-space:nowrap" class="ft322">,&#160;27,&#160;1179–1180.&#160;<a href="http://doi.org/10.1093/bioinformatics/btr095">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/21349861">[PubMed]</a></p>
<p style="position:absolute;top:545px;left:54px;white-space:nowrap" class="ft322">76.</p>
<p style="position:absolute;top:545px;left:86px;white-space:nowrap" class="ft326">Sero,&#160;J.E.;&#160;Bakal,&#160;C.&#160;Multiparametric&#160;Analysis&#160;of&#160;Cell&#160;Shape&#160;Demonstrates&#160;that&#160;beta-PIX&#160;Directly&#160;Couples&#160;YAP&#160;Activation&#160;to<br/>Extracellular&#160;Matrix&#160;Adhesion.&#160;Cell&#160;Syst.&#160;<b>2017</b>,&#160;4,&#160;84–96.e6.&#160;<a href="http://doi.org/10.1016/j.cels.2016.11.015">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/28065575">[PubMed]</a></p>
<p style="position:absolute;top:579px;left:54px;white-space:nowrap" class="ft322">77.</p>
<p style="position:absolute;top:579px;left:86px;white-space:nowrap" class="ft326">Pan,&#160;J.Q.;&#160;Baez-Nieto,&#160;D.;&#160;Allen,&#160;A.;&#160;Wang,&#160;H.R.;&#160;Cottrell,&#160;J.R.&#160;Developing&#160;High-Throughput&#160;Assays&#160;to&#160;Analyze&#160;and&#160;Screen<br/>Electrophysiological&#160;Phenotypes.&#160;Methods&#160;Mol.&#160;Biol.&#160;<b>2018</b>,&#160;1787,&#160;235–252.&#160;<a href="http://doi.org/10.1007/978-1-4939-7847-2_18">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/29736723">[PubMed]</a></p>
<p style="position:absolute;top:614px;left:54px;white-space:nowrap" class="ft322">78.</p>
<p style="position:absolute;top:614px;left:86px;white-space:nowrap" class="ft322">Petho,&#160;Z.;&#160;Najder,&#160;K.;&#160;Carvalho,&#160;T.;&#160;McMorrow,&#160;R.;&#160;Todesca,&#160;L.M.;&#160;Rugi,&#160;M.;&#160;Bulk,&#160;E.;&#160;Chan,&#160;A.;&#160;Lowik,&#160;C.;&#160;Reshkin,&#160;S.J.;&#160;et&#160;al.</p>
<p style="position:absolute;top:631px;left:85px;white-space:nowrap" class="ft322">pH-Channeling&#160;in&#160;Cancer:&#160;How&#160;pH-Dependence&#160;of&#160;Cation&#160;Channels&#160;Shapes&#160;Cancer&#160;Pathophysiology.&#160;Cancers&#160;<b>2020</b>,&#160;12,&#160;2484.</p>
<p style="position:absolute;top:648px;left:86px;white-space:nowrap" class="ft322"><a href="http://doi.org/10.3390/cancers12092484">[CrossRef]</a></p>
<p style="position:absolute;top:665px;left:54px;white-space:nowrap" class="ft322">79.</p>
<p style="position:absolute;top:665px;left:86px;white-space:nowrap" class="ft326">Abdul&#160;Kadir,&#160;L.;&#160;Stacey,&#160;M.;&#160;Barrett-Jolley,&#160;R.&#160;Emerging&#160;Roles&#160;of&#160;the&#160;Membrane&#160;Potential:&#160;Action&#160;beyond&#160;the&#160;Action&#160;Potential.<br/>Front.&#160;Physiol.&#160;<b>2018</b>,&#160;9,&#160;1661.&#160;<a href="http://doi.org/10.3389/fphys.2018.01661">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/30519193">[PubMed]</a></p>
<p style="position:absolute;top:700px;left:54px;white-space:nowrap" class="ft322">80.</p>
<p style="position:absolute;top:700px;left:86px;white-space:nowrap" class="ft326">Yang,&#160;M.;&#160;James,&#160;A.D.;&#160;Suman,&#160;R.;&#160;Kasprowicz,&#160;R.;&#160;Nelson,&#160;M.;&#160;O’Toole,&#160;P.J.;&#160;Brackenbury,&#160;W.J.&#160;Voltage-dependent&#160;activation&#160;of<br/>Rac1&#160;by&#160;Nav&#160;1.5&#160;channels&#160;promotes&#160;cell&#160;migration.&#160;J.&#160;Cell.&#160;Physiol.&#160;<b>2020</b>,&#160;235,&#160;3950–3972.&#160;<a href="http://doi.org/10.1002/jcp.29290">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/31612502">[PubMed]</a></p>
<p style="position:absolute;top:734px;left:54px;white-space:nowrap" class="ft322">81.</p>
<p style="position:absolute;top:734px;left:86px;white-space:nowrap" class="ft326">Chinnaiyan,&#160;P.;&#160;Won,&#160;M.;&#160;Wen,&#160;P.Y.;&#160;Rojiani,&#160;A.M.;&#160;Werner-Wasik,&#160;M.;&#160;Shih,&#160;H.A.;&#160;Ashby,&#160;L.S.;&#160;Michael&#160;Yu,&#160;H.H.;&#160;Stieber,&#160;V.W.;<br/>Malone,&#160;S.C.;&#160;et&#160;al.&#160;A&#160;randomized&#160;phase&#160;II&#160;study&#160;of&#160;everolimus&#160;in&#160;combination&#160;with&#160;chemoradiation&#160;in&#160;newly&#160;diagnosed<br/>glioblastoma:&#160;Results&#160;of&#160;NRG&#160;Oncology&#160;RTOG&#160;0913.&#160;Neuro&#160;Oncol.&#160;<b>2018</b>,&#160;20,&#160;666–673.&#160;<a href="http://doi.org/10.1093/neuonc/nox209">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/29126203">[PubMed]</a></p>
<p style="position:absolute;top:786px;left:54px;white-space:nowrap" class="ft322">82.</p>
<p style="position:absolute;top:786px;left:86px;white-space:nowrap" class="ft326">Fouladi,&#160;M.;&#160;Laningham,&#160;F.;&#160;Wu,&#160;J.;&#160;O’Shaughnessy,&#160;M.A.;&#160;Molina,&#160;K.;&#160;Broniscer,&#160;A.;&#160;Spunt,&#160;S.L.;&#160;Luckett,&#160;I.;&#160;Stewart,&#160;C.F.;<br/>Houghton,&#160;P.J.;&#160;et&#160;al.&#160;Phase&#160;I&#160;study&#160;of&#160;everolimus&#160;in&#160;pediatric&#160;patients&#160;with&#160;refractory&#160;solid&#160;tumors.&#160;J.&#160;Clin.&#160;Oncol.&#160;<b>2007</b>,&#160;25,<br/>4806–4812.&#160;<a href="http://doi.org/10.1200/JCO.2007.11.4017">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/17947729">[PubMed]</a></p>
<p style="position:absolute;top:838px;left:54px;white-space:nowrap" class="ft322">83.</p>
<p style="position:absolute;top:838px;left:86px;white-space:nowrap" class="ft326">Geeviman,&#160;K.;&#160;Babu,&#160;D.;&#160;Prakash&#160;Babu,&#160;P.&#160;Pantoprazole&#160;Induces&#160;Mitochondrial&#160;Apoptosis&#160;and&#160;Attenuates&#160;NF-kappaB&#160;Signaling<br/>in&#160;Glioma&#160;Cells.&#160;Cell.&#160;Mol.&#160;Neurobiol.&#160;<b>2018</b>,&#160;38,&#160;1491–1504.&#160;<a href="http://doi.org/10.1007/s10571-018-0623-4">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/30302629">[PubMed]</a></p>
<p style="position:absolute;top:873px;left:54px;white-space:nowrap" class="ft322">84.</p>
<p style="position:absolute;top:873px;left:86px;white-space:nowrap" class="ft326">Beier,&#160;D.;&#160;Schriefer,&#160;B.;&#160;Brawanski,&#160;K.;&#160;Hau,&#160;P.;&#160;Weis,&#160;J.;&#160;Schulz,&#160;J.B.;&#160;Beier,&#160;C.P.&#160;Efficacy&#160;of&#160;clinically&#160;relevant&#160;temozolomide&#160;dosing<br/>schemes&#160;in&#160;glioblastoma&#160;cancer&#160;stem&#160;cell&#160;lines.&#160;J.&#160;Neurooncol.&#160;<b>2012</b>,&#160;109,&#160;45–52.&#160;<a href="http://doi.org/10.1007/s11060-012-0878-4">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/22544650">[PubMed]</a></p>
<p style="position:absolute;top:907px;left:54px;white-space:nowrap" class="ft322">85.</p>
<p style="position:absolute;top:907px;left:86px;white-space:nowrap" class="ft326">Li,&#160;P.;&#160;Chen,&#160;X.;&#160;Zhang,&#160;Q.;&#160;Zheng,&#160;Y.;&#160;Jiang,&#160;H.;&#160;Yang,&#160;H.;&#160;Gao,&#160;Z.&#160;The&#160;human&#160;ether-a-go-go-related&#160;gene&#160;activator&#160;NS1643<br/>enhances&#160;epilepsy-associated&#160;KCNQ&#160;channels.&#160;J.&#160;Pharmacol.&#160;Exp.&#160;Ther.&#160;<b>2014</b>,&#160;351,&#160;596–604.&#160;<a href="http://doi.org/10.1124/jpet.114.217703">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/25232191">[PubMed]</a></p>
<p style="position:absolute;top:942px;left:54px;white-space:nowrap" class="ft322">86.</p>
<p style="position:absolute;top:942px;left:86px;white-space:nowrap" class="ft326">Shen,&#160;W.;&#160;Zou,&#160;X.;&#160;Chen,&#160;M.;&#160;Shen,&#160;Y.;&#160;Huang,&#160;S.;&#160;Guo,&#160;H.;&#160;Zhang,&#160;L.;&#160;Liu,&#160;P.&#160;Effect&#160;of&#160;pantoprazole&#160;on&#160;human&#160;gastric&#160;adenocarci-<br/>noma&#160;SGC7901&#160;cells&#160;through&#160;regulation&#160;of&#160;phospho-LRP6&#160;expression&#160;in&#160;Wnt/β-catenin&#160;signaling.&#160;Oncol.&#160;Rep.&#160;<b>2013</b>,&#160;30,&#160;851–855.<br/><a href="http://doi.org/10.3892/or.2013.2524">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/23754096">[PubMed]</a></p>
<p style="position:absolute;top:993px;left:54px;white-space:nowrap" class="ft322">87.</p>
<p style="position:absolute;top:993px;left:86px;white-space:nowrap" class="ft326">Gunthorpe,&#160;M.J.;&#160;Large,&#160;C.H.;&#160;Sankar,&#160;R.&#160;The&#160;mechanism&#160;of&#160;action&#160;of&#160;retigabine&#160;(ezogabine),&#160;a&#160;first-in-class&#160;K+&#160;channel&#160;opener&#160;for<br/>the&#160;treatment&#160;of&#160;epilepsy.&#160;Epilepsia&#160;<b>2012</b>,&#160;53,&#160;412–424.&#160;<a href="http://doi.org/10.1111/j.1528-1167.2011.03365.x">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/22220513">[PubMed]</a></p>
<p style="position:absolute;top:1028px;left:54px;white-space:nowrap" class="ft322">88.</p>
<p style="position:absolute;top:1028px;left:86px;white-space:nowrap" class="ft322">Lagrange,&#160;A.&#160;Retigabine:&#160;Bending&#160;potassium&#160;channels&#160;to&#160;our&#160;will.&#160;Epilepsy&#160;Curr.&#160;<b>2005</b>,&#160;5,&#160;166–168.&#160;<a href="http://doi.org/10.1111/j.1535-7511.2005.00052.x">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/16175213">[PubMed]</a></p>
<p style="position:absolute;top:1045px;left:54px;white-space:nowrap" class="ft322">89.</p>
<p style="position:absolute;top:1045px;left:86px;white-space:nowrap" class="ft326">Nakatani,&#160;Y.;&#160;Masuko,&#160;H.;&#160;Amano,&#160;T.&#160;Effect&#160;of&#160;lamotrigine&#160;on&#160;Na(v)1.4&#160;voltage-gated&#160;sodium&#160;channels.&#160;J.&#160;Pharmacol.&#160;Sci.&#160;<b>2013</b>,&#160;123,<br/>203–206.&#160;<a href="http://doi.org/10.1254/jphs.13116SC">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/24096830">[PubMed]</a></p>
<p style="position:absolute;top:1080px;left:54px;white-space:nowrap" class="ft322">90.</p>
<p style="position:absolute;top:1080px;left:86px;white-space:nowrap" class="ft326">Chin,&#160;T.Y.;&#160;Kao,&#160;C.H.;&#160;Wang,&#160;H.Y.;&#160;Huang,&#160;W.P.;&#160;Ma,&#160;K.H.;&#160;Chueh,&#160;S.H.&#160;Inhibition&#160;of&#160;the&#160;mammalian&#160;target&#160;of&#160;rapamycin&#160;promotes<br/>cyclic&#160;AMP-induced&#160;differentiation&#160;of&#160;NG108-15&#160;cells.&#160;Autophagy&#160;<b>2010</b>,&#160;6,&#160;1139–1156.&#160;<a href="http://doi.org/10.4161/auto.6.8.13564">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/20935515">[PubMed]</a></p>
<p style="position:absolute;top:1114px;left:54px;white-space:nowrap" class="ft322">91.</p>
<p style="position:absolute;top:1114px;left:86px;white-space:nowrap" class="ft326">Raker,&#160;V.K.;&#160;Becker,&#160;C.;&#160;Steinbrink,&#160;K.&#160;The&#160;cAMP&#160;Pathway&#160;as&#160;Therapeutic&#160;Target&#160;in&#160;Autoimmune&#160;and&#160;Inflammatory&#160;Diseases.<br/>Front.&#160;Immunol.&#160;<b>2016</b>,&#160;7,&#160;123.&#160;<a href="http://doi.org/10.3389/fimmu.2016.00123">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/27065076">[PubMed]</a></p>
<p style="position:absolute;top:1149px;left:54px;white-space:nowrap" class="ft322">92.</p>
<p style="position:absolute;top:1149px;left:86px;white-space:nowrap" class="ft322">Lee,&#160;S.Y.&#160;Temozolomide&#160;resistance&#160;in&#160;glioblastoma&#160;multiforme.&#160;Genes&#160;Dis.&#160;<b>2016</b>,&#160;3,&#160;198–210.&#160;<a href="http://doi.org/10.1016/j.gendis.2016.04.007">[CrossRef]</a></p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft330{font-size:9px;font-family:Times;color:#000000;}
	.ft331{font-size:9px;font-family:Times;color:#000000;}
	.ft332{font-size:11px;font-family:Times;color:#000000;}
	.ft333{font-size:8px;font-family:Times;color:#000000;}
	.ft334{font-size:11px;font-family:Times;color:#000000;}
	.ft335{font-size:11px;font-family:Times;color:#0775b7;}
	.ft336{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page33-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft330">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft330">33&#160;of&#160;36</p>
<p style="position:absolute;top:148px;left:54px;white-space:nowrap" class="ft332">93.</p>
<p style="position:absolute;top:148px;left:86px;white-space:nowrap" class="ft332">Yeh,&#160;P.S.;&#160;Wu,&#160;S.J.;&#160;Hung,&#160;T.Y.;&#160;Huang,&#160;Y.M.;&#160;Hsu,&#160;C.W.;&#160;Sze,&#160;C.I.;&#160;Hsieh,&#160;Y.J.;&#160;Huang,&#160;C.W.;&#160;Wu,&#160;S.N.&#160;Evidence&#160;for&#160;the&#160;Inhibition&#160;by</p>
<p style="position:absolute;top:165px;left:85px;white-space:nowrap" class="ft332">Temozolomide,&#160;an&#160;Imidazotetrazine&#160;Family&#160;Alkylator,&#160;of&#160;Intermediate-Conductance&#160;Ca2+-Activated&#160;K+&#160;Channels&#160;in&#160;Glioma</p>
<p style="position:absolute;top:182px;left:86px;white-space:nowrap" class="ft332">Cells.&#160;Cell.&#160;Physiol.&#160;Biochem.&#160;<b>2016</b>,&#160;38,&#160;1727–1742.&#160;<a href="http://doi.org/10.1159/000443112">[CrossRef]</a></p>
<p style="position:absolute;top:199px;left:54px;white-space:nowrap" class="ft332">94.</p>
<p style="position:absolute;top:199px;left:86px;white-space:nowrap" class="ft336">Soltani,&#160;M.H.;&#160;Pichardo,&#160;R.;&#160;Song,&#160;Z.;&#160;Sangha,&#160;N.;&#160;Camacho,&#160;F.;&#160;Satyamoorthy,&#160;K.;&#160;Sangueza,&#160;O.P.;&#160;Setaluri,&#160;V.&#160;Microtubule-<br/>associated&#160;protein&#160;2,&#160;a&#160;marker&#160;of&#160;neuronal&#160;differentiation,&#160;induces&#160;mitotic&#160;defects,&#160;inhibits&#160;growth&#160;of&#160;melanoma&#160;cells,&#160;and&#160;predicts<br/>metastatic&#160;potential&#160;of&#160;cutaneous&#160;melanoma.&#160;Am.&#160;J.&#160;Pathol.&#160;<b>2005</b>,&#160;166,&#160;1841–1850.&#160;<a href="http://doi.org/10.1016/S0002-9440(10)62493-5">[CrossRef]</a></p>
<p style="position:absolute;top:251px;left:54px;white-space:nowrap" class="ft332">95.</p>
<p style="position:absolute;top:251px;left:86px;white-space:nowrap" class="ft336">Sabelstrom,&#160;H.;&#160;Petri,&#160;R.;&#160;Shchors,&#160;K.;&#160;Jandial,&#160;R.;&#160;Schmidt,&#160;C.;&#160;Sacheva,&#160;R.;&#160;Masic,&#160;S.;&#160;Yuan,&#160;E.;&#160;Fenster,&#160;T.;&#160;Martinez,&#160;M.;&#160;et&#160;al.<br/>Driving&#160;Neuronal&#160;Differentiation&#160;through&#160;Reversal&#160;of&#160;an&#160;ERK1/2-miR-124-SOX9&#160;Axis&#160;Abrogates&#160;Glioblastoma&#160;Aggressiveness.</p>
<p style="position:absolute;top:286px;left:85px;white-space:nowrap" class="ft332">Cell&#160;Rep.&#160;<b>2019</b>,&#160;28,&#160;2064–2079.e11.&#160;<a href="http://doi.org/10.1016/j.celrep.2019.07.071">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/31433983">[PubMed]</a></p>
<p style="position:absolute;top:303px;left:54px;white-space:nowrap" class="ft332">96.</p>
<p style="position:absolute;top:303px;left:86px;white-space:nowrap" class="ft336">Yan,&#160;T.;&#160;Skaftnesmo,&#160;K.O.;&#160;Leiss,&#160;L.;&#160;Sleire,&#160;L.;&#160;Wang,&#160;J.;&#160;Li,&#160;X.;&#160;Enger,&#160;P.O.&#160;Neuronal&#160;markers&#160;are&#160;expressed&#160;in&#160;human&#160;gliomas<br/>and&#160;NSE&#160;knockdown&#160;sensitizes&#160;glioblastoma&#160;cells&#160;to&#160;radiotherapy&#160;and&#160;temozolomide.&#160;BMC&#160;Cancer&#160;<b>2011</b>,&#160;11,&#160;524.&#160;<a href="http://doi.org/10.1186/1471-2407-11-524">[CrossRef]<br/></a><a href="http://www.ncbi.nlm.nih.gov/pubmed/22185371">[PubMed]</a></p>
<p style="position:absolute;top:355px;left:54px;white-space:nowrap" class="ft332">97.</p>
<p style="position:absolute;top:355px;left:86px;white-space:nowrap" class="ft332">Yuan,&#160;A.;&#160;Rao,&#160;M.V.;&#160;Veeranna;&#160;Nixon,&#160;R.A.&#160;A.&#160;Neurofilaments&#160;and&#160;Neurofilament&#160;Proteins&#160;in&#160;Health&#160;and&#160;Disease.&#160;Cold&#160;Spring</p>
<p style="position:absolute;top:372px;left:85px;white-space:nowrap" class="ft332">Harb.&#160;Perspect.&#160;Biol.&#160;<b>2017</b>,&#160;9,&#160;a018309.&#160;<a href="http://doi.org/10.1101/cshperspect.a018309">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/28373358">[PubMed]</a></p>
<p style="position:absolute;top:389px;left:54px;white-space:nowrap" class="ft332">98.</p>
<p style="position:absolute;top:389px;left:86px;white-space:nowrap" class="ft336">Du,&#160;J.;&#160;Yi,&#160;M.;&#160;Zhou,&#160;F.;&#160;He,&#160;W.;&#160;Yang,&#160;A.;&#160;Qiu,&#160;M.;&#160;Huang,&#160;H.&#160;S100B&#160;is&#160;selectively&#160;expressed&#160;by&#160;gray&#160;matter&#160;protoplasmic&#160;astrocytes<br/>and&#160;myelinating&#160;oligodendrocytes&#160;in&#160;the&#160;developing&#160;CNS.&#160;Mol.&#160;Brain&#160;<b>2021</b>,&#160;14,&#160;154.&#160;<a href="http://doi.org/10.1186/s13041-021-00865-9">[CrossRef]</a></p>
<p style="position:absolute;top:424px;left:54px;white-space:nowrap" class="ft332">99.</p>
<p style="position:absolute;top:424px;left:86px;white-space:nowrap" class="ft336">Yang,&#160;Z.;&#160;Wang,&#160;K.K.&#160;Glial&#160;fibrillary&#160;acidic&#160;protein:&#160;From&#160;intermediate&#160;filament&#160;assembly&#160;and&#160;gliosis&#160;to&#160;neurobiomarker.&#160;Trends<br/>Neurosci.&#160;<b>2015</b>,&#160;38,&#160;364–374.&#160;<a href="http://doi.org/10.1016/j.tins.2015.04.003">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/25975510">[PubMed]</a></p>
<p style="position:absolute;top:458px;left:54px;white-space:nowrap" class="ft332">100.&#160;Landeira,&#160;B.S.;&#160;Santana,&#160;T.;&#160;Araujo,&#160;J.A.M.;&#160;Tabet,&#160;E.I.;&#160;Tannous,&#160;B.A.;&#160;Schroeder,&#160;T.;&#160;Costa,&#160;M.R.&#160;Activity-Independent&#160;Effects&#160;of</p>
<p style="position:absolute;top:476px;left:86px;white-space:nowrap" class="ft336">CREB&#160;on&#160;Neuronal&#160;Survival&#160;and&#160;Differentiation&#160;during&#160;Mouse&#160;Cerebral&#160;Cortex&#160;Development.&#160;Cereb.&#160;Cortex.&#160;<b>2018</b>,&#160;28,&#160;538–548.<br/><a href="http://doi.org/10.1093/cercor/bhw387">[CrossRef]</a></p>
<p style="position:absolute;top:510px;left:54px;white-space:nowrap" class="ft332">101.&#160;Li,&#160;Y.;&#160;Yin,&#160;W.;&#160;Wang,&#160;X.;&#160;Zhu,&#160;W.;&#160;Huang,&#160;Y.;&#160;Yan,&#160;G.&#160;Cholera&#160;toxin&#160;induces&#160;malignant&#160;glioma&#160;cell&#160;differentiation&#160;via&#160;the</p>
<p style="position:absolute;top:527px;left:86px;white-space:nowrap" class="ft332">PKA/CREB&#160;pathway.&#160;Proc.&#160;Natl.&#160;Acad.&#160;Sci.&#160;USA&#160;<b>2007</b>,&#160;104,&#160;13438–13443.&#160;<a href="http://doi.org/10.1073/pnas.0701990104">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/17679696">[PubMed]</a></p>
<p style="position:absolute;top:545px;left:54px;white-space:nowrap" class="ft332">102.&#160;Shiga,&#160;H.;&#160;Yamane,&#160;Y.;&#160;Kubo,&#160;M.;&#160;Sakurai,&#160;Y.;&#160;Asou,&#160;H.;&#160;Ito,&#160;E.&#160;Differentiation&#160;of&#160;immature&#160;oligodendrocytes&#160;is&#160;regulated&#160;by</p>
<p style="position:absolute;top:562px;left:85px;white-space:nowrap" class="ft332">phosphorylation&#160;of&#160;cyclic&#160;AMP-response&#160;element&#160;binding&#160;protein&#160;by&#160;a&#160;protein&#160;kinase&#160;C&#160;signaling&#160;cascade.&#160;J.&#160;Neurosci.&#160;Res.&#160;<b>2005</b>,</p>
<p style="position:absolute;top:579px;left:86px;white-space:nowrap" class="ft332">80,&#160;767–776.&#160;<a href="http://doi.org/10.1002/jnr.20513">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/15898102">[PubMed]</a></p>
<p style="position:absolute;top:596px;left:54px;white-space:nowrap" class="ft332">103.&#160;Bender,&#160;R.A.;&#160;Lauterborn,&#160;J.C.;&#160;Gall,&#160;C.M.;&#160;Cariaga,&#160;W.;&#160;Baram,&#160;T.Z.&#160;Enhanced&#160;CREB&#160;phosphorylation&#160;in&#160;immature&#160;dentate&#160;gyrus</p>
<p style="position:absolute;top:614px;left:86px;white-space:nowrap" class="ft336">granule&#160;cells&#160;precedes&#160;neurotrophin&#160;expression&#160;and&#160;indicates&#160;a&#160;specific&#160;role&#160;of&#160;CREB&#160;in&#160;granule&#160;cell&#160;differentiation.&#160;Eur.&#160;J.&#160;Neurosci.<br/><b>2001</b></p>
<p style="position:absolute;top:631px;left:113px;white-space:nowrap" class="ft332">,&#160;13,&#160;679–686.&#160;<a href="http://doi.org/10.1046/j.1460-9568.2001.01432.x">[CrossRef]</a></p>
<p style="position:absolute;top:648px;left:54px;white-space:nowrap" class="ft332">104.&#160;Hitomi,&#160;M.;&#160;Deleyrolle,&#160;L.P.;&#160;Mulkearns-Hubert,&#160;E.E.;&#160;Jarrar,&#160;A.;&#160;Li,&#160;M.;&#160;Sinyuk,&#160;M.;&#160;Otvos,&#160;B.;&#160;Brunet,&#160;S.;&#160;Flavahan,&#160;W.A.;&#160;Hubert,</p>
<p style="position:absolute;top:665px;left:86px;white-space:nowrap" class="ft336">C.G.;&#160;et&#160;al.&#160;Differential&#160;connexin&#160;function&#160;enhances&#160;self-renewal&#160;in&#160;glioblastoma.&#160;Cell&#160;Rep.&#160;<b>2015</b>,&#160;11,&#160;1031–1042.&#160;<a href="http://doi.org/10.1016/j.celrep.2015.04.021">[CrossRef]<br/></a><a href="http://www.ncbi.nlm.nih.gov/pubmed/25959821">[PubMed]</a></p>
<p style="position:absolute;top:700px;left:54px;white-space:nowrap" class="ft332">105.&#160;Lee,&#160;B.Y.;&#160;Han,&#160;J.A.;&#160;Im,&#160;J.S.;&#160;Morrone,&#160;A.;&#160;Johung,&#160;K.;&#160;Goodwin,&#160;E.C.;&#160;Kleijer,&#160;W.J.;&#160;DiMaio,&#160;D.;&#160;Hwang,&#160;E.S.&#160;Senescence-associated</p>
<p style="position:absolute;top:717px;left:86px;white-space:nowrap" class="ft332">beta-galactosidase&#160;is&#160;lysosomal&#160;beta-galactosidase.&#160;Aging&#160;Cell&#160;<b>2006</b>,&#160;5,&#160;187–195.&#160;<a href="http://doi.org/10.1111/j.1474-9726.2006.00199.x">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/16626397">[PubMed]</a></p>
<p style="position:absolute;top:734px;left:54px;white-space:nowrap" class="ft332">106.&#160;Tang,&#160;X.M.;&#160;Beesley,&#160;J.S.;&#160;Grinspan,&#160;J.B.;&#160;Seth,&#160;P.;&#160;Kamholz,&#160;J.;&#160;Cambi,&#160;F.&#160;Cell&#160;Cycle&#160;Arrest&#160;Induced&#160;by&#160;Ectopic&#160;Expression&#160;of&#160;p27&#160;Is</p>
<p style="position:absolute;top:752px;left:86px;white-space:nowrap" class="ft332">Not&#160;Sufficient&#160;to&#160;Promote&#160;Oligodendrocyte&#160;Differentiation.&#160;J.&#160;Cell.&#160;Biochem.&#160;<b>1999</b>,&#160;76,&#160;270–279.&#160;<a href="http://doi.org/10.1002/(SICI)1097-4644(20000201)76:2&lt;270::AID-JCB10&gt;3.0.CO;2-6">[CrossRef]</a></p>
<p style="position:absolute;top:769px;left:54px;white-space:nowrap" class="ft332">107.&#160;Schiappacassi,&#160;M.;&#160;Lovat,&#160;F.;&#160;Canzonieri,&#160;V.;&#160;Belletti,&#160;B.;&#160;Berton,&#160;S.;&#160;Di&#160;Stefano,&#160;D.;&#160;Vecchione,&#160;A.;&#160;Colombatti,&#160;A.;&#160;Baldassarre,</p>
<p style="position:absolute;top:786px;left:86px;white-space:nowrap" class="ft332">G.&#160;p27Kip1&#160;expression&#160;inhibits&#160;glioblastoma&#160;growth,&#160;invasion,&#160;and&#160;tumor-induced&#160;neoangiogenesis.&#160;Mol.&#160;Cancer&#160;Ther.&#160;<b>2008</b>,&#160;7,</p>
<p style="position:absolute;top:803px;left:85px;white-space:nowrap" class="ft332">1164–1175.&#160;<a href="http://doi.org/10.1158/1535-7163.MCT-07-2154">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/18483304">[PubMed]</a></p>
<p style="position:absolute;top:821px;left:54px;white-space:nowrap" class="ft332">108.&#160;Lloyd,&#160;R.V.;&#160;Erickson,&#160;L.A.;&#160;Jin,&#160;L.;&#160;Kulig,&#160;E.;&#160;Qian,&#160;X.;&#160;Cheville,&#160;J.C.;&#160;Scheithauer,&#160;B.W.&#160;p27kip1:&#160;A&#160;multifunctional&#160;cyclin-dependent</p>
<p style="position:absolute;top:838px;left:86px;white-space:nowrap" class="ft332">kinase&#160;inhibitor&#160;with&#160;prognostic&#160;significance&#160;in&#160;human&#160;cancers.&#160;Am.&#160;J.&#160;Pathol.&#160;<b>1999</b>,&#160;154,&#160;313–323.&#160;<a href="http://doi.org/10.1016/S0002-9440(10)65277-7">[CrossRef]</a></p>
<p style="position:absolute;top:855px;left:54px;white-space:nowrap" class="ft332">109.&#160;McKay,&#160;L.K.;&#160;White,&#160;J.P.&#160;The&#160;AMPK/p27(Kip1)&#160;Pathway&#160;as&#160;a&#160;Novel&#160;Target&#160;to&#160;Promote&#160;Autophagy&#160;and&#160;Resilience&#160;in&#160;Aged&#160;Cells.</p>
<p style="position:absolute;top:872px;left:85px;white-space:nowrap" class="ft332">Cells&#160;<b>2021</b>,&#160;10,&#160;1430.&#160;<a href="http://doi.org/10.3390/cells10061430">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/34201101">[PubMed]</a></p>
<p style="position:absolute;top:890px;left:54px;white-space:nowrap" class="ft336">110.&#160;Love,&#160;R.&#160;Cyclin&#160;D1&#160;and&#160;P27KIP1:&#160;The&#160;Gatekeepers&#160;of&#160;Dysplasia.&#160;J.&#160;Immunol.&#160;Sci.&#160;<b>2018</b>,&#160;2,&#160;30–39.&#160;<a href="http://doi.org/10.29245/2578-3009/2018/3.1142">[CrossRef]<br/></a>111.&#160;Collado,&#160;M.;&#160;Medema,&#160;R.H.;&#160;Garcia-Cao,&#160;I.;&#160;Dubuisson,&#160;M.L.;&#160;Barradas,&#160;M.;&#160;Glassford,&#160;J.;&#160;Rivas,&#160;C.;&#160;Burgering,&#160;B.M.;&#160;Serrano,&#160;M.;</p>
<p style="position:absolute;top:924px;left:86px;white-space:nowrap" class="ft332">Lam,&#160;E.W.&#160;Inhibition&#160;of&#160;the&#160;phosphoinositide&#160;3-kinase&#160;pathway&#160;induces&#160;a&#160;senescence-like&#160;arrest&#160;mediated&#160;by&#160;p27Kip1.&#160;J.&#160;Biol.</p>
<p style="position:absolute;top:941px;left:85px;white-space:nowrap" class="ft332">Chem.&#160;<b>2000</b>,&#160;275,&#160;21960–21968.&#160;<a href="http://doi.org/10.1074/jbc.M000759200">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/10791951">[PubMed]</a></p>
<p style="position:absolute;top:959px;left:54px;white-space:nowrap" class="ft332">112.&#160;Tsai,&#160;C.H.;&#160;Chang,&#160;C.Y.;&#160;Lin,&#160;B.Z.;&#160;Wu,&#160;Y.L.;&#160;Wu,&#160;M.H.;&#160;Lin,&#160;L.T.;&#160;Huang,&#160;W.C.;&#160;Holz,&#160;J.D.;&#160;Sheu,&#160;T.J.;&#160;Lee,&#160;J.S.;&#160;et&#160;al.&#160;Up-regulation&#160;of</p>
<p style="position:absolute;top:976px;left:86px;white-space:nowrap" class="ft336">cofilin-1&#160;in&#160;cell&#160;senescence&#160;associates&#160;with&#160;morphological&#160;change&#160;and&#160;p27(kip1)&#160;-mediated&#160;growth&#160;delay.&#160;Aging&#160;Cell&#160;<b>2021</b>,&#160;20,<br/>e13288.&#160;<a href="http://doi.org/10.1111/acel.13288">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/33336885">[PubMed]</a></p>
<p style="position:absolute;top:1011px;left:54px;white-space:nowrap" class="ft332">113.&#160;Kawamata,&#160;S.;&#160;Sakaida,&#160;H.;&#160;Hori,&#160;T.;&#160;Maeda,&#160;M.;&#160;Uchiyama,&#160;T.&#160;The&#160;upregulation&#160;of&#160;p27Kip1&#160;by&#160;rapamycin&#160;results&#160;in&#160;G1&#160;arrest&#160;in</p>
<p style="position:absolute;top:1028px;left:86px;white-space:nowrap" class="ft332">exponentially&#160;growing&#160;T-cell&#160;lines.&#160;Blood&#160;<b>1998</b>,&#160;91,&#160;561–569.&#160;<a href="http://doi.org/10.1182/blood.V91.2.561">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/9427710">[PubMed]</a></p>
<p style="position:absolute;top:1045px;left:54px;white-space:nowrap" class="ft332">114.&#160;O’Leary,&#160;L.A.;&#160;Davoli,&#160;M.A.;&#160;Belliveau,&#160;C.;&#160;Tanti,&#160;A.;&#160;Ma,&#160;J.C.;&#160;Farmer,&#160;W.T.;&#160;Turecki,&#160;G.;&#160;Murai,&#160;K.K.;&#160;Mechawar,&#160;N.&#160;Characterization</p>
<p style="position:absolute;top:1062px;left:86px;white-space:nowrap" class="ft332">of&#160;Vimentin-Immunoreactive&#160;Astrocytes&#160;in&#160;the&#160;Human&#160;Brain.&#160;Front.&#160;Neuroanat.&#160;<b>2020</b>,&#160;14,&#160;31.&#160;<a href="http://doi.org/10.3389/fnana.2020.00031">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/32848635">[PubMed]</a></p>
<p style="position:absolute;top:1080px;left:54px;white-space:nowrap" class="ft332">115.&#160;Deng,&#160;Z.;&#160;Du,&#160;W.W.;&#160;Fang,&#160;L.;&#160;Shan,&#160;S.W.;&#160;Qian,&#160;J.;&#160;Lin,&#160;J.;&#160;Qian,&#160;W.;&#160;Ma,&#160;J.;&#160;Rutnam,&#160;Z.J.;&#160;Yang,&#160;B.B.&#160;The&#160;intermediate&#160;filament</p>
<p style="position:absolute;top:1097px;left:85px;white-space:nowrap" class="ft336">vimentin&#160;mediates&#160;microRNA&#160;miR-378&#160;function&#160;in&#160;cellular&#160;self-renewal&#160;by&#160;regulating&#160;the&#160;expression&#160;of&#160;the&#160;Sox2&#160;transcription<br/>factor.&#160;J.&#160;Biol.&#160;Chem.&#160;<b>2013</b>,&#160;288,&#160;319–331.&#160;<a href="http://doi.org/10.1074/jbc.M112.418830">[CrossRef]</a></p>
<p style="position:absolute;top:1131px;left:54px;white-space:nowrap" class="ft332">116.&#160;Adams,&#160;D.S.;&#160;Levin,&#160;M.&#160;Measuring&#160;resting&#160;membrane&#160;potential&#160;using&#160;the&#160;fluorescent&#160;voltage&#160;reporters&#160;DiBAC4(3)&#160;and&#160;CC2-DMPE.</p>
<p style="position:absolute;top:1149px;left:85px;white-space:nowrap" class="ft332">Cold&#160;Spring&#160;Harb.&#160;Protoc.&#160;<b>2012</b>,&#160;2012,&#160;459–464.&#160;<a href="http://doi.org/10.1101/pdb.prot067702">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/22474652">[PubMed]</a></p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft340{font-size:9px;font-family:Times;color:#000000;}
	.ft341{font-size:9px;font-family:Times;color:#000000;}
	.ft342{font-size:11px;font-family:Times;color:#000000;}
	.ft343{font-size:11px;font-family:Times;color:#000000;}
	.ft344{font-size:11px;font-family:Times;color:#0775b7;}
	.ft345{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page34-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft340">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft340">34&#160;of&#160;36</p>
<p style="position:absolute;top:148px;left:54px;white-space:nowrap" class="ft342">117.&#160;Adams,&#160;D.S.;&#160;Levin,&#160;M.&#160;General&#160;principles&#160;for&#160;measuring&#160;resting&#160;membrane&#160;potential&#160;and&#160;ion&#160;concentration&#160;using&#160;fluorescent</p>
<p style="position:absolute;top:165px;left:86px;white-space:nowrap" class="ft342">bioelectricity&#160;reporters.&#160;Cold&#160;Spring&#160;Harb.&#160;Protoc.&#160;<b>2012</b>,&#160;2012,&#160;385–397.&#160;<a href="http://doi.org/10.1101/pdb.top067710">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/22474653">[PubMed]</a></p>
<p style="position:absolute;top:182px;left:54px;white-space:nowrap" class="ft342">118.&#160;Lu,&#160;Z.N.;&#160;Shi,&#160;Z.Y.;&#160;Dang,&#160;Y.F.;&#160;Cheng,&#160;Y.N.;&#160;Guan,&#160;Y.H.;&#160;Hao,&#160;Z.J.;&#160;Tian,&#160;B.;&#160;He,&#160;H.W.;&#160;Guo,&#160;X.L.&#160;Pantoprazole&#160;pretreatment&#160;elevates</p>
<p style="position:absolute;top:199px;left:86px;white-space:nowrap" class="ft345">sensitivity&#160;to&#160;vincristine&#160;in&#160;drug-resistant&#160;oral&#160;epidermoid&#160;carcinoma&#160;in&#160;vitro&#160;and&#160;in&#160;vivo.&#160;Biomed.&#160;Pharmacother.&#160;<b>2019</b>,&#160;120,&#160;109478.<br/><a href="http://doi.org/10.1016/j.biopha.2019.109478">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/31568987">[PubMed]</a></p>
<p style="position:absolute;top:234px;left:54px;white-space:nowrap" class="ft342">119.&#160;Liu,&#160;W.;&#160;Baker,&#160;S.S.;&#160;Trinidad,&#160;J.;&#160;Burlingame,&#160;A.L.;&#160;Baker,&#160;R.D.;&#160;Forte,&#160;J.G.;&#160;Virtuoso,&#160;L.P.;&#160;Egilmez,&#160;N.K.;&#160;Zhu,&#160;L.&#160;Inhibition&#160;of</p>
<p style="position:absolute;top:251px;left:86px;white-space:nowrap" class="ft342">lysosomal&#160;enzyme&#160;activities&#160;by&#160;proton&#160;pump&#160;inhibitors.&#160;J.&#160;Gastroenterol.&#160;<b>2013</b>,&#160;48,&#160;1343–1352.&#160;<a href="http://doi.org/10.1007/s00535-013-0774-5">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/23478938">[PubMed]</a></p>
<p style="position:absolute;top:268px;left:54px;white-space:nowrap" class="ft342">120.&#160;Cao,&#160;Y.;&#160;Chen,&#160;M.;&#160;Tang,&#160;D.H.;&#160;Yan,&#160;H.L.;&#160;Ding,&#160;X.W.;&#160;Zhou,&#160;F.;&#160;Zhang,&#160;M.M.;&#160;Xu,&#160;G.F.;&#160;Zhang,&#160;W.J.;&#160;Zhang,&#160;S.;&#160;et&#160;al.&#160;The&#160;proton</p>
<p style="position:absolute;top:286px;left:85px;white-space:nowrap" class="ft345">pump&#160;inhibitor&#160;pantoprazole&#160;disrupts&#160;protein&#160;degradation&#160;systems&#160;and&#160;sensitizes&#160;cancer&#160;cells&#160;to&#160;death&#160;under&#160;various&#160;stresses.<br/>Cell&#160;Death&#160;Dis.&#160;<b>2018</b>,&#160;9,&#160;604.&#160;<a href="http://doi.org/10.1038/s41419-018-0642-6">[CrossRef]</a></p>
<p style="position:absolute;top:320px;left:54px;white-space:nowrap" class="ft342">121.&#160;Lu,&#160;Z.N.;&#160;Niu,&#160;W.X.;&#160;Zhang,&#160;N.;&#160;Ge,&#160;M.X.;&#160;Bao,&#160;Y.Y.;&#160;Ren,&#160;Y.;&#160;Guo,&#160;X.L.;&#160;He,&#160;H.W.&#160;Pantoprazole&#160;ameliorates&#160;liver&#160;fibrosis&#160;and</p>
<p style="position:absolute;top:337px;left:86px;white-space:nowrap" class="ft342">suppresses&#160;hepatic&#160;stellate&#160;cell&#160;activation&#160;in&#160;bile&#160;duct&#160;ligation&#160;rats&#160;by&#160;promoting&#160;YAP&#160;degradation.&#160;Acta&#160;Pharmacol.&#160;Sin.&#160;<b>2021</b>,&#160;42,</p>
<p style="position:absolute;top:355px;left:85px;white-space:nowrap" class="ft342">1808–1820.&#160;<a href="http://doi.org/10.1038/s41401-021-00754-w">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/34465912">[PubMed]</a></p>
<p style="position:absolute;top:372px;left:54px;white-space:nowrap" class="ft342">122.&#160;He,&#160;J.;&#160;Shi,&#160;X.Y.;&#160;Li,&#160;Z.M.;&#160;Pan,&#160;X.H.;&#160;Li,&#160;Z.L.;&#160;Chen,&#160;Y.;&#160;Yan,&#160;S.J.;&#160;Xiao,&#160;L.&#160;Proton&#160;pump&#160;inhibitors&#160;can&#160;reverse&#160;the&#160;YAP&#160;mediated</p>
<p style="position:absolute;top:389px;left:85px;white-space:nowrap" class="ft342">paclitaxel&#160;resistance&#160;in&#160;epithelial&#160;ovarian&#160;cancer.&#160;BMC&#160;Mol.&#160;Cell&#160;Biol.&#160;<b>2019</b>,&#160;20,&#160;49.&#160;<a href="http://doi.org/10.1186/s12860-019-0227-y">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/31718559">[PubMed]</a></p>
<p style="position:absolute;top:407px;left:54px;white-space:nowrap" class="ft342">123.&#160;Lian,&#160;I.;&#160;Kim,&#160;J.;&#160;Okazawa,&#160;H.;&#160;Zhao,&#160;J.;&#160;Zhao,&#160;B.;&#160;Yu,&#160;J.;&#160;Chinnaiyan,&#160;A.;&#160;Israel,&#160;M.A.;&#160;Goldstein,&#160;L.S.;&#160;Abujarour,&#160;R.;&#160;et&#160;al.&#160;The</p>
<p style="position:absolute;top:424px;left:86px;white-space:nowrap" class="ft345">role&#160;of&#160;YAP&#160;transcription&#160;coactivator&#160;in&#160;regulating&#160;stem&#160;cell&#160;self-renewal&#160;and&#160;differentiation.&#160;Genes&#160;Dev.&#160;<b>2010</b>,&#160;24,&#160;1106–1118.<br/><a href="http://doi.org/10.1101/gad.1903310">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/20516196">[PubMed]</a></p>
<p style="position:absolute;top:458px;left:54px;white-space:nowrap" class="ft342">124.&#160;Zou,&#160;R.;&#160;Xu,&#160;Y.H.;&#160;Feng,&#160;Y.F.;&#160;Shen,&#160;M.Q.;&#160;Yuan,&#160;F.;&#160;Yuan,&#160;Y.Z.&#160;YAP&#160;nuclear-cytoplasmic&#160;translocation&#160;is&#160;regulated&#160;by&#160;mechanical</p>
<p style="position:absolute;top:476px;left:86px;white-space:nowrap" class="ft342">signaling,&#160;protein&#160;modification,&#160;and&#160;metabolism.&#160;Cell&#160;Biol.&#160;Int.&#160;<b>2020</b>,&#160;44,&#160;1416–1425.&#160;<a href="http://doi.org/10.1002/cbin.11345">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/32190949">[PubMed]</a></p>
<p style="position:absolute;top:493px;left:54px;white-space:nowrap" class="ft345">125.&#160;Zanconato,&#160;F.;&#160;Cordenonsi,&#160;M.;&#160;Piccolo,&#160;S.&#160;YAP/TAZ&#160;at&#160;the&#160;Roots&#160;of&#160;Cancer.&#160;Cancer&#160;Cell&#160;<b>2016</b>,&#160;29,&#160;783–803.&#160;<a href="http://doi.org/10.1016/j.ccell.2016.05.005">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/27300434">[PubMed]<br/></a>126.&#160;Markowska,&#160;A.;&#160;Kaysiewicz,&#160;J.;&#160;Markowska,&#160;J.;&#160;Huczynski,&#160;A.&#160;Doxycycline,&#160;salinomycin,&#160;monensin&#160;and&#160;ivermectin&#160;repositioned</p>
<p style="position:absolute;top:527px;left:86px;white-space:nowrap" class="ft342">as&#160;cancer&#160;drugs.&#160;Bioorg.&#160;Med.&#160;Chem.&#160;Lett.&#160;<b>2019</b>,&#160;29,&#160;1549–1554.&#160;<a href="http://doi.org/10.1016/j.bmcl.2019.04.045">[CrossRef]</a></p>
<p style="position:absolute;top:545px;left:54px;white-space:nowrap" class="ft342">127.&#160;Jiang,&#160;L.;&#160;Wang,&#160;P.;&#160;Sun,&#160;Y.J.;&#160;Wu,&#160;Y.J.&#160;Ivermectin&#160;reverses&#160;the&#160;drug&#160;resistance&#160;in&#160;cancer&#160;cells&#160;through&#160;EGFR/ERK/Akt/NF-kappaB</p>
<p style="position:absolute;top:562px;left:85px;white-space:nowrap" class="ft342">pathway.&#160;J.&#160;Exp.&#160;Clin.&#160;Cancer&#160;Res.&#160;<b>2019</b>,&#160;38,&#160;265.&#160;<a href="http://doi.org/10.1186/s13046-019-1251-7">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/31215501">[PubMed]</a></p>
<p style="position:absolute;top:579px;left:54px;white-space:nowrap" class="ft342">128.&#160;Intuyod,&#160;K.;&#160;Hahnvajanawong,&#160;C.;&#160;Pinlaor,&#160;P.;&#160;Pinlaor,&#160;S.&#160;Anti-parasitic&#160;Drug&#160;Ivermectin&#160;Exhibits&#160;Potent&#160;Anticancer&#160;Activity</p>
<p style="position:absolute;top:596px;left:86px;white-space:nowrap" class="ft342">against&#160;Gemcitabine-resistant&#160;Cholangiocarcinoma&#160;In&#160;Vitro.&#160;Anticancer&#160;Res.&#160;<b>2019</b>,&#160;39,&#160;4837–4843.&#160;<a href="http://doi.org/10.21873/anticanres.13669">[CrossRef]</a></p>
<p style="position:absolute;top:614px;left:54px;white-space:nowrap" class="ft342">129.&#160;Juarez,&#160;M.;&#160;Schcolnik-Cabrera,&#160;A.;&#160;Duenas-Gonzalez,&#160;A.&#160;The&#160;multitargeted&#160;drug&#160;ivermectin:&#160;From&#160;an&#160;antiparasitic&#160;agent&#160;to&#160;a</p>
<p style="position:absolute;top:631px;left:86px;white-space:nowrap" class="ft342">repositioned&#160;cancer&#160;drug.&#160;Am.&#160;J.&#160;Cancer&#160;Res.&#160;<b>2018</b>,&#160;8,&#160;317–331.</p>
<p style="position:absolute;top:648px;left:54px;white-space:nowrap" class="ft342">130.&#160;Gupta,&#160;P.B.;&#160;Onder,&#160;T.T.;&#160;Jiang,&#160;G.;&#160;Tao,&#160;K.;&#160;Kuperwasser,&#160;C.;&#160;Weinberg,&#160;R.A.;&#160;Lander,&#160;E.S.&#160;Identification&#160;of&#160;selective&#160;inhibitors&#160;of</p>
<p style="position:absolute;top:665px;left:86px;white-space:nowrap" class="ft342">cancer&#160;stem&#160;cells&#160;by&#160;high-throughput&#160;screening.&#160;Cell&#160;<b>2009</b>,&#160;138,&#160;645–659.&#160;<a href="http://doi.org/10.1016/j.cell.2009.06.034">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/19682730">[PubMed]</a></p>
<p style="position:absolute;top:683px;left:54px;white-space:nowrap" class="ft342">131.&#160;Fukushiro-Lopes,&#160;D.F.;&#160;Hegel,&#160;A.D.;&#160;Rao,&#160;V.;&#160;Wyatt,&#160;D.;&#160;Baker,&#160;A.;&#160;Breuer,&#160;E.K.;&#160;Osipo,&#160;C.;&#160;Zartman,&#160;J.J.;&#160;Burnette,&#160;M.;&#160;Kaja,&#160;S.;</p>
<p style="position:absolute;top:700px;left:86px;white-space:nowrap" class="ft345">et&#160;al.&#160;Preclinical&#160;study&#160;of&#160;a&#160;Kv11.1&#160;potassium&#160;channel&#160;activator&#160;as&#160;antineoplastic&#160;approach&#160;for&#160;breast&#160;cancer.&#160;Oncotarget&#160;<b>2018</b>,&#160;9,<br/>3321–3337.&#160;<a href="http://doi.org/10.18632/oncotarget.22925">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/29423049">[PubMed]</a></p>
<p style="position:absolute;top:734px;left:54px;white-space:nowrap" class="ft345">132.&#160;Gentile,&#160;S.&#160;hERG1&#160;potassium&#160;channel&#160;in&#160;cancer&#160;cells:&#160;A&#160;tool&#160;to&#160;reprogram&#160;immortality.&#160;Eur.&#160;Biophys.&#160;J.&#160;<b>2016</b>,&#160;45,&#160;649–655.&#160;<a href="http://doi.org/10.1007/s00249-016-1169-3">[CrossRef]<br/></a>133.&#160;Perez-Neut,&#160;M.;&#160;Shum,&#160;A.;&#160;Cuevas,&#160;B.D.;&#160;Miller,&#160;R.;&#160;Gentile,&#160;S.&#160;Stimulation&#160;of&#160;hERG1&#160;channel&#160;activity&#160;promotes&#160;a&#160;calcium-</p>
<p style="position:absolute;top:769px;left:86px;white-space:nowrap" class="ft342">dependent&#160;degradation&#160;of&#160;cyclin&#160;E2,&#160;but&#160;not&#160;cyclin&#160;E1,&#160;in&#160;breast&#160;cancer&#160;cells.&#160;Oncotarget&#160;<b>2015</b>,&#160;6,&#160;1631–1639.&#160;<a href="http://doi.org/10.18632/oncotarget.2829">[CrossRef]</a></p>
<p style="position:absolute;top:786px;left:54px;white-space:nowrap" class="ft342">134.&#160;Perez-Neut,&#160;M.;&#160;Rao,&#160;V.R.;&#160;Gentile,&#160;S.&#160;hERG1/Kv11.1&#160;activation&#160;stimulates&#160;transcription&#160;of&#160;p21waf/cip&#160;in&#160;breast&#160;cancer&#160;cells&#160;via&#160;a</p>
<p style="position:absolute;top:803px;left:86px;white-space:nowrap" class="ft342">calcineurin-dependent&#160;mechanism.&#160;Oncotarget&#160;<b>2015</b>,&#160;7,&#160;58893–58902.&#160;<a href="http://doi.org/10.18632/oncotarget.3797">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/25945833">[PubMed]</a></p>
<p style="position:absolute;top:821px;left:54px;white-space:nowrap" class="ft342">135.&#160;Spugnini,&#160;E.P.;&#160;Citro,&#160;G.;&#160;Fais,&#160;S.&#160;Proton&#160;pump&#160;inhibitors&#160;as&#160;anti&#160;vacuolar-ATPases&#160;drugs:&#160;A&#160;novel&#160;anticancer&#160;strategy.&#160;J.&#160;Exp.&#160;Clin.</p>
<p style="position:absolute;top:838px;left:85px;white-space:nowrap" class="ft342">Cancer&#160;Res.&#160;<b>2010</b>,&#160;29,&#160;44.&#160;<a href="http://doi.org/10.1186/1756-9966-29-44">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/20459683">[PubMed]</a></p>
<p style="position:absolute;top:855px;left:54px;white-space:nowrap" class="ft342">136.&#160;Kale,&#160;V.P.;&#160;Amin,&#160;S.G.;&#160;Pandey,&#160;M.K.&#160;Targeting&#160;ion&#160;channels&#160;for&#160;cancer&#160;therapy&#160;by&#160;repurposing&#160;the&#160;approved&#160;drugs.&#160;Biochim.</p>
<p style="position:absolute;top:872px;left:85px;white-space:nowrap" class="ft342">Biophys.&#160;Acta&#160;<b>2015</b>,&#160;1848&#160;Pt&#160;B,&#160;2747–2755.&#160;<a href="http://doi.org/10.1016/j.bbamem.2015.03.034">[CrossRef]</a></p>
<p style="position:absolute;top:890px;left:54px;white-space:nowrap" class="ft342">137.&#160;Villalonga,&#160;N.;&#160;Ferreres,&#160;J.C.;&#160;Argiles,&#160;J.M.;&#160;Condom,&#160;E.;&#160;Felipe,&#160;A.&#160;Potassium&#160;channels&#160;are&#160;a&#160;new&#160;target&#160;field&#160;in&#160;anticancer&#160;drug</p>
<p style="position:absolute;top:907px;left:86px;white-space:nowrap" class="ft342">design.&#160;Recent&#160;Pat.&#160;Anti-Cancer&#160;Drug&#160;Discov.&#160;<b>2007</b>,&#160;2,&#160;212–223.&#160;<a href="http://doi.org/10.2174/157489207782497181">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/18221064">[PubMed]</a></p>
<p style="position:absolute;top:924px;left:54px;white-space:nowrap" class="ft342">138.&#160;Becchetti,&#160;A.&#160;Ion&#160;channels&#160;and&#160;transporters&#160;in&#160;cancer.&#160;1.&#160;Ion&#160;channels&#160;and&#160;cell&#160;proliferation&#160;in&#160;cancer.&#160;Am.&#160;J.&#160;Physiol.&#160;Cell&#160;Physiol.</p>
<p style="position:absolute;top:942px;left:86px;white-space:nowrap" class="ft343"><b>2011</b></p>
<p style="position:absolute;top:942px;left:113px;white-space:nowrap" class="ft342">,&#160;301,&#160;C255–C265.&#160;<a href="http://doi.org/10.1152/ajpcell.00047.2011">[CrossRef]</a></p>
<p style="position:absolute;top:959px;left:54px;white-space:nowrap" class="ft342">139.&#160;Arcangeli,&#160;A.;&#160;Crociani,&#160;O.;&#160;Lastraioli,&#160;E.;&#160;Masi,&#160;A.;&#160;Pillozzi,&#160;S.;&#160;Becchetti,&#160;A.&#160;Targeting&#160;ion&#160;channels&#160;in&#160;cancer:&#160;A&#160;novel&#160;frontier&#160;in</p>
<p style="position:absolute;top:976px;left:86px;white-space:nowrap" class="ft342">antineoplastic&#160;therapy.&#160;Curr.&#160;Med.&#160;Chem.&#160;<b>2009</b>,&#160;16,&#160;66–93.&#160;<a href="http://doi.org/10.2174/092986709787002835">[CrossRef]</a></p>
<p style="position:absolute;top:993px;left:54px;white-space:nowrap" class="ft342">140.&#160;Churchill,&#160;C.D.M.;&#160;Winter,&#160;P.;&#160;Tuszynski,&#160;J.A.;&#160;Levin,&#160;M.&#160;EDEn—Electroceutical&#160;Design&#160;Environment:&#160;An&#160;Ion&#160;Channel&#160;Database</p>
<p style="position:absolute;top:1011px;left:85px;white-space:nowrap" class="ft342">with&#160;Small&#160;Molecule&#160;Modulators&#160;and&#160;Tissue&#160;Expression&#160;Information.&#160;iScience&#160;<b>2018</b>,&#160;11,&#160;42–56.&#160;<a href="http://doi.org/10.1016/j.isci.2018.12.003">[CrossRef]</a></p>
<p style="position:absolute;top:1028px;left:54px;white-space:nowrap" class="ft342">141.&#160;Tuszynski,&#160;J.;&#160;Tilli,&#160;T.M.;&#160;Levin,&#160;M.&#160;Ion&#160;Channel&#160;and&#160;Neurotransmitter&#160;Modulators&#160;as&#160;Electroceutical&#160;Approaches&#160;to&#160;the&#160;Control&#160;of</p>
<p style="position:absolute;top:1045px;left:86px;white-space:nowrap" class="ft342">Cancer.&#160;Curr.&#160;Pharm.&#160;Des.&#160;<b>2017</b>,&#160;23,&#160;4827–4841.&#160;<a href="http://doi.org/10.2174/1381612823666170530105837">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/28554310">[PubMed]</a></p>
<p style="position:absolute;top:1062px;left:54px;white-space:nowrap" class="ft342">142.&#160;Pai,&#160;V.P.;&#160;Cervera,&#160;J.;&#160;Mafe,&#160;S.;&#160;Willocq,&#160;V.;&#160;Lederer,&#160;E.K.;&#160;Levin,&#160;M.&#160;HCN2&#160;Channel-Induced&#160;Rescue&#160;of&#160;Brain&#160;Teratogenesis&#160;via</p>
<p style="position:absolute;top:1080px;left:86px;white-space:nowrap" class="ft342">Local&#160;and&#160;Long-Range&#160;Bioelectric&#160;Repair.&#160;Front.&#160;Cell.&#160;Neurosci.&#160;<b>2020</b>,&#160;14,&#160;136.&#160;<a href="http://doi.org/10.3389/fncel.2020.00136">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/32528251">[PubMed]</a></p>
<p style="position:absolute;top:1097px;left:54px;white-space:nowrap" class="ft342">143.&#160;Pai,&#160;V.P.;&#160;Pietak,&#160;A.;&#160;Willocq,&#160;V.;&#160;Ye,&#160;B.;&#160;Shi,&#160;N.Q.;&#160;Levin,&#160;M.&#160;HCN2&#160;Rescues&#160;brain&#160;defects&#160;by&#160;enforcing&#160;endogenous&#160;voltage</p>
<p style="position:absolute;top:1114px;left:85px;white-space:nowrap" class="ft342">pre-patterns.&#160;Nat.&#160;Commun.&#160;<b>2018</b>,&#160;9,&#160;998.&#160;<a href="http://doi.org/10.1038/s41467-018-03334-5">[CrossRef]</a></p>
<p style="position:absolute;top:1131px;left:54px;white-space:nowrap" class="ft342">144.&#160;Levin,&#160;M.&#160;Bioelectrical&#160;approaches&#160;to&#160;cancer&#160;as&#160;a&#160;problem&#160;of&#160;the&#160;scaling&#160;of&#160;the&#160;cellular&#160;self.&#160;Prog.&#160;Biophys.&#160;Mol.&#160;Biol.&#160;<b>2021</b>,&#160;165,</p>
<p style="position:absolute;top:1149px;left:85px;white-space:nowrap" class="ft342">102–113.&#160;<a href="http://doi.org/10.1016/j.pbiomolbio.2021.04.007">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/33961843">[PubMed]</a></p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft350{font-size:9px;font-family:Times;color:#000000;}
	.ft351{font-size:9px;font-family:Times;color:#000000;}
	.ft352{font-size:11px;font-family:Times;color:#000000;}
	.ft353{font-size:11px;font-family:Times;color:#000000;}
	.ft354{font-size:11px;font-family:Times;color:#0775b7;}
	.ft355{font-size:12px;font-family:Times;color:#000000;}
	.ft356{font-size:8px;font-family:Times;color:#000000;}
	.ft357{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page35-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft350">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft350">35&#160;of&#160;36</p>
<p style="position:absolute;top:148px;left:54px;white-space:nowrap" class="ft352">145.&#160;Tojima,&#160;T.;&#160;Yamane,&#160;Y.;&#160;Takahashi,&#160;M.;&#160;Ito,&#160;E.&#160;Acquisition&#160;of&#160;neuronal&#160;proteins&#160;during&#160;differentiation&#160;of&#160;NG108-15&#160;cells.&#160;Neurosci.</p>
<p style="position:absolute;top:165px;left:85px;white-space:nowrap" class="ft352">Res.&#160;<b>2000</b>,&#160;37,&#160;153–161.&#160;<a href="http://doi.org/10.1016/S0168-0102(00)00110-3">[CrossRef]</a></p>
<p style="position:absolute;top:182px;left:54px;white-space:nowrap" class="ft352">146.&#160;Seidman,&#160;K.J.;&#160;Barsuk,&#160;J.H.;&#160;Johnson,&#160;R.F.;&#160;Weyhenmeyer,&#160;J.A.&#160;Differentiation&#160;of&#160;NG108-15&#160;neuroblastoma&#160;cells&#160;by&#160;serum</p>
<p style="position:absolute;top:199px;left:86px;white-space:nowrap" class="ft357">starvation&#160;or&#160;dimethyl&#160;sulfoxide&#160;results&#160;in&#160;marked&#160;differences&#160;in&#160;angiotensin&#160;II&#160;receptor&#160;subtype&#160;expression.&#160;J.&#160;Neurochem.&#160;<b>1996</b>,<br/>66,&#160;1011–1018.&#160;<a href="http://doi.org/10.1046/j.1471-4159.1996.66031011.x">[CrossRef]</a></p>
<p style="position:absolute;top:234px;left:54px;white-space:nowrap" class="ft352">147.&#160;Ma,&#160;W.;&#160;Pancrazio,&#160;J.J.;&#160;Coulombe,&#160;M.;&#160;Dumm,&#160;J.;&#160;Sathanoori,&#160;R.;&#160;Barker,&#160;J.L.;&#160;Kowtha,&#160;V.C.;&#160;Stenger,&#160;D.A.;&#160;Hickman,&#160;J.J.</p>
<p style="position:absolute;top:251px;left:86px;white-space:nowrap" class="ft357">Neuronal&#160;and&#160;glial&#160;epitopes&#160;and&#160;transmitter-synthesizing&#160;enzymes&#160;appear&#160;in&#160;parallel&#160;with&#160;membrane&#160;excitability&#160;during<br/>neuroblastoma×glioma&#160;hybrid&#160;differentiation.&#160;Dev.&#160;Brain&#160;Res.&#160;<b>1998</b>,&#160;106,&#160;155–163.&#160;<a href="http://doi.org/10.1016/S0165-3806(97)00208-3">[CrossRef]</a></p>
<p style="position:absolute;top:286px;left:54px;white-space:nowrap" class="ft357">148.&#160;Nurse,&#160;P.&#160;A&#160;long&#160;twentieth&#160;century&#160;of&#160;the&#160;cell&#160;cycle&#160;and&#160;beyond.&#160;Cell&#160;<b>2000</b>,&#160;100,&#160;71–78.&#160;<a href="http://doi.org/10.1016/S0092-8674(00)81684-0">[CrossRef]<br/></a>149.&#160;Rieske,&#160;P.;&#160;Golanska,&#160;E.;&#160;Zakrzewska,&#160;M.;&#160;Piaskowski,&#160;S.;&#160;Hulas-Bigoszewska,&#160;K.;&#160;Wolanczyk,&#160;M.;&#160;Szybka,&#160;M.;&#160;Witusik-Perkowska,</p>
<p style="position:absolute;top:320px;left:86px;white-space:nowrap" class="ft357">M.;&#160;Jaskolski,&#160;D.J.;&#160;Zakrzewski,&#160;K.;&#160;et&#160;al.&#160;Arrested&#160;neural&#160;and&#160;advanced&#160;mesenchymal&#160;differentiation&#160;of&#160;glioblastoma&#160;cells-<br/>comparative&#160;study&#160;with&#160;neural&#160;progenitors.&#160;BMC&#160;Cancer&#160;<b>2009</b>,&#160;9,&#160;54.&#160;<a href="http://doi.org/10.1186/1471-2407-9-54">[CrossRef]</a></p>
<p style="position:absolute;top:355px;left:54px;white-space:nowrap" class="ft352">150.&#160;Wolanczyk,&#160;M.;&#160;Hulas-Bigoszewska,&#160;K.;&#160;Witusik-Perkowska,&#160;M.;&#160;Papierz,&#160;W.;&#160;Jaskolski,&#160;D.;&#160;Liberski,&#160;P.P.;&#160;Rieske,&#160;P.&#160;Imperfect</p>
<p style="position:absolute;top:372px;left:86px;white-space:nowrap" class="ft352">oligodendrocytic&#160;and&#160;neuronal&#160;differentiation&#160;of&#160;glioblastoma&#160;cells.&#160;Folia&#160;Neuropathol.&#160;<b>2010</b>,&#160;48,&#160;27–34.&#160;<a href="http://www.ncbi.nlm.nih.gov/pubmed/20383808">[PubMed]</a></p>
<p style="position:absolute;top:389px;left:54px;white-space:nowrap" class="ft352">151.&#160;Zhou,&#160;X.;&#160;Song,&#160;M.;&#160;Chen,&#160;D.;&#160;Wei,&#160;L.;&#160;Yu,&#160;S.P.&#160;Potential&#160;role&#160;of&#160;KCNQ/M-channels&#160;in&#160;regulating&#160;neuronal&#160;differentiation&#160;in&#160;mouse</p>
<p style="position:absolute;top:407px;left:86px;white-space:nowrap" class="ft352">hippocampal&#160;and&#160;embryonic&#160;stem&#160;cell-derived&#160;neuronal&#160;cultures.&#160;Exp.&#160;Neurol.&#160;<b>2011</b>,&#160;229,&#160;471–483.&#160;<a href="http://doi.org/10.1016/j.expneurol.2011.03.018">[CrossRef]</a></p>
<p style="position:absolute;top:424px;left:54px;white-space:nowrap" class="ft352">152.&#160;Bilet,&#160;A.;&#160;Bauer,&#160;C.K.&#160;Effects&#160;of&#160;the&#160;small&#160;molecule&#160;HERG&#160;activator&#160;NS1643&#160;on&#160;Kv11.3&#160;channels.&#160;PLoS&#160;ONE&#160;<b>2012</b>,&#160;7,&#160;e50886.</p>
<p style="position:absolute;top:441px;left:86px;white-space:nowrap" class="ft352"><a href="http://doi.org/10.1371/journal.pone.0050886">[CrossRef]</a></p>
<p style="position:absolute;top:458px;left:54px;white-space:nowrap" class="ft352">153.&#160;Zanconato,&#160;F.;&#160;Cordenonsi,&#160;M.;&#160;Piccolo,&#160;S.&#160;YAP&#160;and&#160;TAZ:&#160;A&#160;signalling&#160;hub&#160;of&#160;the&#160;tumour&#160;microenvironment.&#160;Nat.&#160;Rev.&#160;Cancer</p>
<p style="position:absolute;top:476px;left:86px;white-space:nowrap" class="ft353"><b>2019</b></p>
<p style="position:absolute;top:476px;left:113px;white-space:nowrap" class="ft352">,&#160;19,&#160;454–464.&#160;<a href="http://doi.org/10.1038/s41568-019-0168-y">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/31270418">[PubMed]</a></p>
<p style="position:absolute;top:493px;left:54px;white-space:nowrap" class="ft352">154.&#160;Xie,&#160;Q.;&#160;Chen,&#160;J.;&#160;Feng,&#160;H.;&#160;Peng,&#160;S.;&#160;Adams,&#160;U.;&#160;Bai,&#160;Y.;&#160;Huang,&#160;L.;&#160;Li,&#160;J.;&#160;Huang,&#160;J.;&#160;Meng,&#160;S.;&#160;et&#160;al.&#160;YAP/TEAD-mediated</p>
<p style="position:absolute;top:510px;left:86px;white-space:nowrap" class="ft352">transcription&#160;controls&#160;cellular&#160;senescence.&#160;Cancer&#160;Res.&#160;<b>2013</b>,&#160;73,&#160;3615–3624.&#160;<a href="http://doi.org/10.1158/0008-5472.CAN-12-3793">[CrossRef]</a></p>
<p style="position:absolute;top:527px;left:54px;white-space:nowrap" class="ft352">155.&#160;Wolff,&#160;C.;&#160;Fuks,&#160;B.;&#160;Chatelain,&#160;P.&#160;Comparative&#160;study&#160;of&#160;membrane&#160;potential-sensitive&#160;fluorescent&#160;probes&#160;and&#160;their&#160;use&#160;in&#160;ion</p>
<p style="position:absolute;top:545px;left:86px;white-space:nowrap" class="ft352">channel&#160;screening&#160;assays.&#160;J.&#160;Biomol.&#160;Screen.&#160;<b>2003</b>,&#160;8,&#160;533–543.&#160;<a href="http://doi.org/10.1177/1087057103257806">[CrossRef]</a></p>
<p style="position:absolute;top:562px;left:54px;white-space:nowrap" class="ft352">156.&#160;Yamada,&#160;A.;&#160;Gaja,&#160;N.;&#160;Ohya,&#160;S.;&#160;Muraki,&#160;K.;&#160;Narita,&#160;H.;&#160;Ohwada,&#160;T.;&#160;Imaizumi,&#160;Y.&#160;Usefulness&#160;and&#160;limitation&#160;of&#160;DiBAC4(3),&#160;a</p>
<p style="position:absolute;top:579px;left:85px;white-space:nowrap" class="ft357">voltage-sensitive&#160;fluorescent&#160;dye,&#160;for&#160;the&#160;measurement&#160;of&#160;membrane&#160;potentials&#160;regulated&#160;by&#160;recombinant&#160;large&#160;conductance<br/>Ca2+-activated&#160;K+&#160;channels&#160;in&#160;HEK293&#160;cells.&#160;Jpn.&#160;J.&#160;Pharmacol.&#160;<b>2001</b>,&#160;86,&#160;342–350.&#160;<a href="http://doi.org/10.1254/jjp.86.342">[CrossRef]</a></p>
<p style="position:absolute;top:614px;left:54px;white-space:nowrap" class="ft352">157.&#160;Perez-Neut,&#160;M.;&#160;Haar,&#160;L.;&#160;Rao,&#160;V.;&#160;Santha,&#160;S.;&#160;Lansu,&#160;K.;&#160;Rana,&#160;B.;&#160;Jones,&#160;W.K.;&#160;Gentile,&#160;S.&#160;Activation&#160;of&#160;hERG3&#160;channel&#160;stimulates</p>
<p style="position:absolute;top:631px;left:86px;white-space:nowrap" class="ft352">autophagy&#160;and&#160;promotes&#160;cellular&#160;senescence&#160;in&#160;melanoma.&#160;Oncotarget&#160;<b>2016</b>,&#160;7,&#160;21991–22004.&#160;<a href="http://doi.org/10.18632/oncotarget.7831">[CrossRef]</a></p>
<p style="position:absolute;top:648px;left:54px;white-space:nowrap" class="ft352">158.&#160;Santini,&#160;M.P.;&#160;Talora,&#160;C.;&#160;Seki,&#160;T.;&#160;Bolgan,&#160;L.;&#160;Dotto,&#160;G.P.&#160;Cross&#160;talk&#160;among&#160;calcineurin,&#160;Sp1/Sp3,&#160;and&#160;NFAT&#160;in&#160;control&#160;of</p>
<p style="position:absolute;top:665px;left:85px;white-space:nowrap" class="ft352">p21(WAF1/CIP1)&#160;expression&#160;in&#160;keratinocyte&#160;differentiation.&#160;Proc.&#160;Natl.&#160;Acad.&#160;Sci.&#160;USA&#160;<b>2001</b>,&#160;98,&#160;9575–9580.&#160;<a href="http://doi.org/10.1073/pnas.161299698">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/11493684">[PubMed]</a></p>
<p style="position:absolute;top:683px;left:54px;white-space:nowrap" class="ft352">159.&#160;Moon,&#160;J.H.;&#160;Hong,&#160;J.M.;&#160;Park,&#160;S.Y.&#160;Calcineurin&#160;Activation&#160;by&#160;Prion&#160;Protein&#160;Induces&#160;Neurotoxicity&#160;via&#160;Mitochondrial&#160;Reactive</p>
<p style="position:absolute;top:700px;left:86px;white-space:nowrap" class="ft352">Oxygen&#160;Species.&#160;Oxidative&#160;Med.&#160;Cell.&#160;Longev.&#160;<b>2021</b>,&#160;2021,&#160;5572129.&#160;<a href="http://doi.org/10.1155/2021/5572129">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/34394828">[PubMed]</a></p>
<p style="position:absolute;top:717px;left:54px;white-space:nowrap" class="ft352">160.&#160;Livnat-Levanon,&#160;N.;&#160;Kevei,&#160;E.;&#160;Kleifeld,&#160;O.;&#160;Krutauz,&#160;D.;&#160;Segref,&#160;A.;&#160;Rinaldi,&#160;T.;&#160;Erpapazoglou,&#160;Z.;&#160;Cohen,&#160;M.;&#160;Reis,&#160;N.;&#160;Hoppe,&#160;T.;</p>
<p style="position:absolute;top:734px;left:86px;white-space:nowrap" class="ft352">et&#160;al.&#160;Reversible&#160;26S&#160;proteasome&#160;disassembly&#160;upon&#160;mitochondrial&#160;stress.&#160;Cell&#160;Rep.&#160;<b>2014</b>,&#160;7,&#160;1371–1380.&#160;<a href="http://doi.org/10.1016/j.celrep.2014.04.030">[CrossRef]</a></p>
<p style="position:absolute;top:752px;left:54px;white-space:nowrap" class="ft352">161.&#160;Kudo,&#160;Y.;&#160;Takata,&#160;T.;&#160;Ogawa,&#160;I.;&#160;Kaneda,&#160;T.;&#160;Sato,&#160;S.;&#160;Takekoshi,&#160;T.;&#160;Zhao,&#160;M.;&#160;Miyauchi,&#160;M.;&#160;Nikai,&#160;H.&#160;p27Kip1&#160;accumulation&#160;by</p>
<p style="position:absolute;top:769px;left:86px;white-space:nowrap" class="ft357">inhibition&#160;of&#160;proteasome&#160;function&#160;induces&#160;apoptosis&#160;in&#160;oral&#160;squamous&#160;cell&#160;carcinoma&#160;cells.&#160;Clin.&#160;Cancer&#160;Res.&#160;<b>2000</b>,&#160;6,&#160;916–923.<br/><a href="http://www.ncbi.nlm.nih.gov/pubmed/10741716">[PubMed]</a></p>
<p style="position:absolute;top:803px;left:54px;white-space:nowrap" class="ft352">162.&#160;Kossatz,&#160;U.;&#160;Dietrich,&#160;N.;&#160;Zender,&#160;L.;&#160;Buer,&#160;J.;&#160;Manns,&#160;M.P.;&#160;Malek,&#160;N.P.&#160;Skp2-dependent&#160;degradation&#160;of&#160;p27kip1&#160;is&#160;essential&#160;for&#160;cell</p>
<p style="position:absolute;top:821px;left:86px;white-space:nowrap" class="ft352">cycle&#160;progression.&#160;Gene&#160;Dev.&#160;<b>2004</b>,&#160;18,&#160;2602–2607.&#160;<a href="http://doi.org/10.1101/gad.321004">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/15520280">[PubMed]</a></p>
<p style="position:absolute;top:838px;left:54px;white-space:nowrap" class="ft352">163.&#160;Lee,&#160;J.J.;&#160;Kim,&#160;B.C.;&#160;Park,&#160;M.J.;&#160;Lee,&#160;Y.S.;&#160;Kim,&#160;Y.N.;&#160;Lee,&#160;B.L.;&#160;Lee,&#160;J.S.&#160;PTEN&#160;status&#160;switches&#160;cell&#160;fate&#160;between&#160;premature&#160;senescence</p>
<p style="position:absolute;top:855px;left:86px;white-space:nowrap" class="ft352">and&#160;apoptosis&#160;in&#160;glioma&#160;exposed&#160;to&#160;ionizing&#160;radiation.&#160;Cell&#160;Death&#160;Differ.&#160;<b>2011</b>,&#160;18,&#160;666–677.&#160;<a href="http://doi.org/10.1038/cdd.2010.139">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/21072054">[PubMed]</a></p>
<p style="position:absolute;top:873px;left:54px;white-space:nowrap" class="ft352">164.&#160;Tompson,&#160;D.J.;&#160;Crean,&#160;C.S.;&#160;Reeve,&#160;R.;&#160;Berry,&#160;N.S.&#160;Efficacy&#160;and&#160;tolerability&#160;exposure-response&#160;relationship&#160;of&#160;retigabine&#160;(ezogabine)</p>
<p style="position:absolute;top:890px;left:86px;white-space:nowrap" class="ft352">immediate-release&#160;tablets&#160;in&#160;patients&#160;with&#160;partial-onset&#160;seizures.&#160;Clin.&#160;Ther.&#160;<b>2013</b>,&#160;35,&#160;1174–1185.e4.&#160;<a href="http://doi.org/10.1016/j.clinthera.2013.06.012">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/23916044">[PubMed]</a></p>
<p style="position:absolute;top:907px;left:54px;white-space:nowrap" class="ft352">165.&#160;Large,&#160;C.H.;&#160;Sokal,&#160;D.M.;&#160;Nehlig,&#160;A.;&#160;Gunthorpe,&#160;M.J.;&#160;Sankar,&#160;R.;&#160;Crean,&#160;C.S.;&#160;Vanlandingham,&#160;K.E.;&#160;White,&#160;H.S.&#160;The&#160;spectrum</p>
<p style="position:absolute;top:924px;left:86px;white-space:nowrap" class="ft357">of&#160;anticonvulsant&#160;efficacy&#160;of&#160;retigabine&#160;(ezogabine)&#160;in&#160;animal&#160;models:&#160;Implications&#160;for&#160;clinical&#160;use.&#160;Epilepsia&#160;<b>2012</b>,&#160;53,&#160;425–436.<br/><a href="http://doi.org/10.1111/j.1528-1167.2011.03364.x">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/22221318">[PubMed]</a></p>
<p style="position:absolute;top:959px;left:54px;white-space:nowrap" class="ft352">166.&#160;Myatt,&#160;D.P.&#160;The&#160;correlation&#160;of&#160;plasma&#160;proteins&#160;binding&#160;capacity&#160;and&#160;flavopiridol&#160;cellular&#160;and&#160;clinical&#160;trial&#160;studies.&#160;Biomed.</p>
<p style="position:absolute;top:976px;left:85px;white-space:nowrap" class="ft352">Spectrosc.&#160;Imaging&#160;<b>2017</b>,&#160;6,&#160;59–73.&#160;<a href="http://doi.org/10.3233/BSI-170165">[CrossRef]</a></p>
<p style="position:absolute;top:993px;left:54px;white-space:nowrap" class="ft352">167.&#160;Basa-Denes,&#160;O.;&#160;Angi,&#160;R.;&#160;Karpati,&#160;B.;&#160;Jordan,&#160;T.;&#160;Otvos,&#160;Z.;&#160;Erdosi,&#160;N.;&#160;Ujhelyi,&#160;A.;&#160;Ordasi,&#160;B.;&#160;Molnar,&#160;L.;&#160;McDermott,&#160;J.;&#160;et&#160;al.</p>
<p style="position:absolute;top:1011px;left:86px;white-space:nowrap" class="ft352">Dose&#160;Escalation&#160;Study&#160;to&#160;Assess&#160;the&#160;Pharmacokinetic&#160;Parameters&#160;of&#160;a&#160;Nano-amorphous&#160;Oral&#160;Sirolimus&#160;Formulation&#160;in&#160;Healthy</p>
<p style="position:absolute;top:1028px;left:85px;white-space:nowrap" class="ft352">Volunteers.&#160;Eur.&#160;J.&#160;Drug&#160;Metab.&#160;Pharmacokinet.&#160;<b>2019</b>,&#160;44,&#160;777–785.&#160;<a href="http://doi.org/10.1007/s13318-019-00562-y">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/31089971">[PubMed]</a></p>
<p style="position:absolute;top:1045px;left:54px;white-space:nowrap" class="ft352">168.&#160;Cloughesy,&#160;T.F.;&#160;Yoshimoto,&#160;K.;&#160;Nghiemphu,&#160;P.;&#160;Brown,&#160;K.;&#160;Dang,&#160;J.;&#160;Zhu,&#160;S.;&#160;Hsueh,&#160;T.;&#160;Chen,&#160;Y.;&#160;Wang,&#160;W.;&#160;Youngkin,&#160;D.;&#160;et&#160;al.</p>
<p style="position:absolute;top:1062px;left:85px;white-space:nowrap" class="ft352">Antitumor&#160;activity&#160;of&#160;rapamycin&#160;in&#160;a&#160;Phase&#160;I&#160;trial&#160;for&#160;patients&#160;with&#160;recurrent&#160;PTEN-deficient&#160;glioblastoma.&#160;PLoS&#160;Med.&#160;<b>2008</b>,&#160;5,&#160;e8.</p>
<p style="position:absolute;top:1080px;left:86px;white-space:nowrap" class="ft352"><a href="http://doi.org/10.1371/journal.pmed.0050008">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/18215105">[PubMed]</a></p>
<p style="position:absolute;top:1097px;left:54px;white-space:nowrap" class="ft352">169.&#160;Cheer,&#160;S.M.;&#160;Prakash,&#160;A.;&#160;Faulds,&#160;D.;&#160;Lamb,&#160;H.M.&#160;Pantoprazole:&#160;An&#160;update&#160;of&#160;its&#160;pharmacological&#160;properties&#160;and&#160;therapeutic&#160;use</p>
<p style="position:absolute;top:1114px;left:86px;white-space:nowrap" class="ft352">in&#160;the&#160;management&#160;of&#160;acid-related&#160;disorders.&#160;Drugs&#160;<b>2003</b>,&#160;63,&#160;101–133.&#160;<a href="http://doi.org/10.2165/00003495-200363010-00006">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/12487624">[PubMed]</a></p>
</div>
</body>
</html>
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>18c018a9e0aa0e8c5cdc2d633e07fa8f-html.html</title>

<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
 <br/>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft360{font-size:9px;font-family:Times;color:#000000;}
	.ft361{font-size:9px;font-family:Times;color:#000000;}
	.ft362{font-size:11px;font-family:Times;color:#000000;}
	.ft363{font-size:11px;font-family:Times;color:#000000;}
	.ft364{font-size:11px;font-family:Times;color:#0775b7;}
	.ft365{font-size:8px;font-family:Times;color:#000000;}
	.ft366{font-size:11px;line-height:17px;font-family:Times;color:#000000;}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<div id="page36-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:86px;left:53px;white-space:nowrap" class="ft360">Cancers&#160;<b>2022</b>,&#160;14,&#160;1499</p>
<p style="position:absolute;top:86px;left:799px;white-space:nowrap" class="ft360">36&#160;of&#160;36</p>
<p style="position:absolute;top:148px;left:54px;white-space:nowrap" class="ft362">170.&#160;Sigaroudi,&#160;A.;&#160;Stelzer,&#160;C.;&#160;Braun,&#160;T.;&#160;Frechen,&#160;S.;&#160;Huttner,&#160;S.;&#160;Schroter,&#160;M.;&#160;Kinzig,&#160;M.;&#160;Fuhr,&#160;U.;&#160;Holzgrabe,&#160;U.;&#160;Sorgel,&#160;F.</p>
<p style="position:absolute;top:165px;left:86px;white-space:nowrap" class="ft366">Comparison&#160;of&#160;Pantoprazole&#160;Concentrations&#160;in&#160;Simultaneous&#160;Cerebrospinal&#160;Fluid&#160;and&#160;Serum&#160;Samples.&#160;Pharmacology&#160;<b>2016</b>,&#160;98,<br/>70–72.&#160;<a href="http://doi.org/10.1159/000445720">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/27104875">[PubMed]</a></p>
<p style="position:absolute;top:199px;left:54px;white-space:nowrap" class="ft362">171.&#160;Terstappen,&#160;G.C.;&#160;Meyer,&#160;A.H.;&#160;Bell,&#160;R.D.;&#160;Zhang,&#160;W.&#160;Strategies&#160;for&#160;delivering&#160;therapeutics&#160;across&#160;the&#160;blood-brain&#160;barrier.&#160;Nat.&#160;Rev.</p>
<p style="position:absolute;top:217px;left:85px;white-space:nowrap" class="ft362">Drug&#160;Discov.&#160;<b>2021</b>,&#160;20,&#160;362–383.&#160;<a href="http://doi.org/10.1038/s41573-021-00139-y">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/33649582">[PubMed]</a></p>
<p style="position:absolute;top:234px;left:54px;white-space:nowrap" class="ft362">172.&#160;Lugini,&#160;L.;&#160;Federici,&#160;C.;&#160;Borghi,&#160;M.;&#160;Azzarito,&#160;T.;&#160;Marino,&#160;M.L.;&#160;Cesolini,&#160;A.;&#160;Spugnini,&#160;E.P.;&#160;Fais,&#160;S.&#160;Proton&#160;pump&#160;inhibitors&#160;while</p>
<p style="position:absolute;top:251px;left:86px;white-space:nowrap" class="ft366">belonging&#160;to&#160;the&#160;same&#160;family&#160;of&#160;generic&#160;drugs&#160;show&#160;different&#160;anti-tumor&#160;effect.&#160;J.&#160;Enzym.&#160;Inhib.&#160;Med.&#160;Chem.&#160;<b>2016</b>,&#160;31,&#160;538–545.<br/><a href="http://doi.org/10.3109/14756366.2015.1046062">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/26018420">[PubMed]</a></p>
<p style="position:absolute;top:286px;left:54px;white-space:nowrap" class="ft362">173.&#160;Urrego,&#160;D.;&#160;Tomczak,&#160;A.P.;&#160;Zahed,&#160;F.;&#160;Stuhmer,&#160;W.;&#160;Pardo,&#160;L.A.&#160;Potassium&#160;channels&#160;in&#160;cell&#160;cycle&#160;and&#160;cell&#160;proliferation.&#160;Philos.&#160;Trans.</p>
<p style="position:absolute;top:303px;left:85px;white-space:nowrap" class="ft362">R.&#160;Soc.&#160;B&#160;Biol.&#160;Sci.&#160;<b>2014</b>,&#160;369,&#160;20130094.&#160;<a href="http://doi.org/10.1098/rstb.2013.0094">[CrossRef]</a></p>
<p style="position:absolute;top:320px;left:54px;white-space:nowrap" class="ft362">174.&#160;Ghiani,&#160;C.A.;&#160;Yuan,&#160;X.;&#160;Eisen,&#160;A.M.;&#160;Knutson,&#160;P.L.;&#160;DePinho,&#160;R.A.;&#160;McBain,&#160;C.J.;&#160;Gallo,&#160;V.&#160;Voltage-Activated&#160;K+&#160;Channels&#160;and</p>
<p style="position:absolute;top:337px;left:86px;white-space:nowrap" class="ft366">Membrane&#160;Depolarization&#160;Regulate&#160;Accumulation&#160;of&#160;the&#160;Cyclin-Dependent&#160;Kinase&#160;Inhibitors&#160;p27Kip1and&#160;p21CIP1in&#160;Glial<br/>Progenitor&#160;Cells.&#160;J.&#160;Neurosci.&#160;<b>1999</b>,&#160;19,&#160;5380–5392.&#160;<a href="http://doi.org/10.1523/JNEUROSCI.19-13-05380.1999">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/10377348">[PubMed]</a></p>
<p style="position:absolute;top:372px;left:54px;white-space:nowrap" class="ft362">175.&#160;Chittajallu,&#160;R.;&#160;Chen,&#160;Y.;&#160;Wang,&#160;H.;&#160;Yuan,&#160;X.;&#160;Ghiani,&#160;C.A.;&#160;Heckman,&#160;T.;&#160;McBain,&#160;C.J.;&#160;Gallo,&#160;V.&#160;Regulation&#160;of&#160;Kv1&#160;subunit</p>
<p style="position:absolute;top:389px;left:86px;white-space:nowrap" class="ft362">expression&#160;in&#160;oligodendrocyte&#160;progenitor&#160;cells&#160;and&#160;their&#160;role&#160;in&#160;G1/S&#160;phase&#160;progression&#160;of&#160;the&#160;cell&#160;cycle.&#160;Proc.&#160;Natl.&#160;Acad.&#160;Sci.</p>
<p style="position:absolute;top:406px;left:85px;white-space:nowrap" class="ft362">USA&#160;<b>2002</b>,&#160;99,&#160;2350–2355.&#160;<a href="http://doi.org/10.1073/pnas.042698399">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/11854528">[PubMed]</a></p>
<p style="position:absolute;top:424px;left:54px;white-space:nowrap" class="ft362">176.&#160;Harley,&#160;W.;&#160;Floyd,&#160;C.;&#160;Dunn,&#160;T.;&#160;Zhang,&#160;X.D.;&#160;Chen,&#160;T.Y.;&#160;Hegde,&#160;M.;&#160;Palandoken,&#160;H.;&#160;Nantz,&#160;M.H.;&#160;Leon,&#160;L.;&#160;Carraway,&#160;K.L.,&#160;3rd;</p>
<p style="position:absolute;top:441px;left:86px;white-space:nowrap" class="ft362">et&#160;al.&#160;Dual&#160;inhibition&#160;of&#160;sodium-mediated&#160;proton&#160;and&#160;calcium&#160;efflux&#160;triggers&#160;non-apoptotic&#160;cell&#160;death&#160;in&#160;malignant&#160;gliomas.&#160;Brain</p>
<p style="position:absolute;top:458px;left:85px;white-space:nowrap" class="ft362">Res.&#160;<b>2010</b>,&#160;1363,&#160;159–169.&#160;<a href="http://doi.org/10.1016/j.brainres.2010.09.059">[CrossRef]</a></p>
<p style="position:absolute;top:476px;left:54px;white-space:nowrap" class="ft362">177.&#160;Marathe,&#160;K.;&#160;McVicar,&#160;N.;&#160;Li,&#160;A.;&#160;Bellyou,&#160;M.;&#160;Meakin,&#160;S.;&#160;Bartha,&#160;R.&#160;Topiramate&#160;induces&#160;acute&#160;intracellular&#160;acidification&#160;in</p>
<p style="position:absolute;top:493px;left:86px;white-space:nowrap" class="ft362">glioblastoma.&#160;J.&#160;Neurooncol.&#160;<b>2016</b>,&#160;130,&#160;465–472.&#160;<a href="http://doi.org/10.1007/s11060-016-2258-y">[CrossRef]</a></p>
<p style="position:absolute;top:510px;left:54px;white-space:nowrap" class="ft362">178.&#160;Gatti,&#160;M.;&#160;Pinato,&#160;S.;&#160;Maspero,&#160;E.;&#160;Soffientini,&#160;P.;&#160;Polo,&#160;S.;&#160;Penengo,&#160;L.&#160;A&#160;novel&#160;ubiquitin&#160;mark&#160;at&#160;the&#160;N-terminal&#160;tail&#160;of&#160;histone</p>
<p style="position:absolute;top:527px;left:86px;white-space:nowrap" class="ft362">H2As&#160;targeted&#160;by&#160;RNF168&#160;ubiquitin&#160;ligase.&#160;Cell&#160;Cycle&#160;<b>2012</b>,&#160;11,&#160;2538–2544.&#160;<a href="http://doi.org/10.4161/cc.20919">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/22713238">[PubMed]</a></p>
<p style="position:absolute;top:545px;left:54px;white-space:nowrap" class="ft362">179.&#160;Wu,&#160;L.;&#160;Bernal,&#160;G.M.;&#160;Cahill,&#160;K.E.;&#160;Pytel,&#160;P.;&#160;Fitzpatrick,&#160;C.A.;&#160;Mashek,&#160;H.;&#160;Weichselbaum,&#160;R.R.;&#160;Yamini,&#160;B.&#160;BCL3&#160;expression</p>
<p style="position:absolute;top:562px;left:85px;white-space:nowrap" class="ft362">promotes&#160;resistance&#160;to&#160;alkylating&#160;chemotherapy&#160;in&#160;gliomas.&#160;Sci.&#160;Transl.&#160;Med.&#160;<b>2018</b>,&#160;10,&#160;eaar2238.&#160;<a href="http://doi.org/10.1126/scitranslmed.aar2238">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/29973405">[PubMed]</a></p>
<p style="position:absolute;top:579px;left:54px;white-space:nowrap" class="ft362">180.&#160;Liu,&#160;Y.;&#160;Tang,&#160;Z.G.;&#160;Yang,&#160;J.Q.;&#160;Zhou,&#160;Y.;&#160;Meng,&#160;L.H.;&#160;Wang,&#160;H.;&#160;Li,&#160;C.L.&#160;Low&#160;concentration&#160;of&#160;quercetin&#160;antagonizes&#160;the&#160;invasion</p>
<p style="position:absolute;top:596px;left:86px;white-space:nowrap" class="ft362">and&#160;angiogenesis&#160;of&#160;human&#160;glioblastoma&#160;U251&#160;cells.&#160;Onco.&#160;Targets&#160;Ther.&#160;<b>2017</b>,&#160;10,&#160;4023–4028.&#160;<a href="http://doi.org/10.2147/OTT.S136821">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/28860810">[PubMed]</a></p>
<p style="position:absolute;top:614px;left:54px;white-space:nowrap" class="ft362">181.&#160;Vengoji,&#160;R.;&#160;Macha,&#160;M.A.;&#160;Batra,&#160;S.K.;&#160;Shonka,&#160;N.A.&#160;Natural&#160;products:&#160;A&#160;hope&#160;for&#160;glioblastoma&#160;patients.&#160;Oncotarget&#160;<b>2018</b>,&#160;9,</p>
<p style="position:absolute;top:631px;left:86px;white-space:nowrap" class="ft362">22194–22219.&#160;<a href="http://doi.org/10.18632/oncotarget.25175">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/29774132">[PubMed]</a></p>
<p style="position:absolute;top:648px;left:54px;white-space:nowrap" class="ft362">182.&#160;Cenciarini,&#160;M.;&#160;Valentino,&#160;M.;&#160;Belia,&#160;S.;&#160;Sforna,&#160;L.;&#160;Rosa,&#160;P.;&#160;Ronchetti,&#160;S.;&#160;D’Adamo,&#160;M.C.;&#160;Pessia,&#160;M.&#160;Dexamethasone&#160;in</p>
<p style="position:absolute;top:665px;left:86px;white-space:nowrap" class="ft362">Glioblastoma&#160;Multiforme&#160;Therapy:&#160;Mechanisms&#160;and&#160;Controversies.&#160;Front.&#160;Mol.&#160;Neurosci.&#160;<b>2019</b>,&#160;12,&#160;65.&#160;<a href="http://doi.org/10.3389/fnmol.2019.00065">[CrossRef]</a></p>
<p style="position:absolute;top:683px;left:54px;white-space:nowrap" class="ft362">183.&#160;Bernstock,&#160;J.D.;&#160;Ye,&#160;D.;&#160;Gessler,&#160;F.A.;&#160;Lee,&#160;Y.J.;&#160;Peruzzotti-Jametti,&#160;L.;&#160;Baumgarten,&#160;P.;&#160;Johnson,&#160;K.R.;&#160;Maric,&#160;D.;&#160;Yang,&#160;W.;&#160;Kogel,</p>
<p style="position:absolute;top:700px;left:86px;white-space:nowrap" class="ft366">D.;&#160;et&#160;al.&#160;Topotecan&#160;is&#160;a&#160;potent&#160;inhibitor&#160;of&#160;SUMOylation&#160;in&#160;glioblastoma&#160;multiforme&#160;and&#160;alters&#160;both&#160;cellular&#160;replication&#160;and<br/>metabolic&#160;programming.&#160;Sci.&#160;Rep.&#160;<b>2017</b>,&#160;7,&#160;7425.&#160;<a href="http://doi.org/10.1038/s41598-017-07631-9">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/28785061">[PubMed]</a></p>
<p style="position:absolute;top:734px;left:54px;white-space:nowrap" class="ft362">184.&#160;Morgan,&#160;R.J.;&#160;Synold,&#160;T.;&#160;Mamelak,&#160;A.;&#160;Lim,&#160;D.;&#160;Al-Kadhimi,&#160;Z.;&#160;Twardowski,&#160;P.;&#160;Leong,&#160;L.;&#160;Chow,&#160;W.;&#160;Margolin,&#160;K.;&#160;Shibata,&#160;S.;&#160;et&#160;al.</p>
<p style="position:absolute;top:752px;left:86px;white-space:nowrap" class="ft366">Plasma&#160;and&#160;cerebrospinal&#160;fluid&#160;pharmacokinetics&#160;of&#160;topotecan&#160;in&#160;a&#160;phase&#160;I&#160;trial&#160;of&#160;topotecan,&#160;tamoxifen,&#160;and&#160;carboplatin,&#160;in&#160;the<br/>treatment&#160;of&#160;recurrent&#160;or&#160;refractory&#160;brain&#160;or&#160;spinal&#160;cord&#160;tumors.&#160;Cancer&#160;Chemother.&#160;Pharmacol.&#160;<b>2010</b>,&#160;66,&#160;927–933.&#160;<a href="http://doi.org/10.1007/s00280-010-1242-z">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/20107803">[PubMed]</a></p>
<p style="position:absolute;top:786px;left:54px;white-space:nowrap" class="ft362">185.&#160;Macdonald,&#160;D.;&#160;Cairncross,&#160;G.;&#160;Stewart,&#160;D.;&#160;Forsyth,&#160;P.;&#160;Sawka,&#160;C.;&#160;Wainman,&#160;N.;&#160;Eisenhauer,&#160;E.&#160;Phase&#160;II&#160;study&#160;of&#160;topotecan</p>
<p style="position:absolute;top:803px;left:86px;white-space:nowrap" class="ft366">in&#160;patients&#160;with&#160;recurrent&#160;malignant&#160;glioma.&#160;National&#160;Clinical&#160;Institute&#160;of&#160;Canada&#160;Clinical&#160;Trials&#160;Group.&#160;Ann.&#160;Oncol.&#160;<b>1996</b>,&#160;7,<br/>205–207.&#160;<a href="http://doi.org/10.1093/oxfordjournals.annonc.a010550">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/8777179">[PubMed]</a></p>
<p style="position:absolute;top:838px;left:54px;white-space:nowrap" class="ft362">186.&#160;Kim,&#160;Y.Y.;&#160;Park,&#160;C.K.;&#160;Kim,&#160;S.K.;&#160;Phi,&#160;J.H.;&#160;Kim,&#160;J.H.;&#160;Kim,&#160;C.Y.;&#160;Wang,&#160;K.C.;&#160;Cho,&#160;B.K.&#160;CKD-602,&#160;a&#160;camptothecin&#160;derivative,&#160;inhibits</p>
<p style="position:absolute;top:855px;left:85px;white-space:nowrap" class="ft362">proliferation&#160;and&#160;induces&#160;apoptosis&#160;in&#160;glioma&#160;cell&#160;lines.&#160;Oncol.&#160;Rep.&#160;<b>2009</b>,&#160;21,&#160;1413–1419.&#160;<a href="http://doi.org/10.3892/or_00000369">[CrossRef]</a></p>
<p style="position:absolute;top:873px;left:54px;white-space:nowrap" class="ft362">187.&#160;Graham,&#160;C.D.;&#160;Kaza,&#160;N.;&#160;Klocke,&#160;B.J.;&#160;Gillespie,&#160;G.Y.;&#160;Shevde,&#160;L.A.;&#160;Carroll,&#160;S.L.;&#160;Roth,&#160;K.A.&#160;Tamoxifen&#160;Induces&#160;Cytotoxic</p>
<p style="position:absolute;top:890px;left:85px;white-space:nowrap" class="ft362">Autophagy&#160;in&#160;Glioblastoma.&#160;J.&#160;Neuropathol.&#160;Exp.&#160;Neurol.&#160;<b>2016</b>,&#160;75,&#160;946–954.&#160;<a href="http://doi.org/10.1093/jnen/nlw071">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/27516117">[PubMed]</a></p>
<p style="position:absolute;top:907px;left:54px;white-space:nowrap" class="ft362">188.&#160;Wan,&#160;W.;&#160;Zhang,&#160;X.;&#160;Huang,&#160;C.;&#160;Chen,&#160;L.;&#160;Yang,&#160;X.;&#160;Bao,&#160;K.;&#160;Peng,&#160;T.&#160;Monensin&#160;inhibits&#160;glioblastoma&#160;angiogenesis&#160;via&#160;targeting</p>
<p style="position:absolute;top:924px;left:86px;white-space:nowrap" class="ft362">multiple&#160;growth&#160;factor&#160;receptor&#160;signaling.&#160;Biochem.&#160;Biophys.&#160;Res.&#160;Commun.&#160;<b>2020</b>,&#160;530,&#160;479–484.&#160;<a href="http://doi.org/10.1016/j.bbrc.2020.05.057">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/32595038">[PubMed]</a></p>
<p style="position:absolute;top:942px;left:54px;white-space:nowrap" class="ft362">189.&#160;Yoon,&#160;M.J.;&#160;Kang,&#160;Y.J.;&#160;Kim,&#160;I.Y.;&#160;Kim,&#160;E.H.;&#160;Lee,&#160;J.A.;&#160;Lim,&#160;J.H.;&#160;Kwon,&#160;T.K.;&#160;Choi,&#160;K.S.&#160;Monensin,&#160;a&#160;polyether&#160;ionophore&#160;antibiotic,</p>
<p style="position:absolute;top:959px;left:86px;white-space:nowrap" class="ft362">overcomes&#160;TRAIL&#160;resistance&#160;in&#160;glioma&#160;cells&#160;via&#160;endoplasmic&#160;reticulum&#160;stress,&#160;DR5&#160;upregulation&#160;and&#160;c-FLIP&#160;downregulation.</p>
<p style="position:absolute;top:976px;left:85px;white-space:nowrap" class="ft362">Carcinogenesis&#160;<b>2013</b>,&#160;34,&#160;1918–1928.&#160;<a href="http://doi.org/10.1093/carcin/bgt137">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/23615398">[PubMed]</a></p>
<p style="position:absolute;top:993px;left:54px;white-space:nowrap" class="ft362">190.&#160;Enriquez&#160;Perez,&#160;J.;&#160;Fritzell,&#160;S.;&#160;Kopecky,&#160;J.;&#160;Visse,&#160;E.;&#160;Darabi,&#160;A.;&#160;Siesjo,&#160;P.&#160;The&#160;effect&#160;of&#160;locally&#160;delivered&#160;cisplatin&#160;is&#160;dependent&#160;on</p>
<p style="position:absolute;top:1011px;left:86px;white-space:nowrap" class="ft362">an&#160;intact&#160;immune&#160;function&#160;in&#160;an&#160;experimental&#160;glioma&#160;model.&#160;Sci.&#160;Rep.&#160;<b>2019</b>,&#160;9,&#160;5632.&#160;<a href="http://doi.org/10.1038/s41598-019-42001-7">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/30948731">[PubMed]</a></p>
<p style="position:absolute;top:1028px;left:54px;white-space:nowrap" class="ft362">191.&#160;Nakagawa,&#160;H.;&#160;Sasagawa,&#160;S.;&#160;Itoh,&#160;K.&#160;Sodium&#160;butyrate&#160;induces&#160;senescence&#160;and&#160;inhibits&#160;the&#160;invasiveness&#160;of&#160;glioblastoma&#160;cells.</p>
<p style="position:absolute;top:1045px;left:85px;white-space:nowrap" class="ft362">Oncol.&#160;Lett.&#160;<b>2018</b>,&#160;15,&#160;1495–1502.&#160;<a href="http://doi.org/10.3892/ol.2017.7518">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/29434841">[PubMed]</a></p>
<p style="position:absolute;top:1062px;left:54px;white-space:nowrap" class="ft362">192.&#160;Engelhard,&#160;H.H.;&#160;Duncan,&#160;H.A.;&#160;Kim,&#160;S.;&#160;Criswell,&#160;P.S.;&#160;Van&#160;Eldik,&#160;L.&#160;Therapeutic&#160;effects&#160;of&#160;sodium&#160;butyrate&#160;on&#160;glioma&#160;cells</p>
<p style="position:absolute;top:1080px;left:86px;white-space:nowrap" class="ft362">in&#160;vitro&#160;and&#160;in&#160;the&#160;rat&#160;C6&#160;glioma&#160;model.&#160;Neurosurgery&#160;<b>2001</b>,&#160;48,&#160;616–624,&#160;discussion&#160;624–625.&#160;<a href="http://doi.org/10.1097/00006123-200103000-00035">[CrossRef]&#160;</a><a href="http://www.ncbi.nlm.nih.gov/pubmed/11270553">[PubMed]</a></p>
</div>
</body>
</html>
